id	sid	tid	token	lemma	pos
dpc-2121	1	1	dermatology	dermatology	NOUN
dpc-2121	1	2	:	:	PUNCT
dpc-2121	1	3	practical	practical	ADJ
dpc-2121	1	4	and	and	CCONJ
dpc-2121	1	5	conceptual	conceptual	ADJ
dpc-2121	1	6	dermatology	dermatology	NOUN
dpc-2121	1	7	practical	practical	ADJ
dpc-2121	1	8	&	&	CCONJ
dpc-2121	1	9	conceptual	conceptual	ADJ
dpc-2121	1	10	review	review	NOUN
dpc-2121	1	11	|	|	ADV
dpc-2121	1	12	dermatol	dermatol	ADJ
dpc-2121	1	13	pract	pract	NOUN
dpc-2121	1	14	concept	concept	NOUN
dpc-2121	1	15	.	.	PUNCT
dpc-2121	2	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	2	2	1	1	NUM
dpc-2121	2	3	janus	janus	PROPN
dpc-2121	2	4	kinase	kinase	PROPN
dpc-2121	2	5	inhibitors	inhibitor	NOUN
dpc-2121	2	6	for	for	ADP
dpc-2121	2	7	the	the	DET
dpc-2121	2	8	treatment	treatment	NOUN
dpc-2121	2	9	of	of	ADP
dpc-2121	2	10	atopic	atopic	NOUN
dpc-2121	2	11	dermatitis	dermatitis	NOUN
dpc-2121	2	12	:	:	PUNCT
dpc-2121	2	13	focus	focus	VERB
dpc-2121	2	14	on	on	ADP
dpc-2121	2	15	abrocitinib	abrocitinib	NOUN
dpc-2121	2	16	,	,	PUNCT
dpc-2121	2	17	baricitinib	baricitinib	NOUN
dpc-2121	2	18	,	,	PUNCT
dpc-2121	2	19	and	and	CCONJ
dpc-2121	2	20	upadacitinib	upadacitinib	NOUN
dpc-2121	2	21	miguel	miguel	PROPN
dpc-2121	2	22	nogueira1	nogueira1	PROPN
dpc-2121	2	23	,	,	PUNCT
dpc-2121	2	24	tiago	tiago	PROPN
dpc-2121	2	25	torres1,2	torres1,2	PROPN
dpc-2121	2	26	1	1	NUM
dpc-2121	2	27	department	department	NOUN
dpc-2121	2	28	of	of	ADP
dpc-2121	2	29	dermatology	dermatology	NOUN
dpc-2121	2	30	,	,	PUNCT
dpc-2121	2	31	centro	centro	PROPN
dpc-2121	2	32	hospitalar	hospitalar	PROPN
dpc-2121	2	33	universitário	universitário	PROPN
dpc-2121	2	34	do	do	AUX
dpc-2121	2	35	porto	porto	PROPN
dpc-2121	2	36	,	,	PUNCT
dpc-2121	2	37	porto	porto	PROPN
dpc-2121	2	38	,	,	PUNCT
dpc-2121	2	39	portugal	portugal	PROPN
dpc-2121	2	40	2	2	NUM
dpc-2121	2	41	instituto	instituto	PROPN
dpc-2121	2	42	de	de	PROPN
dpc-2121	2	43	ciências	ciências	PROPN
dpc-2121	2	44	biomédicas	biomédicas	PROPN
dpc-2121	2	45	abel	abel	PROPN
dpc-2121	2	46	salazar	salazar	PROPN
dpc-2121	2	47	,	,	PUNCT
dpc-2121	2	48	university	university	PROPN
dpc-2121	2	49	of	of	ADP
dpc-2121	2	50	porto	porto	PROPN
dpc-2121	2	51	,	,	PUNCT
dpc-2121	2	52	porto	porto	PROPN
dpc-2121	2	53	,	,	PUNCT
dpc-2121	2	54	portugal	portugal	PROPN
dpc-2121	2	55	key	key	ADJ
dpc-2121	2	56	words	word	NOUN
dpc-2121	2	57	:	:	PUNCT
dpc-2121	2	58	atopic	atopic	NOUN
dpc-2121	2	59	dermatitis	dermatitis	NOUN
dpc-2121	2	60	,	,	PUNCT
dpc-2121	2	61	treatment	treatment	NOUN
dpc-2121	2	62	,	,	PUNCT
dpc-2121	2	63	janus	janus	PROPN
dpc-2121	2	64	kinase	kinase	PROPN
dpc-2121	2	65	inhibitors	inhibitor	NOUN
dpc-2121	2	66	,	,	PUNCT
dpc-2121	2	67	abrocitinib	abrocitinib	NOUN
dpc-2121	2	68	,	,	PUNCT
dpc-2121	2	69	baricitinib	baricitinib	NOUN
dpc-2121	2	70	,	,	PUNCT
dpc-2121	2	71	upadacitinib	upadacitinib	NOUN
dpc-2121	2	72	citation	citation	NOUN
dpc-2121	2	73	:	:	PUNCT
dpc-2121	2	74	nogueira	nogueira	PROPN
dpc-2121	2	75	m	m	PROPN
dpc-2121	2	76	,	,	PUNCT
dpc-2121	2	77	torres	torre	VERB
dpc-2121	2	78	t.	t.	PROPN
dpc-2121	2	79	janus	janus	PROPN
dpc-2121	2	80	kinase	kinase	PROPN
dpc-2121	2	81	inhibitors	inhibitor	NOUN
dpc-2121	2	82	for	for	ADP
dpc-2121	2	83	the	the	DET
dpc-2121	2	84	treatment	treatment	NOUN
dpc-2121	2	85	of	of	ADP
dpc-2121	2	86	atopic	atopic	NOUN
dpc-2121	2	87	dermatitis	dermatitis	NOUN
dpc-2121	2	88	:	:	PUNCT
dpc-2121	2	89	focus	focus	VERB
dpc-2121	2	90	on	on	ADP
dpc-2121	2	91	abrocitinib	abrocitinib	NOUN
dpc-2121	2	92	,	,	PUNCT
dpc-2121	2	93	baricitinib	baricitinib	NOUN
dpc-2121	2	94	,	,	PUNCT
dpc-2121	2	95	and	and	CCONJ
dpc-2121	2	96	upadacitinib	upadacitinib	NOUN
dpc-2121	2	97	.	.	PUNCT
dpc-2121	3	1	dermatol	dermatol	NOUN
dpc-2121	3	2	pract	pract	PROPN
dpc-2121	3	3	concept	concept	NOUN
dpc-2121	3	4	.	.	PUNCT
dpc-2121	4	1	2021;11(4):e2021145	2021;11(4):e2021145	X
dpc-2121	4	2	.	.	PUNCT
dpc-2121	4	3	doi	doi	NOUN
dpc-2121	4	4	:	:	PUNCT
dpc-2121	4	5	https://doi.org/10.5826/dpc.1104a145	https://doi.org/10.5826/dpc.1104a145	PROPN
dpc-2121	4	6	accepted	accept	VERB
dpc-2121	4	7	:	:	PUNCT
dpc-2121	4	8	october	october	PROPN
dpc-2121	4	9	15	15	NUM
dpc-2121	4	10	,	,	PUNCT
dpc-2121	4	11	2021	2021	NUM
dpc-2121	4	12	;	;	PUNCT
dpc-2121	4	13	published	publish	VERB
dpc-2121	4	14	:	:	PUNCT
dpc-2121	4	15	october	october	PROPN
dpc-2121	4	16	,	,	PUNCT
dpc-2121	4	17	2021	2021	NUM
dpc-2121	4	18	copyright	copyright	NOUN
dpc-2121	4	19	:	:	PUNCT
dpc-2121	5	1	©	©	PROPN
dpc-2121	5	2	2021	2021	NUM
dpc-2121	5	3	nogueira	nogueira	PROPN
dpc-2121	5	4	et	et	PROPN
dpc-2121	5	5	al	al	PROPN
dpc-2121	5	6	.	.	PUNCT
dpc-2121	6	1	this	this	PRON
dpc-2121	6	2	is	be	AUX
dpc-2121	6	3	an	an	DET
dpc-2121	6	4	open	open	ADJ
dpc-2121	6	5	-	-	PUNCT
dpc-2121	6	6	access	access	NOUN
dpc-2121	6	7	article	article	NOUN
dpc-2121	6	8	distributed	distribute	VERB
dpc-2121	6	9	under	under	ADP
dpc-2121	6	10	the	the	DET
dpc-2121	6	11	terms	term	NOUN
dpc-2121	6	12	of	of	ADP
dpc-2121	6	13	the	the	DET
dpc-2121	6	14	creative	creative	ADJ
dpc-2121	6	15	commons	common	NOUN
dpc-2121	6	16	attribution	attribution	NOUN
dpc-2121	6	17	license	license	NOUN
dpc-2121	6	18	by	by	ADP
dpc-2121	6	19	-	-	PUNCT
dpc-2121	6	20	nc-4.0	nc-4.0	NOUN
dpc-2121	6	21	,	,	PUNCT
dpc-2121	6	22	which	which	PRON
dpc-2121	6	23	permits	permit	VERB
dpc-2121	6	24	unrestricted	unrestricted	ADJ
dpc-2121	6	25	noncommercial	noncommercial	ADJ
dpc-2121	6	26	use	use	NOUN
dpc-2121	6	27	,	,	PUNCT
dpc-2121	6	28	distribution	distribution	NOUN
dpc-2121	6	29	,	,	PUNCT
dpc-2121	6	30	and	and	CCONJ
dpc-2121	6	31	reproduction	reproduction	NOUN
dpc-2121	6	32	in	in	ADP
dpc-2121	6	33	any	any	DET
dpc-2121	6	34	medium	medium	NOUN
dpc-2121	6	35	,	,	PUNCT
dpc-2121	6	36	provided	provide	VERB
dpc-2121	6	37	the	the	DET
dpc-2121	6	38	original	original	ADJ
dpc-2121	6	39	authors	author	NOUN
dpc-2121	6	40	and	and	CCONJ
dpc-2121	6	41	source	source	NOUN
dpc-2121	6	42	are	be	AUX
dpc-2121	6	43	credited	credit	VERB
dpc-2121	6	44	.	.	PUNCT
dpc-2121	7	1	funding	funding	NOUN
dpc-2121	7	2	:	:	PUNCT
dpc-2121	7	3	none	none	NOUN
dpc-2121	7	4	.	.	PUNCT
dpc-2121	8	1	competing	compete	VERB
dpc-2121	8	2	interests	interest	NOUN
dpc-2121	8	3	:	:	PUNCT
dpc-2121	8	4	miguel	miguel	PROPN
dpc-2121	8	5	nogueira	nogueira	PROPN
dpc-2121	8	6	has	have	AUX
dpc-2121	8	7	received	receive	VERB
dpc-2121	8	8	grants	grant	NOUN
dpc-2121	8	9	and/or	and/or	CCONJ
dpc-2121	8	10	consulting	consult	VERB
dpc-2121	8	11	fees	fee	NOUN
dpc-2121	8	12	from	from	ADP
dpc-2121	8	13	abbvie	abbvie	PROPN
dpc-2121	8	14	,	,	PUNCT
dpc-2121	8	15	leo	leo	PROPN
dpc-2121	8	16	pharma	pharma	PROPN
dpc-2121	8	17	.	.	PUNCT
dpc-2121	9	1	tiago	tiago	PROPN
dpc-2121	9	2	torres	torres	PROPN
dpc-2121	9	3	has	have	AUX
dpc-2121	9	4	received	receive	VERB
dpc-2121	9	5	research	research	NOUN
dpc-2121	9	6	grants	grant	NOUN
dpc-2121	9	7	and/or	and/or	CCONJ
dpc-2121	9	8	consulting	consult	VERB
dpc-2121	9	9	fees	fee	NOUN
dpc-2121	9	10	from	from	ADP
dpc-2121	9	11	abbvie	abbvie	PROPN
dpc-2121	9	12	,	,	PUNCT
dpc-2121	9	13	almirall	almirall	PROPN
dpc-2121	9	14	,	,	PUNCT
dpc-2121	9	15	amgen	amgen	PROPN
dpc-2121	9	16	,	,	PUNCT
dpc-2121	9	17	arena	arena	NOUN
dpc-2121	9	18	pharmaceuticals	pharmaceutical	NOUN
dpc-2121	9	19	,	,	PUNCT
dpc-2121	9	20	biocad	biocad	PROPN
dpc-2121	9	21	,	,	PUNCT
dpc-2121	9	22	boehringer	boehringer	PROPN
dpc-2121	9	23	ingelheim	ingelheim	PROPN
dpc-2121	9	24	,	,	PUNCT
dpc-2121	9	25	bristol	bristol	PROPN
dpc-2121	9	26	-	-	PUNCT
dpc-2121	9	27	myers	myers	PROPN
dpc-2121	9	28	squibb	squibb	PROPN
dpc-2121	9	29	,	,	PUNCT
dpc-2121	9	30	celgene	celgene	PROPN
dpc-2121	9	31	,	,	PUNCT
dpc-2121	9	32	eli	eli	PROPN
dpc-2121	9	33	lilly	lilly	PROPN
dpc-2121	9	34	,	,	PUNCT
dpc-2121	9	35	janssen	janssen	PROPN
dpc-2121	9	36	,	,	PUNCT
dpc-2121	9	37	leo	leo	PROPN
dpc-2121	9	38	pharma	pharma	PROPN
dpc-2121	9	39	,	,	PUNCT
dpc-2121	9	40	msd	msd	PROPN
dpc-2121	9	41	,	,	PUNCT
dpc-2121	9	42	novartis	novartis	NOUN
dpc-2121	9	43	,	,	PUNCT
dpc-2121	9	44	pfizer	pfizer	NOUN
dpc-2121	9	45	,	,	PUNCT
dpc-2121	9	46	samsung	samsung	NOUN
dpc-2121	9	47	-	-	PUNCT
dpc-2121	9	48	bioepis	bioepis	ADJ
dpc-2121	9	49	,	,	PUNCT
dpc-2121	9	50	sandoz	sandoz	PROPN
dpc-2121	9	51	and	and	CCONJ
dpc-2121	9	52	sanofi	sanofi	PROPN
dpc-2121	9	53	.	.	PUNCT
dpc-2121	10	1	authorship	authorship	NOUN
dpc-2121	10	2	:	:	PUNCT
dpc-2121	10	3	all	all	DET
dpc-2121	10	4	authors	author	NOUN
dpc-2121	10	5	have	have	AUX
dpc-2121	10	6	contributed	contribute	VERB
dpc-2121	10	7	significantly	significantly	ADV
dpc-2121	10	8	to	to	ADP
dpc-2121	10	9	this	this	DET
dpc-2121	10	10	publication	publication	NOUN
dpc-2121	10	11	.	.	PUNCT
dpc-2121	11	1	corresponding	correspond	VERB
dpc-2121	11	2	author	author	NOUN
dpc-2121	11	3	:	:	PUNCT
dpc-2121	11	4	tiago	tiago	PROPN
dpc-2121	11	5	torres	torres	PROPN
dpc-2121	11	6	,	,	PUNCT
dpc-2121	11	7	department	department	NOUN
dpc-2121	11	8	of	of	ADP
dpc-2121	11	9	dermatology	dermatology	NOUN
dpc-2121	11	10	,	,	PUNCT
dpc-2121	11	11	centro	centro	PROPN
dpc-2121	11	12	hospitalar	hospitalar	PROPN
dpc-2121	11	13	universitário	universitário	PROPN
dpc-2121	11	14	do	do	AUX
dpc-2121	11	15	porto	porto	PROPN
dpc-2121	11	16	,	,	PUNCT
dpc-2121	11	17	porto	porto	PROPN
dpc-2121	11	18	,	,	PUNCT
dpc-2121	11	19	portugal	portugal	PROPN
dpc-2121	11	20	.	.	PUNCT
dpc-2121	11	21	email	email	NOUN
dpc-2121	11	22	:	:	PUNCT
dpc-2121	11	23	torres.tiago@outlook.com	torres.tiago@outlook.com	X
dpc-2121	11	24	atopic	atopic	NOUN
dpc-2121	11	25	dermatitis	dermatitis	NOUN
dpc-2121	11	26	(	(	PUNCT
dpc-2121	11	27	ad	ad	NOUN
dpc-2121	11	28	)	)	PUNCT
dpc-2121	11	29	is	be	AUX
dpc-2121	11	30	a	a	DET
dpc-2121	11	31	clinically	clinically	ADV
dpc-2121	11	32	heterogenous	heterogenous	ADJ
dpc-2121	11	33	,	,	PUNCT
dpc-2121	11	34	inflammatory	inflammatory	ADJ
dpc-2121	11	35	skin	skin	NOUN
dpc-2121	11	36	condition	condition	NOUN
dpc-2121	11	37	with	with	ADP
dpc-2121	11	38	a	a	DET
dpc-2121	11	39	high	high	ADJ
dpc-2121	11	40	impact	impact	NOUN
dpc-2121	11	41	on	on	ADP
dpc-2121	11	42	patients	patient	NOUN
dpc-2121	11	43	’	'	PUNCT
dpc-2121	11	44	daily	daily	ADJ
dpc-2121	11	45	activities	activity	NOUN
dpc-2121	11	46	that	that	PRON
dpc-2121	11	47	remains	remain	VERB
dpc-2121	11	48	difficult	difficult	ADJ
dpc-2121	11	49	to	to	PART
dpc-2121	11	50	treat	treat	VERB
dpc-2121	11	51	.	.	PUNCT
dpc-2121	12	1	the	the	DET
dpc-2121	12	2	knowledge	knowledge	NOUN
dpc-2121	12	3	acquired	acquire	VERB
dpc-2121	12	4	over	over	ADP
dpc-2121	12	5	the	the	DET
dpc-2121	12	6	last	last	ADJ
dpc-2121	12	7	decade	decade	NOUN
dpc-2121	12	8	on	on	ADP
dpc-2121	12	9	ad	ad	NOUN
dpc-2121	12	10	pathophysiology	pathophysiology	NOUN
dpc-2121	12	11	and	and	CCONJ
dpc-2121	12	12	disease	disease	NOUN
dpc-2121	12	13	burden	burden	NOUN
dpc-2121	12	14	led	lead	VERB
dpc-2121	12	15	to	to	ADP
dpc-2121	12	16	the	the	DET
dpc-2121	12	17	development	development	NOUN
dpc-2121	12	18	of	of	ADP
dpc-2121	12	19	new	new	ADJ
dpc-2121	12	20	targeted	target	VERB
dpc-2121	12	21	therapeutic	therapeutic	ADJ
dpc-2121	12	22	options	option	NOUN
dpc-2121	12	23	that	that	PRON
dpc-2121	12	24	enable	enable	VERB
dpc-2121	12	25	clinicians	clinician	NOUN
dpc-2121	12	26	to	to	PART
dpc-2121	12	27	better	well	ADV
dpc-2121	12	28	manage	manage	VERB
dpc-2121	12	29	ad	ad	NOUN
dpc-2121	12	30	patients	patient	NOUN
dpc-2121	12	31	.	.	PUNCT
dpc-2121	13	1	the	the	DET
dpc-2121	13	2	jak	jak	PROPN
dpc-2121	13	3	/	/	SYM
dpc-2121	13	4	stat	stat	PROPN
dpc-2121	13	5	signaling	signal	VERB
dpc-2121	13	6	pathway	pathway	NOUN
dpc-2121	13	7	modulates	modulate	VERB
dpc-2121	13	8	several	several	ADJ
dpc-2121	13	9	immune	immune	ADJ
dpc-2121	13	10	pathways	pathway	NOUN
dpc-2121	13	11	(	(	PUNCT
dpc-2121	13	12	t	t	NOUN
dpc-2121	13	13	helper	helper	NOUN
dpc-2121	13	14	(	(	PUNCT
dpc-2121	13	15	th)1	th)1	PROPN
dpc-2121	13	16	,	,	PUNCT
dpc-2121	13	17	th2	th2	PROPN
dpc-2121	13	18	,	,	PUNCT
dpc-2121	13	19	th17	th17	PROPN
dpc-2121	13	20	,	,	PUNCT
dpc-2121	13	21	and	and	CCONJ
dpc-2121	13	22	th22	th22	PROPN
dpc-2121	13	23	cells	cell	NOUN
dpc-2121	13	24	)	)	PUNCT
dpc-2121	13	25	that	that	PRON
dpc-2121	13	26	have	have	AUX
dpc-2121	13	27	been	be	AUX
dpc-2121	13	28	found	find	VERB
dpc-2121	13	29	to	to	PART
dpc-2121	13	30	be	be	AUX
dpc-2121	13	31	involved	involve	VERB
dpc-2121	13	32	in	in	ADP
dpc-2121	13	33	ad	ad	NOUN
dpc-2121	13	34	pathogenesis	pathogenesis	NOUN
dpc-2121	13	35	.	.	PUNCT
dpc-2121	14	1	for	for	ADP
dpc-2121	14	2	this	this	DET
dpc-2121	14	3	reason	reason	NOUN
dpc-2121	14	4	,	,	PUNCT
dpc-2121	14	5	jak	jak	PROPN
dpc-2121	14	6	inhibitors	inhibitor	NOUN
dpc-2121	14	7	emerged	emerge	VERB
dpc-2121	14	8	as	as	ADP
dpc-2121	14	9	a	a	DET
dpc-2121	14	10	possible	possible	ADJ
dpc-2121	14	11	therapy	therapy	NOUN
dpc-2121	14	12	for	for	ADP
dpc-2121	14	13	ad	ad	NOUN
dpc-2121	14	14	.	.	PUNCT
dpc-2121	15	1	baricitinib	baricitinib	NOUN
dpc-2121	15	2	,	,	PUNCT
dpc-2121	15	3	upadacitinib	upadacitinib	NOUN
dpc-2121	15	4	,	,	PUNCT
dpc-2121	15	5	and	and	CCONJ
dpc-2121	15	6	abrocitinib	abrocitinib	NOUN
dpc-2121	15	7	are	be	AUX
dpc-2121	15	8	the	the	DET
dpc-2121	15	9	three	three	NUM
dpc-2121	15	10	oral	oral	ADJ
dpc-2121	15	11	jak	jak	PROPN
dpc-2121	15	12	inhibitors	inhibitor	NOUN
dpc-2121	15	13	already	already	ADV
dpc-2121	15	14	approved	approve	VERB
dpc-2121	15	15	or	or	CCONJ
dpc-2121	15	16	in	in	ADP
dpc-2121	15	17	advanced	advanced	ADJ
dpc-2121	15	18	clinical	clinical	ADJ
dpc-2121	15	19	development	development	NOUN
dpc-2121	15	20	for	for	ADP
dpc-2121	15	21	this	this	DET
dpc-2121	15	22	purpose	purpose	NOUN
dpc-2121	15	23	.	.	PUNCT
dpc-2121	16	1	the	the	DET
dpc-2121	16	2	results	result	NOUN
dpc-2121	16	3	showed	show	VERB
dpc-2121	16	4	that	that	SCONJ
dpc-2121	16	5	this	this	DET
dpc-2121	16	6	drug	drug	NOUN
dpc-2121	16	7	class	class	NOUN
dpc-2121	16	8	is	be	AUX
dpc-2121	16	9	highly	highly	ADV
dpc-2121	16	10	effective	effective	ADJ
dpc-2121	16	11	achieving	achieve	VERB
dpc-2121	16	12	symptomatic	symptomatic	ADJ
dpc-2121	16	13	relief	relief	NOUN
dpc-2121	16	14	(	(	PUNCT
dpc-2121	16	15	itch	itch	NOUN
dpc-2121	16	16	control	control	NOUN
dpc-2121	16	17	)	)	PUNCT
dpc-2121	16	18	in	in	ADP
dpc-2121	16	19	the	the	DET
dpc-2121	16	20	short	short	ADJ
dpc-2121	16	21	term	term	NOUN
dpc-2121	16	22	,	,	PUNCT
dpc-2121	16	23	as	as	ADV
dpc-2121	16	24	well	well	ADV
dpc-2121	16	25	as	as	ADP
dpc-2121	16	26	improving	improve	VERB
dpc-2121	16	27	disease	disease	NOUN
dpc-2121	16	28	severity	severity	NOUN
dpc-2121	16	29	in	in	ADP
dpc-2121	16	30	abstract	abstract	ADJ
dpc-2121	16	31	this	this	DET
dpc-2121	16	32	article	article	NOUN
dpc-2121	16	33	is	be	AUX
dpc-2121	16	34	part	part	NOUN
dpc-2121	16	35	of	of	ADP
dpc-2121	16	36	a	a	DET
dpc-2121	16	37	series	series	NOUN
dpc-2121	16	38	of	of	ADP
dpc-2121	16	39	reviews	review	NOUN
dpc-2121	16	40	dedicated	dedicate	VERB
dpc-2121	16	41	to	to	ADP
dpc-2121	16	42	atopic	atopic	NOUN
dpc-2121	16	43	dermatitis	dermatitis	NOUN
dpc-2121	16	44	,	,	PUNCT
dpc-2121	16	45	guest	guest	NOUN
dpc-2121	16	46	edited	edit	VERB
dpc-2121	16	47	by	by	ADP
dpc-2121	16	48	prof	prof	PROPN
dpc-2121	16	49	.	.	PROPN
dpc-2121	17	1	anna	anna	PROPN
dpc-2121	17	2	balato	balato	PROPN
dpc-2121	17	3	.	.	PUNCT
dpc-2121	18	1	guest	guest	PROPN
dpc-2121	18	2	editor	editor	PROPN
dpc-2121	18	3	prof	prof	PROPN
dpc-2121	18	4	.	.	PROPN
dpc-2121	19	1	anna	anna	PROPN
dpc-2121	19	2	balato	balato	PROPN
dpc-2121	19	3	,	,	PUNCT
dpc-2121	19	4	md	md	PROPN
dpc-2121	19	5	,	,	PUNCT
dpc-2121	19	6	phd	phd	NOUN
dpc-2121	19	7	associate	associate	NOUN
dpc-2121	19	8	professor	professor	NOUN
dpc-2121	19	9	of	of	ADP
dpc-2121	19	10	dermatology	dermatology	NOUN
dpc-2121	19	11	,	,	PUNCT
dpc-2121	19	12	dermatology	dermatology	NOUN
dpc-2121	19	13	unit	unit	NOUN
dpc-2121	19	14	,	,	PUNCT
dpc-2121	19	15	university	university	PROPN
dpc-2121	19	16	of	of	ADP
dpc-2121	19	17	campania	campania	PROPN
dpc-2121	19	18	,	,	PUNCT
dpc-2121	19	19	naples	naples	PROPN
dpc-2121	19	20	,	,	PUNCT
dpc-2121	19	21	italy	italy	PROPN
dpc-2121	19	22	2	2	NUM
dpc-2121	19	23	review	review	NOUN
dpc-2121	19	24	|	|	ADV
dpc-2121	19	25	dermatol	dermatol	ADJ
dpc-2121	19	26	pract	pract	NOUN
dpc-2121	19	27	concept	concept	NOUN
dpc-2121	19	28	.	.	PUNCT
dpc-2121	20	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	20	2	introduction	introduction	NOUN
dpc-2121	20	3	atopic	atopic	NOUN
dpc-2121	20	4	dermatitis	dermatitis	NOUN
dpc-2121	20	5	(	(	PUNCT
dpc-2121	20	6	ad	ad	NOUN
dpc-2121	20	7	)	)	PUNCT
dpc-2121	20	8	is	be	AUX
dpc-2121	20	9	a	a	DET
dpc-2121	20	10	chronic	chronic	NOUN
dpc-2121	20	11	,	,	PUNCT
dpc-2121	20	12	relapsing	relapse	VERB
dpc-2121	20	13	,	,	PUNCT
dpc-2121	20	14	clinically	clinically	ADV
dpc-2121	20	15	heterogeneous	heterogeneous	ADJ
dpc-2121	20	16	,	,	PUNCT
dpc-2121	20	17	and	and	CCONJ
dpc-2121	20	18	difficult	difficult	ADJ
dpc-2121	20	19	-	-	PUNCT
dpc-2121	20	20	to	to	ADP
dpc-2121	20	21	-	-	PUNCT
dpc-2121	20	22	treat	treat	NOUN
dpc-2121	20	23	disorder	disorder	NOUN
dpc-2121	20	24	,	,	PUNCT
dpc-2121	20	25	also	also	ADV
dpc-2121	20	26	known	know	VERB
dpc-2121	20	27	for	for	ADP
dpc-2121	20	28	being	be	AUX
dpc-2121	20	29	the	the	DET
dpc-2121	20	30	most	most	ADV
dpc-2121	20	31	prevalent	prevalent	ADJ
dpc-2121	20	32	inflammatory	inflammatory	ADJ
dpc-2121	20	33	skin	skin	NOUN
dpc-2121	20	34	disease	disease	NOUN
dpc-2121	20	35	in	in	ADP
dpc-2121	20	36	developed	develop	VERB
dpc-2121	20	37	countries	country	NOUN
dpc-2121	20	38	with	with	ADP
dpc-2121	20	39	a	a	DET
dpc-2121	20	40	lifetime	lifetime	NOUN
dpc-2121	20	41	prevalence	prevalence	NOUN
dpc-2121	20	42	of	of	ADP
dpc-2121	20	43	up	up	ADP
dpc-2121	20	44	to	to	PART
dpc-2121	20	45	20	20	NUM
dpc-2121	20	46	%	%	NOUN
dpc-2121	20	47	[	[	X
dpc-2121	20	48	1,2	1,2	NUM
dpc-2121	20	49	]	]	PUNCT
dpc-2121	20	50	.	.	PUNCT
dpc-2121	21	1	ad	ad	NOUN
dpc-2121	21	2	was	be	AUX
dpc-2121	21	3	originally	originally	ADV
dpc-2121	21	4	labeled	label	VERB
dpc-2121	21	5	as	as	ADP
dpc-2121	21	6	an	an	DET
dpc-2121	21	7	early	early	ADJ
dpc-2121	21	8	childhood	childhood	NOUN
dpc-2121	21	9	disease	disease	NOUN
dpc-2121	21	10	.	.	PUNCT
dpc-2121	22	1	however	however	ADV
dpc-2121	22	2	,	,	PUNCT
dpc-2121	22	3	it	it	PRON
dpc-2121	22	4	is	be	AUX
dpc-2121	22	5	now	now	ADV
dpc-2121	22	6	known	know	VERB
dpc-2121	22	7	that	that	SCONJ
dpc-2121	22	8	despite	despite	SCONJ
dpc-2121	22	9	the	the	DET
dpc-2121	22	10	incidence	incidence	NOUN
dpc-2121	22	11	peak	peak	NOUN
dpc-2121	22	12	during	during	ADP
dpc-2121	22	13	infancy	infancy	NOUN
dpc-2121	22	14	–	–	PUNCT
dpc-2121	22	15	onset	onset	NOUN
dpc-2121	22	16	of	of	ADP
dpc-2121	22	17	the	the	DET
dpc-2121	22	18	disease	disease	NOUN
dpc-2121	22	19	occurs	occur	VERB
dpc-2121	22	20	before	before	ADP
dpc-2121	22	21	6	6	NUM
dpc-2121	22	22	years	year	NOUN
dpc-2121	22	23	of	of	ADP
dpc-2121	22	24	age	age	NOUN
dpc-2121	22	25	in	in	ADP
dpc-2121	22	26	80	80	NUM
dpc-2121	22	27	%	%	NOUN
dpc-2121	22	28	of	of	ADP
dpc-2121	22	29	patients	patient	NOUN
dpc-2121	22	30	-	-	PUNCT
dpc-2121	22	31	,	,	PUNCT
dpc-2121	22	32	the	the	DET
dpc-2121	22	33	proportion	proportion	NOUN
dpc-2121	22	34	of	of	ADP
dpc-2121	22	35	patients	patient	NOUN
dpc-2121	22	36	with	with	ADP
dpc-2121	22	37	adult	adult	NOUN
dpc-2121	22	38	-	-	PUNCT
dpc-2121	22	39	persistent	persistent	ADJ
dpc-2121	22	40	or	or	CCONJ
dpc-2121	22	41	adult	adult	NOUN
dpc-2121	22	42	-	-	PUNCT
dpc-2121	22	43	onset	onset	NOUN
dpc-2121	22	44	forms	form	NOUN
dpc-2121	22	45	of	of	ADP
dpc-2121	22	46	ad	ad	NOUN
dpc-2121	22	47	is	be	AUX
dpc-2121	22	48	nonnegligible	nonnegligible	ADJ
dpc-2121	22	49	[	[	X
dpc-2121	22	50	2–4	2–4	NUM
dpc-2121	22	51	]	]	PUNCT
dpc-2121	22	52	.	.	PUNCT
dpc-2121	23	1	the	the	DET
dpc-2121	23	2	disease	disease	NOUN
dpc-2121	23	3	is	be	AUX
dpc-2121	23	4	clinically	clinically	ADV
dpc-2121	23	5	associated	associate	VERB
dpc-2121	23	6	with	with	ADP
dpc-2121	23	7	a	a	DET
dpc-2121	23	8	variety	variety	NOUN
dpc-2121	23	9	of	of	ADP
dpc-2121	23	10	features	feature	NOUN
dpc-2121	23	11	ranging	range	VERB
dpc-2121	23	12	from	from	ADP
dpc-2121	23	13	minimal	minimal	ADJ
dpc-2121	23	14	eczema	eczema	NOUN
dpc-2121	23	15	on	on	ADP
dpc-2121	23	16	flexural	flexural	ADJ
dpc-2121	23	17	folds	fold	NOUN
dpc-2121	23	18	or	or	CCONJ
dpc-2121	23	19	hands	hand	NOUN
dpc-2121	23	20	to	to	PART
dpc-2121	23	21	erythroderma	erythroderma	VERB
dpc-2121	23	22	[	[	X
dpc-2121	23	23	2–4	2–4	NUM
dpc-2121	23	24	]	]	PUNCT
dpc-2121	23	25	.	.	PUNCT
dpc-2121	24	1	cutaneous	cutaneous	ADJ
dpc-2121	24	2	manifestations	manifestation	NOUN
dpc-2121	24	3	and	and	CCONJ
dpc-2121	24	4	associated	associated	ADJ
dpc-2121	24	5	symptoms	symptom	NOUN
dpc-2121	24	6	/	/	SYM
dpc-2121	24	7	signals	signal	NOUN
dpc-2121	24	8	,	,	PUNCT
dpc-2121	24	9	such	such	ADJ
dpc-2121	24	10	as	as	ADP
dpc-2121	24	11	redness	redness	NOUN
dpc-2121	24	12	,	,	PUNCT
dpc-2121	24	13	peeling	peel	VERB
dpc-2121	24	14	,	,	PUNCT
dpc-2121	24	15	lichenification	lichenification	NOUN
dpc-2121	24	16	,	,	PUNCT
dpc-2121	24	17	and	and	CCONJ
dpc-2121	24	18	itchiness	itchiness	VERB
dpc-2121	24	19	markedly	markedly	ADV
dpc-2121	24	20	interfere	interfere	VERB
dpc-2121	24	21	with	with	ADP
dpc-2121	24	22	daily	daily	ADJ
dpc-2121	24	23	activities	activity	NOUN
dpc-2121	24	24	and	and	CCONJ
dpc-2121	24	25	may	may	AUX
dpc-2121	24	26	lead	lead	VERB
dpc-2121	24	27	to	to	PART
dpc-2121	24	28	sleep	sleep	VERB
dpc-2121	24	29	loss	loss	NOUN
dpc-2121	24	30	and	and	CCONJ
dpc-2121	24	31	diminished	diminish	VERB
dpc-2121	24	32	self	self	NOUN
dpc-2121	24	33	-	-	PUNCT
dpc-2121	24	34	esteem	esteem	NOUN
dpc-2121	24	35	,	,	PUNCT
dpc-2121	24	36	having	have	VERB
dpc-2121	24	37	a	a	DET
dpc-2121	24	38	high	high	ADJ
dpc-2121	24	39	impact	impact	NOUN
dpc-2121	24	40	on	on	ADP
dpc-2121	24	41	social	social	ADJ
dpc-2121	24	42	interactions	interaction	NOUN
dpc-2121	24	43	and	and	CCONJ
dpc-2121	24	44	school	school	NOUN
dpc-2121	24	45	/	/	SYM
dpc-2121	24	46	work	work	NOUN
dpc-2121	24	47	performance	performance	NOUN
dpc-2121	24	48	[	[	X
dpc-2121	24	49	2–4	2–4	NUM
dpc-2121	24	50	]	]	X
dpc-2121	24	51	.	.	PUNCT
dpc-2121	25	1	consequently	consequently	ADV
dpc-2121	25	2	,	,	PUNCT
dpc-2121	25	3	ad	ad	NOUN
dpc-2121	25	4	is	be	AUX
dpc-2121	25	5	an	an	DET
dpc-2121	25	6	important	important	ADJ
dpc-2121	25	7	health	health	NOUN
dpc-2121	25	8	concern	concern	NOUN
dpc-2121	25	9	worldwide	worldwide	ADV
dpc-2121	25	10	,	,	PUNCT
dpc-2121	25	11	occupying	occupy	VERB
dpc-2121	25	12	the	the	DET
dpc-2121	25	13	top	top	ADJ
dpc-2121	25	14	position	position	NOUN
dpc-2121	25	15	on	on	ADP
dpc-2121	25	16	the	the	DET
dpc-2121	25	17	list	list	NOUN
dpc-2121	25	18	of	of	ADP
dpc-2121	25	19	the	the	DET
dpc-2121	25	20	causes	cause	NOUN
dpc-2121	25	21	of	of	ADP
dpc-2121	25	22	non	non	ADJ
dpc-2121	25	23	-	-	ADJ
dpc-2121	25	24	fatal	fatal	ADJ
dpc-2121	25	25	disease	disease	NOUN
dpc-2121	25	26	burden	burden	NOUN
dpc-2121	25	27	of	of	ADP
dpc-2121	25	28	skin	skin	NOUN
dpc-2121	25	29	disorders	disorder	NOUN
dpc-2121	25	30	[	[	X
dpc-2121	25	31	3	3	NUM
dpc-2121	25	32	]	]	PUNCT
dpc-2121	25	33	.	.	PUNCT
dpc-2121	26	1	the	the	DET
dpc-2121	26	2	pathophysiology	pathophysiology	NOUN
dpc-2121	26	3	of	of	ADP
dpc-2121	26	4	ad	ad	NOUN
dpc-2121	26	5	is	be	AUX
dpc-2121	26	6	thought	think	VERB
dpc-2121	26	7	to	to	PART
dpc-2121	26	8	be	be	AUX
dpc-2121	26	9	a	a	DET
dpc-2121	26	10	result	result	NOUN
dpc-2121	26	11	of	of	ADP
dpc-2121	26	12	the	the	DET
dpc-2121	26	13	interaction	interaction	NOUN
dpc-2121	26	14	between	between	ADP
dpc-2121	26	15	various	various	ADJ
dpc-2121	26	16	critical	critical	ADJ
dpc-2121	26	17	factors	factor	NOUN
dpc-2121	26	18	,	,	PUNCT
dpc-2121	26	19	such	such	ADJ
dpc-2121	26	20	as	as	ADP
dpc-2121	26	21	epidermal	epidermal	ADJ
dpc-2121	26	22	barrier	barrier	NOUN
dpc-2121	26	23	disruption	disruption	NOUN
dpc-2121	26	24	,	,	PUNCT
dpc-2121	26	25	genetic	genetic	ADJ
dpc-2121	26	26	susceptibility	susceptibility	NOUN
dpc-2121	26	27	,	,	PUNCT
dpc-2121	26	28	activation	activation	NOUN
dpc-2121	26	29	of	of	ADP
dpc-2121	26	30	distinct	distinct	ADJ
dpc-2121	26	31	subsets	subset	NOUN
dpc-2121	26	32	of	of	ADP
dpc-2121	26	33	t	t	PROPN
dpc-2121	26	34	-	-	PUNCT
dpc-2121	26	35	cells	cell	NOUN
dpc-2121	26	36	,	,	PUNCT
dpc-2121	26	37	environmental	environmental	ADJ
dpc-2121	26	38	triggers	trigger	NOUN
dpc-2121	26	39	,	,	PUNCT
dpc-2121	26	40	and	and	CCONJ
dpc-2121	26	41	dysbiosis	dysbiosis	NOUN
dpc-2121	26	42	of	of	ADP
dpc-2121	26	43	commensal	commensal	ADJ
dpc-2121	26	44	skin	skin	NOUN
dpc-2121	26	45	microbiota	microbiota	NOUN
dpc-2121	26	46	[	[	X
dpc-2121	26	47	2,5	2,5	NUM
dpc-2121	26	48	]	]	PUNCT
dpc-2121	26	49	.	.	PUNCT
dpc-2121	27	1	the	the	DET
dpc-2121	27	2	strongest	strong	ADJ
dpc-2121	27	3	identified	identify	VERB
dpc-2121	27	4	risk	risk	NOUN
dpc-2121	27	5	factor	factor	NOUN
dpc-2121	27	6	for	for	ADP
dpc-2121	27	7	ad	ad	NOUN
dpc-2121	27	8	is	be	AUX
dpc-2121	27	9	a	a	DET
dpc-2121	27	10	positive	positive	ADJ
dpc-2121	27	11	family	family	NOUN
dpc-2121	27	12	history	history	NOUN
dpc-2121	27	13	of	of	ADP
dpc-2121	27	14	atopy	atopy	NOUN
dpc-2121	27	15	which	which	PRON
dpc-2121	27	16	may	may	AUX
dpc-2121	27	17	result	result	VERB
dpc-2121	27	18	in	in	ADP
dpc-2121	27	19	a	a	DET
dpc-2121	27	20	3	3	NUM
dpc-2121	27	21	or	or	CCONJ
dpc-2121	27	22	5	5	NUM
dpc-2121	27	23	-	-	ADJ
dpc-2121	27	24	fold	fold	ADJ
dpc-2121	27	25	increased	increased	ADJ
dpc-2121	27	26	risk	risk	NOUN
dpc-2121	27	27	for	for	ADP
dpc-2121	27	28	developing	develop	VERB
dpc-2121	27	29	ad	ad	NOUN
dpc-2121	27	30	when	when	SCONJ
dpc-2121	27	31	one	one	NUM
dpc-2121	27	32	or	or	CCONJ
dpc-2121	27	33	both	both	DET
dpc-2121	27	34	parents	parent	NOUN
dpc-2121	27	35	are	be	AUX
dpc-2121	27	36	affected	affect	VERB
dpc-2121	27	37	,	,	PUNCT
dpc-2121	27	38	respectively	respectively	ADV
dpc-2121	27	39	[	[	X
dpc-2121	27	40	2	2	NUM
dpc-2121	27	41	]	]	PUNCT
dpc-2121	27	42	.	.	PUNCT
dpc-2121	28	1	in	in	ADP
dpc-2121	28	2	the	the	DET
dpc-2121	28	3	last	last	ADJ
dpc-2121	28	4	decade	decade	NOUN
dpc-2121	28	5	,	,	PUNCT
dpc-2121	28	6	major	major	ADJ
dpc-2121	28	7	advances	advance	NOUN
dpc-2121	28	8	were	be	AUX
dpc-2121	28	9	made	make	VERB
dpc-2121	28	10	in	in	ADP
dpc-2121	28	11	understanding	understand	VERB
dpc-2121	28	12	the	the	DET
dpc-2121	28	13	molecular	molecular	ADJ
dpc-2121	28	14	bases	basis	NOUN
dpc-2121	28	15	behind	behind	ADP
dpc-2121	28	16	ad	ad	NOUN
dpc-2121	28	17	,	,	PUNCT
dpc-2121	28	18	which	which	PRON
dpc-2121	28	19	also	also	ADV
dpc-2121	28	20	allowed	allow	VERB
dpc-2121	28	21	the	the	DET
dpc-2121	28	22	development	development	NOUN
dpc-2121	28	23	of	of	ADP
dpc-2121	28	24	new	new	ADJ
dpc-2121	28	25	targeted	target	VERB
dpc-2121	28	26	strategies	strategy	NOUN
dpc-2121	28	27	for	for	ADP
dpc-2121	28	28	the	the	DET
dpc-2121	28	29	management	management	NOUN
dpc-2121	28	30	of	of	ADP
dpc-2121	28	31	the	the	DET
dpc-2121	28	32	disease	disease	NOUN
dpc-2121	28	33	[	[	X
dpc-2121	28	34	2,6,7	2,6,7	NUM
dpc-2121	28	35	]	]	PUNCT
dpc-2121	28	36	.	.	PUNCT
dpc-2121	29	1	in	in	ADP
dpc-2121	29	2	addition	addition	NOUN
dpc-2121	29	3	to	to	ADP
dpc-2121	29	4	the	the	DET
dpc-2121	29	5	classic	classic	ADJ
dpc-2121	29	6	treatment	treatment	NOUN
dpc-2121	29	7	approaches	approach	NOUN
dpc-2121	29	8	–	–	PUNCT
dpc-2121	29	9	including	include	VERB
dpc-2121	29	10	avoiding	avoid	VERB
dpc-2121	29	11	environmental	environmental	ADJ
dpc-2121	29	12	triggers	trigger	NOUN
dpc-2121	29	13	,	,	PUNCT
dpc-2121	29	14	topical	topical	ADJ
dpc-2121	29	15	therapies	therapy	NOUN
dpc-2121	29	16	and	and	CCONJ
dpc-2121	29	17	traditional	traditional	ADJ
dpc-2121	29	18	immunosuppressants	immunosuppressant	NOUN
dpc-2121	29	19	–	–	PUNCT
dpc-2121	29	20	several	several	ADJ
dpc-2121	29	21	targeted	target	VERB
dpc-2121	29	22	drugs	drug	NOUN
dpc-2121	29	23	(	(	PUNCT
dpc-2121	29	24	biologic	biologic	NOUN
dpc-2121	29	25	or	or	CCONJ
dpc-2121	29	26	small	small	ADJ
dpc-2121	29	27	molecules	molecule	NOUN
dpc-2121	29	28	)	)	PUNCT
dpc-2121	29	29	were	be	AUX
dpc-2121	29	30	introduced	introduce	VERB
dpc-2121	29	31	as	as	ADP
dpc-2121	29	32	new	new	ADJ
dpc-2121	29	33	treatment	treatment	NOUN
dpc-2121	29	34	options	option	NOUN
dpc-2121	29	35	for	for	ADP
dpc-2121	29	36	ad	ad	NOUN
dpc-2121	29	37	.	.	PUNCT
dpc-2121	30	1	dupilumab	dupilumab	NOUN
dpc-2121	30	2	,	,	PUNCT
dpc-2121	30	3	an	an	DET
dpc-2121	30	4	il-4	il-4	NOUN
dpc-2121	30	5	receptor	receptor	NOUN
dpc-2121	30	6	α	α	PRON
dpc-2121	30	7	inhibitor	inhibitor	NOUN
dpc-2121	30	8	that	that	PRON
dpc-2121	30	9	blocks	block	VERB
dpc-2121	30	10	the	the	DET
dpc-2121	30	11	activity	activity	NOUN
dpc-2121	30	12	of	of	ADP
dpc-2121	30	13	both	both	DET
dpc-2121	30	14	il-4	il-4	X
dpc-2121	30	15	and	and	CCONJ
dpc-2121	30	16	il-13	il-13	PRON
dpc-2121	30	17	,	,	PUNCT
dpc-2121	30	18	was	be	AUX
dpc-2121	30	19	the	the	DET
dpc-2121	30	20	first	first	ADJ
dpc-2121	30	21	non	non	ADJ
dpc-2121	30	22	-	-	ADJ
dpc-2121	30	23	traditional	traditional	ADJ
dpc-2121	30	24	immunomodulator	immunomodulator	NOUN
dpc-2121	30	25	agent	agent	NOUN
dpc-2121	30	26	approved	approve	VERB
dpc-2121	30	27	for	for	ADP
dpc-2121	30	28	the	the	DET
dpc-2121	30	29	treatment	treatment	NOUN
dpc-2121	30	30	of	of	ADP
dpc-2121	30	31	moderate	moderate	ADJ
dpc-2121	30	32	-	-	PUNCT
dpc-2121	30	33	to	to	ADP
dpc-2121	30	34	-	-	PUNCT
dpc-2121	30	35	severe	severe	ADJ
dpc-2121	30	36	ad	ad	NOUN
dpc-2121	30	37	in	in	ADP
dpc-2121	30	38	patients	patient	NOUN
dpc-2121	30	39	with	with	ADP
dpc-2121	30	40	6	6	NUM
dpc-2121	30	41	years	year	NOUN
dpc-2121	30	42	of	of	ADP
dpc-2121	30	43	age	age	NOUN
dpc-2121	30	44	or	or	CCONJ
dpc-2121	30	45	older	old	ADJ
dpc-2121	30	46	.	.	PUNCT
dpc-2121	31	1	however	however	ADV
dpc-2121	31	2	,	,	PUNCT
dpc-2121	31	3	the	the	DET
dpc-2121	31	4	development	development	NOUN
dpc-2121	31	5	of	of	ADP
dpc-2121	31	6	new	new	ADJ
dpc-2121	31	7	treatments	treatment	NOUN
dpc-2121	31	8	for	for	ADP
dpc-2121	31	9	ad	ad	NOUN
dpc-2121	31	10	is	be	AUX
dpc-2121	31	11	crucial	crucial	ADJ
dpc-2121	31	12	,	,	PUNCT
dpc-2121	31	13	as	as	SCONJ
dpc-2121	31	14	a	a	DET
dpc-2121	31	15	considerable	considerable	ADJ
dpc-2121	31	16	number	number	NOUN
dpc-2121	31	17	of	of	ADP
dpc-2121	31	18	patients	patient	NOUN
dpc-2121	31	19	are	be	AUX
dpc-2121	31	20	non	non	NOUN
dpc-2121	31	21	-	-	NOUN
dpc-2121	31	22	responders	responder	NOUN
dpc-2121	31	23	to	to	ADP
dpc-2121	31	24	the	the	DET
dpc-2121	31	25	available	available	ADJ
dpc-2121	31	26	regimens	regimen	NOUN
dpc-2121	31	27	.	.	PUNCT
dpc-2121	32	1	currently	currently	ADV
dpc-2121	32	2	,	,	PUNCT
dpc-2121	32	3	several	several	ADJ
dpc-2121	32	4	small	small	ADJ
dpc-2121	32	5	molecules	molecule	NOUN
dpc-2121	32	6	are	be	AUX
dpc-2121	32	7	already	already	ADV
dpc-2121	32	8	approved	approve	VERB
dpc-2121	32	9	or	or	CCONJ
dpc-2121	32	10	under	under	ADP
dpc-2121	32	11	evaluation	evaluation	NOUN
dpc-2121	32	12	in	in	ADP
dpc-2121	32	13	clinical	clinical	ADJ
dpc-2121	32	14	trials	trial	NOUN
dpc-2121	32	15	for	for	ADP
dpc-2121	32	16	treating	treat	VERB
dpc-2121	32	17	patients	patient	NOUN
dpc-2121	32	18	with	with	ADP
dpc-2121	32	19	ad	ad	NOUN
dpc-2121	33	1	[	[	X
dpc-2121	33	2	4,6–9	4,6–9	NUM
dpc-2121	33	3	]	]	PUNCT
dpc-2121	33	4	.	.	PUNCT
dpc-2121	34	1	janus	janus	PROPN
dpc-2121	34	2	kinase	kinase	PROPN
dpc-2121	34	3	(	(	PUNCT
dpc-2121	34	4	jak)/signal	jak)/signal	ADJ
dpc-2121	34	5	transducer	transducer	NOUN
dpc-2121	34	6	and	and	CCONJ
dpc-2121	34	7	activator	activator	NOUN
dpc-2121	34	8	of	of	ADP
dpc-2121	34	9	transcription	transcription	NOUN
dpc-2121	34	10	(	(	PUNCT
dpc-2121	34	11	stat	stat	NOUN
dpc-2121	34	12	)	)	PUNCT
dpc-2121	34	13	signaling	signal	VERB
dpc-2121	34	14	pathway	pathway	NOUN
dpc-2121	34	15	in	in	ADP
dpc-2121	34	16	atopic	atopic	NOUN
dpc-2121	34	17	dermatitis	dermatitis	NOUN
dpc-2121	34	18	the	the	DET
dpc-2121	34	19	jak	jak	PROPN
dpc-2121	34	20	/	/	SYM
dpc-2121	34	21	stat	stat	PROPN
dpc-2121	34	22	signaling	signal	VERB
dpc-2121	34	23	pathway	pathway	NOUN
dpc-2121	34	24	has	have	AUX
dpc-2121	34	25	been	be	AUX
dpc-2121	34	26	associated	associate	VERB
dpc-2121	34	27	with	with	ADP
dpc-2121	34	28	the	the	DET
dpc-2121	34	29	development	development	NOUN
dpc-2121	34	30	of	of	ADP
dpc-2121	34	31	ad	ad	NOUN
dpc-2121	34	32	as	as	SCONJ
dpc-2121	34	33	it	it	PRON
dpc-2121	34	34	modulates	modulate	VERB
dpc-2121	34	35	several	several	ADJ
dpc-2121	34	36	immune	immune	ADJ
dpc-2121	34	37	pathways	pathway	NOUN
dpc-2121	34	38	that	that	PRON
dpc-2121	34	39	are	be	AUX
dpc-2121	34	40	involved	involve	VERB
dpc-2121	34	41	in	in	ADP
dpc-2121	34	42	its	its	PRON
dpc-2121	34	43	pathogenesis	pathogenesis	NOUN
dpc-2121	34	44	,	,	PUNCT
dpc-2121	34	45	such	such	ADJ
dpc-2121	34	46	as	as	ADP
dpc-2121	34	47	those	those	PRON
dpc-2121	34	48	associated	associate	VERB
dpc-2121	34	49	with	with	ADP
dpc-2121	34	50	t	t	PROPN
dpc-2121	34	51	helper	helper	NOUN
dpc-2121	34	52	(	(	PUNCT
dpc-2121	34	53	th)1	th)1	PROPN
dpc-2121	34	54	,	,	PUNCT
dpc-2121	34	55	th2	th2	PROPN
dpc-2121	34	56	,	,	PUNCT
dpc-2121	34	57	th17	th17	PROPN
dpc-2121	34	58	,	,	PUNCT
dpc-2121	34	59	and	and	CCONJ
dpc-2121	34	60	th22	th22	PROPN
dpc-2121	34	61	cells	cell	NOUN
dpc-2121	34	62	[	[	X
dpc-2121	34	63	10	10	NUM
dpc-2121	34	64	,	,	PUNCT
dpc-2121	34	65	11	11	NUM
dpc-2121	34	66	]	]	PUNCT
dpc-2121	34	67	.	.	PUNCT
dpc-2121	35	1	briefly	briefly	NOUN
dpc-2121	35	2	,	,	PUNCT
dpc-2121	35	3	this	this	DET
dpc-2121	35	4	pathway	pathway	NOUN
dpc-2121	35	5	involves	involve	VERB
dpc-2121	35	6	a	a	DET
dpc-2121	35	7	circulating	circulate	VERB
dpc-2121	35	8	cytokine	cytokine	NOUN
dpc-2121	35	9	,	,	PUNCT
dpc-2121	35	10	such	such	ADJ
dpc-2121	35	11	as	as	ADP
dpc-2121	35	12	an	an	DET
dpc-2121	35	13	interferon	interferon	NOUN
dpc-2121	35	14	(	(	PUNCT
dpc-2121	35	15	ifn	ifn	PROPN
dpc-2121	35	16	)	)	PUNCT
dpc-2121	35	17	or	or	CCONJ
dpc-2121	35	18	an	an	DET
dpc-2121	35	19	interleukin	interleukin	NOUN
dpc-2121	35	20	(	(	PUNCT
dpc-2121	35	21	il	il	PROPN
dpc-2121	35	22	)	)	PUNCT
dpc-2121	35	23	,	,	PUNCT
dpc-2121	35	24	that	that	PRON
dpc-2121	35	25	binds	bind	VERB
dpc-2121	35	26	to	to	ADP
dpc-2121	35	27	its	its	PRON
dpc-2121	35	28	cell	cell	NOUN
dpc-2121	35	29	membrane	membrane	NOUN
dpc-2121	35	30	receptor	receptor	NOUN
dpc-2121	35	31	triggering	trigger	VERB
dpc-2121	35	32	a	a	DET
dpc-2121	35	33	conformational	conformational	ADJ
dpc-2121	35	34	change	change	NOUN
dpc-2121	35	35	with	with	ADP
dpc-2121	35	36	subsequent	subsequent	ADJ
dpc-2121	35	37	jaks	jak	NOUN
dpc-2121	35	38	recruitment	recruitment	NOUN
dpc-2121	35	39	and	and	CCONJ
dpc-2121	35	40	activation	activation	NOUN
dpc-2121	35	41	[	[	X
dpc-2121	35	42	12	12	NUM
dpc-2121	35	43	]	]	PUNCT
dpc-2121	35	44	.	.	PUNCT
dpc-2121	36	1	two	two	NUM
dpc-2121	36	2	activated	activate	VERB
dpc-2121	36	3	and	and	CCONJ
dpc-2121	36	4	combined	combined	ADJ
dpc-2121	36	5	jaks	jak	NOUN
dpc-2121	36	6	have	have	VERB
dpc-2121	36	7	the	the	DET
dpc-2121	36	8	ability	ability	NOUN
dpc-2121	36	9	to	to	PART
dpc-2121	36	10	further	far	ADV
dpc-2121	36	11	phosphorylate	phosphorylate	VERB
dpc-2121	36	12	stat	stat	NOUN
dpc-2121	36	13	proteins	protein	NOUN
dpc-2121	36	14	,	,	PUNCT
dpc-2121	36	15	inducing	induce	VERB
dpc-2121	36	16	their	their	PRON
dpc-2121	36	17	dimerization	dimerization	NOUN
dpc-2121	36	18	and	and	CCONJ
dpc-2121	36	19	subsequent	subsequent	ADJ
dpc-2121	36	20	translocation	translocation	NOUN
dpc-2121	36	21	into	into	ADP
dpc-2121	36	22	the	the	DET
dpc-2121	36	23	cell	cell	NOUN
dpc-2121	36	24	nucleus	nucleus	NOUN
dpc-2121	36	25	.	.	PUNCT
dpc-2121	37	1	once	once	ADV
dpc-2121	37	2	in	in	ADP
dpc-2121	37	3	the	the	DET
dpc-2121	37	4	nucleus	nucleus	NOUN
dpc-2121	37	5	,	,	PUNCT
dpc-2121	37	6	stat	stat	NOUN
dpc-2121	37	7	proteins	protein	NOUN
dpc-2121	37	8	can	can	AUX
dpc-2121	37	9	affect	affect	VERB
dpc-2121	37	10	gene	gene	NOUN
dpc-2121	37	11	expression	expression	NOUN
dpc-2121	37	12	[	[	X
dpc-2121	37	13	12	12	NUM
dpc-2121	37	14	]	]	PUNCT
dpc-2121	37	15	.	.	PUNCT
dpc-2121	38	1	there	there	PRON
dpc-2121	38	2	are	be	VERB
dpc-2121	38	3	four	four	NUM
dpc-2121	38	4	different	different	ADJ
dpc-2121	38	5	jak	jak	PROPN
dpc-2121	38	6	proteins	protein	NOUN
dpc-2121	38	7	(	(	PUNCT
dpc-2121	38	8	jak1	jak1	PROPN
dpc-2121	38	9	,	,	PUNCT
dpc-2121	38	10	jak2	jak2	NOUN
dpc-2121	38	11	,	,	PUNCT
dpc-2121	38	12	jak3	jak3	NOUN
dpc-2121	38	13	,	,	PUNCT
dpc-2121	38	14	and	and	CCONJ
dpc-2121	38	15	tyk2	tyk2	VERB
dpc-2121	38	16	)	)	PUNCT
dpc-2121	38	17	and	and	CCONJ
dpc-2121	38	18	seven	seven	NUM
dpc-2121	38	19	distinct	distinct	ADJ
dpc-2121	38	20	stat	stat	NOUN
dpc-2121	38	21	proteins	protein	NOUN
dpc-2121	38	22	(	(	PUNCT
dpc-2121	38	23	stat1	stat1	PROPN
dpc-2121	38	24	,	,	PUNCT
dpc-2121	38	25	stat2	stat2	PROPN
dpc-2121	38	26	,	,	PUNCT
dpc-2121	38	27	stat3	stat3	NOUN
dpc-2121	38	28	,	,	PUNCT
dpc-2121	38	29	stat4	stat4	NOUN
dpc-2121	38	30	,	,	PUNCT
dpc-2121	38	31	stat5a	stat5a	PROPN
dpc-2121	38	32	,	,	PUNCT
dpc-2121	38	33	stat5b	stat5b	NOUN
dpc-2121	38	34	,	,	PUNCT
dpc-2121	38	35	and	and	CCONJ
dpc-2121	38	36	stat6	stat6	NOUN
dpc-2121	38	37	)	)	PUNCT
dpc-2121	39	1	[	[	X
dpc-2121	39	2	12	12	NUM
dpc-2121	39	3	]	]	PUNCT
dpc-2121	39	4	.	.	PUNCT
dpc-2121	40	1	jak1	jak1	PROPN
dpc-2121	40	2	and	and	CCONJ
dpc-2121	40	3	jak3	jak3	PROPN
dpc-2121	40	4	seem	seem	VERB
dpc-2121	40	5	to	to	PART
dpc-2121	40	6	be	be	AUX
dpc-2121	40	7	responsible	responsible	ADJ
dpc-2121	40	8	for	for	ADP
dpc-2121	40	9	mediating	mediate	VERB
dpc-2121	40	10	the	the	DET
dpc-2121	40	11	signaling	signaling	NOUN
dpc-2121	40	12	of	of	ADP
dpc-2121	40	13	cytokines	cytokine	NOUN
dpc-2121	40	14	from	from	ADP
dpc-2121	40	15	the	the	DET
dpc-2121	40	16	γc	γc	PROPN
dpc-2121	40	17	family	family	NOUN
dpc-2121	40	18	,	,	PUNCT
dpc-2121	40	19	including	include	VERB
dpc-2121	40	20	il-4	il-4	PROPN
dpc-2121	40	21	,	,	PUNCT
dpc-2121	40	22	a	a	DET
dpc-2121	40	23	cytokine	cytokine	NOUN
dpc-2121	40	24	known	know	VERB
dpc-2121	40	25	for	for	ADP
dpc-2121	40	26	its	its	PRON
dpc-2121	40	27	relevant	relevant	ADJ
dpc-2121	40	28	role	role	NOUN
dpc-2121	40	29	in	in	ADP
dpc-2121	40	30	ad	ad	NOUN
dpc-2121	40	31	cascade	cascade	NOUN
dpc-2121	40	32	[	[	X
dpc-2121	40	33	10,11	10,11	NUM
dpc-2121	40	34	]	]	X
dpc-2121	40	35	.	.	PUNCT
dpc-2121	41	1	il-31	il-31	ADV
dpc-2121	41	2	-	-	PUNCT
dpc-2121	41	3	induced	induced	ADJ
dpc-2121	41	4	signaling	signal	VERB
dpc-2121	41	5	pathway	pathway	NOUN
dpc-2121	41	6	,	,	PUNCT
dpc-2121	41	7	particularly	particularly	ADV
dpc-2121	41	8	through	through	ADP
dpc-2121	41	9	jak1	jak1	NOUN
dpc-2121	41	10	,	,	PUNCT
dpc-2121	41	11	is	be	AUX
dpc-2121	41	12	also	also	ADV
dpc-2121	41	13	thought	think	VERB
dpc-2121	41	14	to	to	PART
dpc-2121	41	15	play	play	VERB
dpc-2121	41	16	an	an	DET
dpc-2121	41	17	important	important	ADJ
dpc-2121	41	18	role	role	NOUN
dpc-2121	41	19	in	in	ADP
dpc-2121	41	20	inducing	induce	VERB
dpc-2121	41	21	chronic	chronic	ADJ
dpc-2121	41	22	pruritus	pruritus	NOUN
dpc-2121	42	1	[	[	X
dpc-2121	42	2	11,13	11,13	NUM
dpc-2121	42	3	]	]	PUNCT
dpc-2121	42	4	.	.	PUNCT
dpc-2121	43	1	stat6	stat6	NOUN
dpc-2121	43	2	activation	activation	NOUN
dpc-2121	43	3	,	,	PUNCT
dpc-2121	43	4	which	which	PRON
dpc-2121	43	5	occurs	occur	VERB
dpc-2121	43	6	mainly	mainly	ADV
dpc-2121	43	7	through	through	ADP
dpc-2121	43	8	jak1	jak1	NOUN
dpc-2121	43	9	and	and	CCONJ
dpc-2121	43	10	jak3	jak3	NOUN
dpc-2121	43	11	activation	activation	NOUN
dpc-2121	43	12	after	after	ADP
dpc-2121	43	13	il-4	il-4	PRON
dpc-2121	43	14	and	and	CCONJ
dpc-2121	43	15	il-13	il-13	CCONJ
dpc-2121	43	16	bind	bind	VERB
dpc-2121	43	17	their	their	PRON
dpc-2121	43	18	receptors	receptor	NOUN
dpc-2121	43	19	,	,	PUNCT
dpc-2121	43	20	have	have	AUX
dpc-2121	43	21	also	also	ADV
dpc-2121	43	22	been	be	AUX
dpc-2121	43	23	implicated	implicate	VERB
dpc-2121	43	24	in	in	ADP
dpc-2121	43	25	ad	ad	NOUN
dpc-2121	43	26	development	development	NOUN
dpc-2121	43	27	[	[	X
dpc-2121	43	28	10,11,14,15	10,11,14,15	NUM
dpc-2121	43	29	]	]	PUNCT
dpc-2121	43	30	.	.	PUNCT
dpc-2121	44	1	on	on	ADP
dpc-2121	44	2	the	the	DET
dpc-2121	44	3	other	other	ADJ
dpc-2121	44	4	hand	hand	NOUN
dpc-2121	44	5	,	,	PUNCT
dpc-2121	44	6	jak2	jak2	PROPN
dpc-2121	44	7	and	and	CCONJ
dpc-2121	44	8	tyk2	tyk2	VERB
dpc-2121	44	9	interact	interact	VERB
dpc-2121	44	10	to	to	PART
dpc-2121	44	11	stat4	stat4	VERB
dpc-2121	44	12	and	and	CCONJ
dpc-2121	44	13	seem	seem	VERB
dpc-2121	44	14	to	to	PART
dpc-2121	44	15	mediate	mediate	VERB
dpc-2121	44	16	th1	th1	NOUN
dpc-2121	44	17	differentiation	differentiation	NOUN
dpc-2121	44	18	,	,	PUNCT
dpc-2121	44	19	as	as	ADV
dpc-2121	44	20	well	well	ADV
dpc-2121	44	21	as	as	ADP
dpc-2121	44	22	il-12	il-12	NOUN
dpc-2121	44	23	signaling	signal	VERB
dpc-2121	44	24	[	[	X
dpc-2121	44	25	10,11	10,11	NUM
dpc-2121	44	26	]	]	PUNCT
dpc-2121	44	27	.	.	PUNCT
dpc-2121	45	1	systemic	systemic	PROPN
dpc-2121	45	2	jak	jak	PROPN
dpc-2121	45	3	inhibitors	inhibitor	NOUN
dpc-2121	45	4	in	in	ADP
dpc-2121	45	5	atopic	atopic	NOUN
dpc-2121	45	6	dermatitis	dermatitis	NOUN
dpc-2121	45	7	over	over	ADP
dpc-2121	45	8	the	the	DET
dpc-2121	45	9	last	last	ADJ
dpc-2121	45	10	decade	decade	NOUN
dpc-2121	45	11	,	,	PUNCT
dpc-2121	45	12	the	the	DET
dpc-2121	45	13	marked	mark	VERB
dpc-2121	45	14	advances	advance	NOUN
dpc-2121	45	15	that	that	PRON
dpc-2121	45	16	have	have	AUX
dpc-2121	45	17	been	be	AUX
dpc-2121	45	18	made	make	VERB
dpc-2121	45	19	in	in	ADP
dpc-2121	45	20	understanding	understand	VERB
dpc-2121	45	21	the	the	DET
dpc-2121	45	22	impact	impact	NOUN
dpc-2121	45	23	of	of	ADP
dpc-2121	45	24	jak	jak	PROPN
dpc-2121	45	25	/	/	SYM
dpc-2121	45	26	stat	stat	PROPN
dpc-2121	45	27	signaling	signal	VERB
dpc-2121	45	28	pathway	pathway	NOUN
dpc-2121	45	29	on	on	ADP
dpc-2121	45	30	the	the	DET
dpc-2121	45	31	pathogenesis	pathogenesis	NOUN
dpc-2121	45	32	of	of	ADP
dpc-2121	45	33	ad	ad	NOUN
dpc-2121	45	34	encouraged	encourage	VERB
dpc-2121	45	35	the	the	DET
dpc-2121	45	36	use	use	NOUN
dpc-2121	45	37	of	of	ADP
dpc-2121	45	38	jak	jak	PROPN
dpc-2121	45	39	inhibitors	inhibitor	NOUN
dpc-2121	45	40	as	as	ADP
dpc-2121	45	41	a	a	DET
dpc-2121	45	42	therapeutic	therapeutic	ADJ
dpc-2121	45	43	alternative	alternative	NOUN
dpc-2121	45	44	for	for	ADP
dpc-2121	45	45	this	this	DET
dpc-2121	45	46	disease	disease	NOUN
dpc-2121	45	47	[	[	X
dpc-2121	45	48	10,11,16	10,11,16	NUM
dpc-2121	45	49	]	]	PUNCT
dpc-2121	45	50	.	.	PUNCT
dpc-2121	46	1	although	although	SCONJ
dpc-2121	46	2	jak	jak	PROPN
dpc-2121	46	3	inhibitors	inhibitor	NOUN
dpc-2121	46	4	safety	safety	NOUN
dpc-2121	46	5	profile	profile	NOUN
dpc-2121	46	6	had	have	AUX
dpc-2121	46	7	already	already	ADV
dpc-2121	46	8	been	be	AUX
dpc-2121	46	9	evaluated	evaluate	VERB
dpc-2121	46	10	this	this	DET
dpc-2121	46	11	class	class	NOUN
dpc-2121	46	12	of	of	ADP
dpc-2121	46	13	drugs	drug	NOUN
dpc-2121	46	14	is	be	AUX
dpc-2121	46	15	already	already	ADV
dpc-2121	46	16	approved	approve	VERB
dpc-2121	46	17	for	for	ADP
dpc-2121	46	18	the	the	DET
dpc-2121	46	19	treatment	treatment	NOUN
dpc-2121	46	20	of	of	ADP
dpc-2121	46	21	other	other	ADJ
dpc-2121	46	22	immune	immune	ADJ
dpc-2121	46	23	mediated	mediate	VERB
dpc-2121	46	24	diseases	disease	NOUN
dpc-2121	46	25	such	such	ADJ
dpc-2121	46	26	as	as	ADP
dpc-2121	46	27	rheumatoid	rheumatoid	NOUN
dpc-2121	46	28	arthritis	arthritis	NOUN
dpc-2121	46	29	–	–	PUNCT
dpc-2121	46	30	several	several	ADJ
dpc-2121	46	31	clinical	clinical	ADJ
dpc-2121	46	32	trials	trial	NOUN
dpc-2121	46	33	were	be	AUX
dpc-2121	46	34	conducted	conduct	VERB
dpc-2121	46	35	to	to	PART
dpc-2121	46	36	assess	assess	VERB
dpc-2121	46	37	the	the	DET
dpc-2121	46	38	performance	performance	NOUN
dpc-2121	46	39	of	of	ADP
dpc-2121	46	40	these	these	DET
dpc-2121	46	41	drugs	drug	NOUN
dpc-2121	46	42	in	in	ADP
dpc-2121	46	43	the	the	DET
dpc-2121	46	44	specific	specific	ADJ
dpc-2121	46	45	context	context	NOUN
dpc-2121	46	46	of	of	ADP
dpc-2121	46	47	ad[10,11	ad[10,11	PROPN
dpc-2121	46	48	]	]	PUNCT
dpc-2121	46	49	.	.	PUNCT
dpc-2121	47	1	the	the	DET
dpc-2121	47	2	short	short	ADJ
dpc-2121	47	3	and	and	CCONJ
dpc-2121	47	4	medium	medium	ADJ
dpc-2121	47	5	term	term	NOUN
dpc-2121	47	6	.	.	PUNCT
dpc-2121	48	1	however	however	ADV
dpc-2121	48	2	,	,	PUNCT
dpc-2121	48	3	their	their	PRON
dpc-2121	48	4	efficacy	efficacy	NOUN
dpc-2121	48	5	should	should	AUX
dpc-2121	48	6	be	be	AUX
dpc-2121	48	7	balanced	balance	VERB
dpc-2121	48	8	with	with	ADP
dpc-2121	48	9	possible	possible	ADJ
dpc-2121	48	10	side	side	NOUN
dpc-2121	48	11	effects	effect	NOUN
dpc-2121	48	12	,	,	PUNCT
dpc-2121	48	13	that	that	PRON
dpc-2121	48	14	have	have	AUX
dpc-2121	48	15	been	be	AUX
dpc-2121	48	16	reported	report	VERB
dpc-2121	48	17	in	in	ADP
dpc-2121	48	18	clinical	clinical	ADJ
dpc-2121	48	19	trials	trial	NOUN
dpc-2121	48	20	.	.	PUNCT
dpc-2121	49	1	more	more	ADJ
dpc-2121	49	2	data	datum	NOUN
dpc-2121	49	3	on	on	ADP
dpc-2121	49	4	the	the	DET
dpc-2121	49	5	long	long	ADJ
dpc-2121	49	6	-	-	PUNCT
dpc-2121	49	7	term	term	NOUN
dpc-2121	49	8	efficacy	efficacy	NOUN
dpc-2121	49	9	and	and	CCONJ
dpc-2121	49	10	safety	safety	NOUN
dpc-2121	49	11	,	,	PUNCT
dpc-2121	49	12	as	as	ADV
dpc-2121	49	13	well	well	ADV
dpc-2121	49	14	as	as	ADP
dpc-2121	49	15	from	from	ADP
dpc-2121	49	16	head	head	NOUN
dpc-2121	49	17	-	-	PUNCT
dpc-2121	49	18	to	to	ADP
dpc-2121	49	19	-	-	PUNCT
dpc-2121	49	20	head	head	NOUN
dpc-2121	49	21	comparisons	comparison	NOUN
dpc-2121	49	22	and	and	CCONJ
dpc-2121	49	23	from	from	ADP
dpc-2121	49	24	real	real	ADJ
dpc-2121	49	25	-	-	PUNCT
dpc-2121	49	26	world	world	NOUN
dpc-2121	49	27	setting	setting	NOUN
dpc-2121	49	28	will	will	AUX
dpc-2121	49	29	be	be	AUX
dpc-2121	49	30	crucial	crucial	ADJ
dpc-2121	49	31	to	to	PART
dpc-2121	49	32	position	position	VERB
dpc-2121	49	33	oral	oral	ADJ
dpc-2121	49	34	jak	jak	PROPN
dpc-2121	49	35	inhibitors	inhibitor	NOUN
dpc-2121	49	36	in	in	ADP
dpc-2121	49	37	the	the	DET
dpc-2121	49	38	ad	ad	NOUN
dpc-2121	49	39	therapeutic	therapeutic	ADJ
dpc-2121	49	40	armamentarium	armamentarium	NOUN
dpc-2121	49	41	.	.	PUNCT
dpc-2121	50	1	review	review	NOUN
dpc-2121	50	2	|	|	ADV
dpc-2121	50	3	dermatol	dermatol	ADJ
dpc-2121	50	4	pract	pract	NOUN
dpc-2121	50	5	concept	concept	NOUN
dpc-2121	50	6	.	.	PUNCT
dpc-2121	51	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	51	2	3	3	NUM
dpc-2121	51	3	in	in	ADP
dpc-2121	51	4	the	the	DET
dpc-2121	51	5	following	follow	VERB
dpc-2121	51	6	review	review	NOUN
dpc-2121	51	7	,	,	PUNCT
dpc-2121	51	8	we	we	PRON
dpc-2121	51	9	will	will	AUX
dpc-2121	51	10	focus	focus	VERB
dpc-2121	51	11	on	on	ADP
dpc-2121	51	12	the	the	DET
dpc-2121	51	13	results	result	NOUN
dpc-2121	51	14	of	of	ADP
dpc-2121	51	15	the	the	DET
dpc-2121	51	16	available	available	ADJ
dpc-2121	51	17	phase	phase	NOUN
dpc-2121	51	18	iii	iii	NUM
dpc-2121	51	19	clinical	clinical	ADJ
dpc-2121	51	20	trials	trial	NOUN
dpc-2121	51	21	of	of	ADP
dpc-2121	51	22	oral	oral	ADJ
dpc-2121	51	23	jak	jak	PROPN
dpc-2121	51	24	inhibitors	inhibitor	NOUN
dpc-2121	51	25	used	use	VERB
dpc-2121	51	26	in	in	ADP
dpc-2121	51	27	ad	ad	NOUN
dpc-2121	51	28	patients	patient	NOUN
dpc-2121	51	29	after	after	ADP
dpc-2121	51	30	their	their	PRON
dpc-2121	51	31	positive	positive	ADJ
dpc-2121	51	32	data	datum	NOUN
dpc-2121	51	33	on	on	ADP
dpc-2121	51	34	safety	safety	NOUN
dpc-2121	51	35	and	and	CCONJ
dpc-2121	51	36	efficacy	efficacy	NOUN
dpc-2121	51	37	in	in	ADP
dpc-2121	51	38	phase	phase	NOUN
dpc-2121	51	39	i	i	PRON
dpc-2121	51	40	and	and	CCONJ
dpc-2121	51	41	ii	ii	PROPN
dpc-2121	51	42	studies	study	NOUN
dpc-2121	51	43	,	,	PUNCT
dpc-2121	51	44	namely	namely	ADV
dpc-2121	51	45	baricitinib	baricitinib	NOUN
dpc-2121	51	46	,	,	PUNCT
dpc-2121	51	47	upadacitinib	upadacitinib	NOUN
dpc-2121	51	48	and	and	CCONJ
dpc-2121	51	49	abrocitinib	abrocitinib	NOUN
dpc-2121	51	50	(	(	PUNCT
dpc-2121	51	51	table	table	NOUN
dpc-2121	51	52	1	1	NUM
dpc-2121	51	53	)	)	PUNCT
dpc-2121	51	54	.	.	PUNCT
dpc-2121	52	1	baricitinib	baricitinib	NOUN
dpc-2121	52	2	baricitinib	baricitinib	NOUN
dpc-2121	52	3	is	be	AUX
dpc-2121	52	4	a	a	DET
dpc-2121	52	5	small	small	ADJ
dpc-2121	52	6	molecule	molecule	NOUN
dpc-2121	52	7	that	that	PRON
dpc-2121	52	8	selectively	selectively	ADV
dpc-2121	52	9	inhibits	inhibit	VERB
dpc-2121	52	10	both	both	CCONJ
dpc-2121	52	11	jak1	jak1	PROPN
dpc-2121	52	12	and	and	CCONJ
dpc-2121	52	13	jak2	jak2	PROPN
dpc-2121	52	14	proteins	protein	NOUN
dpc-2121	52	15	[	[	X
dpc-2121	52	16	10,11	10,11	NOUN
dpc-2121	52	17	]	]	PUNCT
dpc-2121	52	18	.	.	PUNCT
dpc-2121	53	1	this	this	DET
dpc-2121	53	2	drug	drug	NOUN
dpc-2121	53	3	is	be	AUX
dpc-2121	53	4	approved	approve	VERB
dpc-2121	53	5	by	by	ADP
dpc-2121	53	6	the	the	DET
dpc-2121	53	7	european	european	PROPN
dpc-2121	53	8	medicines	medicines	PROPN
dpc-2121	53	9	agency	agency	NOUN
dpc-2121	53	10	(	(	PUNCT
dpc-2121	53	11	ema	ema	PROPN
dpc-2121	53	12	)	)	PUNCT
dpc-2121	53	13	for	for	ADP
dpc-2121	53	14	treating	treat	VERB
dpc-2121	53	15	moderate	moderate	ADJ
dpc-2121	53	16	-	-	PUNCT
dpc-2121	53	17	to	to	ADP
dpc-2121	53	18	-	-	PUNCT
dpc-2121	53	19	severe	severe	ADJ
dpc-2121	53	20	atopic	atopic	NOUN
dpc-2121	53	21	dermatitis	dermatitis	NOUN
dpc-2121	53	22	in	in	ADP
dpc-2121	53	23	adult	adult	NOUN
dpc-2121	53	24	patients	patient	NOUN
dpc-2121	53	25	,	,	PUNCT
dpc-2121	53	26	but	but	CCONJ
dpc-2121	53	27	table1	table1	PROPN
dpc-2121	53	28	.	.	PUNCT
dpc-2121	54	1	results	result	NOUN
dpc-2121	54	2	from	from	ADP
dpc-2121	54	3	phase	phase	NOUN
dpc-2121	54	4	iii	iii	NUM
dpc-2121	54	5	clinical	clinical	ADJ
dpc-2121	54	6	trials	trial	NOUN
dpc-2121	54	7	of	of	ADP
dpc-2121	54	8	oral	oral	ADJ
dpc-2121	54	9	jak	jak	PROPN
dpc-2121	54	10	inhibitors	inhibitor	NOUN
dpc-2121	54	11	used	use	VERB
dpc-2121	54	12	for	for	ADP
dpc-2121	54	13	ad	ad	NOUN
dpc-2121	54	14	patients	patient	NOUN
dpc-2121	54	15	:	:	PUNCT
dpc-2121	54	16	baricitinib	baricitinib	NOUN
dpc-2121	54	17	,	,	PUNCT
dpc-2121	54	18	upadacitinib	upadacitinib	NOUN
dpc-2121	54	19	and	and	CCONJ
dpc-2121	54	20	abrocitinib	abrocitinib	NOUN
dpc-2121	54	21	.	.	PUNCT
dpc-2121	55	1	drug	drug	NOUN
dpc-2121	55	2	name	name	NOUN
dpc-2121	55	3	main	main	PROPN
dpc-2121	55	4	jak	jak	PROPN
dpc-2121	55	5	inhibition	inhibition	NOUN
dpc-2121	55	6	trial	trial	NOUN
dpc-2121	55	7	name	name	NOUN
dpc-2121	55	8	patients	patient	NOUN
dpc-2121	55	9	,	,	PUNCT
dpc-2121	55	10	n.	n.	NOUN
dpc-2121	55	11	study	study	NOUN
dpc-2121	55	12	duration	duration	NOUN
dpc-2121	55	13	(	(	PUNCT
dpc-2121	55	14	co)primary	co)primary	NOUN
dpc-2121	55	15	endpoint(s	endpoint(s	PROPN
dpc-2121	55	16	)	)	PUNCT
dpc-2121	55	17	most	most	ADV
dpc-2121	55	18	important	important	ADJ
dpc-2121	55	19	side	side	NOUN
dpc-2121	55	20	effects	effect	NOUN
dpc-2121	55	21	associated	associate	VERB
dpc-2121	55	22	to	to	ADP
dpc-2121	55	23	jak	jak	PROPN
dpc-2121	55	24	inhibitors	inhibitor	NOUN
dpc-2121	55	25	baricitinib	baricitinib	VERB
dpc-2121	55	26	jak1	jak1	NOUN
dpc-2121	55	27	and	and	CCONJ
dpc-2121	55	28	jak2	jak2	PROPN
dpc-2121	55	29	breezead1	breezead1	VERB
dpc-2121	56	1	[	[	X
dpc-2121	56	2	18	18	NUM
dpc-2121	56	3	]	]	SYM
dpc-2121	56	4	624	624	NUM
dpc-2121	56	5	16	16	NUM
dpc-2121	56	6	wks	wk	NOUN
dpc-2121	56	7	viga	viga	NOUN
dpc-2121	56	8	-	-	PUNCT
dpc-2121	56	9	ad	ad	NOUN
dpc-2121	56	10	0/1	0/1	NUM
dpc-2121	56	11	at	at	ADP
dpc-2121	56	12	week	week	NOUN
dpc-2121	56	13	16	16	NUM
dpc-2121	56	14	baricitinib	baricitinib	NOUN
dpc-2121	56	15	2	2	NUM
dpc-2121	56	16	mg	mg	NUM
dpc-2121	56	17	:	:	PUNCT
dpc-2121	56	18	11.4	11.4	NUM
dpc-2121	56	19	%	%	NOUN
dpc-2121	56	20	baricitinib	baricitinib	NOUN
dpc-2121	56	21	4	4	NUM
dpc-2121	56	22	mg	mg	NUM
dpc-2121	56	23	:	:	PUNCT
dpc-2121	56	24	16.8	16.8	NUM
dpc-2121	56	25	%	%	NOUN
dpc-2121	56	26	placebo	placebo	NOUN
dpc-2121	56	27	:	:	PUNCT
dpc-2121	56	28	4.8	4.8	NUM
dpc-2121	56	29	%	%	NOUN
dpc-2121	56	30	increased	increase	VERB
dpc-2121	56	31	blood	blood	NOUN
dpc-2121	56	32	cpk	cpk	PROPN
dpc-2121	56	33	,	,	PUNCT
dpc-2121	56	34	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	56	35	,	,	PUNCT
dpc-2121	56	36	headache	headache	NOUN
dpc-2121	56	37	,	,	PUNCT
dpc-2121	56	38	herpes	herpe	NOUN
dpc-2121	56	39	simplex	simplex	NOUN
dpc-2121	56	40	breezead2	breezead2	PROPN
dpc-2121	57	1	[	[	X
dpc-2121	57	2	18	18	NUM
dpc-2121	57	3	]	]	SYM
dpc-2121	57	4	615	615	NUM
dpc-2121	57	5	16	16	NUM
dpc-2121	57	6	wks	wks	NOUN
dpc-2121	57	7	viga	viga	NOUN
dpc-2121	57	8	-	-	PUNCT
dpc-2121	57	9	ad	ad	NOUN
dpc-2121	57	10	0/1	0/1	NUM
dpc-2121	57	11	at	at	ADP
dpc-2121	57	12	week	week	NOUN
dpc-2121	57	13	16	16	NUM
dpc-2121	57	14	baricitinib	baricitinib	NOUN
dpc-2121	57	15	2	2	NUM
dpc-2121	57	16	mg	mg	NUM
dpc-2121	57	17	:	:	PUNCT
dpc-2121	57	18	10.6	10.6	NUM
dpc-2121	57	19	%	%	NOUN
dpc-2121	57	20	baricitinib	baricitinib	NOUN
dpc-2121	57	21	4	4	NUM
dpc-2121	57	22	mg	mg	NUM
dpc-2121	57	23	:	:	PUNCT
dpc-2121	57	24	13.8	13.8	NUM
dpc-2121	57	25	%	%	NOUN
dpc-2121	57	26	placebo	placebo	NOUN
dpc-2121	57	27	:	:	PUNCT
dpc-2121	57	28	4.5	4.5	NUM
dpc-2121	57	29	%	%	NOUN
dpc-2121	57	30	increased	increase	VERB
dpc-2121	57	31	blood	blood	NOUN
dpc-2121	57	32	cpk	cpk	PROPN
dpc-2121	57	33	,	,	PUNCT
dpc-2121	57	34	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	57	35	,	,	PUNCT
dpc-2121	57	36	headache	headache	NOUN
dpc-2121	57	37	breezead3	breezead3	NOUN
dpc-2121	58	1	[	[	X
dpc-2121	58	2	19	19	NUM
dpc-2121	58	3	]	]	SYM
dpc-2121	58	4	221	221	NUM
dpc-2121	58	5	total/	total/	NUM
dpc-2121	58	6	partial	partial	ADJ
dpc-2121	58	7	responders	responder	NOUN
dpc-2121	58	8	(	(	PUNCT
dpc-2121	58	9	16	16	NUM
dpc-2121	58	10	wks	wks	NOUN
dpc-2121	58	11	from	from	ADP
dpc-2121	58	12	previous	previous	ADJ
dpc-2121	58	13	enrollment	enrollment	NOUN
dpc-2121	58	14	in	in	ADP
dpc-2121	58	15	breeze	breeze	PROPN
dpc-2121	58	16	-	-	PUNCT
dpc-2121	58	17	ad1	ad1	NOUN
dpc-2121	58	18	or	or	CCONJ
dpc-2121	58	19	breeze	breeze	PROPN
dpc-2121	58	20	-	-	PUNCT
dpc-2121	58	21	ad2	ad2	NOUN
dpc-2121	58	22	)	)	PUNCT
dpc-2121	58	23	plus	plus	CCONJ
dpc-2121	58	24	52	52	NUM
dpc-2121	58	25	wks	wks	NOUN
dpc-2121	58	26	viga	viga	NOUN
dpc-2121	58	27	-	-	PUNCT
dpc-2121	58	28	ad	ad	NOUN
dpc-2121	58	29	0/1	0/1	NUM
dpc-2121	58	30	at	at	ADP
dpc-2121	58	31	week	week	NOUN
dpc-2121	58	32	16	16	NUM
dpc-2121	58	33	,	,	PUNCT
dpc-2121	58	34	36	36	NUM
dpc-2121	58	35	and	and	CCONJ
dpc-2121	58	36	52	52	NUM
dpc-2121	58	37	published	publish	VERB
dpc-2121	58	38	results	result	NOUN
dpc-2121	58	39	at	at	ADP
dpc-2121	58	40	week	week	NOUN
dpc-2121	58	41	52	52	NUM
dpc-2121	58	42	:	:	PUNCT
dpc-2121	58	43	baricitinib	baricitinib	NOUN
dpc-2121	58	44	2	2	NUM
dpc-2121	58	45	mg	mg	NUM
dpc-2121	58	46	:	:	PUNCT
dpc-2121	58	47	59.3	59.3	NUM
dpc-2121	58	48	%	%	NOUN
dpc-2121	58	49	baricitinib	baricitinib	NOUN
dpc-2121	58	50	4	4	NUM
dpc-2121	58	51	mg	mg	NOUN
dpc-2121	58	52	:	:	PUNCT
dpc-2121	58	53	47.1	47.1	NUM
dpc-2121	58	54	%	%	NOUN
dpc-2121	58	55	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	58	56	,	,	PUNCT
dpc-2121	58	57	headache	headache	NOUN
dpc-2121	58	58	,	,	PUNCT
dpc-2121	58	59	increased	increase	VERB
dpc-2121	58	60	blood	blood	NOUN
dpc-2121	58	61	cpk	cpk	NOUN
dpc-2121	58	62	and	and	CCONJ
dpc-2121	58	63	diarrhea	diarrhea	NOUN
dpc-2121	58	64	breezead4	breezead4	NOUN
dpc-2121	59	1	[	[	X
dpc-2121	59	2	20	20	NUM
dpc-2121	59	3	]	]	SYM
dpc-2121	59	4	463	463	NUM
dpc-2121	59	5	16	16	NUM
dpc-2121	59	6	wks	wks	NOUN
dpc-2121	59	7	easi75	easi75	NOUN
dpc-2121	59	8	at	at	ADP
dpc-2121	59	9	week	week	NOUN
dpc-2121	59	10	16	16	NUM
dpc-2121	59	11	baricitinib	baricitinib	NOUN
dpc-2121	59	12	2mg+tcs	2mg+tcs	NUM
dpc-2121	59	13	:	:	PUNCT
dpc-2121	59	14	27.6	27.6	NUM
dpc-2121	59	15	%	%	NOUN
dpc-2121	59	16	baricitinib	baricitinib	NOUN
dpc-2121	59	17	4mg+tcs	4mg+tcs	NOUN
dpc-2121	59	18	:	:	PUNCT
dpc-2121	59	19	31.5	31.5	NUM
dpc-2121	59	20	%	%	NOUN
dpc-2121	59	21	placebo+tcs	placebo+tcs	NOUN
dpc-2121	59	22	:	:	PUNCT
dpc-2121	59	23	17.2	17.2	NUM
dpc-2121	59	24	%	%	NOUN
dpc-2121	59	25	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	59	26	,	,	PUNCT
dpc-2121	59	27	headache	headache	NOUN
dpc-2121	59	28	,	,	PUNCT
dpc-2121	59	29	upper	upper	ADJ
dpc-2121	59	30	tract	tract	NOUN
dpc-2121	59	31	respiratory	respiratory	ADJ
dpc-2121	59	32	infections	infection	NOUN
dpc-2121	59	33	breezead7	breezead7	NOUN
dpc-2121	60	1	[	[	X
dpc-2121	60	2	21	21	NUM
dpc-2121	60	3	]	]	SYM
dpc-2121	60	4	329	329	NUM
dpc-2121	60	5	16	16	NUM
dpc-2121	60	6	wks	wk	NOUN
dpc-2121	60	7	viga	viga	NOUN
dpc-2121	60	8	-	-	PUNCT
dpc-2121	60	9	ad	ad	NOUN
dpc-2121	60	10	0/1	0/1	NUM
dpc-2121	60	11	at	at	ADP
dpc-2121	60	12	week	week	NOUN
dpc-2121	60	13	16	16	NUM
dpc-2121	60	14	baricitinib	baricitinib	NOUN
dpc-2121	60	15	2mg+tcs	2mg+tcs	NUM
dpc-2121	60	16	:	:	PUNCT
dpc-2121	60	17	24.0	24.0	NUM
dpc-2121	60	18	%	%	NOUN
dpc-2121	60	19	baricitinib	baricitinib	NOUN
dpc-2121	60	20	4mg+tcs	4mg+tcs	NOUN
dpc-2121	60	21	:	:	PUNCT
dpc-2121	60	22	31.0	31.0	NUM
dpc-2121	60	23	%	%	NOUN
dpc-2121	60	24	placebo+tcs	placebo+tcs	NOUN
dpc-2121	60	25	:	:	PUNCT
dpc-2121	60	26	15.0	15.0	NUM
dpc-2121	60	27	%	%	NOUN
dpc-2121	60	28	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	60	29	,	,	PUNCT
dpc-2121	60	30	folliculitis	folliculitis	NOUN
dpc-2121	60	31	,	,	PUNCT
dpc-2121	60	32	herpes	herpe	NOUN
dpc-2121	60	33	simplex	simplex	NOUN
dpc-2121	60	34	infection	infection	NOUN
dpc-2121	60	35	,	,	PUNCT
dpc-2121	60	36	upper	upper	ADJ
dpc-2121	60	37	respiratory	respiratory	ADJ
dpc-2121	60	38	tract	tract	NOUN
dpc-2121	60	39	infection	infection	NOUN
dpc-2121	60	40	,	,	PUNCT
dpc-2121	60	41	acne	acne	NOUN
dpc-2121	60	42	,	,	PUNCT
dpc-2121	60	43	diarrhea	diarrhea	NOUN
dpc-2121	60	44	,	,	PUNCT
dpc-2121	60	45	and	and	CCONJ
dpc-2121	60	46	back	back	ADJ
dpc-2121	60	47	pain	pain	NOUN
dpc-2121	60	48	upadacitinib	upadacitinib	NOUN
dpc-2121	60	49	jak1	jak1	PROPN
dpc-2121	60	50	measure	measure	VERB
dpc-2121	60	51	up	up	ADP
dpc-2121	60	52	1	1	NUM
dpc-2121	60	53	[	[	X
dpc-2121	60	54	24	24	NUM
dpc-2121	60	55	]	]	SYM
dpc-2121	60	56	847	847	NUM
dpc-2121	60	57	16	16	NUM
dpc-2121	60	58	wks	wks	NOUN
dpc-2121	60	59	easi75	easi75	NOUN
dpc-2121	60	60	at	at	ADP
dpc-2121	60	61	week	week	NOUN
dpc-2121	60	62	16	16	NUM
dpc-2121	60	63	upadacitinib	upadacitinib	NOUN
dpc-2121	60	64	15	15	NUM
dpc-2121	60	65	mg	mg	NUM
dpc-2121	60	66	:	:	PUNCT
dpc-2121	60	67	69.6	69.6	NUM
dpc-2121	60	68	%	%	NOUN
dpc-2121	60	69	upadacitinib	upadacitinib	NOUN
dpc-2121	60	70	30	30	NUM
dpc-2121	60	71	mg	mg	NUM
dpc-2121	60	72	:	:	PUNCT
dpc-2121	60	73	79.9	79.9	NUM
dpc-2121	60	74	%	%	NOUN
dpc-2121	60	75	placebo	placebo	NOUN
dpc-2121	60	76	:	:	PUNCT
dpc-2121	60	77	16.3	16.3	NUM
dpc-2121	60	78	%	%	NOUN
dpc-2121	60	79	viga	viga	NOUN
dpc-2121	60	80	-	-	PUNCT
dpc-2121	60	81	ad	ad	NOUN
dpc-2121	60	82	0/1	0/1	NUM
dpc-2121	60	83	at	at	ADP
dpc-2121	60	84	week	week	NOUN
dpc-2121	60	85	16	16	NUM
dpc-2121	60	86	upadacitinib	upadacitinib	NOUN
dpc-2121	60	87	15	15	NUM
dpc-2121	60	88	mg	mg	NUM
dpc-2121	60	89	:	:	PUNCT
dpc-2121	60	90	48.1	48.1	NUM
dpc-2121	60	91	%	%	NOUN
dpc-2121	60	92	upadacitinib	upadacitinib	NOUN
dpc-2121	60	93	30	30	NUM
dpc-2121	60	94	mg	mg	NUM
dpc-2121	60	95	:	:	PUNCT
dpc-2121	60	96	62.0	62.0	NUM
dpc-2121	60	97	%	%	NOUN
dpc-2121	60	98	placebo	placebo	NOUN
dpc-2121	60	99	:	:	PUNCT
dpc-2121	60	100	8.4	8.4	NUM
dpc-2121	60	101	%	%	NOUN
dpc-2121	60	102	acne	acne	NOUN
dpc-2121	60	103	,	,	PUNCT
dpc-2121	60	104	upper	upper	ADJ
dpc-2121	60	105	respiratory	respiratory	ADJ
dpc-2121	60	106	tract	tract	NOUN
dpc-2121	60	107	infections	infection	NOUN
dpc-2121	60	108	,	,	PUNCT
dpc-2121	60	109	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	60	110	,	,	PUNCT
dpc-2121	60	111	headache	headache	NOUN
dpc-2121	60	112	and	and	CCONJ
dpc-2121	60	113	increased	increase	VERB
dpc-2121	60	114	blood	blood	NOUN
dpc-2121	60	115	cpk	cpk	PROPN
dpc-2121	60	116	measure	measure	VERB
dpc-2121	60	117	up	up	ADP
dpc-2121	60	118	2	2	NUM
dpc-2121	60	119	[	[	X
dpc-2121	60	120	24	24	NUM
dpc-2121	60	121	]	]	SYM
dpc-2121	60	122	836	836	NUM
dpc-2121	60	123	16	16	NUM
dpc-2121	60	124	wks	wks	NOUN
dpc-2121	60	125	easi75	easi75	NOUN
dpc-2121	60	126	at	at	ADP
dpc-2121	60	127	week	week	NOUN
dpc-2121	60	128	16	16	NUM
dpc-2121	60	129	upadacitinib	upadacitinib	NOUN
dpc-2121	60	130	15	15	NUM
dpc-2121	60	131	mg	mg	NUM
dpc-2121	60	132	:	:	PUNCT
dpc-2121	60	133	60.1	60.1	NUM
dpc-2121	60	134	%	%	NOUN
dpc-2121	60	135	upadacitinib	upadacitinib	NOUN
dpc-2121	60	136	30	30	NUM
dpc-2121	60	137	mg	mg	NUM
dpc-2121	60	138	:	:	PUNCT
dpc-2121	60	139	72.9	72.9	NUM
dpc-2121	60	140	%	%	NOUN
dpc-2121	60	141	placebo	placebo	NOUN
dpc-2121	60	142	:	:	PUNCT
dpc-2121	60	143	13.3	13.3	NUM
dpc-2121	60	144	%	%	NOUN
dpc-2121	60	145	viga	viga	NOUN
dpc-2121	60	146	-	-	PUNCT
dpc-2121	60	147	ad	ad	NOUN
dpc-2121	60	148	0/1	0/1	NUM
dpc-2121	60	149	at	at	ADP
dpc-2121	60	150	week	week	NOUN
dpc-2121	60	151	16	16	NUM
dpc-2121	60	152	upadacitinib	upadacitinib	NOUN
dpc-2121	60	153	15	15	NUM
dpc-2121	60	154	mg	mg	NUM
dpc-2121	60	155	:	:	PUNCT
dpc-2121	60	156	38.8	38.8	NUM
dpc-2121	60	157	%	%	NOUN
dpc-2121	60	158	upadacitinib	upadacitinib	NOUN
dpc-2121	60	159	30	30	NUM
dpc-2121	60	160	mg	mg	NUM
dpc-2121	60	161	:	:	PUNCT
dpc-2121	60	162	52.0	52.0	NUM
dpc-2121	60	163	%	%	NOUN
dpc-2121	60	164	placebo	placebo	NOUN
dpc-2121	60	165	:	:	PUNCT
dpc-2121	60	166	4.7	4.7	NUM
dpc-2121	60	167	%	%	NOUN
dpc-2121	60	168	acne	acne	NOUN
dpc-2121	60	169	,	,	PUNCT
dpc-2121	60	170	upper	upper	ADJ
dpc-2121	60	171	respiratory	respiratory	ADJ
dpc-2121	60	172	tract	tract	NOUN
dpc-2121	60	173	infections	infection	NOUN
dpc-2121	60	174	,	,	PUNCT
dpc-2121	60	175	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	60	176	,	,	PUNCT
dpc-2121	60	177	headache	headache	NOUN
dpc-2121	60	178	and	and	CCONJ
dpc-2121	60	179	increased	increase	VERB
dpc-2121	60	180	blood	blood	NOUN
dpc-2121	60	181	cpk	cpk	PROPN
dpc-2121	60	182	ad	ad	NOUN
dpc-2121	60	183	up	up	ADP
dpc-2121	61	1	[	[	X
dpc-2121	61	2	25,26	25,26	X
dpc-2121	61	3	]	]	SYM
dpc-2121	61	4	901	901	NUM
dpc-2121	61	5	52	52	NUM
dpc-2121	61	6	wks	wks	NOUN
dpc-2121	61	7	easi75	easi75	NOUN
dpc-2121	61	8	at	at	ADP
dpc-2121	61	9	week	week	NOUN
dpc-2121	61	10	16	16	NUM
dpc-2121	61	11	upadacitinib	upadacitinib	NOUN
dpc-2121	61	12	15mg+tcs	15mg+tcs	NUM
dpc-2121	61	13	:	:	PUNCT
dpc-2121	61	14	64.6	64.6	NUM
dpc-2121	61	15	%	%	NOUN
dpc-2121	61	16	upadacitinib	upadacitinib	NOUN
dpc-2121	61	17	30mg+tcs	30mg+tcs	NUM
dpc-2121	61	18	:	:	PUNCT
dpc-2121	61	19	77.1	77.1	NUM
dpc-2121	61	20	%	%	NOUN
dpc-2121	61	21	placebo+tcs	placebo+tcs	NOUN
dpc-2121	61	22	:	:	PUNCT
dpc-2121	61	23	26.4	26.4	NUM
dpc-2121	61	24	%	%	NOUN
dpc-2121	61	25	viga	viga	NOUN
dpc-2121	61	26	-	-	PUNCT
dpc-2121	61	27	ad	ad	NOUN
dpc-2121	61	28	0/1	0/1	NUM
dpc-2121	61	29	at	at	ADP
dpc-2121	61	30	week	week	NOUN
dpc-2121	61	31	16	16	NUM
dpc-2121	61	32	upadacitinib	upadacitinib	NOUN
dpc-2121	61	33	15mg+tcs	15mg+tcs	NUM
dpc-2121	61	34	:	:	PUNCT
dpc-2121	61	35	39.6	39.6	NUM
dpc-2121	61	36	%	%	NOUN
dpc-2121	61	37	upadacitinib	upadacitinib	NOUN
dpc-2121	61	38	30mg+tcs	30mg+tcs	NUM
dpc-2121	61	39	:	:	PUNCT
dpc-2121	61	40	58.6	58.6	NUM
dpc-2121	61	41	%	%	NOUN
dpc-2121	61	42	placebo+tcs	placebo+tcs	NOUN
dpc-2121	61	43	:	:	PUNCT
dpc-2121	61	44	10.9	10.9	NUM
dpc-2121	61	45	%	%	NOUN
dpc-2121	61	46	acne	acne	NOUN
dpc-2121	61	47	,	,	PUNCT
dpc-2121	61	48	nasopharyngitis	nasopharyngitis	PROPN
dpc-2121	61	49	,	,	PUNCT
dpc-2121	61	50	increased	increase	VERB
dpc-2121	61	51	blood	blood	NOUN
dpc-2121	61	52	cpk	cpk	PROPN
dpc-2121	61	53	,	,	PUNCT
dpc-2121	61	54	upper	upper	ADJ
dpc-2121	61	55	respiratory	respiratory	ADJ
dpc-2121	61	56	tract	tract	NOUN
dpc-2121	61	57	infection	infection	NOUN
dpc-2121	61	58	,	,	PUNCT
dpc-2121	61	59	herpes	herpe	NOUN
dpc-2121	61	60	simplex	simplex	NOUN
dpc-2121	61	61	infection	infection	NOUN
dpc-2121	61	62	heads	head	VERB
dpc-2121	61	63	up	up	ADP
dpc-2121	61	64	[	[	X
dpc-2121	61	65	27	27	NUM
dpc-2121	61	66	]	]	SYM
dpc-2121	61	67	692	692	NUM
dpc-2121	61	68	24	24	NUM
dpc-2121	61	69	wks	wks	NOUN
dpc-2121	61	70	easi75	easi75	NOUN
dpc-2121	61	71	at	at	ADP
dpc-2121	61	72	week	week	NOUN
dpc-2121	61	73	16	16	NUM
dpc-2121	61	74	upadacitinib	upadacitinib	NOUN
dpc-2121	61	75	30	30	NUM
dpc-2121	61	76	mg	mg	NUM
dpc-2121	61	77	:	:	PUNCT
dpc-2121	61	78	71.0	71.0	NUM
dpc-2121	61	79	%	%	NOUN
dpc-2121	61	80	dupilumab	dupilumab	NOUN
dpc-2121	61	81	:	:	PUNCT
dpc-2121	61	82	61.1	61.1	NUM
dpc-2121	61	83	%	%	NOUN
dpc-2121	61	84	acne	acne	NOUN
dpc-2121	61	85	,	,	PUNCT
dpc-2121	61	86	upper	upper	ADJ
dpc-2121	61	87	respiratory	respiratory	ADJ
dpc-2121	61	88	tract	tract	NOUN
dpc-2121	61	89	infections	infection	NOUN
dpc-2121	61	90	,	,	PUNCT
dpc-2121	61	91	nasopharyngitis	nasopharyngitis	PROPN
dpc-2121	61	92	,	,	PUNCT
dpc-2121	61	93	increased	increase	VERB
dpc-2121	61	94	blood	blood	NOUN
dpc-2121	61	95	cpk	cpk	PROPN
dpc-2121	61	96	table1	table1	PROPN
dpc-2121	61	97	continues	continue	VERB
dpc-2121	61	98	4	4	NUM
dpc-2121	61	99	review	review	NOUN
dpc-2121	61	100	|	|	ADV
dpc-2121	61	101	dermatol	dermatol	ADJ
dpc-2121	61	102	pract	pract	NOUN
dpc-2121	61	103	concept	concept	NOUN
dpc-2121	61	104	.	.	PUNCT
dpc-2121	62	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	62	2	drug	drug	NOUN
dpc-2121	62	3	name	name	NOUN
dpc-2121	62	4	main	main	PROPN
dpc-2121	62	5	jak	jak	PROPN
dpc-2121	62	6	inhibition	inhibition	NOUN
dpc-2121	62	7	trial	trial	NOUN
dpc-2121	62	8	name	name	NOUN
dpc-2121	62	9	patients	patient	NOUN
dpc-2121	62	10	,	,	PUNCT
dpc-2121	62	11	n.	n.	NOUN
dpc-2121	62	12	study	study	NOUN
dpc-2121	62	13	duration	duration	NOUN
dpc-2121	62	14	(	(	PUNCT
dpc-2121	62	15	co)primary	co)primary	NOUN
dpc-2121	62	16	endpoint(s	endpoint(s	PROPN
dpc-2121	62	17	)	)	PUNCT
dpc-2121	62	18	most	most	ADV
dpc-2121	62	19	important	important	ADJ
dpc-2121	62	20	side	side	NOUN
dpc-2121	62	21	effects	effect	NOUN
dpc-2121	62	22	associated	associate	VERB
dpc-2121	62	23	to	to	ADP
dpc-2121	62	24	jak	jak	PROPN
dpc-2121	62	25	inhibitors	inhibitor	NOUN
dpc-2121	62	26	abrocitinib	abrocitinib	NOUN
dpc-2121	62	27	jak1	jak1	PROPN
dpc-2121	62	28	jade	jade	PROPN
dpc-2121	62	29	mono-1	mono-1	PROPN
dpc-2121	63	1	[	[	X
dpc-2121	63	2	28	28	NUM
dpc-2121	63	3	]	]	SYM
dpc-2121	63	4	387	387	NUM
dpc-2121	63	5	12	12	NUM
dpc-2121	63	6	wks	wks	NOUN
dpc-2121	63	7	easi75	easi75	NOUN
dpc-2121	63	8	at	at	ADP
dpc-2121	63	9	week	week	NOUN
dpc-2121	63	10	12	12	NUM
dpc-2121	63	11	abrocitinib	abrocitinib	NOUN
dpc-2121	63	12	100	100	NUM
dpc-2121	63	13	mg	mg	NUM
dpc-2121	63	14	:	:	PUNCT
dpc-2121	63	15	40.0	40.0	NUM
dpc-2121	63	16	%	%	NOUN
dpc-2121	63	17	abrocitinib	abrocitinib	NOUN
dpc-2121	63	18	200	200	NUM
dpc-2121	63	19	mg	mg	NOUN
dpc-2121	63	20	:	:	PUNCT
dpc-2121	63	21	63.0	63.0	NUM
dpc-2121	63	22	%	%	NOUN
dpc-2121	63	23	placebo	placebo	NOUN
dpc-2121	63	24	:	:	PUNCT
dpc-2121	63	25	12.0	12.0	NUM
dpc-2121	63	26	%	%	NOUN
dpc-2121	63	27	iga	iga	PROPN
dpc-2121	63	28	0/1	0/1	PROPN
dpc-2121	63	29	at	at	ADP
dpc-2121	63	30	week	week	NOUN
dpc-2121	63	31	12	12	NUM
dpc-2121	63	32	abrocitinib	abrocitinib	NOUN
dpc-2121	63	33	100	100	NUM
dpc-2121	63	34	mg	mg	NUM
dpc-2121	63	35	:	:	PUNCT
dpc-2121	63	36	24.0	24.0	NUM
dpc-2121	63	37	%	%	NOUN
dpc-2121	63	38	abrocitinib	abrocitinib	NOUN
dpc-2121	63	39	200	200	NUM
dpc-2121	63	40	mg	mg	NOUN
dpc-2121	63	41	:	:	PUNCT
dpc-2121	63	42	44.0	44.0	NUM
dpc-2121	63	43	%	%	NOUN
dpc-2121	63	44	placebo	placebo	NOUN
dpc-2121	63	45	:	:	PUNCT
dpc-2121	63	46	8.0	8.0	NUM
dpc-2121	63	47	%	%	NOUN
dpc-2121	63	48	nausea	nausea	NOUN
dpc-2121	63	49	,	,	PUNCT
dpc-2121	63	50	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	63	51	,	,	PUNCT
dpc-2121	63	52	headache	headache	NOUN
dpc-2121	63	53	,	,	PUNCT
dpc-2121	63	54	upper	upper	ADJ
dpc-2121	63	55	respiratory	respiratory	ADJ
dpc-2121	63	56	tract	tract	NOUN
dpc-2121	63	57	infection	infection	NOUN
dpc-2121	63	58	jade	jade	NOUN
dpc-2121	63	59	mono-2	mono-2	NUM
dpc-2121	63	60	[	[	X
dpc-2121	63	61	29	29	NUM
dpc-2121	63	62	]	]	SYM
dpc-2121	63	63	391	391	NUM
dpc-2121	63	64	12	12	NUM
dpc-2121	63	65	wks	wks	NOUN
dpc-2121	63	66	easi75	easi75	NOUN
dpc-2121	63	67	at	at	ADP
dpc-2121	63	68	week	week	NOUN
dpc-2121	63	69	12	12	NUM
dpc-2121	63	70	abrocitinib	abrocitinib	NOUN
dpc-2121	63	71	100	100	NUM
dpc-2121	63	72	mg	mg	NUM
dpc-2121	63	73	:	:	PUNCT
dpc-2121	63	74	45.0	45.0	NUM
dpc-2121	63	75	%	%	NOUN
dpc-2121	63	76	abrocitinib	abrocitinib	NOUN
dpc-2121	63	77	200	200	NUM
dpc-2121	63	78	mg	mg	NOUN
dpc-2121	63	79	:	:	PUNCT
dpc-2121	63	80	61.0	61.0	NUM
dpc-2121	63	81	%	%	NOUN
dpc-2121	63	82	placebo	placebo	NOUN
dpc-2121	63	83	:	:	PUNCT
dpc-2121	63	84	10.0	10.0	NUM
dpc-2121	63	85	%	%	NOUN
dpc-2121	63	86	iga	iga	PROPN
dpc-2121	63	87	0/1	0/1	PROPN
dpc-2121	63	88	at	at	ADP
dpc-2121	63	89	week	week	NOUN
dpc-2121	63	90	12	12	NUM
dpc-2121	63	91	abrocitinib	abrocitinib	NOUN
dpc-2121	63	92	100	100	NUM
dpc-2121	63	93	mg	mg	NUM
dpc-2121	63	94	:	:	PUNCT
dpc-2121	63	95	28.0	28.0	NUM
dpc-2121	63	96	%	%	NOUN
dpc-2121	63	97	abrocitinib	abrocitinib	NOUN
dpc-2121	63	98	200	200	NUM
dpc-2121	63	99	mg	mg	NOUN
dpc-2121	63	100	:	:	PUNCT
dpc-2121	63	101	38.0	38.0	NUM
dpc-2121	63	102	%	%	NOUN
dpc-2121	63	103	placebo	placebo	NOUN
dpc-2121	63	104	:	:	PUNCT
dpc-2121	63	105	9.0	9.0	NUM
dpc-2121	63	106	%	%	NOUN
dpc-2121	63	107	nausea	nausea	NOUN
dpc-2121	63	108	,	,	PUNCT
dpc-2121	63	109	nasopharyngitis	nasopharyngitis	PROPN
dpc-2121	63	110	jade	jade	PROPN
dpc-2121	63	111	compare	compare	VERB
dpc-2121	63	112	[	[	X
dpc-2121	63	113	30	30	NUM
dpc-2121	63	114	]	]	SYM
dpc-2121	63	115	838	838	NUM
dpc-2121	63	116	16	16	NUM
dpc-2121	63	117	wks	wks	ADJ
dpc-2121	63	118	easi75	easi75	NOUN
dpc-2121	63	119	at	at	ADP
dpc-2121	63	120	week	week	NOUN
dpc-2121	63	121	12	12	NUM
dpc-2121	63	122	(	(	PUNCT
dpc-2121	63	123	vs.	vs.	X
dpc-2121	63	124	placebo	placebo	NOUN
dpc-2121	63	125	)	)	PUNCT
dpc-2121	63	126	abrocitinib	abrocitinib	NOUN
dpc-2121	64	1	100mg+tcs	100mg+tcs	NUM
dpc-2121	64	2	:	:	PUNCT
dpc-2121	64	3	58.7	58.7	NUM
dpc-2121	64	4	%	%	NOUN
dpc-2121	64	5	abrocitinib	abrocitinib	NOUN
dpc-2121	64	6	200mg+tcs	200mg+tcs	NUM
dpc-2121	64	7	:	:	PUNCT
dpc-2121	64	8	70.3	70.3	NUM
dpc-2121	64	9	%	%	NOUN
dpc-2121	64	10	dupilumab	dupilumab	NOUN
dpc-2121	64	11	:	:	PUNCT
dpc-2121	64	12	58.1	58.1	NUM
dpc-2121	64	13	%	%	NOUN
dpc-2121	64	14	placebo+tcs	placebo+tcs	NOUN
dpc-2121	64	15	:	:	PUNCT
dpc-2121	64	16	27.1	27.1	NUM
dpc-2121	64	17	%	%	NOUN
dpc-2121	64	18	iga	iga	PROPN
dpc-2121	64	19	0/1	0/1	PROPN
dpc-2121	64	20	at	at	ADP
dpc-2121	64	21	week	week	NOUN
dpc-2121	64	22	12	12	NUM
dpc-2121	64	23	(	(	PUNCT
dpc-2121	64	24	vs.	vs.	X
dpc-2121	64	25	placebo	placebo	NOUN
dpc-2121	64	26	)	)	PUNCT
dpc-2121	64	27	abrocitinib	abrocitinib	NOUN
dpc-2121	64	28	100mg+tcs	100mg+tcs	NUM
dpc-2121	64	29	:	:	PUNCT
dpc-2121	64	30	36.6	36.6	NUM
dpc-2121	64	31	%	%	NOUN
dpc-2121	64	32	abrocitinib	abrocitinib	NOUN
dpc-2121	64	33	200mg+tcs	200mg+tcs	NUM
dpc-2121	64	34	:	:	PUNCT
dpc-2121	64	35	48.4	48.4	NUM
dpc-2121	64	36	%	%	NOUN
dpc-2121	64	37	dupilumab	dupilumab	NOUN
dpc-2121	64	38	:	:	PUNCT
dpc-2121	64	39	36.5	36.5	NUM
dpc-2121	64	40	%	%	NOUN
dpc-2121	64	41	placebo+tcs	placebo+tcs	NOUN
dpc-2121	64	42	:	:	PUNCT
dpc-2121	64	43	14.0	14.0	NUM
dpc-2121	64	44	%	%	NOUN
dpc-2121	64	45	nausea	nausea	NOUN
dpc-2121	64	46	,	,	PUNCT
dpc-2121	64	47	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	64	48	,	,	PUNCT
dpc-2121	64	49	upper	upper	ADJ
dpc-2121	64	50	respiratory	respiratory	ADJ
dpc-2121	64	51	tract	tract	NOUN
dpc-2121	64	52	infection	infection	NOUN
dpc-2121	64	53	,	,	PUNCT
dpc-2121	64	54	headache	headache	NOUN
dpc-2121	64	55	,	,	PUNCT
dpc-2121	64	56	acne	acne	NOUN
dpc-2121	64	57	,	,	PUNCT
dpc-2121	64	58	herpes	herpe	NOUN
dpc-2121	64	59	zoster	zoster	NOUN
dpc-2121	64	60	,	,	PUNCT
dpc-2121	64	61	thrombocytopenia	thrombocytopenia	PROPN
dpc-2121	64	62	jade	jade	NOUN
dpc-2121	64	63	regimen	regimen	PROPN
dpc-2121	65	1	[	[	X
dpc-2121	65	2	31	31	NUM
dpc-2121	65	3	]	]	SYM
dpc-2121	65	4	1233	1233	NUM
dpc-2121	65	5	(	(	PUNCT
dpc-2121	65	6	798	798	NUM
dpc-2121	65	7	after	after	ADP
dpc-2121	65	8	a	a	DET
dpc-2121	65	9	12	12	NUM
dpc-2121	65	10	-	-	PUNCT
dpc-2121	65	11	week	week	NOUN
dpc-2121	65	12	induction	induction	NOUN
dpc-2121	65	13	period	period	NOUN
dpc-2121	65	14	with	with	ADP
dpc-2121	65	15	abrocitinib	abrocitinib	NOUN
dpc-2121	65	16	200	200	NUM
dpc-2121	65	17	mg	mg	NOUN
dpc-2121	65	18	)	)	PUNCT
dpc-2121	65	19	52	52	NUM
dpc-2121	65	20	wks	wks	NOUN
dpc-2121	65	21	proportion	proportion	NOUN
dpc-2121	65	22	of	of	ADP
dpc-2121	65	23	patients	patient	NOUN
dpc-2121	65	24	that	that	PRON
dpc-2121	65	25	did	do	AUX
dpc-2121	65	26	not	not	PART
dpc-2121	65	27	loss	loss	VERB
dpc-2121	65	28	easi50	easi50	NOUN
dpc-2121	65	29	and	and	CCONJ
dpc-2121	65	30	had	have	VERB
dpc-2121	65	31	iga	iga	PROPN
dpc-2121	65	32	score	score	VERB
dpc-2121	65	33	<3	<3	X
dpc-2121	65	34	at	at	ADP
dpc-2121	65	35	week	week	NOUN
dpc-2121	65	36	52	52	NUM
dpc-2121	65	37	abrocitinib	abrocitinib	NOUN
dpc-2121	65	38	100	100	NUM
dpc-2121	65	39	mg	mg	NUM
dpc-2121	65	40	:	:	PUNCT
dpc-2121	65	41	57.4	57.4	NUM
dpc-2121	65	42	%	%	NOUN
dpc-2121	65	43	abrocitinib	abrocitinib	NOUN
dpc-2121	65	44	200	200	NUM
dpc-2121	65	45	mg	mg	NOUN
dpc-2121	65	46	:	:	PUNCT
dpc-2121	65	47	81.1	81.1	NUM
dpc-2121	65	48	%	%	NOUN
dpc-2121	65	49	placebo	placebo	NOUN
dpc-2121	65	50	:	:	PUNCT
dpc-2121	65	51	19.1	19.1	NUM
dpc-2121	65	52	%	%	NOUN
dpc-2121	65	53	nausea	nausea	NOUN
dpc-2121	65	54	,	,	PUNCT
dpc-2121	65	55	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	65	56	,	,	PUNCT
dpc-2121	65	57	acne	acne	NOUN
dpc-2121	65	58	,	,	PUNCT
dpc-2121	65	59	upper	upper	ADJ
dpc-2121	65	60	respiratory	respiratory	ADJ
dpc-2121	65	61	tract	tract	NOUN
dpc-2121	65	62	infections	infection	NOUN
dpc-2121	65	63	,	,	PUNCT
dpc-2121	65	64	increased	increase	VERB
dpc-2121	65	65	blood	blood	NOUN
dpc-2121	65	66	cpk	cpk	PROPN
dpc-2121	65	67	jade	jade	PROPN
dpc-2121	65	68	teen	teen	PROPN
dpc-2121	66	1	[	[	X
dpc-2121	66	2	32	32	NUM
dpc-2121	66	3	]	]	SYM
dpc-2121	66	4	285	285	NUM
dpc-2121	66	5	12	12	NUM
dpc-2121	66	6	wks	wks	NOUN
dpc-2121	66	7	easi75	easi75	NOUN
dpc-2121	66	8	at	at	ADP
dpc-2121	66	9	week	week	NOUN
dpc-2121	66	10	12	12	NUM
dpc-2121	66	11	abrocitinib	abrocitinib	NOUN
dpc-2121	66	12	100mg+tcs	100mg+tcs	NUM
dpc-2121	66	13	:	:	PUNCT
dpc-2121	66	14	68.5	68.5	NUM
dpc-2121	66	15	%	%	NOUN
dpc-2121	66	16	abrocitinib	abrocitinib	NOUN
dpc-2121	66	17	200mg+tcs	200mg+tcs	NUM
dpc-2121	66	18	:	:	PUNCT
dpc-2121	66	19	72.0	72.0	NUM
dpc-2121	66	20	%	%	NOUN
dpc-2121	66	21	placebo+tcs	placebo+tcs	NOUN
dpc-2121	66	22	:	:	PUNCT
dpc-2121	66	23	41.5	41.5	NUM
dpc-2121	66	24	%	%	NOUN
dpc-2121	66	25	iga	iga	PROPN
dpc-2121	66	26	0/1	0/1	PROPN
dpc-2121	66	27	at	at	ADP
dpc-2121	66	28	week	week	NOUN
dpc-2121	66	29	12	12	NUM
dpc-2121	66	30	abrocitinib	abrocitinib	NOUN
dpc-2121	66	31	100mg+tcs	100mg+tcs	NUM
dpc-2121	66	32	:	:	PUNCT
dpc-2121	66	33	41.6	41.6	NUM
dpc-2121	66	34	%	%	NOUN
dpc-2121	66	35	abrocitinib	abrocitinib	NOUN
dpc-2121	66	36	200mg+tcs	200mg+tcs	NUM
dpc-2121	66	37	:	:	PUNCT
dpc-2121	66	38	46.2	46.2	NUM
dpc-2121	66	39	%	%	NOUN
dpc-2121	66	40	placebo+tcs	placebo+tcs	NOUN
dpc-2121	66	41	:	:	PUNCT
dpc-2121	66	42	24.5	24.5	NUM
dpc-2121	66	43	%	%	NOUN
dpc-2121	66	44	nausea	nausea	NOUN
dpc-2121	66	45	,	,	PUNCT
dpc-2121	66	46	upper	upper	ADJ
dpc-2121	66	47	respiratory	respiratory	ADJ
dpc-2121	66	48	tract	tract	NOUN
dpc-2121	66	49	infections	infection	NOUN
dpc-2121	66	50	,	,	PUNCT
dpc-2121	66	51	headache	headache	NOUN
dpc-2121	66	52	,	,	PUNCT
dpc-2121	66	53	and	and	CCONJ
dpc-2121	66	54	nasopharyngitis	nasopharyngitis	PROPN
dpc-2121	66	55	cpk	cpk	PROPN
dpc-2121	66	56	=	=	SYM
dpc-2121	66	57	creatine	creatine	PROPN
dpc-2121	66	58	phosphokinase	phosphokinase	NOUN
dpc-2121	66	59	;	;	PUNCT
dpc-2121	66	60	easi	easi	NOUN
dpc-2121	66	61	=	=	SYM
dpc-2121	66	62	eczema	eczema	NOUN
dpc-2121	66	63	area	area	NOUN
dpc-2121	66	64	and	and	CCONJ
dpc-2121	66	65	severity	severity	NOUN
dpc-2121	66	66	index	index	NOUN
dpc-2121	66	67	;	;	PUNCT
dpc-2121	66	68	easi-50	easi-50	ADJ
dpc-2121	66	69	=	=	SYM
dpc-2121	66	70	improvement	improvement	NOUN
dpc-2121	66	71	of	of	ADP
dpc-2121	66	72	50	50	NUM
dpc-2121	66	73	%	%	NOUN
dpc-2121	66	74	in	in	ADP
dpc-2121	66	75	easi	easi	NOUN
dpc-2121	66	76	compared	compare	VERB
dpc-2121	66	77	to	to	AUX
dpc-2121	66	78	baseline	baseline	VERB
dpc-2121	66	79	;	;	PUNCT
dpc-2121	66	80	easi-75	easi-75	PROPN
dpc-2121	66	81	=	=	PUNCT
dpc-2121	66	82	improvement	improvement	NOUN
dpc-2121	66	83	of	of	ADP
dpc-2121	66	84	75	75	NUM
dpc-2121	66	85	%	%	NOUN
dpc-2121	66	86	in	in	ADP
dpc-2121	66	87	easi	easi	NOUN
dpc-2121	66	88	compared	compare	VERB
dpc-2121	66	89	to	to	ADP
dpc-2121	66	90	baseline	baseline	VERB
dpc-2121	66	91	;	;	PUNCT
dpc-2121	66	92	iga	iga	PROPN
dpc-2121	66	93	0/1	0/1	NUM
dpc-2121	66	94	=	=	SYM
dpc-2121	66	95	investigator	investigator	NOUN
dpc-2121	66	96	global	global	ADJ
dpc-2121	66	97	assessment	assessment	NOUN
dpc-2121	66	98	score	score	NOUN
dpc-2121	66	99	of	of	ADP
dpc-2121	66	100	0	0	NUM
dpc-2121	66	101	or	or	CCONJ
dpc-2121	66	102	1	1	NUM
dpc-2121	66	103	;	;	PUNCT
dpc-2121	66	104	jak	jak	PROPN
dpc-2121	66	105	=	=	PROPN
dpc-2121	66	106	janus	janus	PROPN
dpc-2121	66	107	kinase	kinase	PROPN
dpc-2121	66	108	;	;	PUNCT
dpc-2121	66	109	tcs	tcs	NOUN
dpc-2121	66	110	=	=	SYM
dpc-2121	66	111	topical	topical	ADJ
dpc-2121	66	112	corticosteroids	corticosteroid	NOUN
dpc-2121	66	113	;	;	PUNCT
dpc-2121	66	114	viga	viga	NOUN
dpc-2121	66	115	-	-	PUNCT
dpc-2121	66	116	ad	ad	NOUN
dpc-2121	66	117	0/1	0/1	NUM
dpc-2121	66	118	=	=	NUM
dpc-2121	66	119	validated	validate	VERB
dpc-2121	66	120	investigator	investigator	NOUN
dpc-2121	66	121	’s	’s	PART
dpc-2121	66	122	global	global	ADJ
dpc-2121	66	123	assessment	assessment	NOUN
dpc-2121	66	124	for	for	ADP
dpc-2121	66	125	atopic	atopic	NOUN
dpc-2121	66	126	dermatitis	dermatitis	NOUN
dpc-2121	66	127	score	score	NOUN
dpc-2121	66	128	of	of	ADP
dpc-2121	66	129	0	0	NUM
dpc-2121	66	130	or	or	CCONJ
dpc-2121	66	131	1	1	NUM
dpc-2121	66	132	;	;	PUNCT
dpc-2121	66	133	wks	wk	NOUN
dpc-2121	66	134	=	=	SYM
dpc-2121	66	135	weeks	week	NOUN
dpc-2121	66	136	table1	table1	PROPN
dpc-2121	66	137	.	.	PUNCT
dpc-2121	67	1	results	result	NOUN
dpc-2121	67	2	from	from	ADP
dpc-2121	67	3	phase	phase	NOUN
dpc-2121	67	4	iii	iii	NUM
dpc-2121	67	5	clinical	clinical	ADJ
dpc-2121	67	6	trials	trial	NOUN
dpc-2121	67	7	of	of	ADP
dpc-2121	67	8	oral	oral	ADJ
dpc-2121	67	9	jak	jak	PROPN
dpc-2121	67	10	inhibitors	inhibitor	NOUN
dpc-2121	67	11	used	use	VERB
dpc-2121	67	12	for	for	ADP
dpc-2121	67	13	ad	ad	NOUN
dpc-2121	67	14	patients	patient	NOUN
dpc-2121	67	15	:	:	PUNCT
dpc-2121	67	16	baricitinib	baricitinib	NOUN
dpc-2121	67	17	,	,	PUNCT
dpc-2121	67	18	upadacitinib	upadacitinib	NOUN
dpc-2121	67	19	and	and	CCONJ
dpc-2121	67	20	abrocitinib	abrocitinib	NOUN
dpc-2121	67	21	.	.	PUNCT
dpc-2121	68	1	(	(	PUNCT
dpc-2121	68	2	continued	continue	VERB
dpc-2121	68	3	)	)	PUNCT
dpc-2121	68	4	is	be	AUX
dpc-2121	68	5	currently	currently	ADV
dpc-2121	68	6	waiting	wait	VERB
dpc-2121	68	7	for	for	ADP
dpc-2121	68	8	the	the	DET
dpc-2121	68	9	approval	approval	NOUN
dpc-2121	68	10	of	of	ADP
dpc-2121	68	11	food	food	NOUN
dpc-2121	68	12	and	and	CCONJ
dpc-2121	68	13	drugs	drug	NOUN
dpc-2121	68	14	administration	administration	NOUN
dpc-2121	68	15	(	(	PUNCT
dpc-2121	68	16	fda	fda	PROPN
dpc-2121	68	17	)	)	PUNCT
dpc-2121	69	1	[	[	X
dpc-2121	69	2	17	17	NUM
dpc-2121	69	3	]	]	PUNCT
dpc-2121	69	4	.	.	PUNCT
dpc-2121	70	1	the	the	DET
dpc-2121	70	2	recommended	recommend	VERB
dpc-2121	70	3	dosage	dosage	NOUN
dpc-2121	70	4	is	be	AUX
dpc-2121	70	5	4	4	NUM
dpc-2121	70	6	mg	mg	ADV
dpc-2121	70	7	once	once	ADV
dpc-2121	70	8	daily	daily	ADV
dpc-2121	70	9	.	.	PUNCT
dpc-2121	71	1	half	half	ADJ
dpc-2121	71	2	dosage	dosage	NOUN
dpc-2121	71	3	schemes	scheme	NOUN
dpc-2121	71	4	(	(	PUNCT
dpc-2121	71	5	2	2	NUM
dpc-2121	71	6	mg	mg	NOUN
dpc-2121	71	7	)	)	PUNCT
dpc-2121	71	8	may	may	AUX
dpc-2121	71	9	be	be	AUX
dpc-2121	71	10	considered	consider	VERB
dpc-2121	71	11	in	in	ADP
dpc-2121	71	12	patients	patient	NOUN
dpc-2121	71	13	aged	age	VERB
dpc-2121	71	14	75	75	NUM
dpc-2121	71	15	years	year	NOUN
dpc-2121	71	16	or	or	CCONJ
dpc-2121	71	17	older	old	ADJ
dpc-2121	71	18	,	,	PUNCT
dpc-2121	71	19	in	in	ADP
dpc-2121	71	20	those	those	PRON
dpc-2121	71	21	with	with	ADP
dpc-2121	71	22	a	a	DET
dpc-2121	71	23	history	history	NOUN
dpc-2121	71	24	of	of	ADP
dpc-2121	71	25	chronic	chronic	ADJ
dpc-2121	71	26	or	or	CCONJ
dpc-2121	71	27	recurrent	recurrent	ADJ
dpc-2121	71	28	infections	infection	NOUN
dpc-2121	71	29	,	,	PUNCT
dpc-2121	71	30	or	or	CCONJ
dpc-2121	71	31	in	in	ADP
dpc-2121	71	32	those	those	PRON
dpc-2121	71	33	who	who	PRON
dpc-2121	71	34	have	have	AUX
dpc-2121	71	35	achieved	achieve	VERB
dpc-2121	71	36	a	a	DET
dpc-2121	71	37	sustained	sustained	ADJ
dpc-2121	71	38	control	control	NOUN
dpc-2121	71	39	of	of	ADP
dpc-2121	71	40	disease	disease	NOUN
dpc-2121	71	41	as	as	ADP
dpc-2121	71	42	a	a	DET
dpc-2121	71	43	dose	dose	NOUN
dpc-2121	71	44	tapering	tapering	NOUN
dpc-2121	71	45	strategy	strategy	NOUN
dpc-2121	71	46	[	[	X
dpc-2121	71	47	17	17	NUM
dpc-2121	71	48	]	]	PUNCT
dpc-2121	71	49	.	.	PUNCT
dpc-2121	72	1	as	as	SCONJ
dpc-2121	72	2	these	these	PRON
dpc-2121	72	3	are	be	AUX
dpc-2121	72	4	the	the	DET
dpc-2121	72	5	recommended	recommend	VERB
dpc-2121	72	6	dosage	dosage	NOUN
dpc-2121	72	7	regimens	regimen	NOUN
dpc-2121	72	8	,	,	PUNCT
dpc-2121	72	9	data	datum	NOUN
dpc-2121	72	10	on	on	ADP
dpc-2121	72	11	the	the	DET
dpc-2121	72	12	usage	usage	NOUN
dpc-2121	72	13	of	of	ADP
dpc-2121	72	14	1	1	NUM
dpc-2121	72	15	mg	mg	NOUN
dpc-2121	72	16	dosage	dosage	NOUN
dpc-2121	72	17	schemes	scheme	NOUN
dpc-2121	72	18	will	will	AUX
dpc-2121	72	19	not	not	PART
dpc-2121	72	20	be	be	AUX
dpc-2121	72	21	discussed	discuss	VERB
dpc-2121	72	22	.	.	PUNCT
dpc-2121	73	1	two	two	NUM
dpc-2121	73	2	independent	independent	ADJ
dpc-2121	73	3	multicentric	multicentric	ADJ
dpc-2121	73	4	double	double	ADJ
dpc-2121	73	5	-	-	PUNCT
dpc-2121	73	6	blinded	blind	VERB
dpc-2121	73	7	16	16	NUM
dpc-2121	73	8	-	-	PUNCT
dpc-2121	73	9	week	week	NOUN
dpc-2121	73	10	phase	phase	NOUN
dpc-2121	73	11	iii	iii	NUM
dpc-2121	73	12	clinical	clinical	ADJ
dpc-2121	73	13	trials	trial	NOUN
dpc-2121	73	14	(	(	PUNCT
dpc-2121	73	15	breeze	breeze	ADJ
dpc-2121	73	16	-	-	PUNCT
dpc-2121	73	17	ad1	ad1	NOUN
dpc-2121	73	18	and	and	CCONJ
dpc-2121	73	19	breeze	breeze	PROPN
dpc-2121	73	20	-	-	PUNCT
dpc-2121	73	21	ad2	ad2	NOUN
dpc-2121	73	22	)	)	PUNCT
dpc-2121	73	23	compared	compare	VERB
dpc-2121	73	24	baricitinib	baricitinib	NOUN
dpc-2121	73	25	monotherapy	monotherapy	NOUN
dpc-2121	73	26	(	(	PUNCT
dpc-2121	73	27	2	2	NUM
dpc-2121	73	28	mg	mg	NOUN
dpc-2121	73	29	and	and	CCONJ
dpc-2121	73	30	4	4	NUM
dpc-2121	73	31	mg	mg	NUM
dpc-2121	73	32	)	)	PUNCT
dpc-2121	73	33	with	with	ADP
dpc-2121	73	34	placebo	placebo	NOUN
dpc-2121	73	35	in	in	ADP
dpc-2121	73	36	adult	adult	NOUN
dpc-2121	73	37	patients	patient	NOUN
dpc-2121	73	38	with	with	ADP
dpc-2121	73	39	moderate	moderate	ADJ
dpc-2121	73	40	-	-	PUNCT
dpc-2121	73	41	to	to	ADP
dpc-2121	73	42	-	-	PUNCT
dpc-2121	73	43	severe	severe	ADJ
dpc-2121	73	44	ad	ad	NOUN
dpc-2121	73	45	[	[	X
dpc-2121	73	46	18	18	NUM
dpc-2121	73	47	]	]	PUNCT
dpc-2121	73	48	.	.	PUNCT
dpc-2121	74	1	the	the	DET
dpc-2121	74	2	results	result	NOUN
dpc-2121	74	3	of	of	ADP
dpc-2121	74	4	both	both	DET
dpc-2121	74	5	trials	trial	NOUN
dpc-2121	74	6	revealed	reveal	VERB
dpc-2121	74	7	that	that	SCONJ
dpc-2121	74	8	the	the	DET
dpc-2121	74	9	primary	primary	ADJ
dpc-2121	74	10	endpoint	endpoint	NOUN
dpc-2121	74	11	[	[	X
dpc-2121	74	12	validated	validate	VERB
dpc-2121	74	13	investigator	investigator	NOUN
dpc-2121	74	14	’s	’s	PART
dpc-2121	74	15	global	global	ADJ
dpc-2121	74	16	assessment	assessment	NOUN
dpc-2121	74	17	for	for	ADP
dpc-2121	74	18	ad	ad	NOUN
dpc-2121	74	19	(	(	PUNCT
dpc-2121	74	20	viga	viga	NOUN
dpc-2121	74	21	-	-	PUNCT
dpc-2121	74	22	ad	ad	NOUN
dpc-2121	74	23	)	)	PUNCT
dpc-2121	74	24	score	score	NOUN
dpc-2121	74	25	of	of	ADP
dpc-2121	74	26	0	0	NUM
dpc-2121	74	27	(	(	PUNCT
dpc-2121	74	28	clear	clear	ADJ
dpc-2121	74	29	)	)	PUNCT
dpc-2121	74	30	or	or	CCONJ
dpc-2121	74	31	1	1	NUM
dpc-2121	74	32	(	(	PUNCT
dpc-2121	74	33	almost	almost	ADV
dpc-2121	74	34	clear	clear	ADJ
dpc-2121	74	35	)	)	PUNCT
dpc-2121	74	36	]	]	PUNCT
dpc-2121	74	37	was	be	AUX
dpc-2121	74	38	achieved	achieve	VERB
dpc-2121	74	39	with	with	ADP
dpc-2121	74	40	both	both	DET
dpc-2121	74	41	baricitinib	baricitinib	NOUN
dpc-2121	74	42	2	2	NUM
dpc-2121	74	43	mg	mg	NOUN
dpc-2121	74	44	and	and	CCONJ
dpc-2121	74	45	4	4	NUM
dpc-2121	74	46	mg	mg	NOUN
dpc-2121	74	47	once	once	ADV
dpc-2121	74	48	daily	daily	ADJ
dpc-2121	74	49	dosing	dosing	ADJ
dpc-2121	74	50	-	-	PUNCT
dpc-2121	74	51	regimens	regimen	NOUN
dpc-2121	74	52	[	[	X
dpc-2121	74	53	breeze	breeze	ADJ
dpc-2121	74	54	-	-	PUNCT
dpc-2121	74	55	ad1	ad1	NOUN
dpc-2121	74	56	:	:	PUNCT
dpc-2121	74	57	n	n	PROPN
dpc-2121	74	58	=	=	SYM
dpc-2121	74	59	624	624	NUM
dpc-2121	74	60	,	,	PUNCT
dpc-2121	74	61	baricitinib	baricitinib	VERB
dpc-2121	74	62	2	2	NUM
dpc-2121	74	63	mg	mg	PROPN
dpc-2121	74	64	11.4	11.4	NUM
dpc-2121	74	65	%	%	NOUN
dpc-2121	74	66	,	,	PUNCT
dpc-2121	74	67	baricitinib	baricitinib	VERB
dpc-2121	74	68	4	4	NUM
dpc-2121	74	69	mg	mg	NUM
dpc-2121	74	70	16.8	16.8	NUM
dpc-2121	74	71	%	%	NOUN
dpc-2121	74	72	vs.	vs.	ADP
dpc-2121	74	73	placebo	placebo	NOUN
dpc-2121	74	74	4.8	4.8	NUM
dpc-2121	74	75	%	%	NOUN
dpc-2121	74	76	(	(	PUNCT
dpc-2121	74	77	p	p	X
dpc-2121	74	78	<	<	X
dpc-2121	74	79	0.05	0.05	NUM
dpc-2121	74	80	and	and	CCONJ
dpc-2121	74	81	p	p	X
dpc-2121	74	82	<	<	X
dpc-2121	74	83	0.001	0.001	NUM
dpc-2121	74	84	,	,	PUNCT
dpc-2121	74	85	respectively	respectively	ADV
dpc-2121	74	86	)	)	PUNCT
dpc-2121	74	87	;	;	PUNCT
dpc-2121	74	88	breeze	breeze	PROPN
dpc-2121	74	89	-	-	PUNCT
dpc-2121	74	90	ad2	ad2	NOUN
dpc-2121	74	91	:	:	PUNCT
dpc-2121	74	92	n	n	PROPN
dpc-2121	74	93	=	=	SYM
dpc-2121	74	94	615	615	NUM
dpc-2121	74	95	,	,	PUNCT
dpc-2121	74	96	baricitinib	baricitinib	VERB
dpc-2121	74	97	2	2	NUM
dpc-2121	74	98	mg	mg	PROPN
dpc-2121	74	99	10.6	10.6	NUM
dpc-2121	74	100	%	%	NOUN
dpc-2121	74	101	,	,	PUNCT
dpc-2121	74	102	baricitinib	baricitinib	VERB
dpc-2121	74	103	4	4	NUM
dpc-2121	74	104	mg	mg	NUM
dpc-2121	74	105	13.8	13.8	NUM
dpc-2121	74	106	%	%	NOUN
dpc-2121	74	107	vs.	vs.	ADP
dpc-2121	74	108	placebo	placebo	NOUN
dpc-2121	74	109	4.5	4.5	NUM
dpc-2121	74	110	%	%	NOUN
dpc-2121	74	111	(	(	PUNCT
dpc-2121	74	112	p	p	X
dpc-2121	74	113	<	<	X
dpc-2121	74	114	0.05	0.05	NUM
dpc-2121	74	115	and	and	CCONJ
dpc-2121	74	116	p	p	NOUN
dpc-2121	74	117	=	=	NOUN
dpc-2121	74	118	0.001	0.001	NUM
dpc-2121	74	119	,	,	PUNCT
dpc-2121	74	120	respectively	respectively	ADV
dpc-2121	74	121	)	)	PUNCT
dpc-2121	74	122	]	]	PUNCT
dpc-2121	74	123	.	.	PUNCT
dpc-2121	75	1	however	however	ADV
dpc-2121	75	2	,	,	PUNCT
dpc-2121	75	3	the	the	DET
dpc-2121	75	4	same	same	ADJ
dpc-2121	75	5	was	be	AUX
dpc-2121	75	6	not	not	PART
dpc-2121	75	7	verified	verify	VERB
dpc-2121	75	8	for	for	ADP
dpc-2121	75	9	secondary	secondary	ADJ
dpc-2121	75	10	endpoints	endpoint	NOUN
dpc-2121	75	11	,	,	PUNCT
dpc-2121	75	12	as	as	SCONJ
dpc-2121	75	13	only	only	ADV
dpc-2121	75	14	baricitinib	baricitinib	NOUN
dpc-2121	75	15	4	4	NUM
dpc-2121	75	16	mg	mg	VERB
dpc-2121	75	17	consistently	consistently	ADV
dpc-2121	75	18	met	meet	VERB
dpc-2121	75	19	the	the	DET
dpc-2121	75	20	key	key	ADJ
dpc-2121	75	21	secondary	secondary	ADJ
dpc-2121	75	22	endpoints	endpoint	NOUN
dpc-2121	75	23	.	.	PUNCT
dpc-2121	76	1	although	although	SCONJ
dpc-2121	76	2	improvements	improvement	NOUN
dpc-2121	76	3	in	in	ADP
dpc-2121	76	4	ad	ad	NOUN
dpc-2121	76	5	-	-	PUNCT
dpc-2121	76	6	associated	associate	VERB
dpc-2121	76	7	symptoms	symptom	NOUN
dpc-2121	76	8	(	(	PUNCT
dpc-2121	76	9	skin	skin	NOUN
dpc-2121	76	10	pain	pain	NOUN
dpc-2121	76	11	and	and	CCONJ
dpc-2121	76	12	review	review	NOUN
dpc-2121	76	13	|	|	ADV
dpc-2121	76	14	dermatol	dermatol	ADJ
dpc-2121	76	15	pract	pract	NOUN
dpc-2121	76	16	concept	concept	NOUN
dpc-2121	76	17	.	.	PUNCT
dpc-2121	77	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	77	2	5	5	NUM
dpc-2121	77	3	night	night	NOUN
dpc-2121	77	4	awakenings	awakening	NOUN
dpc-2121	77	5	)	)	PUNCT
dpc-2121	77	6	were	be	AUX
dpc-2121	77	7	achieved	achieve	VERB
dpc-2121	77	8	at	at	ADP
dpc-2121	77	9	week	week	NOUN
dpc-2121	77	10	1	1	NUM
dpc-2121	77	11	for	for	ADP
dpc-2121	77	12	both	both	DET
dpc-2121	77	13	dosing	dose	VERB
dpc-2121	77	14	regimens	regimen	NOUN
dpc-2121	77	15	,	,	PUNCT
dpc-2121	77	16	the	the	DET
dpc-2121	77	17	same	same	ADJ
dpc-2121	77	18	was	be	AUX
dpc-2121	77	19	not	not	PART
dpc-2121	77	20	verified	verify	VERB
dpc-2121	77	21	for	for	ADP
dpc-2121	77	22	itchiness	itchiness	NOUN
dpc-2121	77	23	it	it	PRON
dpc-2121	77	24	improved	improve	VERB
dpc-2121	77	25	at	at	ADP
dpc-2121	77	26	week	week	NOUN
dpc-2121	77	27	1	1	NUM
dpc-2121	77	28	with	with	ADP
dpc-2121	77	29	baricitinib	baricitinib	NOUN
dpc-2121	77	30	4	4	NUM
dpc-2121	77	31	mg	mg	NUM
dpc-2121	77	32	,	,	PUNCT
dpc-2121	77	33	but	but	CCONJ
dpc-2121	77	34	patients	patient	NOUN
dpc-2121	77	35	receiving	receive	VERB
dpc-2121	77	36	baricitinib	baricitinib	NOUN
dpc-2121	77	37	2	2	NUM
dpc-2121	77	38	mg	mg	NOUN
dpc-2121	77	39	only	only	ADV
dpc-2121	77	40	registered	register	VERB
dpc-2121	77	41	improvements	improvement	NOUN
dpc-2121	77	42	at	at	ADP
dpc-2121	77	43	week	week	NOUN
dpc-2121	77	44	2	2	NUM
dpc-2121	77	45	,	,	PUNCT
dpc-2121	77	46	making	make	VERB
dpc-2121	77	47	the	the	DET
dpc-2121	77	48	first	first	ADJ
dpc-2121	77	49	dosing	dose	VERB
dpc-2121	77	50	regimen	regiman	NOUN
dpc-2121	77	51	superior	superior	ADJ
dpc-2121	77	52	.	.	PUNCT
dpc-2121	78	1	treatment	treatment	NOUN
dpc-2121	78	2	-	-	PUNCT
dpc-2121	78	3	emergent	emergent	ADJ
dpc-2121	78	4	adverse	adverse	ADJ
dpc-2121	78	5	events	event	NOUN
dpc-2121	78	6	were	be	AUX
dpc-2121	78	7	observed	observe	VERB
dpc-2121	78	8	in	in	ADP
dpc-2121	78	9	54	54	NUM
dpc-2121	78	10	to	to	PART
dpc-2121	78	11	58	58	NUM
dpc-2121	78	12	%	%	NOUN
dpc-2121	78	13	of	of	ADP
dpc-2121	78	14	the	the	DET
dpc-2121	78	15	patients	patient	NOUN
dpc-2121	78	16	,	,	PUNCT
dpc-2121	78	17	predominantly	predominantly	ADV
dpc-2121	78	18	mild	mild	ADJ
dpc-2121	78	19	-	-	PUNCT
dpc-2121	78	20	to	to	ADP
dpc-2121	78	21	-	-	PUNCT
dpc-2121	78	22	moderate	moderate	ADJ
dpc-2121	78	23	.	.	PUNCT
dpc-2121	79	1	the	the	DET
dpc-2121	79	2	most	most	ADV
dpc-2121	79	3	reported	report	VERB
dpc-2121	79	4	adverse	adverse	ADJ
dpc-2121	79	5	events	event	NOUN
dpc-2121	79	6	included	include	VERB
dpc-2121	79	7	increased	increase	VERB
dpc-2121	79	8	blood	blood	NOUN
dpc-2121	79	9	creatine	creatine	NOUN
dpc-2121	79	10	phosphokinase	phosphokinase	NOUN
dpc-2121	79	11	(	(	PUNCT
dpc-2121	79	12	cpk	cpk	PROPN
dpc-2121	79	13	)	)	PUNCT
dpc-2121	79	14	,	,	PUNCT
dpc-2121	79	15	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	79	16	and	and	CCONJ
dpc-2121	79	17	headache	headache	NOUN
dpc-2121	79	18	.	.	PUNCT
dpc-2121	80	1	herpes	herpe	NOUN
dpc-2121	80	2	simplex	simplex	NOUN
dpc-2121	80	3	infection	infection	NOUN
dpc-2121	80	4	was	be	AUX
dpc-2121	80	5	more	more	ADV
dpc-2121	80	6	frequent	frequent	ADJ
dpc-2121	80	7	with	with	ADP
dpc-2121	80	8	baricitinib	baricitinib	NOUN
dpc-2121	80	9	compared	compare	VERB
dpc-2121	80	10	to	to	ADP
dpc-2121	80	11	placebo	placebo	NOUN
dpc-2121	80	12	in	in	ADP
dpc-2121	80	13	breeze	breeze	PROPN
dpc-2121	80	14	-	-	PUNCT
dpc-2121	80	15	ad1	ad1	NOUN
dpc-2121	80	16	(	(	PUNCT
dpc-2121	80	17	baricitinib	baricitinib	NOUN
dpc-2121	80	18	2	2	NUM
dpc-2121	80	19	mg	mg	NUM
dpc-2121	80	20	3.3	3.3	NUM
dpc-2121	80	21	%	%	NOUN
dpc-2121	80	22	,	,	PUNCT
dpc-2121	80	23	baricitinib	baricitinib	VERB
dpc-2121	80	24	4	4	NUM
dpc-2121	80	25	mg	mg	NUM
dpc-2121	80	26	7.2	7.2	NUM
dpc-2121	80	27	%	%	NOUN
dpc-2121	80	28	vs.	vs.	ADP
dpc-2121	80	29	placebo	placebo	NOUN
dpc-2121	80	30	1.2	1.2	NUM
dpc-2121	80	31	%	%	NOUN
dpc-2121	80	32	)	)	PUNCT
dpc-2121	80	33	,	,	PUNCT
dpc-2121	80	34	but	but	CCONJ
dpc-2121	80	35	the	the	DET
dpc-2121	80	36	same	same	ADJ
dpc-2121	80	37	was	be	AUX
dpc-2121	80	38	not	not	PART
dpc-2121	80	39	verified	verify	VERB
dpc-2121	80	40	in	in	ADP
dpc-2121	80	41	breeze	breeze	PROPN
dpc-2121	80	42	-	-	PUNCT
dpc-2121	80	43	ad2	ad2	NOUN
dpc-2121	80	44	.	.	PUNCT
dpc-2121	81	1	no	no	DET
dpc-2121	81	2	venous	venous	ADJ
dpc-2121	81	3	thromboembolic	thromboembolic	ADJ
dpc-2121	81	4	events	event	NOUN
dpc-2121	81	5	,	,	PUNCT
dpc-2121	81	6	significant	significant	ADJ
dpc-2121	81	7	hematological	hematological	ADJ
dpc-2121	81	8	abnormalities	abnormality	NOUN
dpc-2121	81	9	,	,	PUNCT
dpc-2121	81	10	cardiovascular	cardiovascular	ADJ
dpc-2121	81	11	events	event	NOUN
dpc-2121	81	12	,	,	PUNCT
dpc-2121	81	13	or	or	CCONJ
dpc-2121	81	14	death	death	NOUN
dpc-2121	81	15	were	be	AUX
dpc-2121	81	16	observed	observe	VERB
dpc-2121	81	17	in	in	ADP
dpc-2121	81	18	any	any	PRON
dpc-2121	81	19	of	of	ADP
dpc-2121	81	20	the	the	DET
dpc-2121	81	21	baricitinib	baricitinib	NOUN
dpc-2121	81	22	groups	group	NOUN
dpc-2121	81	23	.	.	PUNCT
dpc-2121	82	1	after	after	ADP
dpc-2121	82	2	a	a	DET
dpc-2121	82	3	16	16	NUM
dpc-2121	82	4	-	-	PUNCT
dpc-2121	82	5	week	week	NOUN
dpc-2121	82	6	period	period	NOUN
dpc-2121	82	7	,	,	PUNCT
dpc-2121	82	8	adults	adult	NOUN
dpc-2121	82	9	receiving	receive	VERB
dpc-2121	82	10	baricitinib	baricitinib	NOUN
dpc-2121	82	11	4	4	NUM
dpc-2121	82	12	mg	mg	NOUN
dpc-2121	82	13	or	or	CCONJ
dpc-2121	82	14	2	2	NUM
dpc-2121	82	15	mg	mg	NOUN
dpc-2121	82	16	that	that	PRON
dpc-2121	82	17	were	be	AUX
dpc-2121	82	18	responders	responder	NOUN
dpc-2121	82	19	or	or	CCONJ
dpc-2121	82	20	partial	partial	ADJ
dpc-2121	82	21	responders	responder	NOUN
dpc-2121	82	22	(	(	PUNCT
dpc-2121	82	23	viga	viga	NOUN
dpc-2121	82	24	-	-	PUNCT
dpc-2121	82	25	ad	ad	NOUN
dpc-2121	82	26	score	score	NOUN
dpc-2121	82	27	≤	≤	NUM
dpc-2121	82	28	2	2	NUM
dpc-2121	82	29	)	)	PUNCT
dpc-2121	82	30	in	in	ADP
dpc-2121	82	31	breeze	breeze	ADJ
dpc-2121	82	32	-	-	PUNCT
dpc-2121	82	33	ad1	ad1	NOUN
dpc-2121	82	34	and	and	CCONJ
dpc-2121	82	35	breeze	breeze	ADJ
dpc-2121	82	36	-	-	PUNCT
dpc-2121	82	37	ad2	ad2	PROPN
dpc-2121	82	38	trials	trial	NOUN
dpc-2121	82	39	were	be	AUX
dpc-2121	82	40	analyzed	analyze	VERB
dpc-2121	82	41	in	in	ADP
dpc-2121	82	42	a	a	DET
dpc-2121	82	43	long	long	ADJ
dpc-2121	82	44	-	-	PUNCT
dpc-2121	82	45	term	term	NOUN
dpc-2121	82	46	extension	extension	NOUN
dpc-2121	82	47	study	study	NOUN
dpc-2121	82	48	(	(	PUNCT
dpc-2121	82	49	breeze	breeze	PROPN
dpc-2121	82	50	-	-	PUNCT
dpc-2121	82	51	ad3	ad3	NOUN
dpc-2121	82	52	)	)	PUNCT
dpc-2121	83	1	[	[	X
dpc-2121	83	2	19	19	NUM
dpc-2121	83	3	]	]	PUNCT
dpc-2121	83	4	.	.	PUNCT
dpc-2121	84	1	the	the	DET
dpc-2121	84	2	proportion	proportion	NOUN
dpc-2121	84	3	of	of	ADP
dpc-2121	84	4	patients	patient	NOUN
dpc-2121	84	5	receiving	receive	VERB
dpc-2121	84	6	baricitinib	baricitinib	NOUN
dpc-2121	84	7	2	2	NUM
dpc-2121	84	8	mg	mg	NOUN
dpc-2121	84	9	and	and	CCONJ
dpc-2121	84	10	4	4	NUM
dpc-2121	84	11	mg	mg	NOUN
dpc-2121	84	12	that	that	PRON
dpc-2121	84	13	achieved	achieve	VERB
dpc-2121	84	14	a	a	DET
dpc-2121	84	15	viga	viga	NOUN
dpc-2121	84	16	-	-	PUNCT
dpc-2121	84	17	ad	ad	NOUN
dpc-2121	84	18	of	of	ADP
dpc-2121	84	19	0	0	NUM
dpc-2121	84	20	or	or	CCONJ
dpc-2121	84	21	1	1	NUM
dpc-2121	84	22	at	at	ADP
dpc-2121	84	23	week	week	NOUN
dpc-2121	84	24	16	16	NUM
dpc-2121	84	25	(	(	PUNCT
dpc-2121	84	26	breeze	breeze	PROPN
dpc-2121	84	27	-	-	PUNCT
dpc-2121	84	28	ad3	ad3	PROPN
dpc-2121	84	29	study	study	NOUN
dpc-2121	84	30	baseline	baseline	PROPN
dpc-2121	84	31	)	)	PUNCT
dpc-2121	84	32	was	be	AUX
dpc-2121	84	33	46.3	46.3	NUM
dpc-2121	84	34	%	%	NOUN
dpc-2121	84	35	and	and	CCONJ
dpc-2121	84	36	45.7	45.7	NUM
dpc-2121	84	37	%	%	NOUN
dpc-2121	84	38	,	,	PUNCT
dpc-2121	84	39	respectively	respectively	ADV
dpc-2121	84	40	.	.	PUNCT
dpc-2121	85	1	at	at	ADP
dpc-2121	85	2	week	week	NOUN
dpc-2121	85	3	68	68	NUM
dpc-2121	85	4	,	,	PUNCT
dpc-2121	85	5	those	those	DET
dpc-2121	85	6	numbers	number	NOUN
dpc-2121	85	7	improved	improve	VERB
dpc-2121	85	8	to	to	ADP
dpc-2121	85	9	59.3	59.3	NUM
dpc-2121	85	10	%	%	NOUN
dpc-2121	85	11	and	and	CCONJ
dpc-2121	85	12	47.1	47.1	NUM
dpc-2121	85	13	%	%	NOUN
dpc-2121	85	14	,	,	PUNCT
dpc-2121	85	15	with	with	ADP
dpc-2121	85	16	a	a	DET
dpc-2121	85	17	similar	similar	ADJ
dpc-2121	85	18	safety	safety	NOUN
dpc-2121	85	19	profile	profile	NOUN
dpc-2121	85	20	,	,	PUNCT
dpc-2121	85	21	thus	thus	ADV
dpc-2121	85	22	showing	show	VERB
dpc-2121	85	23	the	the	DET
dpc-2121	85	24	sustained	sustain	VERB
dpc-2121	85	25	long	long	ADJ
dpc-2121	85	26	-	-	PUNCT
dpc-2121	85	27	term	term	NOUN
dpc-2121	85	28	efficacy	efficacy	NOUN
dpc-2121	85	29	and	and	CCONJ
dpc-2121	85	30	safety	safety	NOUN
dpc-2121	85	31	of	of	ADP
dpc-2121	85	32	baricitinib	baricitinib	NOUN
dpc-2121	85	33	in	in	ADP
dpc-2121	85	34	these	these	DET
dpc-2121	85	35	patients	patient	NOUN
dpc-2121	85	36	.	.	PUNCT
dpc-2121	86	1	the	the	DET
dpc-2121	86	2	combination	combination	NOUN
dpc-2121	86	3	of	of	ADP
dpc-2121	86	4	baricitinib	baricitinib	NOUN
dpc-2121	86	5	(	(	PUNCT
dpc-2121	86	6	2	2	NUM
dpc-2121	86	7	mg	mg	NOUN
dpc-2121	86	8	and	and	CCONJ
dpc-2121	86	9	4	4	NUM
dpc-2121	86	10	mg	mg	NUM
dpc-2121	86	11	)	)	PUNCT
dpc-2121	86	12	with	with	ADP
dpc-2121	86	13	topical	topical	ADJ
dpc-2121	86	14	corticosteroids	corticosteroid	NOUN
dpc-2121	86	15	was	be	AUX
dpc-2121	86	16	evaluated	evaluate	VERB
dpc-2121	86	17	in	in	ADP
dpc-2121	86	18	two	two	NUM
dpc-2121	86	19	distinctive	distinctive	ADJ
dpc-2121	86	20	phase	phase	NOUN
dpc-2121	86	21	iii	iii	NUM
dpc-2121	86	22	clinical	clinical	ADJ
dpc-2121	86	23	trials	trial	NOUN
dpc-2121	86	24	(	(	PUNCT
dpc-2121	86	25	breeze	breeze	PROPN
dpc-2121	86	26	-	-	PUNCT
dpc-2121	86	27	ad4	ad4	PROPN
dpc-2121	87	1	[	[	X
dpc-2121	87	2	20	20	NUM
dpc-2121	87	3	]	]	PUNCT
dpc-2121	87	4	and	and	CCONJ
dpc-2121	87	5	breeze	breeze	ADJ
dpc-2121	87	6	-	-	PUNCT
dpc-2121	87	7	ad7	ad7	PRON
dpc-2121	87	8	[	[	X
dpc-2121	87	9	21	21	NUM
dpc-2121	87	10	]	]	PUNCT
dpc-2121	87	11	)	)	PUNCT
dpc-2121	87	12	that	that	PRON
dpc-2121	87	13	included	include	VERB
dpc-2121	87	14	adult	adult	NOUN
dpc-2121	87	15	patients	patient	NOUN
dpc-2121	87	16	with	with	ADP
dpc-2121	87	17	moderate	moderate	ADJ
dpc-2121	87	18	-	-	PUNCT
dpc-2121	87	19	to	to	ADP
dpc-2121	87	20	-	-	PUNCT
dpc-2121	87	21	severe	severe	ADJ
dpc-2121	87	22	ad	ad	NOUN
dpc-2121	87	23	.	.	PUNCT
dpc-2121	88	1	in	in	ADP
dpc-2121	88	2	these	these	DET
dpc-2121	88	3	trials	trial	NOUN
dpc-2121	88	4	,	,	PUNCT
dpc-2121	88	5	only	only	ADV
dpc-2121	88	6	baricitinib	baricitinib	NOUN
dpc-2121	88	7	4	4	NUM
dpc-2121	88	8	mg	mg	NOUN
dpc-2121	88	9	met	meet	VERB
dpc-2121	88	10	the	the	DET
dpc-2121	88	11	primary	primary	ADJ
dpc-2121	88	12	endpoint	endpoint	NOUN
dpc-2121	88	13	[	[	X
dpc-2121	88	14	an	an	DET
dpc-2121	88	15	improvement	improvement	NOUN
dpc-2121	88	16	of	of	ADP
dpc-2121	88	17	75	75	NUM
dpc-2121	88	18	%	%	NOUN
dpc-2121	88	19	in	in	ADP
dpc-2121	88	20	eczema	eczema	PROPN
dpc-2121	88	21	area	area	NOUN
dpc-2121	88	22	and	and	CCONJ
dpc-2121	88	23	severity	severity	NOUN
dpc-2121	88	24	index	index	NOUN
dpc-2121	88	25	(	(	PUNCT
dpc-2121	88	26	easi	easi	NOUN
dpc-2121	88	27	)	)	PUNCT
dpc-2121	88	28	compared	compare	VERB
dpc-2121	88	29	to	to	ADP
dpc-2121	88	30	baseline	baseline	VERB
dpc-2121	88	31	(	(	PUNCT
dpc-2121	88	32	easi75	easi75	NOUN
dpc-2121	88	33	)	)	PUNCT
dpc-2121	88	34	in	in	ADP
dpc-2121	88	35	breeze	breeze	PROPN
dpc-2121	88	36	-	-	PUNCT
dpc-2121	88	37	ad4	ad4	PROPN
dpc-2121	88	38	,	,	PUNCT
dpc-2121	88	39	and	and	CCONJ
dpc-2121	88	40	a	a	DET
dpc-2121	88	41	viga	viga	NOUN
dpc-2121	88	42	-	-	PUNCT
dpc-2121	88	43	ad	ad	NOUN
dpc-2121	88	44	score	score	NOUN
dpc-2121	88	45	of	of	ADP
dpc-2121	88	46	0/1	0/1	NUM
dpc-2121	88	47	in	in	ADP
dpc-2121	88	48	breeze	breeze	NOUN
dpc-2121	88	49	-	-	PUNCT
dpc-2121	88	50	ad7	ad7	NOUN
dpc-2121	88	51	]	]	PUNCT
dpc-2121	88	52	at	at	ADP
dpc-2121	88	53	week	week	NOUN
dpc-2121	88	54	16	16	NUM
dpc-2121	88	55	.	.	PUNCT
dpc-2121	89	1	at	at	ADP
dpc-2121	89	2	the	the	DET
dpc-2121	89	3	mentioned	mention	VERB
dpc-2121	89	4	timepoint	timepoint	NOUN
dpc-2121	89	5	,	,	PUNCT
dpc-2121	89	6	a	a	DET
dpc-2121	89	7	total	total	NOUN
dpc-2121	89	8	of	of	ADP
dpc-2121	89	9	31.5	31.5	NUM
dpc-2121	89	10	%	%	NOUN
dpc-2121	89	11	of	of	ADP
dpc-2121	89	12	patients	patient	NOUN
dpc-2121	89	13	receiving	receive	VERB
dpc-2121	89	14	baricitinib	baricitinib	NOUN
dpc-2121	89	15	4	4	NUM
dpc-2121	89	16	mg	mg	NOUN
dpc-2121	89	17	achieved	achieve	VERB
dpc-2121	89	18	easi75	easi75	NOUN
dpc-2121	89	19	(	(	PUNCT
dpc-2121	89	20	baricitinib	baricitinib	NOUN
dpc-2121	89	21	2	2	NUM
dpc-2121	89	22	mg	mg	PROPN
dpc-2121	89	23	27.6	27.6	NUM
dpc-2121	89	24	%	%	NOUN
dpc-2121	89	25	;	;	PUNCT
dpc-2121	89	26	placebo	placebo	NOUN
dpc-2121	89	27	17.2	17.2	NUM
dpc-2121	89	28	%	%	NOUN
dpc-2121	89	29	)	)	PUNCT
dpc-2121	89	30	in	in	ADP
dpc-2121	89	31	breeze	breeze	PROPN
dpc-2121	89	32	-	-	PUNCT
dpc-2121	89	33	ad4	ad4	PROPN
dpc-2121	89	34	,	,	PUNCT
dpc-2121	89	35	while	while	SCONJ
dpc-2121	89	36	31.0	31.0	NUM
dpc-2121	89	37	%	%	NOUN
dpc-2121	89	38	achieved	achieve	VERB
dpc-2121	89	39	viga	viga	NOUN
dpc-2121	89	40	-	-	PUNCT
dpc-2121	89	41	ad	ad	NOUN
dpc-2121	89	42	score	score	NOUN
dpc-2121	89	43	of	of	ADP
dpc-2121	89	44	0/1	0/1	PROPN
dpc-2121	89	45	(	(	PUNCT
dpc-2121	89	46	baricitinib	baricitinib	NOUN
dpc-2121	89	47	2	2	NUM
dpc-2121	89	48	mg	mg	PROPN
dpc-2121	89	49	24.0	24.0	NUM
dpc-2121	89	50	%	%	NOUN
dpc-2121	89	51	;	;	PUNCT
dpc-2121	89	52	placebo	placebo	NOUN
dpc-2121	89	53	15.0	15.0	NUM
dpc-2121	89	54	%	%	NOUN
dpc-2121	89	55	)	)	PUNCT
dpc-2121	89	56	in	in	ADP
dpc-2121	89	57	breeze	breeze	PROPN
dpc-2121	89	58	-	-	PUNCT
dpc-2121	89	59	ad7	ad7	NOUN
dpc-2121	89	60	.	.	PUNCT
dpc-2121	90	1	the	the	DET
dpc-2121	90	2	symptomatic	symptomatic	ADJ
dpc-2121	90	3	relief	relief	NOUN
dpc-2121	90	4	(	(	PUNCT
dpc-2121	90	5	improvement	improvement	NOUN
dpc-2121	90	6	in	in	ADP
dpc-2121	90	7	itch	itch	NOUN
dpc-2121	90	8	scores	score	NOUN
dpc-2121	90	9	)	)	PUNCT
dpc-2121	90	10	was	be	AUX
dpc-2121	90	11	verified	verify	VERB
dpc-2121	90	12	in	in	ADP
dpc-2121	90	13	all	all	DET
dpc-2121	90	14	patients	patient	NOUN
dpc-2121	90	15	receiving	receive	VERB
dpc-2121	90	16	baricitinib	baricitinib	NOUN
dpc-2121	90	17	–	–	PUNCT
dpc-2121	90	18	when	when	SCONJ
dpc-2121	90	19	comparing	compare	VERB
dpc-2121	90	20	to	to	ADP
dpc-2121	90	21	placebo	placebo	NOUN
dpc-2121	90	22	,	,	PUNCT
dpc-2121	90	23	a	a	DET
dpc-2121	90	24	higher	high	ADJ
dpc-2121	90	25	response	response	NOUN
dpc-2121	90	26	of	of	ADP
dpc-2121	90	27	itch	itch	NOUN
dpc-2121	90	28	improvement	improvement	NOUN
dpc-2121	90	29	with	with	ADP
dpc-2121	90	30	baricitinib	baricitinib	NOUN
dpc-2121	90	31	4	4	NUM
dpc-2121	90	32	mg	mg	NOUN
dpc-2121	90	33	was	be	AUX
dpc-2121	90	34	achieved	achieve	VERB
dpc-2121	90	35	as	as	ADV
dpc-2121	90	36	early	early	ADV
dpc-2121	90	37	as	as	ADP
dpc-2121	90	38	on	on	ADP
dpc-2121	90	39	day	day	NOUN
dpc-2121	90	40	4	4	NUM
dpc-2121	90	41	of	of	ADP
dpc-2121	90	42	treatment	treatment	NOUN
dpc-2121	90	43	.	.	PUNCT
dpc-2121	91	1	regarding	regard	VERB
dpc-2121	91	2	side	side	NOUN
dpc-2121	91	3	effects	effect	NOUN
dpc-2121	91	4	,	,	PUNCT
dpc-2121	91	5	infections	infection	NOUN
dpc-2121	91	6	and	and	CCONJ
dpc-2121	91	7	increased	increase	VERB
dpc-2121	91	8	blood	blood	NOUN
dpc-2121	91	9	cpk	cpk	PROPN
dpc-2121	91	10	were	be	AUX
dpc-2121	91	11	the	the	DET
dpc-2121	91	12	most	most	ADV
dpc-2121	91	13	common	common	ADJ
dpc-2121	91	14	reported	report	VERB
dpc-2121	91	15	ones	one	NOUN
dpc-2121	91	16	.	.	PUNCT
dpc-2121	92	1	a	a	DET
dpc-2121	92	2	pulmonary	pulmonary	ADJ
dpc-2121	92	3	thromboembolic	thromboembolic	NOUN
dpc-2121	92	4	event	event	NOUN
dpc-2121	92	5	in	in	ADP
dpc-2121	92	6	a	a	DET
dpc-2121	92	7	patient	patient	NOUN
dpc-2121	92	8	receiving	receiving	NOUN
dpc-2121	92	9	baricitinib	baricitinib	NOUN
dpc-2121	92	10	4	4	NUM
dpc-2121	92	11	mg	mg	NOUN
dpc-2121	92	12	was	be	AUX
dpc-2121	92	13	reported	report	VERB
dpc-2121	92	14	in	in	ADP
dpc-2121	92	15	breeze	breeze	NOUN
dpc-2121	92	16	-	-	PUNCT
dpc-2121	92	17	ad7	ad7	NOUN
dpc-2121	92	18	.	.	PUNCT
dpc-2121	93	1	the	the	DET
dpc-2121	93	2	impact	impact	NOUN
dpc-2121	93	3	of	of	ADP
dpc-2121	93	4	the	the	DET
dpc-2121	93	5	combined	combine	VERB
dpc-2121	93	6	therapy	therapy	NOUN
dpc-2121	93	7	in	in	ADP
dpc-2121	93	8	the	the	DET
dpc-2121	93	9	health	health	NOUN
dpc-2121	93	10	-	-	PUNCT
dpc-2121	93	11	related	relate	VERB
dpc-2121	93	12	quality	quality	NOUN
dpc-2121	93	13	of	of	ADP
dpc-2121	93	14	life	life	NOUN
dpc-2121	93	15	and	and	CCONJ
dpc-2121	93	16	productivity	productivity	NOUN
dpc-2121	93	17	of	of	ADP
dpc-2121	93	18	ad	ad	NOUN
dpc-2121	93	19	patients	patient	NOUN
dpc-2121	93	20	,	,	PUNCT
dpc-2121	93	21	as	as	ADV
dpc-2121	93	22	well	well	ADV
dpc-2121	93	23	as	as	ADP
dpc-2121	93	24	the	the	DET
dpc-2121	93	25	improvement	improvement	NOUN
dpc-2121	93	26	in	in	ADP
dpc-2121	93	27	patient	patient	NOUN
dpc-2121	93	28	-	-	PUNCT
dpc-2121	93	29	reported	report	VERB
dpc-2121	93	30	outcomes	outcome	NOUN
dpc-2121	93	31	were	be	AUX
dpc-2121	93	32	also	also	ADV
dpc-2121	93	33	assessed	assess	VERB
dpc-2121	93	34	in	in	ADP
dpc-2121	93	35	breeze	breeze	NOUN
dpc-2121	93	36	-	-	PUNCT
dpc-2121	93	37	ad7	ad7	PRON
dpc-2121	94	1	[	[	X
dpc-2121	94	2	22	22	NUM
dpc-2121	94	3	]	]	PUNCT
dpc-2121	94	4	.	.	PUNCT
dpc-2121	95	1	both	both	DET
dpc-2121	95	2	dosing	dose	VERB
dpc-2121	95	3	regimens	regimen	NOUN
dpc-2121	95	4	(	(	PUNCT
dpc-2121	95	5	2	2	NUM
dpc-2121	95	6	mg	mg	NOUN
dpc-2121	95	7	and	and	CCONJ
dpc-2121	95	8	4	4	NUM
dpc-2121	95	9	mg	mg	NOUN
dpc-2121	95	10	)	)	PUNCT
dpc-2121	95	11	of	of	ADP
dpc-2121	95	12	baricitinib	baricitinib	NOUN
dpc-2121	95	13	plus	plus	CCONJ
dpc-2121	95	14	topical	topical	ADJ
dpc-2121	95	15	corticosteroids	corticosteroid	NOUN
dpc-2121	95	16	induced	induce	VERB
dpc-2121	95	17	a	a	DET
dpc-2121	95	18	rapid	rapid	ADJ
dpc-2121	95	19	–	–	PUNCT
dpc-2121	95	20	before	before	ADP
dpc-2121	95	21	week	week	NOUN
dpc-2121	95	22	2	2	NUM
dpc-2121	95	23	–	–	PUNCT
dpc-2121	95	24	and	and	CCONJ
dpc-2121	95	25	significant	significant	ADJ
dpc-2121	95	26	improvement	improvement	NOUN
dpc-2121	95	27	in	in	ADP
dpc-2121	95	28	several	several	ADJ
dpc-2121	95	29	of	of	ADP
dpc-2121	95	30	the	the	DET
dpc-2121	95	31	evaluated	evaluate	VERB
dpc-2121	95	32	scores	score	NOUN
dpc-2121	95	33	(	(	PUNCT
dpc-2121	95	34	dermatology	dermatology	NOUN
dpc-2121	95	35	life	life	NOUN
dpc-2121	95	36	quality	quality	NOUN
dpc-2121	95	37	index	index	NOUN
dpc-2121	95	38	,	,	PUNCT
dpc-2121	95	39	work	work	NOUN
dpc-2121	95	40	productivity	productivity	NOUN
dpc-2121	95	41	and	and	CCONJ
dpc-2121	95	42	activity	activity	NOUN
dpc-2121	95	43	impairment	impairment	NOUN
dpc-2121	95	44	,	,	PUNCT
dpc-2121	95	45	patient	patient	NOUN
dpc-2121	95	46	-	-	PUNCT
dpc-2121	95	47	reported	report	VERB
dpc-2121	95	48	outcomes	outcome	NOUN
dpc-2121	95	49	measurement	measurement	NOUN
dpc-2121	95	50	information	information	NOUN
dpc-2121	95	51	system	system	NOUN
dpc-2121	95	52	itch	itch	NOUN
dpc-2121	95	53	and	and	CCONJ
dpc-2121	95	54	sleep	sleep	NOUN
dpc-2121	95	55	)	)	PUNCT
dpc-2121	95	56	when	when	SCONJ
dpc-2121	95	57	compared	compare	VERB
dpc-2121	95	58	to	to	ADP
dpc-2121	95	59	placebo	placebo	NOUN
dpc-2121	95	60	plus	plus	CCONJ
dpc-2121	95	61	topical	topical	ADJ
dpc-2121	95	62	corticosteroids	corticosteroid	NOUN
dpc-2121	95	63	in	in	ADP
dpc-2121	95	64	the	the	DET
dpc-2121	95	65	same	same	ADJ
dpc-2121	95	66	timepoints	timepoint	NOUN
dpc-2121	95	67	.	.	PUNCT
dpc-2121	96	1	upadacitinib	upadacitinib	NOUN
dpc-2121	96	2	upadacitinib	upadacitinib	NOUN
dpc-2121	96	3	is	be	AUX
dpc-2121	96	4	a	a	DET
dpc-2121	96	5	small	small	ADJ
dpc-2121	96	6	molecule	molecule	NOUN
dpc-2121	96	7	that	that	PRON
dpc-2121	96	8	selectively	selectively	ADV
dpc-2121	96	9	inhibits	inhibit	VERB
dpc-2121	96	10	jak1	jak1	NOUN
dpc-2121	97	1	[	[	X
dpc-2121	97	2	23	23	NUM
dpc-2121	97	3	]	]	PUNCT
dpc-2121	97	4	.	.	PUNCT
dpc-2121	98	1	the	the	DET
dpc-2121	98	2	drug	drug	NOUN
dpc-2121	98	3	is	be	AUX
dpc-2121	98	4	approved	approve	VERB
dpc-2121	98	5	by	by	ADP
dpc-2121	98	6	the	the	DET
dpc-2121	98	7	ema	ema	PROPN
dpc-2121	98	8	for	for	ADP
dpc-2121	98	9	the	the	DET
dpc-2121	98	10	treatment	treatment	NOUN
dpc-2121	98	11	of	of	ADP
dpc-2121	98	12	moderate	moderate	ADJ
dpc-2121	98	13	-	-	PUNCT
dpc-2121	98	14	to	to	ADP
dpc-2121	98	15	-	-	PUNCT
dpc-2121	98	16	severe	severe	ADJ
dpc-2121	98	17	ad	ad	NOUN
dpc-2121	98	18	in	in	ADP
dpc-2121	98	19	patients	patient	NOUN
dpc-2121	98	20	aged	age	VERB
dpc-2121	98	21	12	12	NUM
dpc-2121	98	22	years	year	NOUN
dpc-2121	98	23	or	or	CCONJ
dpc-2121	98	24	older	old	ADJ
dpc-2121	98	25	[	[	X
dpc-2121	98	26	23	23	NUM
dpc-2121	98	27	]	]	PUNCT
dpc-2121	98	28	.	.	PUNCT
dpc-2121	99	1	similarly	similarly	ADV
dpc-2121	99	2	to	to	ADP
dpc-2121	99	3	baricitinib	baricitinib	NOUN
dpc-2121	99	4	,	,	PUNCT
dpc-2121	99	5	upadacitinib	upadacitinib	NOUN
dpc-2121	99	6	is	be	AUX
dpc-2121	99	7	currently	currently	ADV
dpc-2121	99	8	under	under	ADP
dpc-2121	99	9	fda	fda	PROPN
dpc-2121	99	10	evaluation	evaluation	NOUN
dpc-2121	99	11	.	.	PUNCT
dpc-2121	100	1	the	the	DET
dpc-2121	100	2	recommended	recommend	VERB
dpc-2121	100	3	dose	dose	NOUN
dpc-2121	100	4	is	be	AUX
dpc-2121	100	5	15	15	NUM
dpc-2121	100	6	mg	mg	NOUN
dpc-2121	100	7	or	or	CCONJ
dpc-2121	100	8	30	30	NUM
dpc-2121	100	9	mg	mg	NOUN
dpc-2121	100	10	once	once	ADV
dpc-2121	100	11	daily	daily	ADV
dpc-2121	100	12	,	,	PUNCT
dpc-2121	100	13	according	accord	VERB
dpc-2121	100	14	to	to	ADP
dpc-2121	100	15	the	the	DET
dpc-2121	100	16	disease	disease	NOUN
dpc-2121	100	17	burden	burden	NOUN
dpc-2121	100	18	and	and	CCONJ
dpc-2121	100	19	age	age	NOUN
dpc-2121	100	20	of	of	ADP
dpc-2121	100	21	the	the	DET
dpc-2121	100	22	patient	patient	NOUN
dpc-2121	100	23	[	[	X
dpc-2121	100	24	23	23	NUM
dpc-2121	100	25	]	]	PUNCT
dpc-2121	100	26	.	.	PUNCT
dpc-2121	101	1	two	two	NUM
dpc-2121	101	2	16	16	NUM
dpc-2121	101	3	-	-	PUNCT
dpc-2121	101	4	week	week	NOUN
dpc-2121	101	5	phase	phase	NOUN
dpc-2121	101	6	iii	iii	NUM
dpc-2121	101	7	clinical	clinical	ADJ
dpc-2121	101	8	trials	trial	NOUN
dpc-2121	101	9	(	(	PUNCT
dpc-2121	101	10	measure	measure	VERB
dpc-2121	101	11	up	up	ADV
dpc-2121	101	12	1	1	NUM
dpc-2121	101	13	and	and	CCONJ
dpc-2121	101	14	measure	measure	VERB
dpc-2121	101	15	up	up	ADP
dpc-2121	101	16	2	2	NUM
dpc-2121	101	17	)	)	PUNCT
dpc-2121	101	18	compared	compare	VERB
dpc-2121	101	19	upadacitinib	upadacitinib	NOUN
dpc-2121	101	20	monotherapy	monotherapy	NOUN
dpc-2121	101	21	with	with	ADP
dpc-2121	101	22	placebo	placebo	NOUN
dpc-2121	101	23	in	in	ADP
dpc-2121	101	24	patients	patient	NOUN
dpc-2121	101	25	aged	age	VERB
dpc-2121	101	26	12	12	NUM
dpc-2121	101	27	to	to	PART
dpc-2121	101	28	75	75	NUM
dpc-2121	101	29	years	year	NOUN
dpc-2121	101	30	with	with	ADP
dpc-2121	101	31	moderate	moderate	ADJ
dpc-2121	101	32	-	-	PUNCT
dpc-2121	101	33	tosevere	tosevere	NOUN
dpc-2121	101	34	ad	ad	NOUN
dpc-2121	101	35	[	[	X
dpc-2121	101	36	24	24	NUM
dpc-2121	101	37	]	]	PUNCT
dpc-2121	101	38	.	.	PUNCT
dpc-2121	102	1	a	a	DET
dpc-2121	102	2	total	total	NOUN
dpc-2121	102	3	of	of	ADP
dpc-2121	102	4	847	847	NUM
dpc-2121	102	5	patients	patient	NOUN
dpc-2121	102	6	in	in	ADP
dpc-2121	102	7	measure	measure	NOUN
dpc-2121	102	8	up	up	ADV
dpc-2121	102	9	1	1	NUM
dpc-2121	102	10	and	and	CCONJ
dpc-2121	102	11	836	836	NUM
dpc-2121	102	12	patients	patient	NOUN
dpc-2121	102	13	in	in	ADP
dpc-2121	102	14	measure	measure	NOUN
dpc-2121	102	15	up	up	ADP
dpc-2121	102	16	2	2	NUM
dpc-2121	102	17	were	be	AUX
dpc-2121	102	18	randomly	randomly	ADV
dpc-2121	102	19	(	(	PUNCT
dpc-2121	102	20	1:1:1	1:1:1	NUM
dpc-2121	102	21	ratio	ratio	NOUN
dpc-2121	102	22	)	)	PUNCT
dpc-2121	102	23	assigned	assign	VERB
dpc-2121	102	24	to	to	PART
dpc-2121	102	25	receive	receive	VERB
dpc-2121	102	26	either	either	DET
dpc-2121	102	27	upadacitinib	upadacitinib	NOUN
dpc-2121	102	28	15	15	NUM
dpc-2121	102	29	mg	mg	NOUN
dpc-2121	102	30	,	,	PUNCT
dpc-2121	102	31	upadacitinib	upadacitinib	NOUN
dpc-2121	102	32	30	30	NUM
dpc-2121	102	33	mg	mg	NOUN
dpc-2121	102	34	,	,	PUNCT
dpc-2121	102	35	or	or	CCONJ
dpc-2121	102	36	placebo	placebo	NOUN
dpc-2121	102	37	.	.	PUNCT
dpc-2121	103	1	the	the	DET
dpc-2121	103	2	coprimary	coprimary	ADJ
dpc-2121	103	3	endpoints	endpoint	NOUN
dpc-2121	103	4	at	at	ADP
dpc-2121	103	5	week	week	NOUN
dpc-2121	103	6	16	16	NUM
dpc-2121	103	7	(	(	PUNCT
dpc-2121	103	8	easi75	easi75	NOUN
dpc-2121	103	9	and	and	CCONJ
dpc-2121	103	10	viga	viga	NOUN
dpc-2121	103	11	-	-	PUNCT
dpc-2121	103	12	ad	ad	NOUN
dpc-2121	103	13	score	score	NOUN
dpc-2121	103	14	of	of	ADP
dpc-2121	103	15	0/1	0/1	NUM
dpc-2121	103	16	)	)	PUNCT
dpc-2121	103	17	were	be	AUX
dpc-2121	103	18	achieved	achieve	VERB
dpc-2121	103	19	in	in	ADP
dpc-2121	103	20	all	all	DET
dpc-2121	103	21	upadacitinib	upadacitinib	NOUN
dpc-2121	103	22	groups	group	NOUN
dpc-2121	103	23	in	in	ADP
dpc-2121	103	24	both	both	DET
dpc-2121	103	25	measure	measure	NOUN
dpc-2121	103	26	up	up	ADP
dpc-2121	103	27	1	1	NUM
dpc-2121	103	28	[	[	X
dpc-2121	103	29	easi75	easi75	ADV
dpc-2121	103	30	:	:	PUNCT
dpc-2121	103	31	upadacitinib	upadacitinib	NOUN
dpc-2121	103	32	15	15	NUM
dpc-2121	103	33	mg	mg	PROPN
dpc-2121	103	34	69.6	69.6	NUM
dpc-2121	103	35	%	%	NOUN
dpc-2121	103	36	,	,	PUNCT
dpc-2121	103	37	upadacitinib	upadacitinib	NOUN
dpc-2121	103	38	30	30	NUM
dpc-2121	103	39	mg	mg	PROPN
dpc-2121	103	40	79.9	79.9	NUM
dpc-2121	103	41	%	%	NOUN
dpc-2121	103	42	vs.	vs.	ADP
dpc-2121	103	43	placebo	placebo	NOUN
dpc-2121	103	44	16.3	16.3	NUM
dpc-2121	103	45	%	%	NOUN
dpc-2121	103	46	(	(	PUNCT
dpc-2121	103	47	p	p	X
dpc-2121	103	48	<	<	X
dpc-2121	103	49	0.0001	0.0001	NUM
dpc-2121	103	50	)	)	PUNCT
dpc-2121	103	51	;	;	PUNCT
dpc-2121	103	52	viga	viga	NOUN
dpc-2121	103	53	-	-	PUNCT
dpc-2121	103	54	ad	ad	NOUN
dpc-2121	103	55	score	score	NOUN
dpc-2121	103	56	of	of	ADP
dpc-2121	103	57	0/1	0/1	NUM
dpc-2121	103	58	:	:	PUNCT
dpc-2121	103	59	upadacitinib	upadacitinib	NOUN
dpc-2121	103	60	15	15	NUM
dpc-2121	103	61	mg	mg	NUM
dpc-2121	103	62	48.1	48.1	NUM
dpc-2121	103	63	%	%	NOUN
dpc-2121	103	64	,	,	PUNCT
dpc-2121	103	65	upadacitinib	upadacitinib	NOUN
dpc-2121	103	66	30	30	NUM
dpc-2121	103	67	mg	mg	PROPN
dpc-2121	103	68	62.0	62.0	NUM
dpc-2121	103	69	%	%	NOUN
dpc-2121	103	70	vs.	vs.	ADP
dpc-2121	103	71	placebo	placebo	NOUN
dpc-2121	103	72	8.4	8.4	NUM
dpc-2121	103	73	%	%	NOUN
dpc-2121	103	74	(	(	PUNCT
dpc-2121	103	75	p	p	X
dpc-2121	103	76	<	<	X
dpc-2121	103	77	0.0001	0.0001	NUM
dpc-2121	103	78	)	)	PUNCT
dpc-2121	103	79	]	]	PUNCT
dpc-2121	103	80	and	and	CCONJ
dpc-2121	103	81	measure	measure	VERB
dpc-2121	103	82	up	up	ADP
dpc-2121	103	83	2	2	NUM
dpc-2121	103	84	[	[	X
dpc-2121	103	85	easi75	easi75	NOUN
dpc-2121	103	86	:	:	PUNCT
dpc-2121	103	87	upadacitinib	upadacitinib	NOUN
dpc-2121	103	88	15	15	NUM
dpc-2121	103	89	mg	mg	PROPN
dpc-2121	103	90	60.1	60.1	NUM
dpc-2121	103	91	%	%	NOUN
dpc-2121	103	92	,	,	PUNCT
dpc-2121	103	93	upadacitinib	upadacitinib	NOUN
dpc-2121	103	94	30	30	NUM
dpc-2121	103	95	mg	mg	NUM
dpc-2121	103	96	72.9	72.9	NUM
dpc-2121	103	97	%	%	NOUN
dpc-2121	103	98	vs.	vs.	ADP
dpc-2121	103	99	placebo	placebo	NOUN
dpc-2121	103	100	13.3	13.3	NUM
dpc-2121	103	101	%	%	NOUN
dpc-2121	103	102	(	(	PUNCT
dpc-2121	103	103	p	p	X
dpc-2121	103	104	<	<	X
dpc-2121	103	105	0.0001	0.0001	NUM
dpc-2121	103	106	)	)	PUNCT
dpc-2121	103	107	;	;	PUNCT
dpc-2121	103	108	viga	viga	NOUN
dpc-2121	103	109	-	-	PUNCT
dpc-2121	103	110	ad	ad	NOUN
dpc-2121	103	111	score	score	NOUN
dpc-2121	103	112	of	of	ADP
dpc-2121	103	113	0/1	0/1	NUM
dpc-2121	103	114	:	:	PUNCT
dpc-2121	103	115	upadacitinib	upadacitinib	NOUN
dpc-2121	103	116	15	15	NUM
dpc-2121	103	117	mg	mg	NUM
dpc-2121	103	118	38.8	38.8	NUM
dpc-2121	103	119	%	%	NOUN
dpc-2121	103	120	,	,	PUNCT
dpc-2121	103	121	upadacitinib	upadacitinib	NOUN
dpc-2121	103	122	30	30	NUM
dpc-2121	103	123	mg	mg	PROPN
dpc-2121	103	124	52.0	52.0	NUM
dpc-2121	103	125	%	%	NOUN
dpc-2121	103	126	vs.	vs.	ADP
dpc-2121	103	127	placebo	placebo	NOUN
dpc-2121	103	128	4.7	4.7	NUM
dpc-2121	103	129	%	%	NOUN
dpc-2121	103	130	(	(	PUNCT
dpc-2121	103	131	p	p	X
dpc-2121	103	132	<	<	X
dpc-2121	103	133	0.0001	0.0001	NUM
dpc-2121	103	134	)	)	PUNCT
dpc-2121	103	135	]	]	PUNCT
dpc-2121	103	136	.	.	PUNCT
dpc-2121	104	1	the	the	DET
dpc-2121	104	2	secondary	secondary	ADJ
dpc-2121	104	3	endpoints	endpoint	NOUN
dpc-2121	104	4	at	at	ADP
dpc-2121	104	5	week	week	NOUN
dpc-2121	104	6	16	16	NUM
dpc-2121	104	7	were	be	AUX
dpc-2121	104	8	also	also	ADV
dpc-2121	104	9	met	meet	VERB
dpc-2121	104	10	in	in	ADP
dpc-2121	104	11	both	both	DET
dpc-2121	104	12	upadacitinib	upadacitinib	NOUN
dpc-2121	104	13	groups	group	NOUN
dpc-2121	104	14	.	.	PUNCT
dpc-2121	105	1	there	there	PRON
dpc-2121	105	2	was	be	VERB
dpc-2121	105	3	a	a	DET
dpc-2121	105	4	similar	similar	ADJ
dpc-2121	105	5	incidence	incidence	NOUN
dpc-2121	105	6	of	of	ADP
dpc-2121	105	7	serious	serious	ADJ
dpc-2121	105	8	adverse	adverse	ADJ
dpc-2121	105	9	events	event	NOUN
dpc-2121	105	10	and	and	CCONJ
dpc-2121	105	11	adverse	adverse	ADJ
dpc-2121	105	12	events	event	NOUN
dpc-2121	105	13	leading	lead	VERB
dpc-2121	105	14	to	to	PART
dpc-2121	105	15	study	study	VERB
dpc-2121	105	16	dropout	dropout	NOUN
dpc-2121	105	17	between	between	ADP
dpc-2121	105	18	groups	group	NOUN
dpc-2121	105	19	.	.	PUNCT
dpc-2121	106	1	acne	acne	NOUN
dpc-2121	106	2	,	,	PUNCT
dpc-2121	106	3	upper	upper	ADJ
dpc-2121	106	4	respiratory	respiratory	ADJ
dpc-2121	106	5	tract	tract	NOUN
dpc-2121	106	6	infections	infection	NOUN
dpc-2121	106	7	,	,	PUNCT
dpc-2121	106	8	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	106	9	,	,	PUNCT
dpc-2121	106	10	headache	headache	NOUN
dpc-2121	106	11	,	,	PUNCT
dpc-2121	106	12	and	and	CCONJ
dpc-2121	106	13	increase	increase	VERB
dpc-2121	106	14	in	in	ADP
dpc-2121	106	15	serum	serum	PROPN
dpc-2121	106	16	cpk	cpk	PROPN
dpc-2121	106	17	levels	level	NOUN
dpc-2121	106	18	were	be	AUX
dpc-2121	106	19	the	the	DET
dpc-2121	106	20	most	most	ADV
dpc-2121	106	21	frequently	frequently	ADV
dpc-2121	106	22	reported	report	VERB
dpc-2121	106	23	adverse	adverse	ADJ
dpc-2121	106	24	events	event	NOUN
dpc-2121	106	25	.	.	PUNCT
dpc-2121	107	1	regarding	regard	VERB
dpc-2121	107	2	herpes	herpe	NOUN
dpc-2121	107	3	zoster	zoster	NOUN
dpc-2121	107	4	,	,	PUNCT
dpc-2121	107	5	the	the	DET
dpc-2121	107	6	rates	rate	NOUN
dpc-2121	107	7	of	of	ADP
dpc-2121	107	8	infection	infection	NOUN
dpc-2121	107	9	in	in	ADP
dpc-2121	107	10	the	the	DET
dpc-2121	107	11	groups	group	NOUN
dpc-2121	107	12	receiving	receive	VERB
dpc-2121	107	13	upadacitinib	upadacitinib	NOUN
dpc-2121	107	14	were	be	AUX
dpc-2121	107	15	low	low	ADJ
dpc-2121	107	16	(	(	PUNCT
dpc-2121	107	17	<	<	X
dpc-2121	107	18	2	2	NUM
dpc-2121	107	19	%	%	NOUN
dpc-2121	107	20	)	)	PUNCT
dpc-2121	107	21	.	.	PUNCT
dpc-2121	108	1	a	a	DET
dpc-2121	108	2	52	52	NUM
dpc-2121	108	3	-	-	PUNCT
dpc-2121	108	4	week	week	NOUN
dpc-2121	108	5	phase	phase	NOUN
dpc-2121	108	6	iii	iii	NOUN
dpc-2121	108	7	trial	trial	NOUN
dpc-2121	108	8	(	(	PUNCT
dpc-2121	108	9	ad	ad	NOUN
dpc-2121	108	10	up	up	ADP
dpc-2121	108	11	)	)	PUNCT
dpc-2121	108	12	evaluated	evaluate	VERB
dpc-2121	108	13	the	the	DET
dpc-2121	108	14	efficacy	efficacy	NOUN
dpc-2121	108	15	and	and	CCONJ
dpc-2121	108	16	safety	safety	NOUN
dpc-2121	108	17	of	of	ADP
dpc-2121	108	18	combining	combine	VERB
dpc-2121	108	19	upadacitinib	upadacitinib	NOUN
dpc-2121	108	20	with	with	ADP
dpc-2121	108	21	topical	topical	ADJ
dpc-2121	108	22	corticosteroids	corticosteroid	NOUN
dpc-2121	108	23	in	in	ADP
dpc-2121	108	24	patients	patient	NOUN
dpc-2121	108	25	aged	age	VERB
dpc-2121	108	26	12	12	NUM
dpc-2121	108	27	to	to	PART
dpc-2121	108	28	75	75	NUM
dpc-2121	108	29	years	year	NOUN
dpc-2121	108	30	old	old	ADJ
dpc-2121	108	31	[	[	X
dpc-2121	108	32	25,26	25,26	NUM
dpc-2121	108	33	]	]	X
dpc-2121	108	34	.	.	PUNCT
dpc-2121	109	1	in	in	ADP
dpc-2121	109	2	a	a	DET
dpc-2121	109	3	1:1:1	1:1:1	NUM
dpc-2121	109	4	ratio	ratio	NOUN
dpc-2121	109	5	randomization	randomization	NOUN
dpc-2121	109	6	,	,	PUNCT
dpc-2121	109	7	901	901	NUM
dpc-2121	109	8	patients	patient	NOUN
dpc-2121	109	9	were	be	AUX
dpc-2121	109	10	assigned	assign	VERB
dpc-2121	109	11	to	to	PART
dpc-2121	109	12	receive	receive	VERB
dpc-2121	109	13	topical	topical	ADJ
dpc-2121	109	14	corticosteroids	corticosteroid	NOUN
dpc-2121	109	15	plus	plus	CCONJ
dpc-2121	109	16	either	either	CCONJ
dpc-2121	109	17	upadacitinib	upadacitinib	NOUN
dpc-2121	109	18	15	15	NUM
dpc-2121	109	19	mg	mg	NOUN
dpc-2121	109	20	,	,	PUNCT
dpc-2121	109	21	upadacitinib	upadacitinib	NOUN
dpc-2121	109	22	30	30	NUM
dpc-2121	109	23	mg	mg	NOUN
dpc-2121	109	24	or	or	CCONJ
dpc-2121	109	25	placebo	placebo	NOUN
dpc-2121	109	26	[	[	X
dpc-2121	109	27	25,26	25,26	NUM
dpc-2121	109	28	]	]	X
dpc-2121	109	29	.	.	PUNCT
dpc-2121	110	1	the	the	DET
dpc-2121	110	2	coprimary	coprimary	ADJ
dpc-2121	110	3	endpoints	endpoint	NOUN
dpc-2121	110	4	at	at	ADP
dpc-2121	110	5	week	week	NOUN
dpc-2121	110	6	16	16	NUM
dpc-2121	110	7	(	(	PUNCT
dpc-2121	110	8	easi75	easi75	NOUN
dpc-2121	110	9	and	and	CCONJ
dpc-2121	110	10	viga	viga	NOUN
dpc-2121	110	11	-	-	PUNCT
dpc-2121	110	12	ad	ad	NOUN
dpc-2121	110	13	score	score	NOUN
dpc-2121	110	14	of	of	ADP
dpc-2121	110	15	0/1	0/1	NUM
dpc-2121	110	16	)	)	PUNCT
dpc-2121	110	17	were	be	AUX
dpc-2121	110	18	achieved	achieve	VERB
dpc-2121	110	19	in	in	ADP
dpc-2121	110	20	the	the	DET
dpc-2121	110	21	two	two	NUM
dpc-2121	110	22	upadacitinib	upadacitinib	NOUN
dpc-2121	110	23	groups	group	NOUN
dpc-2121	110	24	[	[	X
dpc-2121	110	25	easi75	easi75	ADV
dpc-2121	110	26	:	:	PUNCT
dpc-2121	110	27	upadacitinib	upadacitinib	NOUN
dpc-2121	110	28	15	15	NUM
dpc-2121	110	29	mg	mg	PROPN
dpc-2121	110	30	64.6	64.6	NUM
dpc-2121	110	31	%	%	NOUN
dpc-2121	110	32	,	,	PUNCT
dpc-2121	110	33	upadacitinib	upadacitinib	NOUN
dpc-2121	110	34	30	30	NUM
dpc-2121	110	35	mg	mg	PROPN
dpc-2121	110	36	77.1	77.1	NUM
dpc-2121	110	37	%	%	NOUN
dpc-2121	110	38	vs.	vs.	ADP
dpc-2121	110	39	placebo	placebo	NOUN
dpc-2121	110	40	26.4	26.4	NUM
dpc-2121	110	41	%	%	NOUN
dpc-2121	110	42	(	(	PUNCT
dpc-2121	110	43	p	p	X
dpc-2121	110	44	<	<	X
dpc-2121	110	45	0.0001	0.0001	NUM
dpc-2121	110	46	)	)	PUNCT
dpc-2121	110	47	;	;	PUNCT
dpc-2121	110	48	viga	viga	NOUN
dpc-2121	110	49	-	-	PUNCT
dpc-2121	110	50	ad	ad	NOUN
dpc-2121	110	51	score	score	NOUN
dpc-2121	110	52	of	of	ADP
dpc-2121	110	53	0/1	0/1	NUM
dpc-2121	110	54	:	:	PUNCT
dpc-2121	110	55	upadacitinib	upadacitinib	NOUN
dpc-2121	110	56	15	15	NUM
dpc-2121	110	57	mg	mg	PROPN
dpc-2121	110	58	39.6	39.6	NUM
dpc-2121	110	59	%	%	NOUN
dpc-2121	110	60	,	,	PUNCT
dpc-2121	110	61	upadacitinib	upadacitinib	NOUN
dpc-2121	110	62	30	30	NUM
dpc-2121	110	63	mg	mg	PROPN
dpc-2121	110	64	58.6	58.6	NUM
dpc-2121	110	65	%	%	NOUN
dpc-2121	110	66	vs.	vs.	ADP
dpc-2121	110	67	placebo	placebo	NOUN
dpc-2121	110	68	10.9	10.9	NUM
dpc-2121	110	69	%	%	NOUN
dpc-2121	110	70	(	(	PUNCT
dpc-2121	110	71	p	p	X
dpc-2121	110	72	<	<	X
dpc-2121	110	73	0.0001	0.0001	NUM
dpc-2121	110	74	)	)	PUNCT
dpc-2121	110	75	]	]	PUNCT
dpc-2121	110	76	,	,	PUNCT
dpc-2121	110	77	and	and	CCONJ
dpc-2121	110	78	both	both	DET
dpc-2121	110	79	upadacitinib	upadacitinib	NOUN
dpc-2121	110	80	groups	group	NOUN
dpc-2121	110	81	achieved	achieve	VERB
dpc-2121	110	82	higher	high	ADJ
dpc-2121	110	83	response	response	NOUN
dpc-2121	110	84	rates	rate	NOUN
dpc-2121	110	85	than	than	ADP
dpc-2121	110	86	placebo	placebo	NOUN
dpc-2121	110	87	for	for	ADP
dpc-2121	110	88	all	all	DET
dpc-2121	110	89	key	key	ADJ
dpc-2121	110	90	secondary	secondary	ADJ
dpc-2121	110	91	endpoints	endpoint	NOUN
dpc-2121	110	92	[	[	X
dpc-2121	110	93	25	25	NUM
dpc-2121	110	94	]	]	PUNCT
dpc-2121	110	95	.	.	PUNCT
dpc-2121	111	1	not	not	PART
dpc-2121	111	2	only	only	ADV
dpc-2121	111	3	upadacitinib	upadacitinib	NOUN
dpc-2121	111	4	(	(	PUNCT
dpc-2121	111	5	both	both	DET
dpc-2121	111	6	doses	dose	NOUN
dpc-2121	111	7	)	)	PUNCT
dpc-2121	111	8	demonstrated	demonstrate	VERB
dpc-2121	111	9	6	6	NUM
dpc-2121	111	10	review	review	NOUN
dpc-2121	111	11	|	|	ADV
dpc-2121	111	12	dermatol	dermatol	ADJ
dpc-2121	111	13	pract	pract	NOUN
dpc-2121	111	14	concept	concept	NOUN
dpc-2121	111	15	.	.	PUNCT
dpc-2121	112	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	112	2	to	to	PART
dpc-2121	112	3	have	have	VERB
dpc-2121	112	4	a	a	DET
dpc-2121	112	5	higher	high	ADJ
dpc-2121	112	6	efficacy	efficacy	NOUN
dpc-2121	112	7	,	,	PUNCT
dpc-2121	112	8	but	but	CCONJ
dpc-2121	112	9	also	also	ADV
dpc-2121	112	10	a	a	DET
dpc-2121	112	11	rapid	rapid	ADJ
dpc-2121	112	12	onset	onset	NOUN
dpc-2121	112	13	of	of	ADP
dpc-2121	112	14	action	action	NOUN
dpc-2121	112	15	,	,	PUNCT
dpc-2121	112	16	with	with	ADP
dpc-2121	112	17	differences	difference	NOUN
dpc-2121	112	18	observed	observe	VERB
dpc-2121	112	19	as	as	ADV
dpc-2121	112	20	early	early	ADV
dpc-2121	112	21	as	as	ADP
dpc-2121	112	22	week	week	NOUN
dpc-2121	112	23	2	2	NUM
dpc-2121	112	24	[	[	X
dpc-2121	112	25	25	25	NUM
dpc-2121	112	26	]	]	PUNCT
dpc-2121	112	27	.	.	PUNCT
dpc-2121	113	1	although	although	SCONJ
dpc-2121	113	2	similar	similar	ADJ
dpc-2121	113	3	rates	rate	NOUN
dpc-2121	113	4	of	of	ADP
dpc-2121	113	5	herpes	herpe	NOUN
dpc-2121	113	6	zoster	zoster	NOUN
dpc-2121	113	7	infections	infection	NOUN
dpc-2121	113	8	were	be	AUX
dpc-2121	113	9	observed	observe	VERB
dpc-2121	113	10	across	across	ADP
dpc-2121	113	11	groups	group	NOUN
dpc-2121	113	12	(	(	PUNCT
dpc-2121	113	13	1	1	NUM
dpc-2121	113	14	to	to	PART
dpc-2121	113	15	2	2	NUM
dpc-2121	113	16	%	%	NOUN
dpc-2121	113	17	)	)	PUNCT
dpc-2121	113	18	,	,	PUNCT
dpc-2121	113	19	eczema	eczema	PROPN
dpc-2121	113	20	herpeticum	herpeticum	PROPN
dpc-2121	113	21	was	be	AUX
dpc-2121	113	22	only	only	ADV
dpc-2121	113	23	registered	register	VERB
dpc-2121	113	24	in	in	ADP
dpc-2121	113	25	patients	patient	NOUN
dpc-2121	113	26	receiving	receive	VERB
dpc-2121	113	27	upadacitinib	upadacitinib	NOUN
dpc-2121	113	28	[	[	X
dpc-2121	113	29	25	25	NUM
dpc-2121	113	30	]	]	PUNCT
dpc-2121	113	31	.	.	PUNCT
dpc-2121	114	1	no	no	DET
dpc-2121	114	2	new	new	ADJ
dpc-2121	114	3	safety	safety	NOUN
dpc-2121	114	4	findings	finding	NOUN
dpc-2121	114	5	were	be	AUX
dpc-2121	114	6	reported	report	VERB
dpc-2121	114	7	at	at	ADP
dpc-2121	114	8	week	week	NOUN
dpc-2121	114	9	16	16	NUM
dpc-2121	115	1	[	[	X
dpc-2121	115	2	25	25	NUM
dpc-2121	115	3	]	]	PUNCT
dpc-2121	115	4	.	.	PUNCT
dpc-2121	116	1	for	for	ADP
dpc-2121	116	2	all	all	DET
dpc-2121	116	3	endpoints	endpoint	NOUN
dpc-2121	116	4	,	,	PUNCT
dpc-2121	116	5	efficacy	efficacy	NOUN
dpc-2121	116	6	of	of	ADP
dpc-2121	116	7	both	both	DET
dpc-2121	116	8	dosing	dose	VERB
dpc-2121	116	9	regimens	regimen	NOUN
dpc-2121	116	10	of	of	ADP
dpc-2121	116	11	upadacitinib	upadacitinib	NOUN
dpc-2121	116	12	were	be	AUX
dpc-2121	116	13	maintained	maintain	VERB
dpc-2121	116	14	through	through	ADP
dpc-2121	116	15	week	week	NOUN
dpc-2121	116	16	52	52	NUM
dpc-2121	116	17	[	[	X
dpc-2121	116	18	26	26	NUM
dpc-2121	116	19	]	]	PUNCT
dpc-2121	116	20	.	.	PUNCT
dpc-2121	117	1	no	no	DET
dpc-2121	117	2	new	new	ADJ
dpc-2121	117	3	relevant	relevant	ADJ
dpc-2121	117	4	safety	safety	NOUN
dpc-2121	117	5	events	event	NOUN
dpc-2121	117	6	were	be	AUX
dpc-2121	117	7	reported	report	VERB
dpc-2121	117	8	in	in	ADP
dpc-2121	117	9	the	the	DET
dpc-2121	117	10	extended	extended	ADJ
dpc-2121	117	11	period	period	NOUN
dpc-2121	117	12	[	[	X
dpc-2121	117	13	26	26	NUM
dpc-2121	117	14	]	]	PUNCT
dpc-2121	117	15	.	.	PUNCT
dpc-2121	118	1	upadacitinib	upadacitinib	NOUN
dpc-2121	118	2	was	be	AUX
dpc-2121	118	3	also	also	ADV
dpc-2121	118	4	tested	test	VERB
dpc-2121	118	5	in	in	ADP
dpc-2121	118	6	a	a	DET
dpc-2121	118	7	24	24	NUM
dpc-2121	118	8	-	-	PUNCT
dpc-2121	118	9	week	week	NOUN
dpc-2121	118	10	head	head	NOUN
dpc-2121	118	11	-	-	PUNCT
dpc-2121	118	12	to	to	ADP
dpc-2121	118	13	-	-	PUNCT
dpc-2121	118	14	head	head	NOUN
dpc-2121	118	15	phase	phase	NOUN
dpc-2121	118	16	iii	iii	NUM
dpc-2121	118	17	clinical	clinical	ADJ
dpc-2121	118	18	trial	trial	NOUN
dpc-2121	118	19	(	(	PUNCT
dpc-2121	118	20	heads	head	VERB
dpc-2121	118	21	up	up	ADP
dpc-2121	118	22	)	)	PUNCT
dpc-2121	119	1	[	[	X
dpc-2121	119	2	27	27	NUM
dpc-2121	119	3	]	]	PUNCT
dpc-2121	119	4	.	.	PUNCT
dpc-2121	120	1	a	a	DET
dpc-2121	120	2	total	total	NOUN
dpc-2121	120	3	of	of	ADP
dpc-2121	120	4	692	692	NUM
dpc-2121	120	5	adult	adult	NOUN
dpc-2121	120	6	patients	patient	NOUN
dpc-2121	120	7	with	with	ADP
dpc-2121	120	8	moderate	moderate	ADJ
dpc-2121	120	9	-	-	PUNCT
dpc-2121	120	10	to	to	ADP
dpc-2121	120	11	-	-	PUNCT
dpc-2121	120	12	severe	severe	ADJ
dpc-2121	120	13	ad	ad	NOUN
dpc-2121	120	14	were	be	AUX
dpc-2121	120	15	randomized	randomize	VERB
dpc-2121	120	16	(	(	PUNCT
dpc-2121	120	17	1:1	1:1	NUM
dpc-2121	120	18	ratio	ratio	NOUN
dpc-2121	120	19	)	)	PUNCT
dpc-2121	120	20	to	to	PART
dpc-2121	120	21	receive	receive	VERB
dpc-2121	120	22	either	either	DET
dpc-2121	120	23	upadacitinib	upadacitinib	NOUN
dpc-2121	120	24	30	30	NUM
dpc-2121	120	25	mg	mg	NOUN
dpc-2121	120	26	once	once	ADV
dpc-2121	120	27	daily	daily	ADV
dpc-2121	120	28	or	or	CCONJ
dpc-2121	120	29	dupilumab	dupilumab	NOUN
dpc-2121	120	30	300	300	NUM
dpc-2121	120	31	mg	mg	NOUN
dpc-2121	120	32	every	every	DET
dpc-2121	120	33	other	other	ADJ
dpc-2121	120	34	week	week	NOUN
dpc-2121	120	35	(	(	PUNCT
dpc-2121	120	36	600	600	NUM
dpc-2121	120	37	mg	mg	NOUN
dpc-2121	120	38	as	as	ADP
dpc-2121	120	39	initial	initial	ADJ
dpc-2121	120	40	loading	loading	NOUN
dpc-2121	120	41	dose	dose	NOUN
dpc-2121	120	42	)	)	PUNCT
dpc-2121	120	43	.	.	PUNCT
dpc-2121	121	1	at	at	ADP
dpc-2121	121	2	week	week	NOUN
dpc-2121	121	3	16	16	NUM
dpc-2121	121	4	,	,	PUNCT
dpc-2121	121	5	71.0	71.0	NUM
dpc-2121	121	6	%	%	NOUN
dpc-2121	121	7	patients	patient	NOUN
dpc-2121	121	8	in	in	ADP
dpc-2121	121	9	the	the	DET
dpc-2121	121	10	upadacitinib	upadacitinib	NOUN
dpc-2121	121	11	group	group	NOUN
dpc-2121	121	12	achieved	achieve	VERB
dpc-2121	121	13	easi75	easi75	NOUN
dpc-2121	121	14	,	,	PUNCT
dpc-2121	121	15	compared	compare	VERB
dpc-2121	121	16	to	to	ADP
dpc-2121	121	17	61.1	61.1	NUM
dpc-2121	121	18	%	%	NOUN
dpc-2121	121	19	in	in	ADP
dpc-2121	121	20	the	the	DET
dpc-2121	121	21	dupilumab	dupilumab	NOUN
dpc-2121	121	22	one	one	NUM
dpc-2121	121	23	(	(	PUNCT
dpc-2121	121	24	p	p	X
dpc-2121	121	25	=	=	NOUN
dpc-2121	121	26	0.006	0.006	NUM
dpc-2121	121	27	)	)	PUNCT
dpc-2121	121	28	.	.	PUNCT
dpc-2121	122	1	in	in	ADP
dpc-2121	122	2	addition	addition	NOUN
dpc-2121	122	3	,	,	PUNCT
dpc-2121	122	4	upadacitinib	upadacitinib	NOUN
dpc-2121	122	5	demonstrated	demonstrate	VERB
dpc-2121	122	6	to	to	PART
dpc-2121	122	7	have	have	VERB
dpc-2121	122	8	a	a	DET
dpc-2121	122	9	faster	fast	ADJ
dpc-2121	122	10	onset	onset	NOUN
dpc-2121	122	11	of	of	ADP
dpc-2121	122	12	action	action	NOUN
dpc-2121	122	13	when	when	SCONJ
dpc-2121	122	14	compared	compare	VERB
dpc-2121	122	15	to	to	ADP
dpc-2121	122	16	dupilumab	dupilumab	NOUN
dpc-2121	122	17	:	:	PUNCT
dpc-2121	122	18	43.7	43.7	NUM
dpc-2121	122	19	%	%	NOUN
dpc-2121	122	20	of	of	ADP
dpc-2121	122	21	patients	patient	NOUN
dpc-2121	122	22	receiving	receive	VERB
dpc-2121	122	23	upadacitinib	upadacitinib	NOUN
dpc-2121	122	24	achieved	achieve	VERB
dpc-2121	122	25	easi75	easi75	NOUN
dpc-2121	122	26	at	at	ADP
dpc-2121	122	27	week	week	NOUN
dpc-2121	122	28	2	2	NUM
dpc-2121	122	29	,	,	PUNCT
dpc-2121	122	30	compared	compare	VERB
dpc-2121	122	31	to	to	ADP
dpc-2121	122	32	17.4	17.4	NUM
dpc-2121	122	33	%	%	NOUN
dpc-2121	122	34	of	of	ADP
dpc-2121	122	35	those	those	DET
dpc-2121	122	36	receiving	receive	VERB
dpc-2121	122	37	dupilumab	dupilumab	NOUN
dpc-2121	122	38	.	.	PUNCT
dpc-2121	123	1	no	no	DET
dpc-2121	123	2	new	new	ADJ
dpc-2121	123	3	safety	safety	NOUN
dpc-2121	123	4	-	-	PUNCT
dpc-2121	123	5	related	relate	VERB
dpc-2121	123	6	events	event	NOUN
dpc-2121	123	7	were	be	AUX
dpc-2121	123	8	registered	register	VERB
dpc-2121	123	9	compared	compare	VERB
dpc-2121	123	10	to	to	ADP
dpc-2121	123	11	the	the	DET
dpc-2121	123	12	already	already	ADV
dpc-2121	123	13	available	available	ADJ
dpc-2121	123	14	data	datum	NOUN
dpc-2121	123	15	for	for	ADP
dpc-2121	123	16	both	both	DET
dpc-2121	123	17	drugs	drug	NOUN
dpc-2121	123	18	.	.	PUNCT
dpc-2121	124	1	it	it	PRON
dpc-2121	124	2	was	be	AUX
dpc-2121	124	3	verified	verify	VERB
dpc-2121	124	4	a	a	DET
dpc-2121	124	5	higher	high	ADJ
dpc-2121	124	6	rate	rate	NOUN
dpc-2121	124	7	of	of	ADP
dpc-2121	124	8	serious	serious	ADJ
dpc-2121	124	9	infections	infection	NOUN
dpc-2121	124	10	,	,	PUNCT
dpc-2121	124	11	herpes	herpe	NOUN
dpc-2121	124	12	zoster	zoster	NOUN
dpc-2121	124	13	,	,	PUNCT
dpc-2121	124	14	eczema	eczema	NOUN
dpc-2121	124	15	herpeticum	herpeticum	NOUN
dpc-2121	124	16	,	,	PUNCT
dpc-2121	124	17	and	and	CCONJ
dpc-2121	124	18	laboratory	laboratory	NOUN
dpc-2121	124	19	adverse	adverse	ADJ
dpc-2121	124	20	events	event	NOUN
dpc-2121	124	21	in	in	ADP
dpc-2121	124	22	the	the	DET
dpc-2121	124	23	group	group	NOUN
dpc-2121	124	24	of	of	ADP
dpc-2121	124	25	patients	patient	NOUN
dpc-2121	124	26	receiving	receive	VERB
dpc-2121	124	27	upadacitinib	upadacitinib	NOUN
dpc-2121	124	28	whereas	whereas	SCONJ
dpc-2121	124	29	rates	rate	NOUN
dpc-2121	124	30	of	of	ADP
dpc-2121	124	31	conjunctivitis	conjunctivitis	NOUN
dpc-2121	124	32	and	and	CCONJ
dpc-2121	124	33	injection	injection	NOUN
dpc-2121	124	34	-	-	PUNCT
dpc-2121	124	35	site	site	NOUN
dpc-2121	124	36	reactions	reaction	NOUN
dpc-2121	124	37	were	be	AUX
dpc-2121	124	38	higher	high	ADJ
dpc-2121	124	39	in	in	ADP
dpc-2121	124	40	the	the	DET
dpc-2121	124	41	dupilumab	dupilumab	NOUN
dpc-2121	124	42	group	group	NOUN
dpc-2121	124	43	.	.	PUNCT
dpc-2121	125	1	one	one	NUM
dpc-2121	125	2	treatment	treatment	NOUN
dpc-2121	125	3	-	-	PUNCT
dpc-2121	125	4	emergent	emergent	NOUN
dpc-2121	125	5	death	death	NOUN
dpc-2121	125	6	occurred	occur	VERB
dpc-2121	125	7	in	in	ADP
dpc-2121	125	8	the	the	DET
dpc-2121	125	9	upadacitinib	upadacitinib	NOUN
dpc-2121	125	10	group	group	NOUN
dpc-2121	125	11	due	due	ADP
dpc-2121	125	12	to	to	ADP
dpc-2121	125	13	a	a	DET
dpc-2121	125	14	viral	viral	ADJ
dpc-2121	125	15	bronchopneumonia	bronchopneumonia	NOUN
dpc-2121	125	16	.	.	PUNCT
dpc-2121	126	1	abrocitinib	abrocitinib	PROPN
dpc-2121	126	2	abrocitinib	abrocitinib	PROPN
dpc-2121	126	3	is	be	AUX
dpc-2121	126	4	a	a	DET
dpc-2121	126	5	jak1	jak1	NOUN
dpc-2121	126	6	selective	selective	ADJ
dpc-2121	126	7	inhibitor	inhibitor	NOUN
dpc-2121	126	8	that	that	PRON
dpc-2121	126	9	,	,	PUNCT
dpc-2121	126	10	differently	differently	ADV
dpc-2121	126	11	from	from	ADP
dpc-2121	126	12	the	the	DET
dpc-2121	126	13	previous	previous	ADJ
dpc-2121	126	14	drugs	drug	NOUN
dpc-2121	126	15	,	,	PUNCT
dpc-2121	126	16	has	have	AUX
dpc-2121	126	17	neither	neither	CCONJ
dpc-2121	126	18	received	receive	VERB
dpc-2121	126	19	fda	fda	PROPN
dpc-2121	126	20	or	or	CCONJ
dpc-2121	126	21	ema	ema	PROPN
dpc-2121	126	22	approval	approval	NOUN
dpc-2121	126	23	yet	yet	ADV
dpc-2121	126	24	.	.	PUNCT
dpc-2121	127	1	fda	fda	PROPN
dpc-2121	127	2	is	be	AUX
dpc-2121	127	3	now	now	ADV
dpc-2121	127	4	reviewing	review	VERB
dpc-2121	127	5	the	the	DET
dpc-2121	127	6	new	new	ADJ
dpc-2121	127	7	drug	drug	NOUN
dpc-2121	127	8	application	application	NOUN
dpc-2121	127	9	for	for	ADP
dpc-2121	127	10	abrocitinib	abrocitinib	NOUN
dpc-2121	127	11	,	,	PUNCT
dpc-2121	127	12	and	and	CCONJ
dpc-2121	127	13	a	a	DET
dpc-2121	127	14	decision	decision	NOUN
dpc-2121	127	15	is	be	AUX
dpc-2121	127	16	expected	expect	VERB
dpc-2121	127	17	soon	soon	ADV
dpc-2121	127	18	after	after	ADV
dpc-2121	127	19	.	.	PUNCT
dpc-2121	128	1	two	two	NUM
dpc-2121	128	2	12	12	NUM
dpc-2121	128	3	-	-	PUNCT
dpc-2121	128	4	week	week	NOUN
dpc-2121	128	5	similarly	similarly	ADV
dpc-2121	128	6	designed	design	VERB
dpc-2121	128	7	phase	phase	NOUN
dpc-2121	128	8	iii	iii	NUM
dpc-2121	128	9	trials	trial	NOUN
dpc-2121	128	10	(	(	PUNCT
dpc-2121	128	11	jade	jade	NOUN
dpc-2121	128	12	mono-1	mono-1	PROPN
dpc-2121	128	13	and	and	CCONJ
dpc-2121	128	14	jade	jade	PROPN
dpc-2121	128	15	mono-2	mono-2	PROPN
dpc-2121	128	16	)	)	PUNCT
dpc-2121	128	17	[	[	X
dpc-2121	128	18	28,29	28,29	X
dpc-2121	128	19	]	]	PUNCT
dpc-2121	128	20	compared	compare	VERB
dpc-2121	128	21	abrocitinib	abrocitinib	NOUN
dpc-2121	128	22	monotherapy	monotherapy	NOUN
dpc-2121	128	23	(	(	PUNCT
dpc-2121	128	24	100	100	NUM
dpc-2121	128	25	mg	mg	NOUN
dpc-2121	128	26	and	and	CCONJ
dpc-2121	128	27	200	200	NUM
dpc-2121	128	28	mg	mg	NOUN
dpc-2121	128	29	once	once	ADV
dpc-2121	128	30	daily	daily	ADV
dpc-2121	128	31	)	)	PUNCT
dpc-2121	128	32	with	with	ADP
dpc-2121	128	33	placebo	placebo	NOUN
dpc-2121	128	34	in	in	ADP
dpc-2121	128	35	a	a	DET
dpc-2121	128	36	total	total	NOUN
dpc-2121	128	37	of	of	ADP
dpc-2121	128	38	778	778	NUM
dpc-2121	128	39	patients	patient	NOUN
dpc-2121	128	40	with	with	ADP
dpc-2121	128	41	moderate	moderate	ADJ
dpc-2121	128	42	-	-	PUNCT
dpc-2121	128	43	to	to	ADP
dpc-2121	128	44	-	-	PUNCT
dpc-2121	128	45	severe	severe	ADJ
dpc-2121	128	46	ad	ad	NOUN
dpc-2121	128	47	aged	age	VERB
dpc-2121	128	48	12	12	NUM
dpc-2121	128	49	years	year	NOUN
dpc-2121	128	50	or	or	CCONJ
dpc-2121	128	51	older	old	ADJ
dpc-2121	128	52	.	.	PUNCT
dpc-2121	129	1	both	both	DET
dpc-2121	129	2	dosing	dose	VERB
dpc-2121	129	3	regimens	regimen	NOUN
dpc-2121	129	4	of	of	ADP
dpc-2121	129	5	abrocitinib	abrocitinib	NOUN
dpc-2121	129	6	met	meet	VERB
dpc-2121	129	7	the	the	DET
dpc-2121	129	8	coprimary	coprimary	ADJ
dpc-2121	129	9	endpoints	endpoint	NOUN
dpc-2121	129	10	at	at	ADP
dpc-2121	129	11	week	week	NOUN
dpc-2121	129	12	12	12	NUM
dpc-2121	129	13	(	(	PUNCT
dpc-2121	129	14	easi75	easi75	NOUN
dpc-2121	129	15	and	and	CCONJ
dpc-2121	129	16	investigator	investigator	NOUN
dpc-2121	129	17	global	global	ADJ
dpc-2121	129	18	assessment	assessment	NOUN
dpc-2121	129	19	(	(	PUNCT
dpc-2121	129	20	iga	iga	PROPN
dpc-2121	129	21	)	)	PUNCT
dpc-2121	129	22	score	score	NOUN
dpc-2121	129	23	of	of	ADP
dpc-2121	129	24	0	0	NUM
dpc-2121	129	25	or	or	CCONJ
dpc-2121	129	26	1	1	NUM
dpc-2121	129	27	)	)	PUNCT
dpc-2121	129	28	in	in	ADP
dpc-2121	129	29	both	both	DET
dpc-2121	129	30	jade	jade	NOUN
dpc-2121	129	31	mono-1	mono-1	PROPN
dpc-2121	130	1	[	[	X
dpc-2121	130	2	easi75	easi75	ADJ
dpc-2121	130	3	:	:	PUNCT
dpc-2121	130	4	abrocitinib	abrocitinib	NOUN
dpc-2121	130	5	100	100	NUM
dpc-2121	130	6	mg	mg	NUM
dpc-2121	130	7	40	40	NUM
dpc-2121	130	8	%	%	NOUN
dpc-2121	130	9	,	,	PUNCT
dpc-2121	130	10	abrocitinib	abrocitinib	NOUN
dpc-2121	130	11	200	200	NUM
dpc-2121	130	12	mg	mg	NUM
dpc-2121	130	13	63	63	NUM
dpc-2121	130	14	%	%	NOUN
dpc-2121	130	15	vs.	vs.	ADP
dpc-2121	130	16	placebo	placebo	NOUN
dpc-2121	130	17	12	12	NUM
dpc-2121	130	18	%	%	NOUN
dpc-2121	130	19	(	(	PUNCT
dpc-2121	130	20	p	p	X
dpc-2121	130	21	<	<	X
dpc-2121	130	22	0.0001	0.0001	NUM
dpc-2121	130	23	)	)	PUNCT
dpc-2121	130	24	;	;	PUNCT
dpc-2121	130	25	iga	iga	PROPN
dpc-2121	130	26	score	score	NOUN
dpc-2121	130	27	of	of	ADP
dpc-2121	130	28	0/1	0/1	NUM
dpc-2121	130	29	:	:	PUNCT
dpc-2121	130	30	abrocitinib	abrocitinib	NOUN
dpc-2121	130	31	100	100	NUM
dpc-2121	130	32	mg	mg	NUM
dpc-2121	130	33	24	24	NUM
dpc-2121	130	34	%	%	NOUN
dpc-2121	130	35	,	,	PUNCT
dpc-2121	130	36	abrocitinib	abrocitinib	NOUN
dpc-2121	130	37	200	200	NUM
dpc-2121	130	38	mg	mg	NUM
dpc-2121	130	39	44	44	NUM
dpc-2121	130	40	%	%	NOUN
dpc-2121	130	41	vs.	vs.	ADP
dpc-2121	130	42	placebo	placebo	NOUN
dpc-2121	130	43	8	8	NUM
dpc-2121	130	44	%	%	NOUN
dpc-2121	130	45	(	(	PUNCT
dpc-2121	130	46	p	p	NOUN
dpc-2121	130	47	=	=	PROPN
dpc-2121	130	48	0.0037	0.0037	NUM
dpc-2121	130	49	and	and	CCONJ
dpc-2121	130	50	p	p	X
dpc-2121	130	51	<	<	X
dpc-2121	130	52	0.0001	0.0001	NUM
dpc-2121	130	53	,	,	PUNCT
dpc-2121	130	54	respectively	respectively	ADV
dpc-2121	130	55	)	)	PUNCT
dpc-2121	130	56	]	]	PUNCT
dpc-2121	130	57	and	and	CCONJ
dpc-2121	130	58	jade	jade	PROPN
dpc-2121	130	59	mono-2	mono-2	NUM
dpc-2121	130	60	[	[	NOUN
dpc-2121	130	61	easi	easi	NOUN
dpc-2121	130	62	75	75	NUM
dpc-2121	130	63	:	:	PUNCT
dpc-2121	130	64	abrocitinib	abrocitinib	NOUN
dpc-2121	130	65	100	100	NUM
dpc-2121	130	66	mg	mg	NUM
dpc-2121	130	67	45	45	NUM
dpc-2121	130	68	%	%	NOUN
dpc-2121	130	69	,	,	PUNCT
dpc-2121	130	70	abrocitinib	abrocitinib	NOUN
dpc-2121	130	71	200	200	NUM
dpc-2121	130	72	mg	mg	NUM
dpc-2121	130	73	61	61	NUM
dpc-2121	130	74	%	%	NOUN
dpc-2121	130	75	vs.	vs.	ADP
dpc-2121	130	76	placebo	placebo	NOUN
dpc-2121	130	77	10	10	NUM
dpc-2121	130	78	%	%	NOUN
dpc-2121	130	79	(	(	PUNCT
dpc-2121	130	80	p	p	X
dpc-2121	130	81	<	<	X
dpc-2121	130	82	0.001	0.001	NUM
dpc-2121	130	83	)	)	PUNCT
dpc-2121	130	84	;	;	PUNCT
dpc-2121	130	85	iga	iga	PROPN
dpc-2121	130	86	score	score	NOUN
dpc-2121	130	87	of	of	ADP
dpc-2121	130	88	0/1	0/1	NUM
dpc-2121	130	89	:	:	PUNCT
dpc-2121	130	90	abrocitinib	abrocitinib	NOUN
dpc-2121	130	91	100	100	NUM
dpc-2121	130	92	mg	mg	NUM
dpc-2121	130	93	28	28	NUM
dpc-2121	130	94	%	%	NOUN
dpc-2121	130	95	,	,	PUNCT
dpc-2121	130	96	abrocitinib	abrocitinib	NOUN
dpc-2121	130	97	200	200	NUM
dpc-2121	130	98	mg	mg	NUM
dpc-2121	130	99	38	38	NUM
dpc-2121	130	100	%	%	NOUN
dpc-2121	130	101	vs.	vs.	ADP
dpc-2121	130	102	placebo	placebo	NOUN
dpc-2121	130	103	9	9	NUM
dpc-2121	130	104	%	%	NOUN
dpc-2121	130	105	(	(	PUNCT
dpc-2121	130	106	p	p	X
dpc-2121	130	107	<	<	X
dpc-2121	130	108	0.001	0.001	NUM
dpc-2121	130	109	)	)	PUNCT
dpc-2121	130	110	]	]	PUNCT
dpc-2121	130	111	.	.	PUNCT
dpc-2121	131	1	regarding	regard	VERB
dpc-2121	131	2	safety	safety	NOUN
dpc-2121	131	3	,	,	PUNCT
dpc-2121	131	4	treatment	treatment	NOUN
dpc-2121	131	5	-	-	PUNCT
dpc-2121	131	6	emergent	emergent	ADJ
dpc-2121	131	7	adverse	adverse	ADJ
dpc-2121	131	8	events	event	NOUN
dpc-2121	131	9	were	be	AUX
dpc-2121	131	10	more	more	ADV
dpc-2121	131	11	frequently	frequently	ADV
dpc-2121	131	12	registered	register	VERB
dpc-2121	131	13	in	in	ADP
dpc-2121	131	14	patients	patient	NOUN
dpc-2121	131	15	receiving	receive	VERB
dpc-2121	131	16	abrocitinib	abrocitinib	NOUN
dpc-2121	131	17	in	in	ADP
dpc-2121	131	18	both	both	DET
dpc-2121	131	19	trials	trial	NOUN
dpc-2121	131	20	(	(	PUNCT
dpc-2121	131	21	69	69	NUM
dpc-2121	131	22	78	78	NUM
dpc-2121	131	23	%	%	NOUN
dpc-2121	131	24	in	in	ADP
dpc-2121	131	25	abrocitinib	abrocitinib	NOUN
dpc-2121	131	26	groups	group	NOUN
dpc-2121	131	27	and	and	CCONJ
dpc-2121	131	28	57	57	NUM
dpc-2121	131	29	%	%	NOUN
dpc-2121	131	30	in	in	ADP
dpc-2121	131	31	placebo	placebo	NOUN
dpc-2121	131	32	group	group	NOUN
dpc-2121	131	33	in	in	ADP
dpc-2121	131	34	jade	jade	PROPN
dpc-2121	131	35	mono-1	mono-1	PROPN
dpc-2121	131	36	;	;	PUNCT
dpc-2121	131	37	63	63	NUM
dpc-2121	131	38	66	66	NUM
dpc-2121	131	39	%	%	NOUN
dpc-2121	131	40	in	in	ADP
dpc-2121	131	41	abrocitinib	abrocitinib	NOUN
dpc-2121	131	42	groups	group	NOUN
dpc-2121	131	43	and	and	CCONJ
dpc-2121	131	44	42	42	NUM
dpc-2121	131	45	%	%	NOUN
dpc-2121	131	46	in	in	ADP
dpc-2121	131	47	placebo	placebo	NOUN
dpc-2121	131	48	group	group	NOUN
dpc-2121	131	49	in	in	ADP
dpc-2121	131	50	jade	jade	NOUN
dpc-2121	131	51	-	-	PUNCT
dpc-2121	131	52	mono-2	mono-2	NOUN
dpc-2121	131	53	)	)	PUNCT
dpc-2121	131	54	,	,	PUNCT
dpc-2121	131	55	but	but	CCONJ
dpc-2121	131	56	there	there	PRON
dpc-2121	131	57	was	be	VERB
dpc-2121	131	58	a	a	DET
dpc-2121	131	59	similar	similar	ADJ
dpc-2121	131	60	rate	rate	NOUN
dpc-2121	131	61	of	of	ADP
dpc-2121	131	62	serious	serious	ADJ
dpc-2121	131	63	adverse	adverse	ADJ
dpc-2121	131	64	events	event	NOUN
dpc-2121	131	65	with	with	ADP
dpc-2121	131	66	abrocitinib	abrocitinib	NOUN
dpc-2121	131	67	when	when	SCONJ
dpc-2121	131	68	comparing	compare	VERB
dpc-2121	131	69	to	to	ADP
dpc-2121	131	70	the	the	DET
dpc-2121	131	71	placebo	placebo	NOUN
dpc-2121	131	72	group	group	NOUN
dpc-2121	131	73	.	.	PUNCT
dpc-2121	132	1	despite	despite	SCONJ
dpc-2121	132	2	the	the	DET
dpc-2121	132	3	low	low	ADJ
dpc-2121	132	4	rates	rate	NOUN
dpc-2121	132	5	,	,	PUNCT
dpc-2121	132	6	herpes	herpe	NOUN
dpc-2121	132	7	simplex	simplex	NOUN
dpc-2121	132	8	infection	infection	NOUN
dpc-2121	132	9	was	be	AUX
dpc-2121	132	10	only	only	ADV
dpc-2121	132	11	observed	observe	VERB
dpc-2121	132	12	in	in	ADP
dpc-2121	132	13	patients	patient	NOUN
dpc-2121	132	14	receiving	receive	VERB
dpc-2121	132	15	abrocitinib	abrocitinib	NOUN
dpc-2121	132	16	.	.	PUNCT
dpc-2121	133	1	nausea	nausea	NOUN
dpc-2121	133	2	,	,	PUNCT
dpc-2121	133	3	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	133	4	,	,	PUNCT
dpc-2121	133	5	and	and	CCONJ
dpc-2121	133	6	headache	headache	NOUN
dpc-2121	133	7	were	be	AUX
dpc-2121	133	8	the	the	DET
dpc-2121	133	9	most	most	ADV
dpc-2121	133	10	commonly	commonly	ADV
dpc-2121	133	11	reported	report	VERB
dpc-2121	133	12	adverse	adverse	ADJ
dpc-2121	133	13	events	event	NOUN
dpc-2121	133	14	,	,	PUNCT
dpc-2121	133	15	but	but	CCONJ
dpc-2121	133	16	there	there	PRON
dpc-2121	133	17	was	be	VERB
dpc-2121	133	18	also	also	ADV
dpc-2121	133	19	a	a	DET
dpc-2121	133	20	relevant	relevant	ADJ
dpc-2121	133	21	mention	mention	NOUN
dpc-2121	133	22	to	to	PART
dpc-2121	133	23	dose	dose	VERB
dpc-2121	133	24	-	-	PUNCT
dpc-2121	133	25	dependent	dependent	ADJ
dpc-2121	133	26	acne	acne	NOUN
dpc-2121	133	27	after	after	ADP
dpc-2121	133	28	abrocitinib	abrocitinib	NOUN
dpc-2121	133	29	.	.	PUNCT
dpc-2121	134	1	no	no	DET
dpc-2121	134	2	deaths	death	NOUN
dpc-2121	134	3	occurred	occur	VERB
dpc-2121	134	4	.	.	PUNCT
dpc-2121	135	1	patients	patient	NOUN
dpc-2121	135	2	that	that	PRON
dpc-2121	135	3	completed	complete	VERB
dpc-2121	135	4	16	16	NUM
dpc-2121	135	5	weeks	week	NOUN
dpc-2121	135	6	of	of	ADP
dpc-2121	135	7	treatment	treatment	NOUN
dpc-2121	135	8	in	in	ADP
dpc-2121	135	9	jade	jade	PROPN
dpc-2121	135	10	mono-1	mono-1	PROPN
dpc-2121	135	11	and	and	CCONJ
dpc-2121	135	12	jade	jade	PROPN
dpc-2121	135	13	mono-2	mono-2	NUM
dpc-2121	135	14	were	be	AUX
dpc-2121	135	15	invited	invite	VERB
dpc-2121	135	16	to	to	PART
dpc-2121	135	17	enroll	enroll	VERB
dpc-2121	135	18	an	an	DET
dpc-2121	135	19	ongoing	ongoing	ADJ
dpc-2121	135	20	phase	phase	NOUN
dpc-2121	135	21	iii	iii	NUM
dpc-2121	135	22	long	long	ADJ
dpc-2121	135	23	-	-	PUNCT
dpc-2121	135	24	term	term	NOUN
dpc-2121	135	25	extension	extension	NOUN
dpc-2121	135	26	study	study	NOUN
dpc-2121	135	27	(	(	PUNCT
dpc-2121	135	28	jade	jade	NOUN
dpc-2121	135	29	extend	extend	NOUN
dpc-2121	135	30	–	–	PUNCT
dpc-2121	135	31	nct03422822	nct03422822	NOUN
dpc-2121	135	32	)	)	PUNCT
dpc-2121	135	33	including	include	VERB
dpc-2121	135	34	92	92	NUM
dpc-2121	135	35	weeks	week	NOUN
dpc-2121	135	36	of	of	ADP
dpc-2121	135	37	treatment	treatment	NOUN
dpc-2121	135	38	with	with	ADP
dpc-2121	135	39	abrocitinib	abrocitinib	NOUN
dpc-2121	135	40	(	(	PUNCT
dpc-2121	135	41	100	100	NUM
dpc-2121	135	42	mg	mg	ADP
dpc-2121	135	43	or	or	CCONJ
dpc-2121	135	44	200	200	NUM
dpc-2121	135	45	mg	mg	NOUN
dpc-2121	135	46	)	)	PUNCT
dpc-2121	135	47	with	with	ADP
dpc-2121	135	48	or	or	CCONJ
dpc-2121	135	49	without	without	ADP
dpc-2121	135	50	concomitant	concomitant	ADJ
dpc-2121	135	51	topical	topical	ADJ
dpc-2121	135	52	corticosteroids	corticosteroid	NOUN
dpc-2121	135	53	.	.	PUNCT
dpc-2121	136	1	an	an	DET
dpc-2121	136	2	active	active	ADV
dpc-2121	136	3	-	-	PUNCT
dpc-2121	136	4	controlled	control	VERB
dpc-2121	136	5	16	16	NUM
dpc-2121	136	6	-	-	PUNCT
dpc-2121	136	7	week	week	NOUN
dpc-2121	136	8	phase	phase	NOUN
dpc-2121	136	9	iii	iii	NUM
dpc-2121	136	10	clinical	clinical	ADJ
dpc-2121	136	11	trial	trial	NOUN
dpc-2121	136	12	(	(	PUNCT
dpc-2121	136	13	jade	jade	PROPN
dpc-2121	136	14	compare	compare	PROPN
dpc-2121	136	15	)	)	PUNCT
dpc-2121	136	16	enrolled	enrol	VERB
dpc-2121	136	17	a	a	DET
dpc-2121	136	18	total	total	NOUN
dpc-2121	136	19	of	of	ADP
dpc-2121	136	20	838	838	NUM
dpc-2121	136	21	adult	adult	NOUN
dpc-2121	136	22	patients	patient	NOUN
dpc-2121	136	23	with	with	ADP
dpc-2121	136	24	moderate	moderate	ADJ
dpc-2121	136	25	-	-	PUNCT
dpc-2121	136	26	to	to	ADP
dpc-2121	136	27	-	-	PUNCT
dpc-2121	136	28	severe	severe	ADJ
dpc-2121	136	29	ad	ad	NOUN
dpc-2121	136	30	and	and	CCONJ
dpc-2121	136	31	compared	compare	VERB
dpc-2121	136	32	the	the	DET
dpc-2121	136	33	efficacy	efficacy	NOUN
dpc-2121	136	34	and	and	CCONJ
dpc-2121	136	35	safety	safety	NOUN
dpc-2121	136	36	of	of	ADP
dpc-2121	136	37	abrocitinib	abrocitinib	NOUN
dpc-2121	136	38	(	(	PUNCT
dpc-2121	136	39	100	100	NUM
dpc-2121	136	40	mg	mg	ADP
dpc-2121	136	41	or	or	CCONJ
dpc-2121	136	42	200	200	NUM
dpc-2121	136	43	mg	mg	NOUN
dpc-2121	136	44	)	)	PUNCT
dpc-2121	136	45	with	with	ADP
dpc-2121	136	46	dupilumab	dupilumab	NOUN
dpc-2121	136	47	300	300	NUM
dpc-2121	136	48	mg	mg	NOUN
dpc-2121	136	49	every	every	DET
dpc-2121	136	50	other	other	ADJ
dpc-2121	136	51	week	week	NOUN
dpc-2121	136	52	(	(	PUNCT
dpc-2121	136	53	600	600	NUM
dpc-2121	136	54	mg	mg	NOUN
dpc-2121	136	55	of	of	ADP
dpc-2121	136	56	initial	initial	ADJ
dpc-2121	136	57	loading	loading	NOUN
dpc-2121	136	58	dose	dose	NOUN
dpc-2121	136	59	)	)	PUNCT
dpc-2121	136	60	and	and	CCONJ
dpc-2121	136	61	placebo	placebo	NOUN
dpc-2121	136	62	[	[	X
dpc-2121	136	63	30	30	NUM
dpc-2121	136	64	]	]	PUNCT
dpc-2121	136	65	.	.	PUNCT
dpc-2121	137	1	in	in	ADP
dpc-2121	137	2	this	this	DET
dpc-2121	137	3	study	study	NOUN
dpc-2121	137	4	,	,	PUNCT
dpc-2121	137	5	all	all	DET
dpc-2121	137	6	patients	patient	NOUN
dpc-2121	137	7	received	receive	VERB
dpc-2121	137	8	concomitant	concomitant	ADJ
dpc-2121	137	9	topical	topical	ADJ
dpc-2121	137	10	corticosteroids	corticosteroid	NOUN
dpc-2121	137	11	.	.	PUNCT
dpc-2121	138	1	easi75	easi75	PROPN
dpc-2121	138	2	was	be	AUX
dpc-2121	138	3	achieved	achieve	VERB
dpc-2121	138	4	by	by	ADP
dpc-2121	138	5	58.7	58.7	NUM
dpc-2121	138	6	%	%	NOUN
dpc-2121	138	7	of	of	ADP
dpc-2121	138	8	patients	patient	NOUN
dpc-2121	138	9	in	in	ADP
dpc-2121	138	10	abrocitinib	abrocitinib	NOUN
dpc-2121	138	11	100	100	NUM
dpc-2121	138	12	mg	mg	PROPN
dpc-2121	138	13	group	group	NOUN
dpc-2121	138	14	,	,	PUNCT
dpc-2121	138	15	70.3	70.3	NUM
dpc-2121	138	16	%	%	NOUN
dpc-2121	138	17	in	in	ADP
dpc-2121	138	18	abrocitinib	abrocitinib	NOUN
dpc-2121	138	19	200	200	NUM
dpc-2121	138	20	mg	mg	PROPN
dpc-2121	138	21	group	group	NOUN
dpc-2121	138	22	,	,	PUNCT
dpc-2121	138	23	58.1	58.1	NUM
dpc-2121	138	24	%	%	NOUN
dpc-2121	138	25	in	in	ADP
dpc-2121	138	26	dupilumab	dupilumab	NOUN
dpc-2121	138	27	group	group	NOUN
dpc-2121	138	28	,	,	PUNCT
dpc-2121	138	29	and	and	CCONJ
dpc-2121	138	30	27.1	27.1	NUM
dpc-2121	138	31	%	%	NOUN
dpc-2121	138	32	in	in	ADP
dpc-2121	138	33	placebo	placebo	NOUN
dpc-2121	138	34	group	group	NOUN
dpc-2121	138	35	.	.	PUNCT
dpc-2121	139	1	the	the	DET
dpc-2121	139	2	goal	goal	NOUN
dpc-2121	139	3	of	of	ADP
dpc-2121	139	4	an	an	DET
dpc-2121	139	5	iga	iga	PROPN
dpc-2121	139	6	score	score	NOUN
dpc-2121	139	7	of	of	ADP
dpc-2121	139	8	0/1	0/1	NUM
dpc-2121	139	9	was	be	AUX
dpc-2121	139	10	achieved	achieve	VERB
dpc-2121	139	11	by	by	ADP
dpc-2121	139	12	36.6	36.6	NUM
dpc-2121	139	13	%	%	NOUN
dpc-2121	139	14	in	in	ADP
dpc-2121	139	15	the	the	DET
dpc-2121	139	16	abrocitinib	abrocitinib	NOUN
dpc-2121	139	17	100	100	NUM
dpc-2121	139	18	mg	mg	PROPN
dpc-2121	139	19	group	group	NOUN
dpc-2121	139	20	,	,	PUNCT
dpc-2121	139	21	48.4	48.4	NUM
dpc-2121	139	22	%	%	NOUN
dpc-2121	139	23	in	in	ADP
dpc-2121	139	24	the	the	DET
dpc-2121	139	25	abrocitinib	abrocitinib	NOUN
dpc-2121	139	26	200	200	NUM
dpc-2121	139	27	mg	mg	PROPN
dpc-2121	139	28	group	group	NOUN
dpc-2121	139	29	,	,	PUNCT
dpc-2121	139	30	36.5	36.5	NUM
dpc-2121	139	31	%	%	NOUN
dpc-2121	139	32	in	in	ADP
dpc-2121	139	33	the	the	DET
dpc-2121	139	34	dupilumab	dupilumab	NOUN
dpc-2121	139	35	one	one	NUM
dpc-2121	139	36	,	,	PUNCT
dpc-2121	139	37	and	and	CCONJ
dpc-2121	139	38	14.0	14.0	NUM
dpc-2121	139	39	%	%	NOUN
dpc-2121	139	40	in	in	ADP
dpc-2121	139	41	the	the	DET
dpc-2121	139	42	placebo	placebo	NOUN
dpc-2121	139	43	group	group	NOUN
dpc-2121	139	44	(	(	PUNCT
dpc-2121	139	45	p	p	X
dpc-2121	139	46	<	<	X
dpc-2121	139	47	0.001	0.001	NUM
dpc-2121	139	48	for	for	ADP
dpc-2121	139	49	both	both	DET
dpc-2121	139	50	abrocitinib	abrocitinib	NOUN
dpc-2121	139	51	groups	group	NOUN
dpc-2121	139	52	compared	compare	VERB
dpc-2121	139	53	to	to	ADP
dpc-2121	139	54	placebo	placebo	NOUN
dpc-2121	139	55	)	)	PUNCT
dpc-2121	139	56	.	.	PUNCT
dpc-2121	140	1	abrocitinib	abrocitinib	NOUN
dpc-2121	140	2	200	200	NUM
dpc-2121	140	3	mg	mg	NOUN
dpc-2121	140	4	(	(	PUNCT
dpc-2121	140	5	but	but	CCONJ
dpc-2121	140	6	not	not	PART
dpc-2121	140	7	abrocitinib	abrocitinib	NOUN
dpc-2121	140	8	100	100	NUM
dpc-2121	140	9	mg	mg	NOUN
dpc-2121	140	10	)	)	PUNCT
dpc-2121	140	11	was	be	AUX
dpc-2121	140	12	superior	superior	ADJ
dpc-2121	140	13	to	to	PART
dpc-2121	140	14	dupilumab	dupilumab	VERB
dpc-2121	140	15	in	in	ADP
dpc-2121	140	16	achieving	achieve	VERB
dpc-2121	140	17	the	the	DET
dpc-2121	140	18	itch	itch	NOUN
dpc-2121	140	19	-	-	PUNCT
dpc-2121	140	20	relief	relief	NOUN
dpc-2121	140	21	-	-	PUNCT
dpc-2121	140	22	scores	score	NOUN
dpc-2121	140	23	at	at	ADP
dpc-2121	140	24	week	week	NOUN
dpc-2121	140	25	2	2	NUM
dpc-2121	140	26	.	.	PUNCT
dpc-2121	141	1	however	however	ADV
dpc-2121	141	2	,	,	PUNCT
dpc-2121	141	3	at	at	ADP
dpc-2121	141	4	week	week	NOUN
dpc-2121	141	5	16	16	NUM
dpc-2121	141	6	,	,	PUNCT
dpc-2121	141	7	none	none	NOUN
dpc-2121	141	8	of	of	ADP
dpc-2121	141	9	abrocitinib	abrocitinib	NOUN
dpc-2121	141	10	groups	group	NOUN
dpc-2121	141	11	differed	differ	VERB
dpc-2121	141	12	significantly	significantly	ADV
dpc-2121	141	13	from	from	ADP
dpc-2121	141	14	the	the	DET
dpc-2121	141	15	dupilumab	dupilumab	NOUN
dpc-2121	141	16	one	one	NOUN
dpc-2121	141	17	regarding	regard	VERB
dpc-2121	141	18	other	other	ADJ
dpc-2121	141	19	key	key	ADJ
dpc-2121	141	20	secondary	secondary	ADJ
dpc-2121	141	21	endpoints	endpoint	NOUN
dpc-2121	141	22	.	.	PUNCT
dpc-2121	142	1	in	in	ADP
dpc-2121	142	2	what	what	PRON
dpc-2121	142	3	concerns	concern	NOUN
dpc-2121	142	4	to	to	ADP
dpc-2121	142	5	safety	safety	NOUN
dpc-2121	142	6	questions	question	NOUN
dpc-2121	142	7	,	,	PUNCT
dpc-2121	142	8	herpes	herpe	NOUN
dpc-2121	142	9	zoster	zoster	NOUN
dpc-2121	142	10	only	only	ADV
dpc-2121	142	11	occurred	occur	VERB
dpc-2121	142	12	in	in	ADP
dpc-2121	142	13	patients	patient	NOUN
dpc-2121	142	14	receiving	receive	VERB
dpc-2121	142	15	abrocitinib	abrocitinib	NOUN
dpc-2121	142	16	,	,	PUNCT
dpc-2121	142	17	while	while	SCONJ
dpc-2121	142	18	eczema	eczema	PROPN
dpc-2121	142	19	herpeticum	herpeticum	PROPN
dpc-2121	142	20	developed	develop	VERB
dpc-2121	142	21	in	in	ADP
dpc-2121	142	22	2	2	NUM
dpc-2121	142	23	patients	patient	NOUN
dpc-2121	142	24	,	,	PUNCT
dpc-2121	142	25	one	one	NUM
dpc-2121	142	26	from	from	ADP
dpc-2121	142	27	the	the	DET
dpc-2121	142	28	abrocitinib	abrocitinib	NOUN
dpc-2121	142	29	100	100	NUM
dpc-2121	142	30	mg	mg	PROPN
dpc-2121	142	31	group	group	NOUN
dpc-2121	142	32	,	,	PUNCT
dpc-2121	142	33	and	and	CCONJ
dpc-2121	142	34	the	the	DET
dpc-2121	142	35	other	other	ADJ
dpc-2121	142	36	from	from	ADP
dpc-2121	142	37	the	the	DET
dpc-2121	142	38	placebo	placebo	NOUN
dpc-2121	142	39	group	group	NOUN
dpc-2121	142	40	.	.	PUNCT
dpc-2121	143	1	no	no	DET
dpc-2121	143	2	new	new	ADJ
dpc-2121	143	3	safety	safety	NOUN
dpc-2121	143	4	-	-	PUNCT
dpc-2121	143	5	related	relate	VERB
dpc-2121	143	6	events	event	NOUN
dpc-2121	143	7	were	be	AUX
dpc-2121	143	8	noted	note	VERB
dpc-2121	143	9	.	.	PUNCT
dpc-2121	144	1	patients	patient	NOUN
dpc-2121	144	2	that	that	PRON
dpc-2121	144	3	completed	complete	VERB
dpc-2121	144	4	this	this	DET
dpc-2121	144	5	trial	trial	NOUN
dpc-2121	144	6	were	be	AUX
dpc-2121	144	7	also	also	ADV
dpc-2121	144	8	invited	invite	VERB
dpc-2121	144	9	to	to	PART
dpc-2121	144	10	enroll	enroll	VERB
dpc-2121	144	11	the	the	DET
dpc-2121	144	12	jade	jade	NOUN
dpc-2121	144	13	extend	extend	NOUN
dpc-2121	144	14	(	(	PUNCT
dpc-2121	144	15	nct03422822	nct03422822	NOUN
dpc-2121	144	16	)	)	PUNCT
dpc-2121	144	17	.	.	PUNCT
dpc-2121	145	1	in	in	ADP
dpc-2121	145	2	a	a	DET
dpc-2121	145	3	52	52	NUM
dpc-2121	145	4	-	-	PUNCT
dpc-2121	145	5	week	week	NOUN
dpc-2121	145	6	phase	phase	NOUN
dpc-2121	145	7	iii	iii	NUM
dpc-2121	145	8	clinical	clinical	ADJ
dpc-2121	145	9	trial	trial	NOUN
dpc-2121	145	10	(	(	PUNCT
dpc-2121	145	11	jade	jade	NOUN
dpc-2121	145	12	regimen	regimen	PROPN
dpc-2121	145	13	)	)	PUNCT
dpc-2121	145	14	,	,	PUNCT
dpc-2121	145	15	patients	patient	NOUN
dpc-2121	145	16	with	with	ADP
dpc-2121	145	17	moderate	moderate	ADJ
dpc-2121	145	18	-	-	PUNCT
dpc-2121	145	19	to	to	ADP
dpc-2121	145	20	-	-	PUNCT
dpc-2121	145	21	severe	severe	ADJ
dpc-2121	145	22	ad	ad	NOUN
dpc-2121	145	23	aged	age	VERB
dpc-2121	145	24	12	12	NUM
dpc-2121	145	25	years	year	NOUN
dpc-2121	145	26	or	or	CCONJ
dpc-2121	145	27	older	old	ADJ
dpc-2121	145	28	that	that	PRON
dpc-2121	145	29	responded	respond	VERB
dpc-2121	145	30	positively	positively	ADV
dpc-2121	145	31	(	(	PUNCT
dpc-2121	145	32	achieved	achieve	VERB
dpc-2121	145	33	easi75	easi75	NOUN
dpc-2121	145	34	and	and	CCONJ
dpc-2121	145	35	iga	iga	PROPN
dpc-2121	145	36	score	score	NOUN
dpc-2121	145	37	of	of	ADP
dpc-2121	145	38	0/1	0/1	NUM
dpc-2121	145	39	)	)	PUNCT
dpc-2121	145	40	to	to	ADP
dpc-2121	145	41	a	a	DET
dpc-2121	145	42	12	12	NUM
dpc-2121	145	43	-	-	PUNCT
dpc-2121	145	44	week	week	NOUN
dpc-2121	145	45	induction	induction	NOUN
dpc-2121	145	46	period	period	NOUN
dpc-2121	145	47	of	of	ADP
dpc-2121	145	48	an	an	DET
dpc-2121	145	49	open	open	ADJ
dpc-2121	145	50	-	-	PUNCT
dpc-2121	145	51	label	label	NOUN
dpc-2121	145	52	treatment	treatment	NOUN
dpc-2121	145	53	with	with	ADP
dpc-2121	145	54	abrocitinib	abrocitinib	NOUN
dpc-2121	145	55	200	200	NUM
dpc-2121	145	56	mg	mg	NOUN
dpc-2121	145	57	once	once	ADV
dpc-2121	145	58	daily	daily	ADV
dpc-2121	145	59	,	,	PUNCT
dpc-2121	145	60	were	be	AUX
dpc-2121	145	61	randomly	randomly	ADV
dpc-2121	145	62	assigned	assign	VERB
dpc-2121	145	63	to	to	PART
dpc-2121	145	64	receive	receive	VERB
dpc-2121	145	65	blinded	blind	VERB
dpc-2121	145	66	abrocitinib	abrocitinib	NOUN
dpc-2121	145	67	(	(	PUNCT
dpc-2121	145	68	100	100	NUM
dpc-2121	145	69	mg	mg	ADP
dpc-2121	145	70	or	or	CCONJ
dpc-2121	145	71	200	200	NUM
dpc-2121	145	72	mg	mg	NOUN
dpc-2121	145	73	)	)	PUNCT
dpc-2121	145	74	or	or	CCONJ
dpc-2121	145	75	placebo	placebo	NOUN
dpc-2121	145	76	for	for	ADP
dpc-2121	145	77	40	40	NUM
dpc-2121	145	78	weeks	week	NOUN
dpc-2121	146	1	[	[	X
dpc-2121	146	2	31	31	NUM
dpc-2121	146	3	]	]	PUNCT
dpc-2121	146	4	.	.	PUNCT
dpc-2121	147	1	a	a	DET
dpc-2121	147	2	total	total	NOUN
dpc-2121	147	3	of	of	ADP
dpc-2121	147	4	1233	1233	NUM
dpc-2121	147	5	patients	patient	NOUN
dpc-2121	147	6	started	start	VERB
dpc-2121	147	7	at	at	ADP
dpc-2121	147	8	week	week	NOUN
dpc-2121	147	9	0	0	NUM
dpc-2121	147	10	,	,	PUNCT
dpc-2121	147	11	798	798	NUM
dpc-2121	147	12	(	(	PUNCT
dpc-2121	147	13	64.7	64.7	NUM
dpc-2121	147	14	%	%	NOUN
dpc-2121	147	15	)	)	PUNCT
dpc-2121	147	16	responded	respond	VERB
dpc-2121	147	17	to	to	ADP
dpc-2121	147	18	the	the	DET
dpc-2121	147	19	12	12	NUM
dpc-2121	147	20	-	-	PUNCT
dpc-2121	147	21	week	week	NOUN
dpc-2121	147	22	induction	induction	NOUN
dpc-2121	147	23	period	period	NOUN
dpc-2121	147	24	and	and	CCONJ
dpc-2121	147	25	were	be	AUX
dpc-2121	147	26	randomly	randomly	ADV
dpc-2121	147	27	assigned	assign	VERB
dpc-2121	147	28	to	to	ADP
dpc-2121	147	29	the	the	DET
dpc-2121	147	30	abovementioned	abovementioned	ADJ
dpc-2121	147	31	groups	group	NOUN
dpc-2121	147	32	.	.	PUNCT
dpc-2121	148	1	the	the	DET
dpc-2121	148	2	primary	primary	ADJ
dpc-2121	148	3	endpoint	endpoint	NOUN
dpc-2121	148	4	–	–	PUNCT
dpc-2121	148	5	proportion	proportion	NOUN
dpc-2121	148	6	of	of	ADP
dpc-2121	148	7	patients	patient	NOUN
dpc-2121	148	8	that	that	PRON
dpc-2121	148	9	did	do	AUX
dpc-2121	148	10	not	not	PART
dpc-2121	148	11	loss	loss	VERB
dpc-2121	148	12	easi50	easi50	NOUN
dpc-2121	148	13	and	and	CCONJ
dpc-2121	148	14	had	have	VERB
dpc-2121	148	15	iga	iga	PROPN
dpc-2121	148	16	score	score	NOUN
dpc-2121	148	17	<	<	X
dpc-2121	148	18	3	3	NUM
dpc-2121	148	19	(	(	PUNCT
dpc-2121	148	20	mild	mild	ADJ
dpc-2121	148	21	)	)	PUNCT
dpc-2121	148	22	–	–	PUNCT
dpc-2121	148	23	was	be	AUX
dpc-2121	148	24	achieved	achieve	VERB
dpc-2121	148	25	by	by	ADP
dpc-2121	148	26	57.4	57.4	NUM
dpc-2121	148	27	%	%	NOUN
dpc-2121	148	28	in	in	ADP
dpc-2121	148	29	abrocitinib	abrocitinib	NOUN
dpc-2121	148	30	100	100	NUM
dpc-2121	148	31	mg	mg	PROPN
dpc-2121	148	32	group	group	NOUN
dpc-2121	148	33	,	,	PUNCT
dpc-2121	148	34	81.1	81.1	NUM
dpc-2121	148	35	%	%	NOUN
dpc-2121	148	36	patients	patient	NOUN
dpc-2121	148	37	in	in	ADP
dpc-2121	148	38	abrocitinib	abrocitinib	NOUN
dpc-2121	148	39	200	200	NUM
dpc-2121	148	40	mg	mg	PROPN
dpc-2121	148	41	group	group	NOUN
dpc-2121	148	42	,	,	PUNCT
dpc-2121	148	43	and	and	CCONJ
dpc-2121	148	44	19.1	19.1	NUM
dpc-2121	148	45	%	%	NOUN
dpc-2121	148	46	in	in	ADP
dpc-2121	148	47	placebo	placebo	NOUN
dpc-2121	148	48	group	group	NOUN
dpc-2121	148	49	,	,	PUNCT
dpc-2121	148	50	with	with	ADP
dpc-2121	148	51	statistically	statistically	ADJ
dpc-2121	148	52	superiority	superiority	NOUN
dpc-2121	148	53	of	of	ADP
dpc-2121	148	54	abrocitinib	abrocitinib	NOUN
dpc-2121	148	55	200	200	NUM
dpc-2121	148	56	mg	mg	ADV
dpc-2121	148	57	compared	compare	VERB
dpc-2121	148	58	review	review	NOUN
dpc-2121	148	59	|	|	ADV
dpc-2121	148	60	dermatol	dermatol	ADJ
dpc-2121	148	61	pract	pract	NOUN
dpc-2121	148	62	concept	concept	NOUN
dpc-2121	148	63	.	.	PUNCT
dpc-2121	149	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	149	2	7	7	NUM
dpc-2121	149	3	to	to	ADP
dpc-2121	149	4	abrocitinib	abrocitinib	NOUN
dpc-2121	149	5	100	100	NUM
dpc-2121	149	6	mg	mg	NOUN
dpc-2121	149	7	.	.	PUNCT
dpc-2121	150	1	regarding	regard	VERB
dpc-2121	150	2	safety	safety	NOUN
dpc-2121	150	3	,	,	PUNCT
dpc-2121	150	4	treatment	treatment	NOUN
dpc-2121	150	5	-	-	PUNCT
dpc-2121	150	6	emergent	emergent	ADJ
dpc-2121	150	7	adverse	adverse	ADJ
dpc-2121	150	8	events	event	NOUN
dpc-2121	150	9	(	(	PUNCT
dpc-2121	150	10	abrocitinib	abrocitinib	NOUN
dpc-2121	150	11	100	100	NUM
dpc-2121	150	12	mg	mg	PROPN
dpc-2121	150	13	54.0	54.0	NUM
dpc-2121	150	14	%	%	NOUN
dpc-2121	150	15	,	,	PUNCT
dpc-2121	150	16	abrocitinib	abrocitinib	NOUN
dpc-2121	150	17	200	200	NUM
dpc-2121	150	18	mg	mg	NUM
dpc-2121	150	19	63.2	63.2	NUM
dpc-2121	150	20	%	%	NOUN
dpc-2121	150	21	)	)	PUNCT
dpc-2121	150	22	and	and	CCONJ
dpc-2121	150	23	adverse	adverse	ADJ
dpc-2121	150	24	events	event	NOUN
dpc-2121	150	25	leading	lead	VERB
dpc-2121	150	26	to	to	ADP
dpc-2121	150	27	drug	drug	NOUN
dpc-2121	150	28	discontinuation	discontinuation	NOUN
dpc-2121	150	29	(	(	PUNCT
dpc-2121	150	30	abrocitinib	abrocitinib	NOUN
dpc-2121	150	31	100	100	NUM
dpc-2121	150	32	mg	mg	PROPN
dpc-2121	150	33	1.9	1.9	NUM
dpc-2121	150	34	%	%	NOUN
dpc-2121	150	35	,	,	PUNCT
dpc-2121	150	36	abrocitinib	abrocitinib	NOUN
dpc-2121	150	37	200	200	NUM
dpc-2121	150	38	mg	mg	NUM
dpc-2121	150	39	6.0	6.0	NUM
dpc-2121	150	40	%	%	NOUN
dpc-2121	150	41	)	)	PUNCT
dpc-2121	150	42	were	be	AUX
dpc-2121	150	43	higher	high	ADJ
dpc-2121	150	44	with	with	ADP
dpc-2121	150	45	abrocitinib	abrocitinib	NOUN
dpc-2121	150	46	.	.	PUNCT
dpc-2121	151	1	a	a	DET
dpc-2121	151	2	total	total	NOUN
dpc-2121	151	3	of	of	ADP
dpc-2121	151	4	285	285	NUM
dpc-2121	151	5	adolescents	adolescent	NOUN
dpc-2121	151	6	aged	age	VERB
dpc-2121	151	7	12	12	NUM
dpc-2121	151	8	to	to	PART
dpc-2121	151	9	17	17	NUM
dpc-2121	151	10	years	year	NOUN
dpc-2121	151	11	with	with	ADP
dpc-2121	151	12	moderate	moderate	ADJ
dpc-2121	151	13	-	-	PUNCT
dpc-2121	151	14	to	to	ADP
dpc-2121	151	15	-	-	PUNCT
dpc-2121	151	16	severe	severe	ADJ
dpc-2121	151	17	ad	ad	NOUN
dpc-2121	151	18	were	be	AUX
dpc-2121	151	19	enrolled	enrol	VERB
dpc-2121	151	20	in	in	ADP
dpc-2121	151	21	a	a	DET
dpc-2121	151	22	12	12	NUM
dpc-2121	151	23	-	-	PUNCT
dpc-2121	151	24	week	week	NOUN
dpc-2121	151	25	phase	phase	NOUN
dpc-2121	151	26	iii	iii	NUM
dpc-2121	151	27	placebo	placebo	NOUN
dpc-2121	151	28	-	-	PUNCT
dpc-2121	151	29	controlled	control	VERB
dpc-2121	151	30	study	study	NOUN
dpc-2121	151	31	(	(	PUNCT
dpc-2121	151	32	jade	jade	NOUN
dpc-2121	151	33	teen	teen	PROPN
dpc-2121	151	34	)	)	PUNCT
dpc-2121	151	35	and	and	CCONJ
dpc-2121	151	36	randomized	randomize	VERB
dpc-2121	151	37	to	to	PART
dpc-2121	151	38	receive	receive	VERB
dpc-2121	151	39	either	either	CCONJ
dpc-2121	151	40	once	once	ADV
dpc-2121	151	41	daily	daily	ADJ
dpc-2121	151	42	abrocitinib	abrocitinib	NOUN
dpc-2121	151	43	100	100	NUM
dpc-2121	151	44	mg	mg	NOUN
dpc-2121	151	45	,	,	PUNCT
dpc-2121	151	46	abrocitinib	abrocitinib	NOUN
dpc-2121	151	47	200	200	NUM
dpc-2121	151	48	mg	mg	NOUN
dpc-2121	151	49	,	,	PUNCT
dpc-2121	151	50	or	or	CCONJ
dpc-2121	151	51	placebo	placebo	NOUN
dpc-2121	151	52	,	,	PUNCT
dpc-2121	151	53	in	in	ADP
dpc-2121	151	54	combination	combination	NOUN
dpc-2121	151	55	with	with	ADP
dpc-2121	151	56	topical	topical	ADJ
dpc-2121	151	57	corticosteroids	corticosteroid	NOUN
dpc-2121	151	58	[	[	X
dpc-2121	151	59	32	32	NUM
dpc-2121	151	60	]	]	PUNCT
dpc-2121	151	61	.	.	PUNCT
dpc-2121	152	1	the	the	DET
dpc-2121	152	2	coprimary	coprimary	ADJ
dpc-2121	152	3	endpoints	endpoint	NOUN
dpc-2121	152	4	(	(	PUNCT
dpc-2121	152	5	easi75	easi75	NOUN
dpc-2121	152	6	and	and	CCONJ
dpc-2121	152	7	iga	iga	PROPN
dpc-2121	152	8	score	score	NOUN
dpc-2121	152	9	of	of	ADP
dpc-2121	152	10	0/1	0/1	NUM
dpc-2121	152	11	)	)	PUNCT
dpc-2121	152	12	were	be	AUX
dpc-2121	152	13	achieved	achieve	VERB
dpc-2121	152	14	in	in	ADP
dpc-2121	152	15	both	both	DET
dpc-2121	152	16	abrocitinib	abrocitinib	NOUN
dpc-2121	152	17	groups	group	NOUN
dpc-2121	152	18	[	[	X
dpc-2121	152	19	easi75	easi75	ADV
dpc-2121	152	20	:	:	PUNCT
dpc-2121	152	21	abrocitinib	abrocitinib	NOUN
dpc-2121	152	22	100	100	NUM
dpc-2121	152	23	mg	mg	NUM
dpc-2121	152	24	68.5	68.5	NUM
dpc-2121	152	25	%	%	NOUN
dpc-2121	152	26	,	,	PUNCT
dpc-2121	152	27	abrocitinib	abrocitinib	NOUN
dpc-2121	152	28	200	200	NUM
dpc-2121	152	29	mg	mg	NUM
dpc-2121	152	30	72.0	72.0	NUM
dpc-2121	152	31	%	%	NOUN
dpc-2121	152	32	vs.	vs.	ADP
dpc-2121	152	33	placebo	placebo	NOUN
dpc-2121	152	34	41.5	41.5	NUM
dpc-2121	152	35	%	%	NOUN
dpc-2121	152	36	(	(	PUNCT
dpc-2121	152	37	p	p	X
dpc-2121	152	38	<	<	X
dpc-2121	152	39	0.05	0.05	NUM
dpc-2121	152	40	)	)	PUNCT
dpc-2121	152	41	;	;	PUNCT
dpc-2121	152	42	iga	iga	PROPN
dpc-2121	152	43	score	score	NOUN
dpc-2121	152	44	of	of	ADP
dpc-2121	152	45	0/1	0/1	NUM
dpc-2121	152	46	:	:	PUNCT
dpc-2121	152	47	abrocitinib	abrocitinib	NOUN
dpc-2121	152	48	100	100	NUM
dpc-2121	152	49	mg	mg	NUM
dpc-2121	152	50	41.6	41.6	NUM
dpc-2121	152	51	%	%	NOUN
dpc-2121	152	52	,	,	PUNCT
dpc-2121	152	53	abrocitinib	abrocitinib	NOUN
dpc-2121	152	54	200	200	NUM
dpc-2121	152	55	mg	mg	NUM
dpc-2121	152	56	46.2	46.2	NUM
dpc-2121	152	57	%	%	NOUN
dpc-2121	152	58	vs.	vs.	ADP
dpc-2121	152	59	placebo	placebo	NOUN
dpc-2121	152	60	24.5	24.5	NUM
dpc-2121	152	61	%	%	NOUN
dpc-2121	152	62	(	(	PUNCT
dpc-2121	152	63	p	p	X
dpc-2121	152	64	<	<	X
dpc-2121	152	65	0.05	0.05	NUM
dpc-2121	152	66	)	)	PUNCT
dpc-2121	152	67	]	]	PUNCT
dpc-2121	152	68	.	.	PUNCT
dpc-2121	153	1	adverse	adverse	ADJ
dpc-2121	153	2	events	event	NOUN
dpc-2121	153	3	were	be	AUX
dpc-2121	153	4	observed	observe	VERB
dpc-2121	153	5	in	in	ADP
dpc-2121	153	6	52.0	52.0	NUM
dpc-2121	153	7	%	%	NOUN
dpc-2121	153	8	to	to	ADP
dpc-2121	153	9	63.0	63.0	NUM
dpc-2121	153	10	%	%	NOUN
dpc-2121	153	11	of	of	ADP
dpc-2121	153	12	the	the	DET
dpc-2121	153	13	patients	patient	NOUN
dpc-2121	153	14	among	among	ADP
dpc-2121	153	15	all	all	DET
dpc-2121	153	16	groups	group	NOUN
dpc-2121	153	17	,	,	PUNCT
dpc-2121	153	18	and	and	CCONJ
dpc-2121	153	19	the	the	DET
dpc-2121	153	20	most	most	ADV
dpc-2121	153	21	reported	report	VERB
dpc-2121	153	22	were	be	AUX
dpc-2121	153	23	nausea	nausea	NOUN
dpc-2121	153	24	,	,	PUNCT
dpc-2121	153	25	upper	upper	ADJ
dpc-2121	153	26	respiratory	respiratory	ADJ
dpc-2121	153	27	tract	tract	NOUN
dpc-2121	153	28	infections	infection	NOUN
dpc-2121	153	29	,	,	PUNCT
dpc-2121	153	30	headache	headache	NOUN
dpc-2121	153	31	,	,	PUNCT
dpc-2121	153	32	and	and	CCONJ
dpc-2121	153	33	nasopharyngitis	nasopharyngitis	NOUN
dpc-2121	153	34	.	.	PUNCT
dpc-2121	154	1	herpes	herpe	NOUN
dpc-2121	154	2	simplex	simplex	NOUN
dpc-2121	154	3	infection	infection	NOUN
dpc-2121	154	4	was	be	AUX
dpc-2121	154	5	uncommon	uncommon	ADJ
dpc-2121	154	6	(	(	PUNCT
dpc-2121	154	7	1.1	1.1	NUM
dpc-2121	154	8	%	%	NOUN
dpc-2121	154	9	)	)	PUNCT
dpc-2121	154	10	.	.	PUNCT
dpc-2121	155	1	no	no	DET
dpc-2121	155	2	new	new	ADJ
dpc-2121	155	3	safety	safety	NOUN
dpc-2121	155	4	-	-	PUNCT
dpc-2121	155	5	related	relate	VERB
dpc-2121	155	6	events	event	NOUN
dpc-2121	155	7	were	be	AUX
dpc-2121	155	8	noted	note	VERB
dpc-2121	155	9	when	when	SCONJ
dpc-2121	155	10	compared	compare	VERB
dpc-2121	155	11	to	to	ADP
dpc-2121	155	12	the	the	DET
dpc-2121	155	13	available	available	ADJ
dpc-2121	155	14	data	datum	NOUN
dpc-2121	155	15	from	from	ADP
dpc-2121	155	16	previous	previous	ADJ
dpc-2121	155	17	studies	study	NOUN
dpc-2121	155	18	.	.	PUNCT
dpc-2121	156	1	conclusion	conclusion	VERB
dpc-2121	156	2	the	the	DET
dpc-2121	156	3	results	result	NOUN
dpc-2121	156	4	of	of	ADP
dpc-2121	156	5	the	the	DET
dpc-2121	156	6	aforementioned	aforementioned	ADJ
dpc-2121	156	7	trials	trial	NOUN
dpc-2121	156	8	revealed	reveal	VERB
dpc-2121	156	9	that	that	SCONJ
dpc-2121	156	10	jak	jak	PROPN
dpc-2121	156	11	inhibitors	inhibitor	NOUN
dpc-2121	156	12	are	be	AUX
dpc-2121	156	13	an	an	DET
dpc-2121	156	14	effective	effective	ADJ
dpc-2121	156	15	therapeutic	therapeutic	ADJ
dpc-2121	156	16	option	option	NOUN
dpc-2121	156	17	for	for	ADP
dpc-2121	156	18	ad	ad	NOUN
dpc-2121	156	19	.	.	PUNCT
dpc-2121	157	1	not	not	PART
dpc-2121	157	2	only	only	ADV
dpc-2121	157	3	they	they	PRON
dpc-2121	157	4	were	be	AUX
dpc-2121	157	5	able	able	ADJ
dpc-2121	157	6	to	to	PART
dpc-2121	157	7	induce	induce	VERB
dpc-2121	157	8	short	short	ADJ
dpc-2121	157	9	and	and	CCONJ
dpc-2121	157	10	medium	medium	ADJ
dpc-2121	157	11	-	-	PUNCT
dpc-2121	157	12	term	term	NOUN
dpc-2121	157	13	cutaneous	cutaneous	ADJ
dpc-2121	157	14	improvement	improvement	NOUN
dpc-2121	157	15	,	,	PUNCT
dpc-2121	157	16	but	but	CCONJ
dpc-2121	157	17	also	also	ADV
dpc-2121	157	18	to	to	PART
dpc-2121	157	19	induce	induce	VERB
dpc-2121	157	20	symptomatic	symptomatic	ADJ
dpc-2121	157	21	relief	relief	NOUN
dpc-2121	157	22	,	,	PUNCT
dpc-2121	157	23	confirmed	confirm	VERB
dpc-2121	157	24	by	by	ADP
dpc-2121	157	25	their	their	PRON
dpc-2121	157	26	impact	impact	NOUN
dpc-2121	157	27	on	on	ADP
dpc-2121	157	28	itch	itch	NOUN
dpc-2121	157	29	control	control	NOUN
dpc-2121	157	30	and	and	CCONJ
dpc-2121	157	31	on	on	ADP
dpc-2121	157	32	patients	patient	NOUN
dpc-2121	157	33	’	'	PUNCT
dpc-2121	157	34	daily	daily	ADJ
dpc-2121	157	35	activities	activity	NOUN
dpc-2121	157	36	previously	previously	ADV
dpc-2121	157	37	affected	affect	VERB
dpc-2121	157	38	by	by	ADP
dpc-2121	157	39	ad	ad	NOUN
dpc-2121	157	40	.	.	PUNCT
dpc-2121	158	1	another	another	DET
dpc-2121	158	2	important	important	ADJ
dpc-2121	158	3	-	-	PUNCT
dpc-2121	158	4	to	to	ADP
dpc-2121	158	5	-	-	PUNCT
dpc-2121	158	6	mention	mention	VERB
dpc-2121	158	7	finding	finding	NOUN
dpc-2121	158	8	was	be	AUX
dpc-2121	158	9	the	the	DET
dpc-2121	158	10	rapid	rapid	ADJ
dpc-2121	158	11	onset	onset	NOUN
dpc-2121	158	12	of	of	ADP
dpc-2121	158	13	action	action	NOUN
dpc-2121	158	14	of	of	ADP
dpc-2121	158	15	jak	jak	PROPN
dpc-2121	158	16	inhibitors	inhibitor	NOUN
dpc-2121	158	17	,	,	PUNCT
dpc-2121	158	18	able	able	ADJ
dpc-2121	158	19	of	of	ADP
dpc-2121	158	20	inducing	induce	VERB
dpc-2121	158	21	their	their	PRON
dpc-2121	158	22	benefits	benefit	NOUN
dpc-2121	158	23	after	after	ADP
dpc-2121	158	24	just	just	ADV
dpc-2121	158	25	1	1	NUM
dpc-2121	158	26	to	to	PART
dpc-2121	158	27	2	2	NUM
dpc-2121	158	28	weeks	week	NOUN
dpc-2121	158	29	of	of	ADP
dpc-2121	158	30	treatment	treatment	NOUN
dpc-2121	158	31	.	.	PUNCT
dpc-2121	159	1	these	these	DET
dpc-2121	159	2	findings	finding	NOUN
dpc-2121	159	3	support	support	VERB
dpc-2121	159	4	the	the	DET
dpc-2121	159	5	fact	fact	NOUN
dpc-2121	159	6	that	that	SCONJ
dpc-2121	159	7	an	an	DET
dpc-2121	159	8	improvement	improvement	NOUN
dpc-2121	159	9	in	in	ADP
dpc-2121	159	10	ad	ad	NOUN
dpc-2121	159	11	patients	patient	NOUN
dpc-2121	159	12	goes	go	VERB
dpc-2121	159	13	beyond	beyond	ADP
dpc-2121	159	14	the	the	DET
dpc-2121	159	15	sole	sole	ADJ
dpc-2121	159	16	cutaneous	cutaneous	ADJ
dpc-2121	159	17	improvement	improvement	NOUN
dpc-2121	159	18	.	.	PUNCT
dpc-2121	160	1	additionally	additionally	ADV
dpc-2121	160	2	,	,	PUNCT
dpc-2121	160	3	available	available	ADJ
dpc-2121	160	4	data	datum	NOUN
dpc-2121	160	5	on	on	ADP
dpc-2121	160	6	head	head	NOUN
dpc-2121	160	7	-	-	PUNCT
dpc-2121	160	8	to	to	ADP
dpc-2121	160	9	-	-	PUNCT
dpc-2121	160	10	head	head	NOUN
dpc-2121	160	11	comparisons	comparison	NOUN
dpc-2121	160	12	suggested	suggest	VERB
dpc-2121	160	13	that	that	SCONJ
dpc-2121	160	14	jak	jak	PROPN
dpc-2121	160	15	inhibitors	inhibitor	NOUN
dpc-2121	160	16	might	might	AUX
dpc-2121	160	17	be	be	AUX
dpc-2121	160	18	an	an	DET
dpc-2121	160	19	important	important	ADJ
dpc-2121	160	20	option	option	NOUN
dpc-2121	160	21	in	in	ADP
dpc-2121	160	22	ad	ad	NOUN
dpc-2121	160	23	armamentarium	armamentarium	NOUN
dpc-2121	160	24	,	,	PUNCT
dpc-2121	160	25	with	with	ADP
dpc-2121	160	26	a	a	DET
dpc-2121	160	27	slightly	slightly	ADV
dpc-2121	160	28	numerical	numerical	ADJ
dpc-2121	160	29	superiority	superiority	NOUN
dpc-2121	160	30	in	in	ADP
dpc-2121	160	31	efficacy	efficacy	NOUN
dpc-2121	160	32	when	when	SCONJ
dpc-2121	160	33	compared	compare	VERB
dpc-2121	160	34	to	to	ADP
dpc-2121	160	35	the	the	DET
dpc-2121	160	36	already	already	ADV
dpc-2121	160	37	fda	fda	PROPN
dpc-2121	160	38	and	and	CCONJ
dpc-2121	160	39	ema	ema	PROPN
dpc-2121	160	40	approved	approve	VERB
dpc-2121	160	41	dupilumab	dupilumab	NOUN
dpc-2121	160	42	.	.	PUNCT
dpc-2121	161	1	however	however	ADV
dpc-2121	161	2	,	,	PUNCT
dpc-2121	161	3	their	their	PRON
dpc-2121	161	4	potential	potential	ADJ
dpc-2121	161	5	side	side	NOUN
dpc-2121	161	6	effects	effect	NOUN
dpc-2121	161	7	must	must	AUX
dpc-2121	161	8	be	be	AUX
dpc-2121	161	9	considered	consider	VERB
dpc-2121	161	10	when	when	SCONJ
dpc-2121	161	11	opting	opt	VERB
dpc-2121	161	12	for	for	ADP
dpc-2121	161	13	these	these	DET
dpc-2121	161	14	drugs	drug	NOUN
dpc-2121	161	15	.	.	PUNCT
dpc-2121	162	1	in	in	ADP
dpc-2121	162	2	fact	fact	NOUN
dpc-2121	162	3	,	,	PUNCT
dpc-2121	162	4	jak	jak	PROPN
dpc-2121	162	5	/	/	SYM
dpc-2121	162	6	stat	stat	PROPN
dpc-2121	162	7	signaling	signal	VERB
dpc-2121	162	8	pathway	pathway	NOUN
dpc-2121	162	9	has	have	AUX
dpc-2121	162	10	been	be	AUX
dpc-2121	162	11	shown	show	VERB
dpc-2121	162	12	to	to	PART
dpc-2121	162	13	play	play	VERB
dpc-2121	162	14	a	a	DET
dpc-2121	162	15	role	role	NOUN
dpc-2121	162	16	in	in	ADP
dpc-2121	162	17	several	several	ADJ
dpc-2121	162	18	crucial	crucial	ADJ
dpc-2121	162	19	physiological	physiological	ADJ
dpc-2121	162	20	regulatory	regulatory	ADJ
dpc-2121	162	21	processes	process	NOUN
dpc-2121	162	22	,	,	PUNCT
dpc-2121	162	23	that	that	PRON
dpc-2121	162	24	potentially	potentially	ADV
dpc-2121	162	25	increases	increase	VERB
dpc-2121	162	26	their	their	PRON
dpc-2121	162	27	risk	risk	NOUN
dpc-2121	162	28	of	of	ADP
dpc-2121	162	29	side	side	NOUN
dpc-2121	162	30	effects	effect	NOUN
dpc-2121	162	31	.	.	PUNCT
dpc-2121	163	1	although	although	SCONJ
dpc-2121	163	2	most	most	ADJ
dpc-2121	163	3	of	of	ADP
dpc-2121	163	4	them	they	PRON
dpc-2121	163	5	are	be	AUX
dpc-2121	163	6	mild	mild	ADJ
dpc-2121	163	7	-	-	PUNCT
dpc-2121	163	8	to	to	ADP
dpc-2121	163	9	-	-	PUNCT
dpc-2121	163	10	moderate	moderate	ADJ
dpc-2121	163	11	,	,	PUNCT
dpc-2121	163	12	they	they	PRON
dpc-2121	163	13	include	include	VERB
dpc-2121	163	14	infections	infection	NOUN
dpc-2121	163	15	–	–	PUNCT
dpc-2121	163	16	including	include	VERB
dpc-2121	163	17	infection	infection	NOUN
dpc-2121	163	18	by	by	ADP
dpc-2121	163	19	opportunistic	opportunistic	ADJ
dpc-2121	163	20	agents	agent	NOUN
dpc-2121	163	21	such	such	ADJ
dpc-2121	163	22	as	as	ADP
dpc-2121	163	23	mycobacterium	mycobacterium	NOUN
dpc-2121	163	24	tuberculosis	tuberculosis	NOUN
dpc-2121	163	25	or	or	CCONJ
dpc-2121	163	26	herpes	herpe	NOUN
dpc-2121	163	27	zoster	zoster	NOUN
dpc-2121	163	28	–	–	PUNCT
dpc-2121	163	29	,	,	PUNCT
dpc-2121	163	30	thromboembolic	thromboembolic	ADJ
dpc-2121	163	31	events	event	NOUN
dpc-2121	163	32	,	,	PUNCT
dpc-2121	163	33	malignancies	malignancy	NOUN
dpc-2121	163	34	,	,	PUNCT
dpc-2121	163	35	lipid	lipid	NOUN
dpc-2121	163	36	disturbances	disturbance	NOUN
dpc-2121	163	37	(	(	PUNCT
dpc-2121	163	38	increased	increase	VERB
dpc-2121	163	39	total	total	NOUN
dpc-2121	163	40	,	,	PUNCT
dpc-2121	163	41	lowand	lowand	ADJ
dpc-2121	163	42	high	high	ADJ
dpc-2121	163	43	-	-	PUNCT
dpc-2121	163	44	density	density	NOUN
dpc-2121	163	45	lipoprotein	lipoprotein	ADJ
dpc-2121	163	46	cholesterol	cholesterol	NOUN
dpc-2121	163	47	and	and	CCONJ
dpc-2121	163	48	increased	increase	VERB
dpc-2121	163	49	triglycerides	triglyceride	NOUN
dpc-2121	163	50	)	)	PUNCT
dpc-2121	163	51	,	,	PUNCT
dpc-2121	163	52	and	and	CCONJ
dpc-2121	163	53	hematologic	hematologic	NOUN
dpc-2121	163	54	abnormalities	abnormality	NOUN
dpc-2121	163	55	(	(	PUNCT
dpc-2121	163	56	neutropenia	neutropenia	NOUN
dpc-2121	163	57	,	,	PUNCT
dpc-2121	163	58	anemia	anemia	NOUN
dpc-2121	163	59	,	,	PUNCT
dpc-2121	163	60	thrombocytopenia	thrombocytopenia	PROPN
dpc-2121	163	61	)	)	PUNCT
dpc-2121	163	62	,	,	PUNCT
dpc-2121	163	63	and	and	CCONJ
dpc-2121	163	64	transient	transient	ADJ
dpc-2121	163	65	increases	increase	NOUN
dpc-2121	163	66	of	of	ADP
dpc-2121	163	67	liver	liver	NOUN
dpc-2121	163	68	enzymes	enzyme	NOUN
dpc-2121	163	69	,	,	PUNCT
dpc-2121	163	70	creatine	creatine	NOUN
dpc-2121	163	71	phosphokinase	phosphokinase	NOUN
dpc-2121	163	72	(	(	PUNCT
dpc-2121	163	73	cpk	cpk	PROPN
dpc-2121	163	74	)	)	PUNCT
dpc-2121	163	75	,	,	PUNCT
dpc-2121	163	76	or	or	CCONJ
dpc-2121	163	77	creatinine	creatinine	NOUN
dpc-2121	164	1	[	[	X
dpc-2121	164	2	10,11	10,11	NOUN
dpc-2121	164	3	]	]	PUNCT
dpc-2121	164	4	.	.	PUNCT
dpc-2121	165	1	although	although	SCONJ
dpc-2121	165	2	hematologic	hematologic	NOUN
dpc-2121	165	3	disturbances	disturbance	NOUN
dpc-2121	165	4	have	have	AUX
dpc-2121	165	5	also	also	ADV
dpc-2121	165	6	been	be	AUX
dpc-2121	165	7	reported	report	VERB
dpc-2121	165	8	after	after	ADP
dpc-2121	165	9	the	the	DET
dpc-2121	165	10	use	use	NOUN
dpc-2121	165	11	of	of	ADP
dpc-2121	165	12	jak1	jak1	NOUN
dpc-2121	165	13	inhibitors	inhibitor	NOUN
dpc-2121	165	14	–	–	PUNCT
dpc-2121	165	15	by	by	ADP
dpc-2121	165	16	a	a	DET
dpc-2121	165	17	mechanism	mechanism	NOUN
dpc-2121	165	18	that	that	PRON
dpc-2121	165	19	is	be	AUX
dpc-2121	165	20	not	not	PART
dpc-2121	165	21	completely	completely	ADV
dpc-2121	165	22	understood	understand	VERB
dpc-2121	165	23	-	-	PUNCT
dpc-2121	165	24	,	,	PUNCT
dpc-2121	165	25	they	they	PRON
dpc-2121	165	26	are	be	AUX
dpc-2121	165	27	more	more	ADV
dpc-2121	165	28	commonly	commonly	ADV
dpc-2121	165	29	observed	observe	VERB
dpc-2121	165	30	after	after	ADP
dpc-2121	165	31	using	use	VERB
dpc-2121	165	32	jak2	jak2	NOUN
dpc-2121	165	33	inhibitors	inhibitor	NOUN
dpc-2121	165	34	as	as	SCONJ
dpc-2121	165	35	jak2	jak2	PROPN
dpc-2121	165	36	interferes	interfere	VERB
dpc-2121	165	37	with	with	ADP
dpc-2121	165	38	erythropoietin	erythropoietin	NOUN
dpc-2121	165	39	and	and	CCONJ
dpc-2121	165	40	other	other	ADJ
dpc-2121	165	41	colony	colony	NOUN
dpc-2121	165	42	-	-	PUNCT
dpc-2121	165	43	stimulating	stimulate	VERB
dpc-2121	165	44	factors	factor	NOUN
dpc-2121	165	45	(	(	PUNCT
dpc-2121	165	46	csf	csf	NOUN
dpc-2121	165	47	)	)	PUNCT
dpc-2121	165	48	function	function	NOUN
dpc-2121	165	49	[	[	X
dpc-2121	165	50	10,11	10,11	NOUN
dpc-2121	165	51	]	]	PUNCT
dpc-2121	165	52	.	.	PUNCT
dpc-2121	166	1	regarding	regard	VERB
dpc-2121	166	2	lipid	lipid	ADJ
dpc-2121	166	3	abnormalities	abnormality	NOUN
dpc-2121	166	4	,	,	PUNCT
dpc-2121	166	5	they	they	PRON
dpc-2121	166	6	have	have	AUX
dpc-2121	166	7	been	be	AUX
dpc-2121	166	8	mostly	mostly	ADV
dpc-2121	166	9	reported	report	VERB
dpc-2121	166	10	after	after	ADP
dpc-2121	166	11	the	the	DET
dpc-2121	166	12	use	use	NOUN
dpc-2121	166	13	of	of	ADP
dpc-2121	166	14	jak1	jak1	PROPN
dpc-2121	166	15	inhibitors	inhibitor	NOUN
dpc-2121	166	16	,	,	PUNCT
dpc-2121	166	17	however	however	ADV
dpc-2121	166	18	more	more	ADJ
dpc-2121	166	19	data	datum	NOUN
dpc-2121	166	20	is	be	AUX
dpc-2121	166	21	needed	need	VERB
dpc-2121	166	22	to	to	PART
dpc-2121	166	23	better	well	ADV
dpc-2121	166	24	clarify	clarify	VERB
dpc-2121	166	25	this	this	DET
dpc-2121	166	26	interaction	interaction	NOUN
dpc-2121	166	27	as	as	SCONJ
dpc-2121	166	28	some	some	DET
dpc-2121	166	29	reports	report	NOUN
dpc-2121	166	30	suggest	suggest	VERB
dpc-2121	166	31	that	that	SCONJ
dpc-2121	166	32	lipid	lipid	NOUN
dpc-2121	166	33	disturbances	disturbance	NOUN
dpc-2121	166	34	may	may	AUX
dpc-2121	166	35	be	be	AUX
dpc-2121	166	36	related	relate	VERB
dpc-2121	166	37	to	to	ADP
dpc-2121	166	38	inflammation	inflammation	NOUN
dpc-2121	166	39	and	and	CCONJ
dpc-2121	166	40	not	not	PART
dpc-2121	166	41	to	to	PART
dpc-2121	166	42	jak1	jak1	VERB
dpc-2121	166	43	pathway	pathway	NOUN
dpc-2121	166	44	itself	itself	PRON
dpc-2121	167	1	[	[	X
dpc-2121	167	2	10,11	10,11	NOUN
dpc-2121	167	3	]	]	PUNCT
dpc-2121	167	4	.	.	PUNCT
dpc-2121	168	1	over	over	ADP
dpc-2121	168	2	the	the	DET
dpc-2121	168	3	last	last	ADJ
dpc-2121	168	4	decade	decade	NOUN
dpc-2121	168	5	,	,	PUNCT
dpc-2121	168	6	knowledge	knowledge	NOUN
dpc-2121	168	7	on	on	ADP
dpc-2121	168	8	ad	ad	NOUN
dpc-2121	168	9	pathophysiology	pathophysiology	NOUN
dpc-2121	168	10	and	and	CCONJ
dpc-2121	168	11	its	its	PRON
dpc-2121	168	12	impact	impact	NOUN
dpc-2121	168	13	in	in	ADP
dpc-2121	168	14	quality	quality	NOUN
dpc-2121	168	15	of	of	ADP
dpc-2121	168	16	life	life	NOUN
dpc-2121	168	17	has	have	AUX
dpc-2121	168	18	expanded	expand	VERB
dpc-2121	168	19	,	,	PUNCT
dpc-2121	168	20	which	which	PRON
dpc-2121	168	21	promoted	promote	VERB
dpc-2121	168	22	the	the	DET
dpc-2121	168	23	pursuit	pursuit	NOUN
dpc-2121	168	24	for	for	ADP
dpc-2121	168	25	new	new	ADJ
dpc-2121	168	26	targeted	target	VERB
dpc-2121	168	27	therapeutic	therapeutic	ADJ
dpc-2121	168	28	options	option	NOUN
dpc-2121	168	29	that	that	PRON
dpc-2121	168	30	enable	enable	VERB
dpc-2121	168	31	clinicians	clinician	NOUN
dpc-2121	168	32	to	to	PART
dpc-2121	168	33	better	well	ADV
dpc-2121	168	34	manage	manage	VERB
dpc-2121	168	35	their	their	PRON
dpc-2121	168	36	ad	ad	NOUN
dpc-2121	168	37	patients	patient	NOUN
dpc-2121	168	38	.	.	PUNCT
dpc-2121	169	1	dupilumab	dupilumab	NOUN
dpc-2121	169	2	was	be	AUX
dpc-2121	169	3	the	the	DET
dpc-2121	169	4	first	first	ADJ
dpc-2121	169	5	biological	biological	ADJ
dpc-2121	169	6	agent	agent	NOUN
dpc-2121	169	7	approved	approve	VERB
dpc-2121	169	8	for	for	ADP
dpc-2121	169	9	moderate	moderate	ADJ
dpc-2121	169	10	-	-	PUNCT
dpc-2121	169	11	to	to	ADP
dpc-2121	169	12	-	-	PUNCT
dpc-2121	169	13	severe	severe	ADJ
dpc-2121	169	14	ad	ad	NOUN
dpc-2121	169	15	,	,	PUNCT
dpc-2121	169	16	and	and	CCONJ
dpc-2121	169	17	data	datum	NOUN
dpc-2121	169	18	from	from	ADP
dpc-2121	169	19	clinical	clinical	ADJ
dpc-2121	169	20	trials	trial	NOUN
dpc-2121	169	21	and	and	CCONJ
dpc-2121	169	22	real	real	ADJ
dpc-2121	169	23	-	-	PUNCT
dpc-2121	169	24	world	world	NOUN
dpc-2121	169	25	setting	set	VERB
dpc-2121	169	26	studies	study	NOUN
dpc-2121	169	27	have	have	AUX
dpc-2121	169	28	been	be	AUX
dpc-2121	169	29	extensively	extensively	ADV
dpc-2121	169	30	analyzed	analyze	VERB
dpc-2121	169	31	and	and	CCONJ
dpc-2121	169	32	discussed	discuss	VERB
dpc-2121	169	33	in	in	ADP
dpc-2121	169	34	the	the	DET
dpc-2121	169	35	recent	recent	ADJ
dpc-2121	169	36	years	year	NOUN
dpc-2121	170	1	[	[	X
dpc-2121	170	2	33	33	NUM
dpc-2121	170	3	]	]	PUNCT
dpc-2121	170	4	.	.	PUNCT
dpc-2121	171	1	however	however	ADV
dpc-2121	171	2	,	,	PUNCT
dpc-2121	171	3	targeted	target	VERB
dpc-2121	171	4	therapy	therapy	NOUN
dpc-2121	171	5	continued	continue	VERB
dpc-2121	171	6	to	to	PART
dpc-2121	171	7	evolve	evolve	VERB
dpc-2121	171	8	,	,	PUNCT
dpc-2121	171	9	and	and	CCONJ
dpc-2121	171	10	the	the	DET
dpc-2121	171	11	emergence	emergence	NOUN
dpc-2121	171	12	of	of	ADP
dpc-2121	171	13	small	small	ADJ
dpc-2121	171	14	molecules	molecule	NOUN
dpc-2121	171	15	,	,	PUNCT
dpc-2121	171	16	such	such	ADJ
dpc-2121	171	17	as	as	ADP
dpc-2121	171	18	the	the	DET
dpc-2121	171	19	jak	jak	PROPN
dpc-2121	171	20	inhibitors	inhibitor	NOUN
dpc-2121	171	21	baricitinib	baricitinib	NOUN
dpc-2121	171	22	,	,	PUNCT
dpc-2121	171	23	upadacitinib	upadacitinib	NOUN
dpc-2121	171	24	,	,	PUNCT
dpc-2121	171	25	and	and	CCONJ
dpc-2121	171	26	abrocitinib	abrocitinib	NOUN
dpc-2121	171	27	,	,	PUNCT
dpc-2121	171	28	is	be	AUX
dpc-2121	171	29	increasing	increase	VERB
dpc-2121	171	30	the	the	DET
dpc-2121	171	31	range	range	NOUN
dpc-2121	171	32	of	of	ADP
dpc-2121	171	33	options	option	NOUN
dpc-2121	171	34	for	for	ADP
dpc-2121	171	35	dermatologists	dermatologist	NOUN
dpc-2121	171	36	to	to	PART
dpc-2121	171	37	treat	treat	VERB
dpc-2121	171	38	their	their	PRON
dpc-2121	171	39	patients	patient	NOUN
dpc-2121	171	40	.	.	PUNCT
dpc-2121	172	1	jak	jak	PROPN
dpc-2121	172	2	inhibitors	inhibitor	NOUN
dpc-2121	172	3	seem	seem	VERB
dpc-2121	172	4	to	to	PART
dpc-2121	172	5	have	have	VERB
dpc-2121	172	6	a	a	DET
dpc-2121	172	7	faster	fast	ADJ
dpc-2121	172	8	onset	onset	NOUN
dpc-2121	172	9	of	of	ADP
dpc-2121	172	10	action	action	NOUN
dpc-2121	172	11	than	than	ADP
dpc-2121	172	12	alternative	alternative	ADJ
dpc-2121	172	13	agents	agent	NOUN
dpc-2121	172	14	,	,	PUNCT
dpc-2121	172	15	such	such	ADJ
dpc-2121	172	16	as	as	ADP
dpc-2121	172	17	dupilumab	dupilumab	NOUN
dpc-2121	172	18	,	,	PUNCT
dpc-2121	172	19	although	although	SCONJ
dpc-2121	172	20	the	the	DET
dpc-2121	172	21	latter	latter	ADJ
dpc-2121	172	22	have	have	VERB
dpc-2121	172	23	a	a	DET
dpc-2121	172	24	more	more	ADV
dpc-2121	172	25	favorable	favorable	ADJ
dpc-2121	172	26	safety	safety	NOUN
dpc-2121	172	27	profile	profile	NOUN
dpc-2121	172	28	with	with	ADP
dpc-2121	172	29	no	no	DET
dpc-2121	172	30	requirements	requirement	NOUN
dpc-2121	172	31	of	of	ADP
dpc-2121	172	32	blood	blood	NOUN
dpc-2121	172	33	monitoring	monitoring	NOUN
dpc-2121	172	34	.	.	PUNCT
dpc-2121	173	1	despite	despite	SCONJ
dpc-2121	173	2	the	the	DET
dpc-2121	173	3	efficacy	efficacy	NOUN
dpc-2121	173	4	and	and	CCONJ
dpc-2121	173	5	safety	safety	NOUN
dpc-2121	173	6	profile	profile	NOUN
dpc-2121	173	7	that	that	SCONJ
dpc-2121	173	8	jak	jak	PROPN
dpc-2121	173	9	inhibitors	inhibitor	NOUN
dpc-2121	173	10	demonstrated	demonstrate	VERB
dpc-2121	173	11	in	in	ADP
dpc-2121	173	12	clinical	clinical	ADJ
dpc-2121	173	13	trials	trial	NOUN
dpc-2121	173	14	,	,	PUNCT
dpc-2121	173	15	some	some	DET
dpc-2121	173	16	questions	question	NOUN
dpc-2121	173	17	remain	remain	VERB
dpc-2121	173	18	,	,	PUNCT
dpc-2121	173	19	including	include	VERB
dpc-2121	173	20	their	their	PRON
dpc-2121	173	21	long	long	ADJ
dpc-2121	173	22	-	-	PUNCT
dpc-2121	173	23	term	term	NOUN
dpc-2121	173	24	efficacy	efficacy	NOUN
dpc-2121	173	25	(	(	PUNCT
dpc-2121	173	26	rate	rate	NOUN
dpc-2121	173	27	of	of	ADP
dpc-2121	173	28	flares	flare	NOUN
dpc-2121	173	29	)	)	PUNCT
dpc-2121	173	30	,	,	PUNCT
dpc-2121	173	31	long	long	ADJ
dpc-2121	173	32	-	-	PUNCT
dpc-2121	173	33	term	term	NOUN
dpc-2121	173	34	safety	safety	NOUN
dpc-2121	173	35	events	event	NOUN
dpc-2121	173	36	,	,	PUNCT
dpc-2121	173	37	head	head	NOUN
dpc-2121	173	38	-	-	PUNCT
dpc-2121	173	39	to	to	ADP
dpc-2121	173	40	-	-	PUNCT
dpc-2121	173	41	head	head	NOUN
dpc-2121	173	42	comparisons	comparison	NOUN
dpc-2121	173	43	,	,	PUNCT
dpc-2121	173	44	and	and	CCONJ
dpc-2121	173	45	data	datum	NOUN
dpc-2121	173	46	on	on	ADP
dpc-2121	173	47	the	the	DET
dpc-2121	173	48	efficacy	efficacy	NOUN
dpc-2121	173	49	and	and	CCONJ
dpc-2121	173	50	safety	safety	NOUN
dpc-2121	173	51	of	of	ADP
dpc-2121	173	52	the	the	DET
dpc-2121	173	53	drug	drug	NOUN
dpc-2121	173	54	in	in	ADP
dpc-2121	173	55	a	a	DET
dpc-2121	173	56	real	real	ADJ
dpc-2121	173	57	-	-	PUNCT
dpc-2121	173	58	world	world	NOUN
dpc-2121	173	59	setting	setting	NOUN
dpc-2121	173	60	.	.	PUNCT
dpc-2121	174	1	in	in	ADP
dpc-2121	174	2	summary	summary	NOUN
dpc-2121	174	3	,	,	PUNCT
dpc-2121	174	4	the	the	DET
dpc-2121	174	5	improvement	improvement	NOUN
dpc-2121	174	6	on	on	ADP
dpc-2121	174	7	the	the	DET
dpc-2121	174	8	knowledge	knowledge	NOUN
dpc-2121	174	9	of	of	ADP
dpc-2121	174	10	the	the	DET
dpc-2121	174	11	pathophysiology	pathophysiology	NOUN
dpc-2121	174	12	of	of	ADP
dpc-2121	174	13	ad	ad	NOUN
dpc-2121	174	14	is	be	AUX
dpc-2121	174	15	allowing	allow	VERB
dpc-2121	174	16	the	the	DET
dpc-2121	174	17	targeting	targeting	NOUN
dpc-2121	174	18	of	of	ADP
dpc-2121	174	19	the	the	DET
dpc-2121	174	20	treatment	treatment	NOUN
dpc-2121	174	21	of	of	ADP
dpc-2121	174	22	patients	patient	NOUN
dpc-2121	174	23	on	on	ADP
dpc-2121	174	24	a	a	DET
dpc-2121	174	25	molecular	molecular	ADJ
dpc-2121	174	26	basis	basis	NOUN
dpc-2121	174	27	[	[	X
dpc-2121	174	28	11,34–37	11,34–37	NOUN
dpc-2121	174	29	]	]	PUNCT
dpc-2121	174	30	.	.	PUNCT
dpc-2121	175	1	new	new	ADJ
dpc-2121	175	2	emergent	emergent	ADJ
dpc-2121	175	3	drugs	drug	NOUN
dpc-2121	175	4	are	be	AUX
dpc-2121	175	5	allowing	allow	VERB
dpc-2121	175	6	a	a	DET
dpc-2121	175	7	smoother	smooth	ADJ
dpc-2121	175	8	balance	balance	NOUN
dpc-2121	175	9	between	between	ADP
dpc-2121	175	10	efficacy	efficacy	NOUN
dpc-2121	175	11	and	and	CCONJ
dpc-2121	175	12	side	side	NOUN
dpc-2121	175	13	effects	effect	NOUN
dpc-2121	175	14	[	[	X
dpc-2121	175	15	11,34–37	11,34–37	NOUN
dpc-2121	175	16	]	]	PUNCT
dpc-2121	175	17	.	.	PUNCT
dpc-2121	176	1	these	these	DET
dpc-2121	176	2	new	new	ADJ
dpc-2121	176	3	drugs	drug	NOUN
dpc-2121	176	4	are	be	AUX
dpc-2121	176	5	crucial	crucial	ADJ
dpc-2121	176	6	to	to	PART
dpc-2121	176	7	improve	improve	VERB
dpc-2121	176	8	success	success	NOUN
dpc-2121	176	9	in	in	ADP
dpc-2121	176	10	ad	ad	NOUN
dpc-2121	176	11	management	management	NOUN
dpc-2121	176	12	.	.	PUNCT
dpc-2121	177	1	this	this	PRON
dpc-2121	177	2	applies	apply	VERB
dpc-2121	177	3	particularly	particularly	ADV
dpc-2121	177	4	to	to	ADP
dpc-2121	177	5	non	non	ADJ
dpc-2121	177	6	-	-	ADJ
dpc-2121	177	7	responder	responder	ADJ
dpc-2121	177	8	patients	patient	NOUN
dpc-2121	177	9	,	,	PUNCT
dpc-2121	177	10	that	that	PRON
dpc-2121	177	11	represent	represent	VERB
dpc-2121	177	12	an	an	DET
dpc-2121	177	13	important	important	ADJ
dpc-2121	177	14	group	group	NOUN
dpc-2121	177	15	whose	whose	DET
dpc-2121	177	16	needs	need	NOUN
dpc-2121	177	17	have	have	VERB
dpc-2121	177	18	to	to	PART
dpc-2121	177	19	be	be	AUX
dpc-2121	177	20	addressed	address	VERB
dpc-2121	177	21	.	.	PUNCT
dpc-2121	178	1	references	reference	NOUN
dpc-2121	178	2	1	1	NUM
dpc-2121	178	3	.	.	PUNCT
dpc-2121	179	1	tsai	tsai	PROPN
dpc-2121	179	2	h	h	PROPN
dpc-2121	179	3	-	-	PUNCT
dpc-2121	179	4	r	r	NOUN
dpc-2121	179	5	,	,	PUNCT
dpc-2121	179	6	lu	lu	PROPN
dpc-2121	179	7	j	j	PROPN
dpc-2121	179	8	-	-	PUNCT
dpc-2121	179	9	w	w	PROPN
dpc-2121	179	10	,	,	PUNCT
dpc-2121	179	11	chen	chen	PROPN
dpc-2121	179	12	l	l	PROPN
dpc-2121	179	13	-	-	PROPN
dpc-2121	179	14	y	y	PROPN
dpc-2121	179	15	,	,	PUNCT
dpc-2121	179	16	chen	chen	PROPN
dpc-2121	179	17	t	t	PROPN
dpc-2121	179	18	-	-	PUNCT
dpc-2121	179	19	l.	l.	PROPN
dpc-2121	179	20	application	application	NOUN
dpc-2121	179	21	of	of	ADP
dpc-2121	179	22	janus	janus	PROPN
dpc-2121	179	23	kinase	kinase	PROPN
dpc-2121	179	24	inhibitors	inhibitor	NOUN
dpc-2121	179	25	in	in	ADP
dpc-2121	179	26	atopic	atopic	NOUN
dpc-2121	179	27	dermatitis	dermatitis	NOUN
dpc-2121	179	28	:	:	PUNCT
dpc-2121	179	29	an	an	DET
dpc-2121	179	30	updated	update	VERB
dpc-2121	179	31	systematic	systematic	ADJ
dpc-2121	179	32	review	review	NOUN
dpc-2121	179	33	and	and	CCONJ
dpc-2121	179	34	meta	meta	NOUN
dpc-2121	179	35	-	-	PUNCT
dpc-2121	179	36	analysis	analysis	NOUN
dpc-2121	179	37	of	of	ADP
dpc-2121	179	38	clinical	clinical	ADJ
dpc-2121	179	39	trials	trial	NOUN
dpc-2121	179	40	.	.	PUNCT
dpc-2121	180	1	j	j	PROPN
dpc-2121	180	2	pers	per	NOUN
dpc-2121	180	3	med	me	VERB
dpc-2121	180	4	.	.	PUNCT
dpc-2121	181	1	2021;11(4):279	2021;11(4):279	NOUN
dpc-2121	181	2	.	.	PUNCT
dpc-2121	181	3	doi:10.3390	doi:10.3390	NOUN
dpc-2121	181	4	/	/	SYM
dpc-2121	181	5	jpm11040279	jpm11040279	PROPN
dpc-2121	181	6	.	.	PUNCT
dpc-2121	182	1	pmid	pmid	NOUN
dpc-2121	182	2	:	:	PUNCT
dpc-2121	182	3	33917069	33917069	NUM
dpc-2121	182	4	.	.	PUNCT
dpc-2121	183	1	pmcid	pmcid	NOUN
dpc-2121	183	2	:	:	PUNCT
dpc-2121	183	3	pmc8067719	pmc8067719	NOUN
dpc-2121	183	4	.	.	PUNCT
dpc-2121	184	1	2	2	NUM
dpc-2121	184	2	.	.	X
dpc-2121	184	3	weidinger	weidinger	PROPN
dpc-2121	184	4	s	s	PROPN
dpc-2121	184	5	,	,	PUNCT
dpc-2121	184	6	beck	beck	PROPN
dpc-2121	184	7	la	la	PROPN
dpc-2121	184	8	,	,	PUNCT
dpc-2121	184	9	bieber	bieber	PROPN
dpc-2121	184	10	t	t	PROPN
dpc-2121	184	11	,	,	PUNCT
dpc-2121	184	12	kabashima	kabashima	PROPN
dpc-2121	184	13	k	k	PROPN
dpc-2121	184	14	,	,	PUNCT
dpc-2121	184	15	irvine	irvine	PROPN
dpc-2121	184	16	ad	ad	NOUN
dpc-2121	184	17	.	.	PUNCT
dpc-2121	185	1	atopic	atopic	NOUN
dpc-2121	185	2	dermatitis	dermatitis	PROPN
dpc-2121	185	3	.	.	PUNCT
dpc-2121	186	1	nat	nat	PROPN
dpc-2121	186	2	rev	rev	VERB
dpc-2121	186	3	dis	dis	PROPN
dpc-2121	186	4	prim	prim	PROPN
dpc-2121	186	5	.	.	PUNCT
dpc-2121	187	1	2018;4(1):1	2018;4(1):1	PROPN
dpc-2121	187	2	.	.	PUNCT
dpc-2121	188	1	doi:10.1038	doi:10.1038	NOUN
dpc-2121	188	2	/	/	SYM
dpc-2121	188	3	s41572018	s41572018	PROPN
dpc-2121	188	4	-	-	PUNCT
dpc-2121	188	5	0001	0001	NUM
dpc-2121	188	6	-	-	PUNCT
dpc-2121	188	7	z.	z.	NOUN
dpc-2121	188	8	pmid	pmid	PROPN
dpc-2121	188	9	:	:	PUNCT
dpc-2121	188	10	29930242	29930242	NUM
dpc-2121	188	11	.	.	PUNCT
dpc-2121	189	1	3	3	X
dpc-2121	189	2	.	.	X
dpc-2121	189	3	hay	hay	PROPN
dpc-2121	189	4	rj	rj	PROPN
dpc-2121	189	5	,	,	PUNCT
dpc-2121	189	6	johns	johns	PROPN
dpc-2121	189	7	ne	ne	PROPN
dpc-2121	189	8	,	,	PUNCT
dpc-2121	189	9	williams	williams	PROPN
dpc-2121	189	10	hc	hc	PROPN
dpc-2121	189	11	,	,	PUNCT
dpc-2121	189	12	et	et	PROPN
dpc-2121	189	13	al	al	PROPN
dpc-2121	189	14	.	.	PUNCT
dpc-2121	190	1	the	the	DET
dpc-2121	190	2	global	global	ADJ
dpc-2121	190	3	burden	burden	NOUN
dpc-2121	190	4	of	of	ADP
dpc-2121	190	5	skin	skin	NOUN
dpc-2121	190	6	disease	disease	NOUN
dpc-2121	190	7	in	in	ADP
dpc-2121	190	8	2010	2010	NUM
dpc-2121	190	9	:	:	PUNCT
dpc-2121	190	10	an	an	DET
dpc-2121	190	11	analysis	analysis	NOUN
dpc-2121	190	12	of	of	ADP
dpc-2121	190	13	the	the	DET
dpc-2121	190	14	prevalence	prevalence	NOUN
dpc-2121	190	15	and	and	CCONJ
dpc-2121	190	16	impact	impact	NOUN
dpc-2121	190	17	of	of	ADP
dpc-2121	190	18	skin	skin	NOUN
dpc-2121	190	19	conditions	condition	NOUN
dpc-2121	190	20	.	.	PUNCT
dpc-2121	191	1	j	j	PROPN
dpc-2121	191	2	invest	invest	VERB
dpc-2121	191	3	dermatol	dermatol	NOUN
dpc-2121	191	4	.	.	PUNCT
dpc-2121	192	1	2014;134(6):1534	2014;134(6):1534	NUM
dpc-2121	192	2	.	.	X
dpc-2121	193	1	doi:10.1038/	doi:10.1038/	NOUN
dpc-2121	193	2	jid.2013.446	jid.2013.446	PROPN
dpc-2121	193	3	.	.	PUNCT
dpc-2121	194	1	pmid	pmid	NOUN
dpc-2121	194	2	:	:	PUNCT
dpc-2121	194	3	24166134	24166134	NUM
dpc-2121	194	4	.	.	PUNCT
dpc-2121	194	5	8	8	NUM
dpc-2121	194	6	review	review	NOUN
dpc-2121	194	7	|	|	ADV
dpc-2121	194	8	dermatol	dermatol	ADJ
dpc-2121	194	9	pract	pract	NOUN
dpc-2121	194	10	concept	concept	NOUN
dpc-2121	194	11	.	.	PUNCT
dpc-2121	195	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	195	2	4	4	NUM
dpc-2121	195	3	.	.	PUNCT
dpc-2121	196	1	cartron	cartron	PROPN
dpc-2121	196	2	a	a	PRON
dpc-2121	196	3	,	,	PUNCT
dpc-2121	196	4	nguyen	nguyen	PROPN
dpc-2121	196	5	t	t	PROPN
dpc-2121	196	6	,	,	PUNCT
dpc-2121	196	7	roh	roh	PROPN
dpc-2121	196	8	y	y	PROPN
dpc-2121	196	9	,	,	PUNCT
dpc-2121	196	10	kwatra	kwatra	PROPN
dpc-2121	196	11	m	m	PROPN
dpc-2121	196	12	,	,	PUNCT
dpc-2121	196	13	kwatra	kwatra	PROPN
dpc-2121	196	14	s.	s.	PROPN
dpc-2121	196	15	janus	janus	PROPN
dpc-2121	196	16	kinase	kinase	PROPN
dpc-2121	196	17	inhibitors	inhibitor	NOUN
dpc-2121	196	18	for	for	ADP
dpc-2121	196	19	atopic	atopic	NOUN
dpc-2121	196	20	dermatitis	dermatitis	NOUN
dpc-2121	196	21	:	:	PUNCT
dpc-2121	196	22	a	a	DET
dpc-2121	196	23	promising	promising	ADJ
dpc-2121	196	24	treatment	treatment	NOUN
dpc-2121	196	25	modality	modality	NOUN
dpc-2121	196	26	.	.	PUNCT
dpc-2121	197	1	clin	clin	PROPN
dpc-2121	197	2	exp	exp	NOUN
dpc-2121	197	3	dermatol	dermatol	NOUN
dpc-2121	197	4	.	.	PUNCT
dpc-2121	198	1	2021;46(5):820	2021;46(5):820	NUM
dpc-2121	198	2	-	-	PUNCT
dpc-2121	198	3	824	824	NUM
dpc-2121	198	4	.	.	PUNCT
dpc-2121	199	1	doi:10.1111/	doi:10.1111/	NOUN
dpc-2121	199	2	ced.14567	ced.14567	X
dpc-2121	199	3	.	.	PUNCT
dpc-2121	200	1	pmid	pmid	NOUN
dpc-2121	200	2	:	:	PUNCT
dpc-2121	200	3	33484582	33484582	NUM
dpc-2121	200	4	.	.	PUNCT
dpc-2121	201	1	5	5	X
dpc-2121	201	2	.	.	X
dpc-2121	201	3	kim	kim	PROPN
dpc-2121	201	4	j	j	PROPN
dpc-2121	201	5	,	,	PUNCT
dpc-2121	201	6	kim	kim	PROPN
dpc-2121	201	7	be	be	PROPN
dpc-2121	201	8	,	,	PUNCT
dpc-2121	201	9	leung	leung	PROPN
dpc-2121	201	10	dym	dym	PROPN
dpc-2121	201	11	.	.	PROPN
dpc-2121	201	12	pathophysiology	pathophysiology	PROPN
dpc-2121	201	13	of	of	ADP
dpc-2121	201	14	atopic	atopic	NOUN
dpc-2121	201	15	dermatitis	dermatitis	NOUN
dpc-2121	201	16	:	:	PUNCT
dpc-2121	201	17	clinical	clinical	ADJ
dpc-2121	201	18	implications	implication	NOUN
dpc-2121	201	19	.	.	PUNCT
dpc-2121	202	1	allergy	allergy	NOUN
dpc-2121	202	2	asthma	asthma	PROPN
dpc-2121	202	3	proc	proc	PROPN
dpc-2121	202	4	.	.	PUNCT
dpc-2121	203	1	2019;40(2):84	2019;40(2):84	NUM
dpc-2121	203	2	-	-	SYM
dpc-2121	203	3	92	92	NUM
dpc-2121	203	4	.	.	PUNCT
dpc-2121	203	5	doi:10.2500	doi:10.2500	NOUN
dpc-2121	203	6	/	/	SYM
dpc-2121	203	7	aap.2019.40.4202	aap.2019.40.4202	PROPN
dpc-2121	203	8	.	.	PUNCT
dpc-2121	204	1	pmid	pmid	NOUN
dpc-2121	204	2	:	:	PUNCT
dpc-2121	204	3	30819278	30819278	NUM
dpc-2121	204	4	.	.	PUNCT
dpc-2121	205	1	pmcid	pmcid	NOUN
dpc-2121	205	2	:	:	PUNCT
dpc-2121	205	3	pmc6399565	pmc6399565	NOUN
dpc-2121	205	4	.	.	PUNCT
dpc-2121	206	1	6	6	X
dpc-2121	206	2	.	.	X
dpc-2121	206	3	torres	torres	PROPN
dpc-2121	206	4	t	t	PROPN
dpc-2121	206	5	,	,	PUNCT
dpc-2121	206	6	ferreira	ferreira	PROPN
dpc-2121	206	7	eo	eo	PROPN
dpc-2121	206	8	,	,	PUNCT
dpc-2121	206	9	gonçalo	gonçalo	PROPN
dpc-2121	206	10	m	m	PROPN
dpc-2121	206	11	,	,	PUNCT
dpc-2121	206	12	mendes	mende	NOUN
dpc-2121	206	13	-	-	PUNCT
dpc-2121	206	14	bastos	basto	NOUN
dpc-2121	206	15	p	p	X
dpc-2121	206	16	,	,	PUNCT
dpc-2121	206	17	selores	selore	NOUN
dpc-2121	206	18	m	m	PROPN
dpc-2121	206	19	,	,	PUNCT
dpc-2121	206	20	filipe	filipe	PROPN
dpc-2121	206	21	p.	p.	PROPN
dpc-2121	206	22	update	update	NOUN
dpc-2121	206	23	on	on	ADP
dpc-2121	206	24	atopic	atopic	NOUN
dpc-2121	206	25	dermatitis	dermatitis	NOUN
dpc-2121	206	26	.	.	PUNCT
dpc-2121	207	1	acta	acta	PROPN
dpc-2121	207	2	med	med	PROPN
dpc-2121	207	3	port	port	NOUN
dpc-2121	207	4	.	.	PUNCT
dpc-2121	208	1	2019;32(9):606	2019;32(9):606	NUM
dpc-2121	208	2	-	-	SYM
dpc-2121	208	3	613	613	PROPN
dpc-2121	208	4	.	.	PUNCT
dpc-2121	208	5	doi:10.20344	doi:10.20344	NOUN
dpc-2121	208	6	/	/	SYM
dpc-2121	208	7	amp.11963	amp.11963	PROPN
dpc-2121	208	8	.	.	PUNCT
dpc-2121	209	1	pmid	pmid	NOUN
dpc-2121	209	2	:	:	PUNCT
dpc-2121	209	3	31493365	31493365	NUM
dpc-2121	209	4	.	.	PUNCT
dpc-2121	210	1	7	7	X
dpc-2121	210	2	.	.	X
dpc-2121	210	3	dattola	dattola	PROPN
dpc-2121	210	4	a	a	PRON
dpc-2121	210	5	,	,	PUNCT
dpc-2121	210	6	bennardo	bennardo	PROPN
dpc-2121	210	7	l	l	NOUN
dpc-2121	210	8	,	,	PUNCT
dpc-2121	210	9	silvestri	silvestri	PROPN
dpc-2121	210	10	m	m	PROPN
dpc-2121	210	11	,	,	PUNCT
dpc-2121	210	12	nistico	nistico	NOUN
dpc-2121	210	13	sp	sp	NOUN
dpc-2121	210	14	.	.	PUNCT
dpc-2121	211	1	what	what	PRON
dpc-2121	211	2	’s	’	VERB
dpc-2121	211	3	new	new	ADJ
dpc-2121	211	4	in	in	ADP
dpc-2121	211	5	the	the	DET
dpc-2121	211	6	treatment	treatment	NOUN
dpc-2121	211	7	of	of	ADP
dpc-2121	211	8	atopic	atopic	NOUN
dpc-2121	211	9	dermatitis	dermatitis	NOUN
dpc-2121	211	10	?	?	PUNCT
dpc-2121	212	1	dermatol	dermatol	NOUN
dpc-2121	212	2	ther	ther	ADV
dpc-2121	212	3	.	.	PUNCT
dpc-2121	213	1	2019;32(2):e12787	2019;32(2):e12787	NUM
dpc-2121	213	2	.	.	PUNCT
dpc-2121	214	1	doi:10.1111	doi:10.1111	NOUN
dpc-2121	214	2	/	/	SYM
dpc-2121	214	3	dth.12787	dth.12787	PROPN
dpc-2121	214	4	.	.	PUNCT
dpc-2121	215	1	pmid	pmid	NOUN
dpc-2121	215	2	:	:	PUNCT
dpc-2121	215	3	30548724	30548724	NUM
dpc-2121	215	4	.	.	PUNCT
dpc-2121	216	1	8	8	X
dpc-2121	216	2	.	.	X
dpc-2121	217	1	ratchataswan	ratchataswan	PROPN
dpc-2121	217	2	t	t	PROPN
dpc-2121	217	3	,	,	PUNCT
dpc-2121	217	4	banzon	banzon	PROPN
dpc-2121	217	5	tm	tm	PROPN
dpc-2121	217	6	,	,	PUNCT
dpc-2121	217	7	thyssen	thyssen	PROPN
dpc-2121	217	8	jp	jp	PROPN
dpc-2121	217	9	,	,	PUNCT
dpc-2121	217	10	weidinger	weidinger	NOUN
dpc-2121	217	11	s	s	PROPN
dpc-2121	217	12	,	,	PUNCT
dpc-2121	217	13	guttman	guttman	ADJ
dpc-2121	217	14	-	-	PUNCT
dpc-2121	217	15	yassky	yassky	NOUN
dpc-2121	217	16	e	e	NOUN
dpc-2121	217	17	,	,	PUNCT
dpc-2121	217	18	phipatanakul	phipatanakul	PROPN
dpc-2121	217	19	w.	w.	NOUN
dpc-2121	217	20	biologics	biologic	NOUN
dpc-2121	217	21	for	for	ADP
dpc-2121	217	22	treatment	treatment	NOUN
dpc-2121	217	23	of	of	ADP
dpc-2121	217	24	atopic	atopic	NOUN
dpc-2121	217	25	dermatitis	dermatitis	NOUN
dpc-2121	217	26	:	:	PUNCT
dpc-2121	217	27	current	current	ADJ
dpc-2121	217	28	status	status	NOUN
dpc-2121	217	29	and	and	CCONJ
dpc-2121	217	30	future	future	ADJ
dpc-2121	217	31	prospect	prospect	NOUN
dpc-2121	217	32	.	.	PUNCT
dpc-2121	218	1	j	j	PROPN
dpc-2121	218	2	allergy	allergy	PROPN
dpc-2121	218	3	clin	clin	PROPN
dpc-2121	218	4	immunol	immunol	PROPN
dpc-2121	218	5	pr	pr	PROPN
dpc-2121	218	6	.	.	PUNCT
dpc-2121	219	1	2021;9(3):1053	2021;9(3):1053	NUM
dpc-2121	219	2	-	-	SYM
dpc-2121	219	3	1065	1065	NUM
dpc-2121	219	4	.	.	PUNCT
dpc-2121	220	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	220	2	/	/	SYM
dpc-2121	220	3	j.	j.	PROPN
dpc-2121	220	4	jaip.2020.11.034	jaip.2020.11.034	PROPN
dpc-2121	220	5	.	.	PUNCT
dpc-2121	221	1	pmid	pmid	NOUN
dpc-2121	221	2	:	:	PUNCT
dpc-2121	221	3	33685604	33685604	NUM
dpc-2121	221	4	.	.	PUNCT
dpc-2121	222	1	9	9	X
dpc-2121	222	2	.	.	X
dpc-2121	222	3	european	european	ADJ
dpc-2121	222	4	medicines	medicine	NOUN
dpc-2121	222	5	agency	agency	NOUN
dpc-2121	222	6	.	.	PUNCT
dpc-2121	223	1	dupixent	dupixent	PROPN
dpc-2121	223	2	®	®	NOUN
dpc-2121	223	3	(	(	PUNCT
dpc-2121	223	4	dupilumab	dupilumab	NOUN
dpc-2121	223	5	):	):	PUNCT
dpc-2121	223	6	epar	epar	NOUN
dpc-2121	223	7	product	product	NOUN
dpc-2121	223	8	information	information	NOUN
dpc-2121	223	9	.	.	PUNCT
dpc-2121	224	1	https://www.ema.europa.eu/en/documents/	https://www.ema.europa.eu/en/documents/	NOUN
dpc-2121	224	2	product	product	NOUN
dpc-2121	224	3	-	-	PUNCT
dpc-2121	224	4	information	information	NOUN
dpc-2121	224	5	/	/	SYM
dpc-2121	224	6	dupixent	dupixent	NOUN
dpc-2121	224	7	-	-	PUNCT
dpc-2121	224	8	epar	epar	NOUN
dpc-2121	224	9	-	-	PUNCT
dpc-2121	224	10	product	product	NOUN
dpc-2121	224	11	-	-	PUNCT
dpc-2121	224	12	information_en.pdf	information_en.pdf	NOUN
dpc-2121	224	13	.	.	PUNCT
dpc-2121	225	1	published	publish	VERB
dpc-2121	225	2	2021	2021	NUM
dpc-2121	225	3	.	.	PUNCT
dpc-2121	226	1	accessed	access	VERB
dpc-2121	226	2	july	july	PROPN
dpc-2121	226	3	27	27	NUM
dpc-2121	226	4	,	,	PUNCT
dpc-2121	226	5	2021	2021	NUM
dpc-2121	226	6	.	.	PUNCT
dpc-2121	227	1	10	10	NUM
dpc-2121	227	2	.	.	PUNCT
dpc-2121	227	3	rodrigues	rodrigues	PROPN
dpc-2121	227	4	ma	ma	PROPN
dpc-2121	227	5	,	,	PUNCT
dpc-2121	227	6	torres	torre	VERB
dpc-2121	227	7	t.	t.	PROPN
dpc-2121	227	8	jak	jak	PROPN
dpc-2121	227	9	/	/	SYM
dpc-2121	227	10	stat	stat	PROPN
dpc-2121	227	11	inhibitors	inhibitor	NOUN
dpc-2121	227	12	for	for	ADP
dpc-2121	227	13	the	the	DET
dpc-2121	227	14	treatment	treatment	NOUN
dpc-2121	227	15	of	of	ADP
dpc-2121	227	16	atopic	atopic	NOUN
dpc-2121	227	17	dermatitis	dermatitis	NOUN
dpc-2121	227	18	.	.	PUNCT
dpc-2121	228	1	j	j	PROPN
dpc-2121	228	2	dermatolog	dermatolog	PROPN
dpc-2121	228	3	treat	treat	NOUN
dpc-2121	228	4	.	.	PUNCT
dpc-2121	229	1	2020;31(1):33	2020;31(1):33	NUM
dpc-2121	229	2	-	-	SYM
dpc-2121	229	3	40	40	NUM
dpc-2121	229	4	.	.	PUNCT
dpc-2121	230	1	do	do	VERB
dpc-2121	230	2	i:10.1080/09546634.2019.1577549	i:10.1080/09546634.2019.1577549	PROPN
dpc-2121	230	3	.	.	PUNCT
dpc-2121	231	1	pmid	pmid	NOUN
dpc-2121	231	2	:	:	PUNCT
dpc-2121	231	3	30703333	30703333	NUM
dpc-2121	231	4	.	.	PUNCT
dpc-2121	232	1	11	11	NUM
dpc-2121	232	2	.	.	X
dpc-2121	233	1	he	he	PRON
dpc-2121	233	2	h	h	NOUN
dpc-2121	233	3	,	,	PUNCT
dpc-2121	233	4	guttman	guttman	ADJ
dpc-2121	233	5	-	-	PUNCT
dpc-2121	233	6	yassky	yassky	NOUN
dpc-2121	233	7	e.	e.	PROPN
dpc-2121	233	8	jak	jak	PROPN
dpc-2121	233	9	inhibitors	inhibitor	NOUN
dpc-2121	233	10	for	for	ADP
dpc-2121	233	11	atopic	atopic	NOUN
dpc-2121	233	12	dermatitis	dermatitis	NOUN
dpc-2121	233	13	:	:	PUNCT
dpc-2121	233	14	an	an	DET
dpc-2121	233	15	update	update	NOUN
dpc-2121	233	16	.	.	PUNCT
dpc-2121	234	1	am	be	AUX
dpc-2121	234	2	j	j	PROPN
dpc-2121	234	3	clin	clin	PROPN
dpc-2121	234	4	dermatol	dermatol	NOUN
dpc-2121	234	5	.	.	PUNCT
dpc-2121	235	1	2019;20(2):181	2019;20(2):181	NUM
dpc-2121	235	2	-	-	PUNCT
dpc-2121	235	3	192	192	NUM
dpc-2121	235	4	.	.	PUNCT
dpc-2121	236	1	doi:10.1007	doi:10.1007	VERB
dpc-2121	236	2	/	/	SYM
dpc-2121	236	3	s40257	s40257	NOUN
dpc-2121	236	4	-	-	PUNCT
dpc-2121	236	5	018	018	NUM
dpc-2121	236	6	-	-	PUNCT
dpc-2121	236	7	0413	0413	NUM
dpc-2121	236	8	-	-	PUNCT
dpc-2121	236	9	2	2	NUM
dpc-2121	236	10	.	.	PUNCT
dpc-2121	236	11	pmid	pmid	NOUN
dpc-2121	236	12	:	:	PUNCT
dpc-2121	236	13	30536048	30536048	NUM
dpc-2121	236	14	.	.	PUNCT
dpc-2121	237	1	12	12	NUM
dpc-2121	237	2	.	.	PUNCT
dpc-2121	238	1	harrison	harrison	PROPN
dpc-2121	238	2	da	da	PROPN
dpc-2121	238	3	.	.	PUNCT
dpc-2121	239	1	the	the	DET
dpc-2121	239	2	jak	jak	PROPN
dpc-2121	239	3	/	/	SYM
dpc-2121	239	4	stat	stat	PROPN
dpc-2121	239	5	pathway	pathway	NOUN
dpc-2121	239	6	.	.	PUNCT
dpc-2121	240	1	cold	cold	ADJ
dpc-2121	240	2	spring	spring	NOUN
dpc-2121	240	3	harb	harb	PROPN
dpc-2121	240	4	perspect	perspect	VERB
dpc-2121	240	5	biol	biol	PROPN
dpc-2121	240	6	.	.	PUNCT
dpc-2121	241	1	2012;4(3):a011205	2012;4(3):a011205	PROPN
dpc-2121	241	2	.	.	PUNCT
dpc-2121	241	3	doi:10.1101	doi:10.1101	NOUN
dpc-2121	241	4	/	/	SYM
dpc-2121	241	5	cshperspect	cshperspect	ADJ
dpc-2121	241	6	.	.	PUNCT
dpc-2121	242	1	a011205	a011205	PROPN
dpc-2121	242	2	.	.	PUNCT
dpc-2121	243	1	pmid	pmid	NOUN
dpc-2121	243	2	:	:	PUNCT
dpc-2121	243	3	22383755	22383755	NUM
dpc-2121	243	4	.	.	PUNCT
dpc-2121	244	1	pmcid	pmcid	NOUN
dpc-2121	244	2	:	:	PUNCT
dpc-2121	244	3	pmc3282412	pmc3282412	NOUN
dpc-2121	244	4	.	.	PUNCT
dpc-2121	245	1	13	13	NUM
dpc-2121	245	2	.	.	X
dpc-2121	246	1	oetjen	oetjen	PROPN
dpc-2121	246	2	lk	lk	PROPN
dpc-2121	246	3	,	,	PUNCT
dpc-2121	246	4	mack	mack	PROPN
dpc-2121	246	5	mr	mr	PROPN
dpc-2121	246	6	,	,	PUNCT
dpc-2121	246	7	feng	feng	PROPN
dpc-2121	246	8	j	j	PROPN
dpc-2121	246	9	,	,	PUNCT
dpc-2121	246	10	et	et	PROPN
dpc-2121	246	11	al	al	PROPN
dpc-2121	246	12	.	.	PUNCT
dpc-2121	247	1	sensory	sensory	ADJ
dpc-2121	247	2	neurons	neuron	NOUN
dpc-2121	247	3	co	co	ADJ
dpc-2121	247	4	-	-	ADJ
dpc-2121	247	5	opt	opt	ADJ
dpc-2121	247	6	classical	classical	ADJ
dpc-2121	247	7	immune	immune	NOUN
dpc-2121	247	8	signaling	signal	VERB
dpc-2121	247	9	pathways	pathway	NOUN
dpc-2121	247	10	to	to	PART
dpc-2121	247	11	mediate	mediate	VERB
dpc-2121	247	12	chronic	chronic	ADJ
dpc-2121	247	13	itch	itch	NOUN
dpc-2121	247	14	.	.	PUNCT
dpc-2121	248	1	cell	cell	NOUN
dpc-2121	248	2	.	.	PUNCT
dpc-2121	249	1	2017;171(1):217	2017;171(1):217	X
dpc-2121	249	2	-	-	PUNCT
dpc-2121	249	3	228.e13	228.e13	NUM
dpc-2121	249	4	.	.	PUNCT
dpc-2121	250	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	250	2	/	/	SYM
dpc-2121	250	3	j.	j.	PROPN
dpc-2121	250	4	cell.2017.08.006.pmid	cell.2017.08.006.pmid	PROPN
dpc-2121	250	5	:	:	PUNCT
dpc-2121	250	6	28890086	28890086	NUM
dpc-2121	250	7	.	.	PUNCT
dpc-2121	251	1	pmcid	pmcid	NOUN
dpc-2121	251	2	:	:	PUNCT
dpc-2121	251	3	pmc5658016	pmc5658016	NOUN
dpc-2121	251	4	.	.	PUNCT
dpc-2121	252	1	14	14	NUM
dpc-2121	252	2	.	.	PUNCT
dpc-2121	253	1	tamura	tamura	PROPN
dpc-2121	253	2	k	k	PROPN
dpc-2121	253	3	,	,	PUNCT
dpc-2121	253	4	arakawa	arakawa	PROPN
dpc-2121	253	5	h	h	PROPN
dpc-2121	253	6	,	,	PUNCT
dpc-2121	253	7	suzuki	suzuki	PROPN
dpc-2121	253	8	m	m	PROPN
dpc-2121	253	9	,	,	PUNCT
dpc-2121	253	10	et	et	PROPN
dpc-2121	253	11	al	al	PROPN
dpc-2121	253	12	.	.	PROPN
dpc-2121	253	13	novel	novel	ADJ
dpc-2121	253	14	dinucleotide	dinucleotide	NOUN
dpc-2121	253	15	repeat	repeat	NOUN
dpc-2121	253	16	polymorphism	polymorphism	NOUN
dpc-2121	253	17	in	in	ADP
dpc-2121	253	18	the	the	DET
dpc-2121	253	19	first	first	ADJ
dpc-2121	253	20	exon	exon	NOUN
dpc-2121	253	21	of	of	ADP
dpc-2121	253	22	the	the	DET
dpc-2121	253	23	stat-6	stat-6	NUM
dpc-2121	253	24	gene	gene	NOUN
dpc-2121	253	25	is	be	AUX
dpc-2121	253	26	associated	associate	VERB
dpc-2121	253	27	with	with	ADP
dpc-2121	253	28	allergic	allergic	ADJ
dpc-2121	253	29	diseases	disease	NOUN
dpc-2121	253	30	.	.	PUNCT
dpc-2121	254	1	clin	clin	PROPN
dpc-2121	254	2	exp	exp	NOUN
dpc-2121	254	3	allergy	allergy	PROPN
dpc-2121	254	4	.	.	PUNCT
dpc-2121	255	1	2001;31(10):1509	2001;31(10):1509	NUM
dpc-2121	255	2	-	-	SYM
dpc-2121	255	3	1514	1514	NUM
dpc-2121	255	4	.	.	PUNCT
dpc-2121	256	1	doi:10.1046	doi:10.1046	ADJ
dpc-2121	256	2	/	/	SYM
dpc-2121	256	3	j.1365	j.1365	NOUN
dpc-2121	256	4	-	-	PUNCT
dpc-2121	256	5	2222.2001.01191.x	2222.2001.01191.x	NUM
dpc-2121	256	6	.	.	PUNCT
dpc-2121	257	1	pmid	pmid	NOUN
dpc-2121	257	2	:	:	PUNCT
dpc-2121	257	3	11678849	11678849	NUM
dpc-2121	257	4	.	.	PUNCT
dpc-2121	258	1	15	15	NUM
dpc-2121	258	2	.	.	PUNCT
dpc-2121	259	1	czimmerer	czimmerer	PROPN
dpc-2121	259	2	z	z	PROPN
dpc-2121	259	3	,	,	PUNCT
dpc-2121	259	4	daniel	daniel	PROPN
dpc-2121	259	5	b	b	PROPN
dpc-2121	259	6	,	,	PUNCT
dpc-2121	259	7	horvath	horvath	PROPN
dpc-2121	259	8	a	a	PROPN
dpc-2121	259	9	,	,	PUNCT
dpc-2121	259	10	et	et	PROPN
dpc-2121	259	11	al	al	PROPN
dpc-2121	259	12	.	.	PUNCT
dpc-2121	260	1	the	the	DET
dpc-2121	260	2	transcription	transcription	NOUN
dpc-2121	260	3	factor	factor	NOUN
dpc-2121	260	4	stat6	stat6	NOUN
dpc-2121	260	5	mediates	mediate	VERB
dpc-2121	260	6	direct	direct	ADJ
dpc-2121	260	7	repression	repression	NOUN
dpc-2121	260	8	of	of	ADP
dpc-2121	260	9	inflammatory	inflammatory	ADJ
dpc-2121	260	10	enhancers	enhancer	NOUN
dpc-2121	260	11	and	and	CCONJ
dpc-2121	260	12	limits	limit	VERB
dpc-2121	260	13	activation	activation	NOUN
dpc-2121	260	14	of	of	ADP
dpc-2121	260	15	alternatively	alternatively	ADV
dpc-2121	260	16	polarized	polarize	VERB
dpc-2121	260	17	macrophages	macrophage	NOUN
dpc-2121	260	18	.	.	PUNCT
dpc-2121	261	1	immunity	immunity	NOUN
dpc-2121	261	2	.	.	PUNCT
dpc-2121	262	1	2018;48(1):75	2018;48(1):75	NUM
dpc-2121	262	2	-	-	PUNCT
dpc-2121	262	3	90.e6	90.e6	NUM
dpc-2121	262	4	.	.	PUNCT
dpc-2121	262	5	doi:10.1016	doi:10.1016	PROPN
dpc-2121	262	6	/	/	SYM
dpc-2121	262	7	j.immuni.2017.12.010	j.immuni.2017.12.010	PROPN
dpc-2121	262	8	.	.	PUNCT
dpc-2121	263	1	pmid	pmid	NOUN
dpc-2121	263	2	:	:	PUNCT
dpc-2121	263	3	29343442	29343442	NUM
dpc-2121	263	4	.	.	PUNCT
dpc-2121	264	1	pmcid	pmcid	NOUN
dpc-2121	264	2	:	:	PUNCT
dpc-2121	264	3	pmc5772169	pmc5772169	NOUN
dpc-2121	264	4	.	.	PUNCT
dpc-2121	265	1	16	16	NUM
dpc-2121	265	2	.	.	PUNCT
dpc-2121	266	1	li	li	PROPN
dpc-2121	266	2	h	h	PROPN
dpc-2121	266	3	,	,	PUNCT
dpc-2121	266	4	zuo	zuo	PROPN
dpc-2121	266	5	j	j	PROPN
dpc-2121	266	6	,	,	PUNCT
dpc-2121	266	7	tang	tang	PROPN
dpc-2121	266	8	w.	w.	PROPN
dpc-2121	266	9	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-2121	266	10	inhibitors	inhibitor	NOUN
dpc-2121	266	11	for	for	ADP
dpc-2121	266	12	the	the	DET
dpc-2121	266	13	treatment	treatment	NOUN
dpc-2121	266	14	of	of	ADP
dpc-2121	266	15	inflammatory	inflammatory	ADJ
dpc-2121	266	16	diseases	disease	NOUN
dpc-2121	266	17	.	.	PUNCT
dpc-2121	267	1	front	front	ADJ
dpc-2121	267	2	pharmacol	pharmacol	PROPN
dpc-2121	267	3	.	.	PUNCT
dpc-2121	267	4	2018;9:1048	2018;9:1048	PROPN
dpc-2121	267	5	.	.	PUNCT
dpc-2121	268	1	doi:10.3389	doi:10.3389	PROPN
dpc-2121	268	2	/	/	SYM
dpc-2121	268	3	fphar.2018.01048	fphar.2018.01048	PROPN
dpc-2121	268	4	.	.	PUNCT
dpc-2121	269	1	pmid	pmid	NOUN
dpc-2121	269	2	:	:	PUNCT
dpc-2121	269	3	30386231	30386231	NUM
dpc-2121	269	4	.	.	PUNCT
dpc-2121	270	1	pmcid	pmcid	NOUN
dpc-2121	270	2	:	:	PUNCT
dpc-2121	270	3	pmc6199465	pmc6199465	NOUN
dpc-2121	270	4	.	.	PUNCT
dpc-2121	271	1	17	17	NUM
dpc-2121	271	2	.	.	PUNCT
dpc-2121	272	1	european	european	PROPN
dpc-2121	272	2	medicines	medicine	NOUN
dpc-2121	272	3	agency	agency	NOUN
dpc-2121	272	4	.	.	PUNCT
dpc-2121	273	1	olumiant	olumiant	ADJ
dpc-2121	273	2	®	®	NOUN
dpc-2121	273	3	(	(	PUNCT
dpc-2121	273	4	baricitinib	baricitinib	NOUN
dpc-2121	273	5	):	):	PUNCT
dpc-2121	273	6	epar	epar	NOUN
dpc-2121	273	7	product	product	NOUN
dpc-2121	273	8	information	information	NOUN
dpc-2121	273	9	.	.	PUNCT
dpc-2121	274	1	https://www.ema.europa.eu/en/documents/	https://www.ema.europa.eu/en/documents/	NOUN
dpc-2121	274	2	product	product	NOUN
dpc-2121	274	3	-	-	PUNCT
dpc-2121	274	4	information	information	NOUN
dpc-2121	274	5	/	/	SYM
dpc-2121	274	6	olumiant	olumiant	NOUN
dpc-2121	274	7	-	-	PUNCT
dpc-2121	274	8	epar	epar	NOUN
dpc-2121	274	9	-	-	PUNCT
dpc-2121	274	10	product	product	NOUN
dpc-2121	274	11	-	-	PUNCT
dpc-2121	274	12	information_en.pdf	information_en.pdf	NOUN
dpc-2121	274	13	.	.	PUNCT
dpc-2121	275	1	published	publish	VERB
dpc-2121	275	2	2021	2021	NUM
dpc-2121	275	3	.	.	PUNCT
dpc-2121	276	1	accessed	access	VERB
dpc-2121	276	2	july	july	PROPN
dpc-2121	276	3	27	27	NUM
dpc-2121	276	4	,	,	PUNCT
dpc-2121	276	5	2021	2021	NUM
dpc-2121	276	6	.	.	PUNCT
dpc-2121	277	1	18	18	NUM
dpc-2121	277	2	.	.	PUNCT
dpc-2121	278	1	simpson	simpson	PROPN
dpc-2121	278	2	e	e	PROPN
dpc-2121	278	3	,	,	PUNCT
dpc-2121	278	4	lacour	lacour	PROPN
dpc-2121	278	5	j	j	PROPN
dpc-2121	278	6	-	-	PUNCT
dpc-2121	278	7	p	p	PROPN
dpc-2121	278	8	,	,	PUNCT
dpc-2121	278	9	spelman	spelman	PROPN
dpc-2121	278	10	l	l	PROPN
dpc-2121	278	11	,	,	PUNCT
dpc-2121	278	12	et	et	PROPN
dpc-2121	278	13	al	al	PROPN
dpc-2121	278	14	.	.	PROPN
dpc-2121	278	15	baricitinib	baricitinib	NOUN
dpc-2121	278	16	in	in	ADP
dpc-2121	278	17	patients	patient	NOUN
dpc-2121	278	18	with	with	ADP
dpc-2121	278	19	moderate	moderate	ADJ
dpc-2121	278	20	-	-	PUNCT
dpc-2121	278	21	to	to	ADP
dpc-2121	278	22	-	-	PUNCT
dpc-2121	278	23	severe	severe	ADJ
dpc-2121	278	24	atopic	atopic	NOUN
dpc-2121	278	25	dermatitis	dermatitis	NOUN
dpc-2121	278	26	and	and	CCONJ
dpc-2121	278	27	inadequate	inadequate	ADJ
dpc-2121	278	28	response	response	NOUN
dpc-2121	278	29	to	to	ADP
dpc-2121	278	30	topical	topical	ADJ
dpc-2121	278	31	corticosteroids	corticosteroid	NOUN
dpc-2121	278	32	:	:	PUNCT
dpc-2121	278	33	results	result	NOUN
dpc-2121	278	34	from	from	ADP
dpc-2121	278	35	two	two	NUM
dpc-2121	278	36	randomized	randomized	ADJ
dpc-2121	278	37	monotherapy	monotherapy	NOUN
dpc-2121	278	38	phase	phase	NOUN
dpc-2121	278	39	iii	iii	NUM
dpc-2121	278	40	trials	trial	NOUN
dpc-2121	278	41	.	.	PUNCT
dpc-2121	279	1	br	br	PROPN
dpc-2121	279	2	j	j	PROPN
dpc-2121	279	3	dermatol	dermatol	NOUN
dpc-2121	279	4	.	.	PUNCT
dpc-2121	280	1	2020;183(2):242255	2020;183(2):242255	NUM
dpc-2121	280	2	.	.	PUNCT
dpc-2121	281	1	doi:10.1111	doi:10.1111	PROPN
dpc-2121	281	2	/	/	SYM
dpc-2121	281	3	bjd.18898	bjd.18898	PROPN
dpc-2121	281	4	.	.	PUNCT
dpc-2121	282	1	pmid	pmid	NOUN
dpc-2121	282	2	:	:	PUNCT
dpc-2121	282	3	31995838	31995838	NUM
dpc-2121	282	4	.	.	PUNCT
dpc-2121	283	1	19	19	NUM
dpc-2121	283	2	.	.	PUNCT
dpc-2121	284	1	silverberg	silverberg	PROPN
dpc-2121	284	2	ji	ji	PROPN
dpc-2121	284	3	,	,	PUNCT
dpc-2121	284	4	simpson	simpson	PROPN
dpc-2121	284	5	el	el	PROPN
dpc-2121	284	6	,	,	PUNCT
dpc-2121	284	7	wollenberg	wollenberg	PROPN
dpc-2121	284	8	a	a	PROPN
dpc-2121	284	9	,	,	PUNCT
dpc-2121	284	10	et	et	PROPN
dpc-2121	284	11	al	al	PROPN
dpc-2121	284	12	.	.	PUNCT
dpc-2121	284	13	long	long	ADJ
dpc-2121	284	14	-	-	PUNCT
dpc-2121	284	15	term	term	NOUN
dpc-2121	284	16	efficacy	efficacy	NOUN
dpc-2121	284	17	of	of	ADP
dpc-2121	284	18	baricitinib	baricitinib	NOUN
dpc-2121	284	19	in	in	ADP
dpc-2121	284	20	adults	adult	NOUN
dpc-2121	284	21	with	with	ADP
dpc-2121	284	22	moderate	moderate	ADJ
dpc-2121	284	23	to	to	ADP
dpc-2121	284	24	severe	severe	ADJ
dpc-2121	284	25	atopic	atopic	NOUN
dpc-2121	284	26	dermatitis	dermatitis	NOUN
dpc-2121	284	27	who	who	PRON
dpc-2121	284	28	were	be	AUX
dpc-2121	284	29	treatment	treatment	NOUN
dpc-2121	284	30	responders	responder	NOUN
dpc-2121	284	31	or	or	CCONJ
dpc-2121	284	32	partial	partial	ADJ
dpc-2121	284	33	responders	responder	NOUN
dpc-2121	284	34	:	:	PUNCT
dpc-2121	284	35	an	an	DET
dpc-2121	284	36	extension	extension	NOUN
dpc-2121	284	37	study	study	NOUN
dpc-2121	284	38	of	of	ADP
dpc-2121	284	39	2	2	NUM
dpc-2121	284	40	randomized	randomize	VERB
dpc-2121	284	41	clinical	clinical	ADJ
dpc-2121	284	42	trials	trial	NOUN
dpc-2121	284	43	.	.	PUNCT
dpc-2121	285	1	jama	jama	PROPN
dpc-2121	285	2	dermatol	dermatol	NOUN
dpc-2121	285	3	.	.	PUNCT
dpc-2121	286	1	2021;157(6):691	2021;157(6):691	NUM
dpc-2121	286	2	-	-	SYM
dpc-2121	286	3	699	699	NUM
dpc-2121	286	4	.	.	PUNCT
dpc-2121	287	1	doi:10.1001	doi:10.1001	PROPN
dpc-2121	287	2	/	/	SYM
dpc-2121	287	3	jamadermatol.2021.1273	jamadermatol.2021.1273	PROPN
dpc-2121	287	4	.	.	PUNCT
dpc-2121	288	1	pmid	pmid	NOUN
dpc-2121	288	2	:	:	PUNCT
dpc-2121	288	3	33978711	33978711	NUM
dpc-2121	288	4	.	.	PUNCT
dpc-2121	289	1	pmcid	pmcid	NOUN
dpc-2121	289	2	:	:	PUNCT
dpc-2121	289	3	pmc8117062	pmc8117062	NOUN
dpc-2121	289	4	.	.	PUNCT
dpc-2121	290	1	20	20	NUM
dpc-2121	290	2	.	.	PUNCT
dpc-2121	291	1	lilly	lilly	PROPN
dpc-2121	291	2	.	.	PUNCT
dpc-2121	292	1	lilly	lilly	PROPN
dpc-2121	292	2	and	and	CCONJ
dpc-2121	292	3	incyte	incyte	PROPN
dpc-2121	292	4	announce	announce	VERB
dpc-2121	292	5	top	top	ADJ
dpc-2121	292	6	-	-	PUNCT
dpc-2121	292	7	line	line	NOUN
dpc-2121	292	8	results	result	NOUN
dpc-2121	292	9	from	from	ADP
dpc-2121	292	10	phase	phase	NOUN
dpc-2121	292	11	3	3	NUM
dpc-2121	292	12	study	study	NOUN
dpc-2121	292	13	(	(	PUNCT
dpc-2121	292	14	breeze	breeze	PROPN
dpc-2121	292	15	-	-	PUNCT
dpc-2121	292	16	ad4	ad4	PROPN
dpc-2121	292	17	)	)	PUNCT
dpc-2121	292	18	of	of	ADP
dpc-2121	292	19	oral	oral	ADJ
dpc-2121	292	20	selective	selective	ADJ
dpc-2121	292	21	jak	jak	PROPN
dpc-2121	292	22	inhibitor	inhibitor	NOUN
dpc-2121	292	23	baricitinib	baricitinib	NOUN
dpc-2121	292	24	in	in	ADP
dpc-2121	292	25	combination	combination	NOUN
dpc-2121	292	26	with	with	ADP
dpc-2121	292	27	topical	topical	ADJ
dpc-2121	292	28	corticosteroids	corticosteroid	NOUN
dpc-2121	292	29	in	in	ADP
dpc-2121	292	30	patients	patient	NOUN
dpc-2121	292	31	with	with	ADP
dpc-2121	292	32	moderate	moderate	ADJ
dpc-2121	292	33	to	to	ADP
dpc-2121	292	34	severe	severe	ADJ
dpc-2121	292	35	atopic	atopic	NOUN
dpc-2121	292	36	dermatitis	dermatitis	NOUN
dpc-2121	292	37	not	not	PART
dpc-2121	292	38	controlled	control	VERB
dpc-2121	292	39	with	with	ADP
dpc-2121	292	40	cyclosporine	cyclosporine	NOUN
dpc-2121	292	41	.	.	PUNCT
dpc-2121	293	1	https://investor.lilly.com/news-releases/news-release-details/	https://investor.lilly.com/news-releases/news-release-details/	PROPN
dpc-2121	293	2	lilly	lilly	PROPN
dpc-2121	293	3	-	-	PUNCT
dpc-2121	293	4	and	and	CCONJ
dpc-2121	293	5	-	-	PUNCT
dpc-2121	293	6	incyte	incyte	ADJ
dpc-2121	293	7	-	-	PUNCT
dpc-2121	293	8	announce	announce	NOUN
dpc-2121	293	9	-	-	PUNCT
dpc-2121	293	10	top	top	ADJ
dpc-2121	293	11	-	-	PUNCT
dpc-2121	293	12	line	line	NOUN
dpc-2121	293	13	-	-	PUNCT
dpc-2121	293	14	results	result	NOUN
dpc-2121	293	15	-	-	PUNCT
dpc-2121	293	16	phase-3	phase-3	NUM
dpc-2121	293	17	-	-	PUNCT
dpc-2121	293	18	study	study	NOUN
dpc-2121	293	19	-	-	PUNCT
dpc-2121	293	20	breeze	breeze	NOUN
dpc-2121	293	21	.	.	PUNCT
dpc-2121	294	1	published	publish	VERB
dpc-2121	294	2	2020	2020	NUM
dpc-2121	294	3	.	.	PUNCT
dpc-2121	295	1	accessed	access	VERB
dpc-2121	295	2	september	september	PROPN
dpc-2121	295	3	28	28	NUM
dpc-2121	295	4	,	,	PUNCT
dpc-2121	295	5	2021	2021	NUM
dpc-2121	295	6	.	.	PUNCT
dpc-2121	296	1	21	21	NUM
dpc-2121	296	2	.	.	PUNCT
dpc-2121	297	1	reich	reich	PROPN
dpc-2121	297	2	k	k	PROPN
dpc-2121	297	3	,	,	PUNCT
dpc-2121	297	4	kabashima	kabashima	PROPN
dpc-2121	297	5	k	k	PROPN
dpc-2121	297	6	,	,	PUNCT
dpc-2121	297	7	peris	peris	PROPN
dpc-2121	297	8	k	k	PROPN
dpc-2121	297	9	,	,	PUNCT
dpc-2121	297	10	et	et	PROPN
dpc-2121	297	11	al	al	PROPN
dpc-2121	297	12	.	.	PROPN
dpc-2121	297	13	efficacy	efficacy	NOUN
dpc-2121	297	14	and	and	CCONJ
dpc-2121	297	15	safety	safety	NOUN
dpc-2121	297	16	of	of	ADP
dpc-2121	297	17	baricitinib	baricitinib	NOUN
dpc-2121	297	18	combined	combine	VERB
dpc-2121	297	19	with	with	ADP
dpc-2121	297	20	topical	topical	ADJ
dpc-2121	297	21	corticosteroids	corticosteroid	NOUN
dpc-2121	297	22	for	for	ADP
dpc-2121	297	23	treatment	treatment	NOUN
dpc-2121	297	24	of	of	ADP
dpc-2121	297	25	moderate	moderate	ADJ
dpc-2121	297	26	to	to	ADP
dpc-2121	297	27	severe	severe	ADJ
dpc-2121	297	28	atopic	atopic	NOUN
dpc-2121	297	29	dermatitis	dermatitis	NOUN
dpc-2121	297	30	:	:	PUNCT
dpc-2121	297	31	a	a	DET
dpc-2121	297	32	randomized	randomized	ADJ
dpc-2121	297	33	clinical	clinical	ADJ
dpc-2121	297	34	trial	trial	NOUN
dpc-2121	297	35	.	.	PUNCT
dpc-2121	298	1	jama	jama	PROPN
dpc-2121	298	2	dermatol	dermatol	NOUN
dpc-2121	298	3	.	.	PUNCT
dpc-2121	299	1	2020;156(12):1333	2020;156(12):1333	NOUN
dpc-2121	299	2	-	-	SYM
dpc-2121	299	3	1343	1343	NUM
dpc-2121	299	4	.	.	PUNCT
dpc-2121	300	1	doi:10.1001/	doi:10.1001/	PROPN
dpc-2121	301	1	jamadermatol.2020.3260	jamadermatol.2020.3260	NOUN
dpc-2121	301	2	.	.	PUNCT
dpc-2121	302	1	pmid	pmid	NOUN
dpc-2121	302	2	:	:	PUNCT
dpc-2121	302	3	33001140	33001140	NUM
dpc-2121	302	4	 	 	SPACE
dpc-2121	302	5	.	.	PUNCT
dpc-2121	303	1	pmcid	pmcid	NOUN
dpc-2121	303	2	:	:	PUNCT
dpc-2121	303	3	pmc7527941	pmc7527941	PROPN
dpc-2121	303	4	.	.	PUNCT
dpc-2121	304	1	22	22	NUM
dpc-2121	304	2	.	.	PUNCT
dpc-2121	305	1	wollenberg	wollenberg	PROPN
dpc-2121	305	2	a	a	PRON
dpc-2121	305	3	,	,	PUNCT
dpc-2121	305	4	nakahara	nakahara	PROPN
dpc-2121	305	5	t	t	PROPN
dpc-2121	305	6	,	,	PUNCT
dpc-2121	305	7	maari	maari	PROPN
dpc-2121	305	8	c	c	AUX
dpc-2121	305	9	,	,	PUNCT
dpc-2121	305	10	et	et	PROPN
dpc-2121	305	11	al	al	PROPN
dpc-2121	305	12	.	.	PROPN
dpc-2121	305	13	impact	impact	NOUN
dpc-2121	305	14	of	of	ADP
dpc-2121	305	15	baricitinib	baricitinib	NOUN
dpc-2121	305	16	in	in	ADP
dpc-2121	305	17	combination	combination	NOUN
dpc-2121	305	18	with	with	ADP
dpc-2121	305	19	topical	topical	ADJ
dpc-2121	305	20	steroids	steroid	NOUN
dpc-2121	305	21	on	on	ADP
dpc-2121	305	22	atopic	atopic	NOUN
dpc-2121	305	23	dermatitis	dermatitis	NOUN
dpc-2121	305	24	symptoms	symptom	NOUN
dpc-2121	305	25	,	,	PUNCT
dpc-2121	305	26	quality	quality	NOUN
dpc-2121	305	27	of	of	ADP
dpc-2121	305	28	life	life	NOUN
dpc-2121	305	29	and	and	CCONJ
dpc-2121	305	30	functioning	function	VERB
dpc-2121	305	31	in	in	ADP
dpc-2121	305	32	adult	adult	NOUN
dpc-2121	305	33	patients	patient	NOUN
dpc-2121	305	34	with	with	ADP
dpc-2121	305	35	moderate	moderate	ADJ
dpc-2121	305	36	-	-	PUNCT
dpc-2121	305	37	to	to	ADP
dpc-2121	305	38	-	-	PUNCT
dpc-2121	305	39	severe	severe	ADJ
dpc-2121	305	40	atopic	atopic	NOUN
dpc-2121	305	41	dermatitis	dermatitis	NOUN
dpc-2121	305	42	from	from	ADP
dpc-2121	305	43	the	the	DET
dpc-2121	305	44	breezead7	breezead7	NOUN
dpc-2121	305	45	phase	phase	NOUN
dpc-2121	305	46	3	3	NUM
dpc-2121	305	47	randomized	randomized	ADJ
dpc-2121	305	48	trial	trial	NOUN
dpc-2121	305	49	.	.	PUNCT
dpc-2121	306	1	j	j	PROPN
dpc-2121	306	2	eur	eur	PROPN
dpc-2121	306	3	acad	acad	PROPN
dpc-2121	306	4	dermatol	dermatol	NOUN
dpc-2121	306	5	venereol	venereol	NOUN
dpc-2121	306	6	.	.	PUNCT
dpc-2121	307	1	2021;35(7):1543	2021;35(7):1543	NUM
dpc-2121	307	2	-	-	SYM
dpc-2121	307	3	1552	1552	NUM
dpc-2121	307	4	.	.	PUNCT
dpc-2121	308	1	doi:10.1111	doi:10.1111	NOUN
dpc-2121	308	2	/	/	SYM
dpc-2121	308	3	jdv.17278	jdv.17278	PROPN
dpc-2121	308	4	.	.	PUNCT
dpc-2121	309	1	pmid	pmid	NOUN
dpc-2121	309	2	:	:	PUNCT
dpc-2121	309	3	33834521	33834521	NUM
dpc-2121	309	4	.	.	PUNCT
dpc-2121	310	1	pmcid	pmcid	ADJ
dpc-2121	310	2	:	:	PUNCT
dpc-2121	310	3	pmc8251919	pmc8251919	NOUN
dpc-2121	310	4	.	.	PUNCT
dpc-2121	311	1	23	23	NUM
dpc-2121	311	2	.	.	PUNCT
dpc-2121	312	1	european	european	PROPN
dpc-2121	312	2	medicines	medicine	NOUN
dpc-2121	312	3	agency	agency	NOUN
dpc-2121	312	4	.	.	PUNCT
dpc-2121	313	1	rinvoq	rinvoq	PROPN
dpc-2121	313	2	®	®	PROPN
dpc-2121	313	3	(	(	PUNCT
dpc-2121	313	4	upadacitinib	upadacitinib	NOUN
dpc-2121	313	5	):	):	PUNCT
dpc-2121	313	6	epar	epar	NOUN
dpc-2121	313	7	product	product	NOUN
dpc-2121	313	8	information	information	NOUN
dpc-2121	313	9	.	.	PUNCT
dpc-2121	314	1	https://www.ema.europa.eu/en/documents/	https://www.ema.europa.eu/en/documents/	NOUN
dpc-2121	314	2	product	product	NOUN
dpc-2121	314	3	-	-	PUNCT
dpc-2121	314	4	information	information	NOUN
dpc-2121	314	5	/	/	SYM
dpc-2121	314	6	rinvoq	rinvoq	NOUN
dpc-2121	314	7	-	-	PUNCT
dpc-2121	314	8	epar	epar	NOUN
dpc-2121	314	9	-	-	PUNCT
dpc-2121	314	10	product	product	NOUN
dpc-2121	314	11	-	-	PUNCT
dpc-2121	314	12	information_en.pdf	information_en.pdf	NOUN
dpc-2121	314	13	.	.	PUNCT
dpc-2121	315	1	published	publish	VERB
dpc-2121	315	2	2021	2021	NUM
dpc-2121	315	3	.	.	PUNCT
dpc-2121	316	1	accessed	access	VERB
dpc-2121	316	2	july	july	PROPN
dpc-2121	316	3	27	27	NUM
dpc-2121	316	4	,	,	PUNCT
dpc-2121	316	5	2021	2021	NUM
dpc-2121	316	6	.	.	PUNCT
dpc-2121	317	1	24	24	NUM
dpc-2121	317	2	.	.	PUNCT
dpc-2121	318	1	guttman	guttman	ADJ
dpc-2121	318	2	-	-	PUNCT
dpc-2121	318	3	yassky	yassky	NOUN
dpc-2121	318	4	e	e	NOUN
dpc-2121	318	5	,	,	PUNCT
dpc-2121	318	6	teixeira	teixeira	PROPN
dpc-2121	318	7	hd	hd	PROPN
dpc-2121	318	8	,	,	PUNCT
dpc-2121	318	9	simpson	simpson	PROPN
dpc-2121	318	10	el	el	PROPN
dpc-2121	318	11	,	,	PUNCT
dpc-2121	318	12	et	et	PROPN
dpc-2121	318	13	al	al	PROPN
dpc-2121	318	14	.	.	PROPN
dpc-2121	319	1	once	once	ADV
dpc-2121	319	2	-	-	PUNCT
dpc-2121	319	3	daily	daily	ADJ
dpc-2121	319	4	upadacitinib	upadacitinib	NOUN
dpc-2121	319	5	versus	versus	ADP
dpc-2121	319	6	placebo	placebo	NOUN
dpc-2121	319	7	in	in	ADP
dpc-2121	319	8	adolescents	adolescent	NOUN
dpc-2121	319	9	and	and	CCONJ
dpc-2121	319	10	adults	adult	NOUN
dpc-2121	319	11	with	with	ADP
dpc-2121	319	12	moderate	moderate	ADJ
dpc-2121	319	13	-	-	PUNCT
dpc-2121	319	14	to	to	ADP
dpc-2121	319	15	-	-	PUNCT
dpc-2121	319	16	severe	severe	ADJ
dpc-2121	319	17	atopic	atopic	NOUN
dpc-2121	319	18	dermatitis	dermatitis	NOUN
dpc-2121	319	19	(	(	PUNCT
dpc-2121	319	20	measure	measure	VERB
dpc-2121	319	21	up	up	ADV
dpc-2121	319	22	1	1	NUM
dpc-2121	319	23	and	and	CCONJ
dpc-2121	319	24	measure	measure	VERB
dpc-2121	319	25	up	up	ADV
dpc-2121	319	26	2	2	NUM
dpc-2121	319	27	):	):	PUNCT
dpc-2121	319	28	results	result	NOUN
dpc-2121	319	29	from	from	ADP
dpc-2121	319	30	two	two	NUM
dpc-2121	319	31	replicate	replicate	ADJ
dpc-2121	319	32	double	double	ADJ
dpc-2121	319	33	-	-	PUNCT
dpc-2121	319	34	blind	blind	ADJ
dpc-2121	319	35	,	,	PUNCT
dpc-2121	319	36	randomised	randomise	VERB
dpc-2121	319	37	controlled	control	VERB
dpc-2121	319	38	phase	phase	NOUN
dpc-2121	319	39	3	3	NUM
dpc-2121	319	40	trials	trial	NOUN
dpc-2121	319	41	.	.	PUNCT
dpc-2121	320	1	lancet	lancet	VERB
dpc-2121	320	2	.	.	PUNCT
dpc-2121	321	1	2021;397(10290):2151	2021;397(10290):2151	NUM
dpc-2121	321	2	-	-	SYM
dpc-2121	321	3	2168	2168	NUM
dpc-2121	321	4	.	.	PUNCT
dpc-2121	322	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	322	2	/	/	SYM
dpc-2121	322	3	s0140	s0140	PROPN
dpc-2121	322	4	-	-	PUNCT
dpc-2121	322	5	6736(21)00588	6736(21)00588	NOUN
dpc-2121	322	6	-	-	PUNCT
dpc-2121	322	7	2	2	NUM
dpc-2121	322	8	.	.	NUM
dpc-2121	322	9	25	25	NUM
dpc-2121	322	10	.	.	PUNCT
dpc-2121	323	1	reich	reich	PROPN
dpc-2121	323	2	k	k	PROPN
dpc-2121	323	3	,	,	PUNCT
dpc-2121	323	4	teixeira	teixeira	PROPN
dpc-2121	323	5	hd	hd	PROPN
dpc-2121	323	6	,	,	PUNCT
dpc-2121	323	7	de	de	X
dpc-2121	323	8	bruin	bruin	NOUN
dpc-2121	323	9	-	-	PUNCT
dpc-2121	323	10	weller	weller	PROPN
dpc-2121	323	11	m	m	PROPN
dpc-2121	323	12	,	,	PUNCT
dpc-2121	323	13	et	et	PROPN
dpc-2121	323	14	al	al	PROPN
dpc-2121	323	15	.	.	PROPN
dpc-2121	323	16	safety	safety	NOUN
dpc-2121	323	17	and	and	CCONJ
dpc-2121	323	18	efficacy	efficacy	NOUN
dpc-2121	323	19	of	of	ADP
dpc-2121	323	20	upadacitinib	upadacitinib	NOUN
dpc-2121	323	21	in	in	ADP
dpc-2121	323	22	combination	combination	NOUN
dpc-2121	323	23	with	with	ADP
dpc-2121	323	24	topical	topical	ADJ
dpc-2121	323	25	corticosteroids	corticosteroid	NOUN
dpc-2121	323	26	in	in	ADP
dpc-2121	323	27	adolescents	adolescent	NOUN
dpc-2121	323	28	and	and	CCONJ
dpc-2121	323	29	adults	adult	NOUN
dpc-2121	323	30	with	with	ADP
dpc-2121	323	31	moderate	moderate	ADJ
dpc-2121	323	32	-	-	PUNCT
dpc-2121	323	33	to	to	ADP
dpc-2121	323	34	-	-	PUNCT
dpc-2121	323	35	severe	severe	ADJ
dpc-2121	323	36	atopic	atopic	NOUN
dpc-2121	323	37	dermatitis	dermatitis	NOUN
dpc-2121	323	38	(	(	PUNCT
dpc-2121	323	39	ad	ad	NOUN
dpc-2121	323	40	up	up	ADP
dpc-2121	323	41	):	):	PUNCT
dpc-2121	323	42	results	result	NOUN
dpc-2121	323	43	from	from	ADP
dpc-2121	323	44	a	a	DET
dpc-2121	323	45	randomised	randomised	ADJ
dpc-2121	323	46	,	,	PUNCT
dpc-2121	323	47	double	double	ADJ
dpc-2121	323	48	-	-	PUNCT
dpc-2121	323	49	blind	blind	ADJ
dpc-2121	323	50	,	,	PUNCT
dpc-2121	323	51	placebo	placebo	NOUN
dpc-2121	323	52	-	-	PUNCT
dpc-2121	323	53	controlled	control	VERB
dpc-2121	323	54	,	,	PUNCT
dpc-2121	323	55	phase	phase	NOUN
dpc-2121	323	56	3	3	NUM
dpc-2121	323	57	trial	trial	NOUN
dpc-2121	323	58	.	.	PUNCT
dpc-2121	324	1	lancet	lancet	PROPN
dpc-2121	324	2	.	.	PUNCT
dpc-2121	325	1	2021;397(10290):2169	2021;397(10290):2169	NUM
dpc-2121	325	2	-	-	SYM
dpc-2121	325	3	2181	2181	NUM
dpc-2121	325	4	.	.	PUNCT
dpc-2121	326	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	326	2	/	/	SYM
dpc-2121	326	3	s0140	s0140	PROPN
dpc-2121	326	4	-	-	PUNCT
dpc-2121	326	5	6736(21)00589	6736(21)00589	NUM
dpc-2121	326	6	-	-	SYM
dpc-2121	326	7	4	4	NUM
dpc-2121	326	8	26	26	NUM
dpc-2121	326	9	.	.	PUNCT
dpc-2121	327	1	silverberg	silverberg	PROPN
dpc-2121	327	2	ji	ji	PROPN
dpc-2121	327	3	,	,	PUNCT
dpc-2121	327	4	de	de	PROPN
dpc-2121	327	5	bruin	bruin	NOUN
dpc-2121	327	6	-	-	PUNCT
dpc-2121	327	7	weller	weller	PROPN
dpc-2121	327	8	m	m	PROPN
dpc-2121	327	9	,	,	PUNCT
dpc-2121	327	10	bieber	bieber	PROPN
dpc-2121	327	11	t	t	PROPN
dpc-2121	327	12	,	,	PUNCT
dpc-2121	327	13	et	et	PROPN
dpc-2121	327	14	al	al	PROPN
dpc-2121	327	15	.	.	PROPN
dpc-2121	327	16	upadacitinib	upadacitinib	NOUN
dpc-2121	327	17	plus	plus	CCONJ
dpc-2121	327	18	topical	topical	ADJ
dpc-2121	327	19	corticosteroids	corticosteroid	NOUN
dpc-2121	327	20	in	in	ADP
dpc-2121	327	21	atopic	atopic	NOUN
dpc-2121	327	22	dermatitis	dermatitis	NOUN
dpc-2121	327	23	:	:	PUNCT
dpc-2121	327	24	week-52	week-52	PROPN
dpc-2121	327	25	ad	ad	NOUN
dpc-2121	327	26	up	up	ADP
dpc-2121	327	27	study	study	NOUN
dpc-2121	327	28	results	result	NOUN
dpc-2121	327	29	.	.	PUNCT
dpc-2121	328	1	j	j	PROPN
dpc-2121	328	2	allergy	allergy	PROPN
dpc-2121	328	3	clin	clin	PROPN
dpc-2121	328	4	immunol	immunol	PROPN
dpc-2121	328	5	.	.	PUNCT
dpc-2121	329	1	august	august	PROPN
dpc-2121	329	2	2021	2021	NUM
dpc-2121	329	3	.	.	PUNCT
dpc-2121	330	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	330	2	/	/	SYM
dpc-2121	330	3	j.	j.	PROPN
dpc-2121	330	4	jaci.2021.07.036	jaci.2021.07.036	PROPN
dpc-2121	330	5	.	.	PUNCT
dpc-2121	331	1	pmid	pmid	NOUN
dpc-2121	331	2	:	:	PUNCT
dpc-2121	331	3	34403658	34403658	NUM
dpc-2121	331	4	.	.	PUNCT
dpc-2121	332	1	27	27	NUM
dpc-2121	332	2	.	.	PUNCT
dpc-2121	333	1	blauvelt	blauvelt	VERB
dpc-2121	333	2	a	a	DET
dpc-2121	333	3	,	,	PUNCT
dpc-2121	333	4	teixeira	teixeira	PROPN
dpc-2121	333	5	hd	hd	PROPN
dpc-2121	333	6	,	,	PUNCT
dpc-2121	333	7	simpson	simpson	PROPN
dpc-2121	333	8	el	el	PROPN
dpc-2121	333	9	,	,	PUNCT
dpc-2121	333	10	et	et	PROPN
dpc-2121	333	11	al	al	PROPN
dpc-2121	333	12	.	.	PROPN
dpc-2121	334	1	efficacy	efficacy	NOUN
dpc-2121	334	2	and	and	CCONJ
dpc-2121	334	3	safety	safety	NOUN
dpc-2121	334	4	of	of	ADP
dpc-2121	334	5	upadacitinib	upadacitinib	NOUN
dpc-2121	334	6	vs	vs	ADP
dpc-2121	334	7	dupilumab	dupilumab	NOUN
dpc-2121	334	8	in	in	ADP
dpc-2121	334	9	adults	adult	NOUN
dpc-2121	334	10	with	with	ADP
dpc-2121	334	11	moderate	moderate	ADJ
dpc-2121	334	12	-	-	PUNCT
dpc-2121	334	13	to	to	ADP
dpc-2121	334	14	-	-	PUNCT
dpc-2121	334	15	severe	severe	ADJ
dpc-2121	334	16	atopic	atopic	NOUN
dpc-2121	334	17	dermatitis	dermatitis	NOUN
dpc-2121	334	18	:	:	PUNCT
dpc-2121	334	19	a	a	DET
dpc-2121	334	20	randomized	randomized	ADJ
dpc-2121	334	21	clinical	clinical	ADJ
dpc-2121	334	22	trial	trial	NOUN
dpc-2121	334	23	.	.	PUNCT
dpc-2121	335	1	jama	jama	PROPN
dpc-2121	335	2	dermatology	dermatology	NOUN
dpc-2121	335	3	.	.	PUNCT
dpc-2121	336	1	2021;157(9):1047	2021;157(9):1047	NUM
dpc-2121	336	2	-	-	SYM
dpc-2121	336	3	1055	1055	NUM
dpc-2121	336	4	.	.	PUNCT
dpc-2121	337	1	doi:10.1001	doi:10.1001	PROPN
dpc-2121	337	2	/	/	SYM
dpc-2121	337	3	jamadermatol.2021.3023	jamadermatol.2021.3023	PROPN
dpc-2121	337	4	.	.	PUNCT
dpc-2121	338	1	pmid	pmid	NOUN
dpc-2121	338	2	:	:	PUNCT
dpc-2121	338	3	34347860	34347860	NUM
dpc-2121	338	4	.	.	PUNCT
dpc-2121	339	1	pmcid	pmcid	NOUN
dpc-2121	339	2	:	:	PUNCT
dpc-2121	339	3	pmc8340015	pmc8340015	PROPN
dpc-2121	339	4	.	.	PUNCT
dpc-2121	340	1	28	28	NUM
dpc-2121	340	2	.	.	PUNCT
dpc-2121	340	3	simpson	simpson	PROPN
dpc-2121	340	4	el	el	PROPN
dpc-2121	340	5	,	,	PUNCT
dpc-2121	340	6	sinclair	sinclair	PROPN
dpc-2121	340	7	r	r	PROPN
dpc-2121	340	8	,	,	PUNCT
dpc-2121	340	9	forman	forman	NOUN
dpc-2121	340	10	s	s	PROPN
dpc-2121	340	11	,	,	PUNCT
dpc-2121	340	12	et	et	PROPN
dpc-2121	340	13	al	al	PROPN
dpc-2121	340	14	.	.	PROPN
dpc-2121	340	15	efficacy	efficacy	NOUN
dpc-2121	340	16	and	and	CCONJ
dpc-2121	340	17	safety	safety	NOUN
dpc-2121	340	18	of	of	ADP
dpc-2121	340	19	abrocitinib	abrocitinib	NOUN
dpc-2121	340	20	in	in	ADP
dpc-2121	340	21	adults	adult	NOUN
dpc-2121	340	22	and	and	CCONJ
dpc-2121	340	23	adolescents	adolescent	NOUN
dpc-2121	340	24	with	with	ADP
dpc-2121	340	25	moderate	moderate	ADJ
dpc-2121	340	26	-	-	PUNCT
dpc-2121	340	27	to	to	ADP
dpc-2121	340	28	-	-	PUNCT
dpc-2121	340	29	severe	severe	ADJ
dpc-2121	340	30	atopic	atopic	NOUN
dpc-2121	340	31	dermatitis	dermatitis	NOUN
dpc-2121	340	32	(	(	PUNCT
dpc-2121	340	33	jade	jade	NOUN
dpc-2121	340	34	mono-1	mono-1	PROPN
dpc-2121	340	35	):	):	PUNCT
dpc-2121	340	36	a	a	DET
dpc-2121	340	37	multicentre	multicentre	NOUN
dpc-2121	340	38	,	,	PUNCT
dpc-2121	340	39	double	double	ADJ
dpc-2121	340	40	-	-	PUNCT
dpc-2121	340	41	blind	blind	ADJ
dpc-2121	340	42	,	,	PUNCT
dpc-2121	340	43	randomised	randomise	VERB
dpc-2121	340	44	,	,	PUNCT
dpc-2121	340	45	placebo	placebo	NOUN
dpc-2121	340	46	-	-	PUNCT
dpc-2121	340	47	controlled	control	VERB
dpc-2121	340	48	,	,	PUNCT
dpc-2121	340	49	phase	phase	NOUN
dpc-2121	340	50	3	3	NUM
dpc-2121	340	51	trial	trial	NOUN
dpc-2121	340	52	.	.	PUNCT
dpc-2121	341	1	lancet	lancet	NOUN
dpc-2121	341	2	.	.	PUNCT
dpc-2121	342	1	2020;396(10246):255	2020;396(10246):255	NUM
dpc-2121	342	2	-	-	SYM
dpc-2121	342	3	266	266	NUM
dpc-2121	342	4	.	.	PUNCT
dpc-2121	343	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	343	2	/	/	SYM
dpc-2121	343	3	s01406736(20)30732	s01406736(20)30732	PROPN
dpc-2121	343	4	-	-	PUNCT
dpc-2121	343	5	7	7	NUM
dpc-2121	343	6	29	29	NUM
dpc-2121	343	7	.	.	PUNCT
dpc-2121	344	1	silverberg	silverberg	PROPN
dpc-2121	344	2	ji	ji	PROPN
dpc-2121	344	3	,	,	PUNCT
dpc-2121	344	4	simpson	simpson	PROPN
dpc-2121	344	5	el	el	PROPN
dpc-2121	344	6	,	,	PUNCT
dpc-2121	344	7	thyssen	thyssen	PROPN
dpc-2121	344	8	jp	jp	PROPN
dpc-2121	344	9	,	,	PUNCT
dpc-2121	344	10	et	et	PROPN
dpc-2121	344	11	al	al	PROPN
dpc-2121	344	12	.	.	PROPN
dpc-2121	344	13	efficacy	efficacy	NOUN
dpc-2121	344	14	and	and	CCONJ
dpc-2121	344	15	safety	safety	NOUN
dpc-2121	344	16	of	of	ADP
dpc-2121	344	17	abrocitinib	abrocitinib	NOUN
dpc-2121	344	18	in	in	ADP
dpc-2121	344	19	patients	patient	NOUN
dpc-2121	344	20	with	with	ADP
dpc-2121	344	21	moderate	moderate	ADJ
dpc-2121	344	22	-	-	PUNCT
dpc-2121	344	23	to	to	ADP
dpc-2121	344	24	-	-	PUNCT
dpc-2121	344	25	severe	severe	ADJ
dpc-2121	344	26	atopic	atopic	NOUN
dpc-2121	344	27	dermatitis	dermatitis	NOUN
dpc-2121	344	28	:	:	PUNCT
dpc-2121	344	29	a	a	DET
dpc-2121	344	30	randomized	randomized	ADJ
dpc-2121	344	31	clinical	clinical	ADJ
dpc-2121	344	32	trial	trial	NOUN
dpc-2121	344	33	.	.	PUNCT
dpc-2121	345	1	jama	jama	PROPN
dpc-2121	345	2	derreview	derreview	VERB
dpc-2121	345	3	|	|	ADV
dpc-2121	345	4	dermatol	dermatol	ADJ
dpc-2121	345	5	pract	pract	NOUN
dpc-2121	345	6	concept	concept	NOUN
dpc-2121	345	7	.	.	PUNCT
dpc-2121	346	1	2021;11(4):e2021145	2021;11(4):e2021145	NUM
dpc-2121	346	2	9	9	NUM
dpc-2121	346	3	matol	matol	NOUN
dpc-2121	346	4	.	.	PUNCT
dpc-2121	347	1	2020;156(8):863	2020;156(8):863	NUM
dpc-2121	347	2	-	-	SYM
dpc-2121	347	3	873	873	NUM
dpc-2121	347	4	.	.	PUNCT
dpc-2121	348	1	doi:10.1001	doi:10.1001	PROPN
dpc-2121	348	2	/	/	SYM
dpc-2121	348	3	jamadermatol.2020.1406	jamadermatol.2020.1406	PROPN
dpc-2121	348	4	.	.	PUNCT
dpc-2121	349	1	pmid	pmid	NOUN
dpc-2121	349	2	:	:	PUNCT
dpc-2121	349	3	32492087	32492087	NUM
dpc-2121	349	4	.	.	PUNCT
dpc-2121	350	1	pmcid	pmcid	NOUN
dpc-2121	350	2	:	:	PUNCT
dpc-2121	350	3	pmc7271424	pmc7271424	ADJ
dpc-2121	350	4	.	.	PUNCT
dpc-2121	351	1	30	30	NUM
dpc-2121	351	2	.	.	PUNCT
dpc-2121	352	1	bieber	bieber	PROPN
dpc-2121	352	2	t	t	PROPN
dpc-2121	352	3	,	,	PUNCT
dpc-2121	352	4	simpson	simpson	PROPN
dpc-2121	352	5	el	el	PROPN
dpc-2121	352	6	,	,	PUNCT
dpc-2121	352	7	silverberg	silverberg	PROPN
dpc-2121	352	8	ji	ji	PROPN
dpc-2121	352	9	,	,	PUNCT
dpc-2121	352	10	et	et	PROPN
dpc-2121	352	11	al	al	PROPN
dpc-2121	352	12	.	.	PROPN
dpc-2121	352	13	abrocitinib	abrocitinib	NOUN
dpc-2121	352	14	versus	versus	ADP
dpc-2121	352	15	placebo	placebo	NOUN
dpc-2121	352	16	or	or	CCONJ
dpc-2121	352	17	dupilumab	dupilumab	NOUN
dpc-2121	352	18	for	for	ADP
dpc-2121	352	19	atopic	atopic	NOUN
dpc-2121	352	20	dermatitis	dermatitis	NOUN
dpc-2121	352	21	.	.	PUNCT
dpc-2121	353	1	n	n	PROPN
dpc-2121	353	2	engl	engl	PROPN
dpc-2121	353	3	j	j	PROPN
dpc-2121	353	4	med	med	PROPN
dpc-2121	353	5	.	.	PUNCT
dpc-2121	354	1	2021;384(12):1101	2021;384(12):1101	NUM
dpc-2121	354	2	-	-	SYM
dpc-2121	354	3	1112	1112	NUM
dpc-2121	354	4	.	.	PUNCT
dpc-2121	355	1	doi:10.1056	doi:10.1056	PROPN
dpc-2121	355	2	/	/	SYM
dpc-2121	355	3	nejmoa2019380	nejmoa2019380	PROPN
dpc-2121	355	4	.	.	PUNCT
dpc-2121	356	1	pmid:33761207	pmid:33761207	NOUN
dpc-2121	356	2	.	.	PUNCT
dpc-2121	357	1	31	31	NUM
dpc-2121	357	2	.	.	PUNCT
dpc-2121	358	1	blauvelt	blauvelt	VERB
dpc-2121	358	2	a	a	PRON
dpc-2121	358	3	,	,	PUNCT
dpc-2121	358	4	silverberg	silverberg	PROPN
dpc-2121	358	5	ji	ji	PROPN
dpc-2121	358	6	,	,	PUNCT
dpc-2121	358	7	lynde	lynde	PROPN
dpc-2121	358	8	cw	cw	PROPN
dpc-2121	358	9	,	,	PUNCT
dpc-2121	358	10	et	et	PROPN
dpc-2121	358	11	al	al	PROPN
dpc-2121	358	12	.	.	PROPN
dpc-2121	358	13	abrocitinib	abrocitinib	PROPN
dpc-2121	358	14	induction	induction	NOUN
dpc-2121	358	15	,	,	PUNCT
dpc-2121	358	16	randomized	randomize	VERB
dpc-2121	358	17	withdrawal	withdrawal	NOUN
dpc-2121	358	18	,	,	PUNCT
dpc-2121	358	19	and	and	CCONJ
dpc-2121	358	20	retreatment	retreatment	NOUN
dpc-2121	358	21	in	in	ADP
dpc-2121	358	22	patients	patient	NOUN
dpc-2121	358	23	with	with	ADP
dpc-2121	358	24	moderate	moderate	ADJ
dpc-2121	358	25	-	-	PUNCT
dpc-2121	358	26	to	to	ADP
dpc-2121	358	27	-	-	PUNCT
dpc-2121	358	28	severe	severe	ADJ
dpc-2121	358	29	atopic	atopic	NOUN
dpc-2121	358	30	dermatitis	dermatitis	NOUN
dpc-2121	358	31	:	:	PUNCT
dpc-2121	358	32	results	result	NOUN
dpc-2121	358	33	from	from	ADP
dpc-2121	358	34	the	the	DET
dpc-2121	358	35	jak1	jak1	PROPN
dpc-2121	358	36	atopic	atopic	NOUN
dpc-2121	358	37	dermatitis	dermatitis	PROPN
dpc-2121	358	38	efficacy	efficacy	NOUN
dpc-2121	358	39	and	and	CCONJ
dpc-2121	358	40	safety	safety	NOUN
dpc-2121	358	41	(	(	PUNCT
dpc-2121	358	42	jade	jade	NOUN
dpc-2121	358	43	)	)	PUNCT
dpc-2121	358	44	regimen	regiman	NOUN
dpc-2121	358	45	phase	phase	NOUN
dpc-2121	358	46	3	3	NUM
dpc-2121	358	47	trial	trial	NOUN
dpc-2121	358	48	.	.	PUNCT
dpc-2121	359	1	j	j	PROPN
dpc-2121	359	2	am	be	AUX
dpc-2121	359	3	acad	acad	ADJ
dpc-2121	359	4	dermatol	dermatol	NOUN
dpc-2121	359	5	.	.	PUNCT
dpc-2121	360	1	august	august	PROPN
dpc-2121	360	2	2021	2021	NUM
dpc-2121	360	3	.	.	PUNCT
dpc-2121	361	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	361	2	/	/	SYM
dpc-2121	361	3	j.	j.	PROPN
dpc-2121	361	4	jaad.2021.05.075	jaad.2021.05.075	PROPN
dpc-2121	361	5	.	.	PUNCT
dpc-2121	362	1	pmcid	pmcid	PROPN
dpc-2121	362	2	:	:	PUNCT
dpc-2121	362	3	pmc7788316	pmc7788316	VERB
dpc-2121	362	4	.	.	PUNCT
dpc-2121	363	1	32	32	NUM
dpc-2121	363	2	.	.	PUNCT
dpc-2121	364	1	eichenfield	eichenfield	PROPN
dpc-2121	364	2	lf	lf	PROPN
dpc-2121	364	3	,	,	PUNCT
dpc-2121	364	4	flohr	flohr	PROPN
dpc-2121	364	5	c	c	NOUN
dpc-2121	364	6	,	,	PUNCT
dpc-2121	364	7	sidbury	sidbury	PROPN
dpc-2121	364	8	r	r	NOUN
dpc-2121	364	9	,	,	PUNCT
dpc-2121	364	10	et	et	PROPN
dpc-2121	364	11	al	al	PROPN
dpc-2121	364	12	.	.	PROPN
dpc-2121	364	13	efficacy	efficacy	NOUN
dpc-2121	364	14	and	and	CCONJ
dpc-2121	364	15	safety	safety	NOUN
dpc-2121	364	16	of	of	ADP
dpc-2121	364	17	abrocitinib	abrocitinib	NOUN
dpc-2121	364	18	in	in	ADP
dpc-2121	364	19	combination	combination	NOUN
dpc-2121	364	20	with	with	ADP
dpc-2121	364	21	topical	topical	ADJ
dpc-2121	364	22	therapy	therapy	NOUN
dpc-2121	364	23	in	in	ADP
dpc-2121	364	24	adolescents	adolescent	NOUN
dpc-2121	364	25	with	with	ADP
dpc-2121	364	26	moderate	moderate	ADJ
dpc-2121	364	27	-	-	PUNCT
dpc-2121	364	28	to	to	ADP
dpc-2121	364	29	-	-	PUNCT
dpc-2121	364	30	severe	severe	ADJ
dpc-2121	364	31	atopic	atopic	NOUN
dpc-2121	364	32	dermatitis	dermatitis	NOUN
dpc-2121	364	33	:	:	PUNCT
dpc-2121	364	34	the	the	DET
dpc-2121	364	35	jade	jade	NOUN
dpc-2121	364	36	teen	teen	NOUN
dpc-2121	364	37	randomized	randomize	VERB
dpc-2121	364	38	clinical	clinical	ADJ
dpc-2121	364	39	trial	trial	NOUN
dpc-2121	364	40	.	.	PUNCT
dpc-2121	365	1	jama	jama	PROPN
dpc-2121	365	2	dermatol	dermatol	NOUN
dpc-2121	365	3	.	.	PUNCT
dpc-2121	366	1	2021	2021	NUM
dpc-2121	366	2	:	:	PUNCT
dpc-2121	366	3	e212830	e212830	PROPN
dpc-2121	366	4	.	.	PUNCT
dpc-2121	367	1	doi:10.1001	doi:10.1001	PROPN
dpc-2121	367	2	/	/	SYM
dpc-2121	367	3	jamadermatol.2021.2830	jamadermatol.2021.2830	PROPN
dpc-2121	367	4	.	.	PUNCT
dpc-2121	368	1	pmid	pmid	NOUN
dpc-2121	368	2	:	:	PUNCT
dpc-2121	368	3	34406366	34406366	NUM
dpc-2121	368	4	.	.	PUNCT
dpc-2121	369	1	pmcid	pmcid	NOUN
dpc-2121	369	2	:	:	PUNCT
dpc-2121	369	3	pmc8374743	pmc8374743	NOUN
dpc-2121	369	4	.	.	PUNCT
dpc-2121	370	1	33	33	NUM
dpc-2121	370	2	.	.	PUNCT
dpc-2121	371	1	seegräber	seegräber	PROPN
dpc-2121	371	2	m	m	PROPN
dpc-2121	371	3	,	,	PUNCT
dpc-2121	371	4	srour	srour	PROPN
dpc-2121	371	5	j	j	PROPN
dpc-2121	371	6	,	,	PUNCT
dpc-2121	371	7	walter	walter	PROPN
dpc-2121	371	8	a	a	PROPN
dpc-2121	371	9	,	,	PUNCT
dpc-2121	371	10	knop	knop	PROPN
dpc-2121	371	11	m	m	PROPN
dpc-2121	371	12	,	,	PUNCT
dpc-2121	371	13	wollenberg	wollenberg	PROPN
dpc-2121	371	14	a.	a.	NOUN
dpc-2121	371	15	dupilumab	dupilumab	NOUN
dpc-2121	371	16	for	for	ADP
dpc-2121	371	17	treatment	treatment	NOUN
dpc-2121	371	18	of	of	ADP
dpc-2121	371	19	atopic	atopic	NOUN
dpc-2121	371	20	dermatitis	dermatitis	NOUN
dpc-2121	371	21	.	.	PUNCT
dpc-2121	372	1	expert	expert	PROPN
dpc-2121	372	2	rev	rev	PROPN
dpc-2121	372	3	clin	clin	PROPN
dpc-2121	372	4	pharmacol	pharmacol	PROPN
dpc-2121	372	5	.	.	PUNCT
dpc-2121	373	1	2018;11(5):467	2018;11(5):467	PROPN
dpc-2121	373	2	-	-	SYM
dpc-2121	373	3	474	474	NUM
dpc-2121	373	4	.	.	PUNCT
dpc-2121	374	1	doi:10.1080/17512433.2018.1449642	doi:10.1080/17512433.2018.1449642	PROPN
dpc-2121	374	2	.	.	PUNCT
dpc-2121	375	1	pmid	pmid	NOUN
dpc-2121	375	2	:	:	PUNCT
dpc-2121	375	3	29557246	29557246	NUM
dpc-2121	375	4	.	.	PUNCT
dpc-2121	376	1	34	34	NUM
dpc-2121	376	2	.	.	PUNCT
dpc-2121	377	1	thyssen	thyssen	PROPN
dpc-2121	377	2	jp	jp	PROPN
dpc-2121	377	3	,	,	PUNCT
dpc-2121	377	4	thomsen	thomsen	PROPN
dpc-2121	377	5	sf	sf	PROPN
dpc-2121	377	6	.	.	PUNCT
dpc-2121	378	1	treatment	treatment	NOUN
dpc-2121	378	2	of	of	ADP
dpc-2121	378	3	atopic	atopic	NOUN
dpc-2121	378	4	dermatitis	dermatitis	NOUN
dpc-2121	378	5	with	with	ADP
dpc-2121	378	6	biologics	biologic	NOUN
dpc-2121	378	7	and	and	CCONJ
dpc-2121	378	8	janus	janus	PROPN
dpc-2121	378	9	kinase	kinase	PROPN
dpc-2121	378	10	inhibitors	inhibitor	NOUN
dpc-2121	378	11	.	.	PUNCT
dpc-2121	379	1	lancet	lancet	PROPN
dpc-2121	379	2	.	.	PUNCT
dpc-2121	380	1	2021;397(10290):21262128	2021;397(10290):21262128	NUM
dpc-2121	380	2	.	.	PUNCT
dpc-2121	381	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	381	2	/	/	SYM
dpc-2121	381	3	s0140	s0140	PROPN
dpc-2121	381	4	-	-	PUNCT
dpc-2121	381	5	6736(21)00717	6736(21)00717	NUM
dpc-2121	381	6	-	-	PUNCT
dpc-2121	381	7	0	0	NUM
dpc-2121	381	8	.	.	NOUN
dpc-2121	381	9	35	35	NUM
dpc-2121	381	10	.	.	PUNCT
dpc-2121	382	1	chovatiya	chovatiya	PROPN
dpc-2121	382	2	r	r	NOUN
dpc-2121	382	3	,	,	PUNCT
dpc-2121	382	4	paller	paller	NOUN
dpc-2121	382	5	a.	a.	PROPN
dpc-2121	382	6	jak	jak	PROPN
dpc-2121	382	7	inhibitors	inhibitor	NOUN
dpc-2121	382	8	in	in	ADP
dpc-2121	382	9	the	the	DET
dpc-2121	382	10	treatment	treatment	NOUN
dpc-2121	382	11	of	of	ADP
dpc-2121	382	12	atopic	atopic	NOUN
dpc-2121	382	13	dermatitis	dermatitis	NOUN
dpc-2121	382	14	.	.	PUNCT
dpc-2121	383	1	j	j	PROPN
dpc-2121	383	2	allergy	allergy	PROPN
dpc-2121	383	3	clin	clin	PROPN
dpc-2121	383	4	immunol	immunol	PROPN
dpc-2121	383	5	.	.	PUNCT
dpc-2121	384	1	august	august	PROPN
dpc-2121	384	2	2021	2021	NUM
dpc-2121	384	3	.	.	PUNCT
dpc-2121	385	1	doi:10.1016	doi:10.1016	PROPN
dpc-2121	385	2	/	/	SYM
dpc-2121	385	3	j.	j.	PROPN
dpc-2121	385	4	jaci.2021.08.009	jaci.2021.08.009	PROPN
dpc-2121	385	5	.	.	PUNCT
dpc-2121	386	1	pmid	pmid	NOUN
dpc-2121	386	2	:	:	PUNCT
dpc-2121	386	3	34437922	34437922	NUM
dpc-2121	386	4	.	.	PUNCT
dpc-2121	387	1	36	36	NUM
dpc-2121	387	2	.	.	PUNCT
dpc-2121	388	1	melo	melo	PROPN
dpc-2121	388	2	a	a	PROPN
dpc-2121	388	3	,	,	PUNCT
dpc-2121	388	4	carrascosa	carrascosa	PROPN
dpc-2121	388	5	jm	jm	PROPN
dpc-2121	388	6	,	,	PUNCT
dpc-2121	388	7	torres	torre	VERB
dpc-2121	388	8	t.	t.	NOUN
dpc-2121	388	9	baricitinib	baricitinib	NOUN
dpc-2121	388	10	for	for	ADP
dpc-2121	388	11	the	the	DET
dpc-2121	388	12	treatment	treatment	NOUN
dpc-2121	388	13	of	of	ADP
dpc-2121	388	14	atopic	atopic	NOUN
dpc-2121	388	15	dermatitis	dermatitis	NOUN
dpc-2121	388	16	.	.	PUNCT
dpc-2121	389	1	j	j	PROPN
dpc-2121	389	2	dermatolog	dermatolog	PROPN
dpc-2121	389	3	treat	treat	NOUN
dpc-2121	389	4	.	.	PUNCT
dpc-2121	390	1	august	august	PROPN
dpc-2121	390	2	2021:1	2021:1	NUM
dpc-2121	390	3	-	-	SYM
dpc-2121	390	4	10	10	NUM
dpc-2121	390	5	.	.	PUNCT
dpc-2121	390	6	doi:1	doi:1	PROPN
dpc-2121	391	1	0.1080/09546634.2021.1967268	0.1080/09546634.2021.1967268	PROPN
dpc-2121	391	2	.	.	PUNCT
dpc-2121	392	1	pmid	pmid	NOUN
dpc-2121	392	2	:	:	PUNCT
dpc-2121	392	3	34379541	34379541	NUM
dpc-2121	392	4	.	.	PUNCT
dpc-2121	393	1	37	37	NUM
dpc-2121	393	2	.	.	PUNCT
dpc-2121	394	1	singh	singh	PROPN
dpc-2121	394	2	r	r	PROPN
dpc-2121	394	3	,	,	PUNCT
dpc-2121	394	4	heron	heron	PROPN
dpc-2121	394	5	ce	ce	PROPN
dpc-2121	394	6	,	,	PUNCT
dpc-2121	394	7	ghamrawi	ghamrawi	ADJ
dpc-2121	394	8	r	r	NOUN
dpc-2121	394	9	,	,	PUNCT
dpc-2121	394	10	strowd	strowd	ADJ
dpc-2121	394	11	lc	lc	PROPN
dpc-2121	394	12	,	,	PUNCT
dpc-2121	394	13	feldman	feldman	PROPN
dpc-2121	394	14	sr	sr	PROPN
dpc-2121	394	15	.	.	PUNCT
dpc-2121	395	1	emerging	emerge	VERB
dpc-2121	395	2	role	role	NOUN
dpc-2121	395	3	of	of	ADP
dpc-2121	395	4	janus	janus	PROPN
dpc-2121	395	5	kinase	kinase	PROPN
dpc-2121	395	6	inhibitors	inhibitor	NOUN
dpc-2121	395	7	for	for	ADP
dpc-2121	395	8	the	the	DET
dpc-2121	395	9	treatment	treatment	NOUN
dpc-2121	395	10	of	of	ADP
dpc-2121	395	11	atopic	atopic	NOUN
dpc-2121	395	12	dermatitis	dermatitis	NOUN
dpc-2121	395	13	.	.	PUNCT
dpc-2121	396	1	immunotargets	immunotarget	VERB
dpc-2121	396	2	ther	ther	ADV
dpc-2121	396	3	.	.	PUNCT
dpc-2121	397	1	2020;9:255	2020;9:255	X
dpc-2121	397	2	-	-	SYM
dpc-2121	397	3	272	272	NUM
dpc-2121	397	4	.	.	PUNCT
dpc-2121	398	1	doi:10.2147/	doi:10.2147/	NUM
dpc-2121	398	2	itt.s229667	itt.s229667	NOUN
dpc-2121	398	3	.	.	PUNCT
dpc-2121	399	1	pmid	pmid	NOUN
dpc-2121	399	2	:	:	PUNCT
dpc-2121	399	3	33204661	33204661	NUM
dpc-2121	399	4	.	.	PUNCT
dpc-2121	400	1	pmcid	pmcid	NOUN
dpc-2121	400	2	:	:	PUNCT
dpc-2121	400	3	pmc7667501	pmc7667501	VERB
dpc-2121	400	4	.	.	PUNCT